Compositions and methods for cancer

ABSTRACT

The present invention relates to novel sequences for use in diagnosis and treatment of carcinomas, especially lymphoma carcinomas. In addition, the present invention describes the use of novel compositions for use in screening methods.

The present application is a continuing application of U.S. Ser. Nos. 09/747,377, filed Dec. 22, 2000 and 09/798,586, filed Mar. 2, 2001, and applications entitled Novel Compositions and Methods for Cancer filed Oct. 23, 2001, Nov. 8, 2001, Nov. 30, 2001, and Dec. 20, 2001, all of which are expressly incorporated herein by reference.

The Sequence Listing (containing SEQ ID NOS:1-1613) is submitted in accordance with 37 CFR §§1.821-1.825 and §§1.52(e) and 1.96(c) on three compact discs labeled “Computer Readable Form (CRF)”, “Copy 1” and “Copy 2”, the contents of which are the same and are expressly incorporated herein by reference. The file names are A71249.ST25, contain 16,870,127 bytes, and were recorded on May 29, 2002.

FIELD OF THE INVENTION

The present invention relates to novel sequences for use in diagnosis and treatment of cancer, especially carcinomas, as well as the use of the novel compositions in screening methods.

BACKGROUND OF THE INVENTION

Oncogenes are genes that can cause cancer. Carcinogenesis can occur by a wide variety of mechanisms, including infection of cells by viruses containing oncogenes, activation of protooncogenes in the host genome, and mutations of protooncogenes and tumor suppressor genes.

There are a number of viruses known to be involved in human cancer as well as in animal cancer. Of particular interest here are viruses that do not contain oncogenes themselves; these are slow-transforming retroviruses. They induce tumors by integrating into the host genome and affecting neighboring protooncogenes in a variety of ways, including promoter insertion, enhancer insertion, and/or truncation of a protooncogene or tumor suppressor gene. The analysis of sequences at or near the insertion sites led to the identification of a number of new protooncogenes.

With respect to lymphoma and leukemia, murine leukemia retrovirus (MuLV), such as SL3-3 or Akv, is a potent inducer of tumors when inoculated into susceptible newborn mice, or when carried in the germline. A number of sequences have been identified as relevant in the induction of lymphoma and leukemia by analyzing the insertion sites; see Sorensen et al., J. of Virology 74:2161 (2000); Hansen et al., Genome Res. 10(2):237-43 (2000); Sorensen et al., J. Virology 70:4063 (1996); Sorensen et al., J. Virology 67:7118 (1993); Joosten et al., Virology 268:308 (2000); and Li et al., Nature Genetics 23:348 (1999); all of which are expressly incorporated by reference herein.

Lymphomas are a collection of cancers involving the lymphatic system and are generally categorized as Hodgkin's disease and Non-Hodgkin lymphoma. Hodgkin's lymphomas are of B lymphocyte origin. Non-Hodgkin lymphomas are a collection of over 30 different types of cancers including T and B lymphomas. Leukemia is a disease of the blood forming tissues and includes B and T cell lymphocytic leukemias. It is characterized by an abnormal and persistent increase in the number of leukocytes and the amount of bone marrow, with enlargement of the spleen and lymph nodes.

Breast cancer is one of the most significant diseases that affects women. At the current rate, American women have a 1 in 8 risk of developing breast cancer by age 95 (American Cancer Society, 1992). Treatment of breast cancer at later stages is often futile and disfiguring, making early detection a high priority in medical management of the disease.

Accordingly, it is an object of the invention to provide sequences involved in cancer and in particular in oncogenesis.

SUMMARY OF THE INVENTION

In accordance with the objects outlined above, the present invention provides methods for screening for compositions which modulate carcinomas, especially lymphoma and leukemia. Also provided herein are methods of inhibiting proliferation of a cell, preferably a lymphoma cell. Methods of treatment of carcinomas, including diagnosis, are also provided herein.

In one aspect, a method of screening drug candidates comprises providing a cell that expresses a carcinoma associated (CA) gene or fragments thereof. Preferred embodiments of CA genes are genes which are differentially expressed in cancer cells, preferably lymphatic, breast, prostate or epithelial cells, compared to other cells. Preferred embodiments of CA genes used in the methods herein include, but are not limited to the nucleic acids selected from Tables 1-112. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the CA gene.

In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of expression in the presence of the drug candidate.

Also provided herein is a method of screening for a bioactive agent capable of binding to a CA protein (CAP), the method comprising combining the CAP and a candidate bioactive agent, and determining the binding of the candidate agent to the CAP.

Further provided herein is a method for screening for a bioactive agent capable of modulating the activity of a CAP. In one embodiment, the method comprises combining the CAP and a candidate bioactive agent, and determining the effect of the candidate agent on the bioactivity of the CAP.

Also provided is a method of evaluating the effect of a candidate carcinoma drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile of the patient to an expression profile of a healthy individual.

In a further aspect, a method for inhibiting the activity of an CA protein is provided. In one embodiment, the method comprises administering to a patient an inhibitor of a CA protein preferably selected from the group consisting of the sequences outlined in Tables 1-112 or their complements.

A method of neutralizing the effect of a CA protein, preferably a protein encoded by a nucleic acid selected from the group of sequences outlined in Tables 1-112, is also provided. Preferably, the method comprises contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization.

Moreover, provided herein is a biochip comprising a nucleic acid segment which encodes a CA protein, preferably selected from the sequences outlined in Tables 1-112.

Also provided herein is a method for diagnosing or determining the propensity to carcinomas, especially lymphoma or leukemia by sequencing at least one carcinoma or lymphoma gene of an individual. In yet another aspect of the invention, a method is provided for determining carcinoma including lymphoma and leukemia gene copy number in an individual.

Novel sequences are also provided herein. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a number of sequences associated with carcinomas, especially lymphoma, breast cancer or prostate cancer. The relatively tight linkage between clonally-integrated proviruses and protooncogenes forms “provirus tagging”, in which slow-transforming retroviruses that act by an insertion mutation mechanism are used to isolate protooncogenes. In some models, uninfected animals have low cancer rates, and infected animals have high cancer rates. It is known that many of the retroviruses involved do not carry transduced host protooncogenes or pathogenic trans-acting viral genes, and thus the cancer incidence must therefor be a direct consequence of proviral integration effects into host protooncogenes. Since proviral integration is random, rare integrants will “activate” host protooncogenes that provide a selective growth advantage, and these rare events result in new proviruses at clonal stoichiometries in tumors.

The use of oncogenic retroviruses, whose sequences insert into the genome of the host organism resulting in carcinoma, allows the identification of host sequences involved in carcinoma. These sequences may then be used in a number of different ways, including diagnosis, prognosis, screening for modulators (including both agonists and antagonists), antibody generation (for immunotherapy and imaging), etc. However, as will be appreciated by those in the art, oncogenes that are identified in one type of cancer such as lymphoma or leukemia have a strong likelihood of being involved in other types of cancers as well. Thus, while the sequences outlined herein are initially identified as correlated with lymphoma, they can also be found in other types of cancers as well, outlined below.

Accordingly, the present invention provides nucleic acid and protein sequences that are associated with carcinoma, herein termed “carcinoma associated” or “CA” sequences. In a preferred embodiment, the present invention provides nucleic acid and protein sequences that are associated with carcinomas which originate in lymphatic tissue, herein termed “lymphoma associated”, “leukemia associated” or “LA” sequences.

Suitable cancers which can be diagnosed or screened for using the methods of the present invention include cancers classified by site or by histological type. Cancers classified by site include cancer of the oral cavity and pharynx (lip, tongue, salivary gland, floor of mouth, gum and other mouth, nasopharynx, tonsil, oropharynx, hypopharynx, other oral/pharynx); cancers of the digestive system (esophagus; stomach; small intestine; colon and rectum; anus, anal canal, and anorectum; liver; intrahepatic bile duct; gallbladder; other biliary; pancreas; retroperitoneum; peritoneum, omentum, and mesentery; other digestive); cancers of the respiratory system (nasal cavity, middle ear, and sinuses; larynx; lung and bronchus; pleura; trachea, mediastinum, and other respiratory); cancers of the mesothelioma; bones and joints; and soft tissue, including heart; skin cancers, including melanomas and other non-epithelial skin cancers; Kaposi's sarcoma and breast cancer; cancer of the female genital system (cervix uteri; corpus uteri; uterus, nos; ovary; vagina; vulva; and other female genital); cancers of the male genital system (prostate gland; testis; penis; and other male genital); cancers of the urinary system (urinary bladder; kidney and renal pelvis; ureter; and other urinary); cancers of the eye and orbit; cancers of the brain and nervous system (brain; and other nervous system); cancers of the endocrine system (thyroid gland and other endocrine, including thymus); cancers of the lymphomas (hodgkin's disease and non-hodgkin's lymphoma), multiple myeloma, and leukemias (lymphocytic leukemia; myeloid leukemia; monocytic leukemia; and other leukemias).

Other cancers, classified by histological type, that may be associated with the sequences of the invention include, but are not limited to, Neoplasm, malignant; Carcinoma, NOS; Carcinoma, undifferentiated, NOS; Giant and spindle cell carcinoma; Small cell carcinoma, NOS; Papillary carcinoma, NOS; Squamous cell carcinoma, NOS; Lymphoepithelial carcinoma; Basal cell carcinoma, NOS; Pilomatrix carcinoma; Transitional cell carcinoma, NOS; Papillary transitional cell carcinoma; Adenocarcinoma, NOS; Gastrinoma, malignant; Cholangiocarcinoma; Hepatocellular carcinoma, NOS; Combined hepatocellular carcinoma and cholangiocarcinoma; Trabecular adenocarcinoma; Adenoid cystic carcinoma; Adenocarcinoma in adenomatous polyp; Adenocarcinoma, familial polyposis coli; Solid carcinoma, NOS; Carcinoid tumor, malignant; Branchiolo-alveolar adenocarcinoma; Papillary adenocarcinoma, NOS; Chromophobe carcinoma; Acidophil carcinoma; Oxyphilic adenocarcinoma; Basophil carcinoma; Clear cell adenocarcinoma, NOS; Granular cell carcinoma; Follicular adenocarcinoma, NOS; Papillary and follicular adenocarcinoma; Nonencapsulating sclerosing carcinoma; Adrenal cortical carcinoma; Endometroid carcinoma; Skin appendage carcinoma; Apocrine adenocarcinoma; Sebaceous adenocarcinoma; Ceruminous adenocarcinoma; Mucoepidermoid carcinoma; Cystadenocarcinoma, NOS; Papillary cystadenocarcinoma, NOS; Papillary serous cystadenocarcinoma; Mucinous cystadenocarcinoma, NOS; Mucinous adenocarcinoma; Signet ring cell carcinoma; Infiltrating duct carcinoma; Medullary carcinoma, NOS; Lobular carcinoma; Inflammatory carcinoma; Paget's disease, mammary; Acinar cell carcinoma; Adenosquamous carcinoma; Adenocarcinoma w/squamous metaplasia; Thymoma, malignant; Ovarian stromal tumor, malignant; Thecoma, malignant; Granulosa cell tumor, malignant; Androblastoma, malignant; Sertoli cell carcinoma; Leydig cell tumor, malignant; Lipid cell tumor, malignant; Paraganglioma, malignant; Extra-mammary paraganglioma, malignant; Pheochromocytoma; Glomangiosarcoma; Malignant melanoma, NOS; Amelanotic melanoma; Superficial spreading melanoma; Malig melanoma in giant pigmented nevus; Epithelioid cell melanoma; Blue nevus, malignant; Sarcoma, NOS; Fibrosarcoma, NOS; Fibrous histiocytoma, malignant; Myxosarcoma; Liposarcoma, NOS; Leiomyosarcoma, NOS; Rhabdomyosarcoma, NOS; Embryonal rhabdomyosarcoma; Alveolar rhabdomyosarcoma; Stromal sarcoma, NOS; Mixed tumor, malignant, NOS; Mullerian mixed tumor; Nephroblastoma; Hepatoblastoma; Carcinosarcoma, NOS; Mesenchymoma, malignant; Brenner tumor, malignant; Phyllodes tumor, malignant; Synovial sarcoma, NOS; Mesothelioma, malignant; Dysgerminoma; Embryonal carcinoma, NOS; Teratoma, malignant, NOS; Struma ovari, malignant; Choriocarcinoma; Mesonephroma, malignant; Hemangiosarcoma; Hemangioendothelioma, malignant; Kaposi's sarcoma; Hemangiopericytoma, malignant; Lymphangiosarcoma; Osteosarcoma, NOS; Juxtacortical osteosarcoma; Chondrosarcoma, NOS; Chondroblastoma, malignant; Mesenchymal chondrosarcoma; Giant cell tumor of bone; Ewing's sarcoma; Odontogenic tumor, malignant; Ameloblastic odontosarcoma; Ameloblastoma, malignant; Ameloblastic fibrosarcoma; Pinealoma, malignant; Chordoma; Glioma, malignant; Ependymoma, NOS; Astrocytoma, NOS; Protoplasmic astrocytoma; Fibrillary astrocytoma; Astroblastoma; Glioblastoma, NOS; Oligodendroglioma, NOS; Oligodendroblastoma; Primitive neuroectodermal; Cerebellar sarcoma, NOS; Ganglioneuroblastoma; Neuroblastoma, NOS; Retinoblastoma, NOS; Olfactory neurogenic tumor; Meningioma, malignant; Neurofibrosarcoma; Neurilemmoma, malignant; Granular cell tumor, malignant; Malignant lymphoma, NOS; Hodgkin's disease, NOS; Hodgkin's; paragranuloma, NOS; Malignant lymphoma, small lymphocytic; Malignant lymphoma, large cell, diffuse; Malignant lymphoma, follicular, NOS; Mycosis fungoides; Other specified non-Hodgkin's lymphomas; Malignant histiocytosis; Multiple myeloma; Mast cell sarcoma; Immunoproliferative small intestinal disease; Leukemia, NOS; Lymphoid leukemia, NOS; Plasma cell leukemia; Erythroleukemia; Lymphosarcoma cell leukemia; Myeloid leukemia, NOS; Basophilic leukemia; Eosinophilic leukemia; Monocytic leukemia, NOS; Mast cell leukemia; Megakaryoblastic leukemia; Myeloid sarcoma; and Hairy cell leukemia.

In addition, the genes may be involved in other diseases, such as but not limited to diseases associated with aging or neurodegenerative diseases.

Association in this context means that the nucleotide or protein sequences are either differentially expressed, activated, inactivated or altered in carcinomas as compared to normal tissue. As outlined below, CA sequences include those that are up-regulated (i.e. expressed at a higher level), as well as those that are down-regulated (i.e. expressed at a lower level), in carcinomas. CA sequences also include sequences which have been altered (i.e., truncated sequences or sequences with substitutions, deletions or insertions, including point mutations) and show either the same expression profile or an altered profile. In a preferred embodiment, the CA sequences are from humans; however, as will be appreciated by those in the art, CA sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other CA sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc). In some cases, prokaryotic CA sequences may be useful. CA sequences from other organisms may be obtained using the techniques outlined below.

CA sequences can include both nucleic acid and amino acid sequences. In a preferred embodiment, the CA sequences are recombinant nucleic acids. By the term “recombinant nucleic acid” herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid by polymerases and endonucleases, in a form not normally found in nature. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e. using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.

Similarly, a “recombinant protein” is a protein made using recombinant techniques, i.e. through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. For example, an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, preferably constituting at least about 0.5%, more preferably at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. The definition includes the production of an CA protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of an inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as discussed below.

In a preferred embodiment, the CA sequences are nucleic acids. As will be appreciated by those in the art and is more fully outlined below, CA sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; for example, biochips comprising nucleic acid probes to the CA sequences can be generated. In the broadest sense, then, by “nucleic acid” or “oligonucleotide” or grammatical equivalents herein means at least two nucleotides covalently linked together. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, as outlined below (for example in antisense applications or when a candidate agent is a nucleic acid), nucleic acid analogs may be used that have alternate backbones, comprising, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805 (1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Pat. No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Pat. Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, “Carbohydrate Modifications in Antisense Research”, Ed. Y. S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 37:743 (1996)) and non-ribose backbones, including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, “Carbohydrate Modifications in Antisense Research”, Ed. Y. S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several nucleic acid analogs are described in Rawls, C & E News Jun. 2, 1997 page 35. All of these references are hereby expressly incorporated by reference. These modifications of the ribose-phosphate backbone may be done for a variety of reasons, for example to increase the stability and half-life of such molecules in physiological environments for use in anti-sense applications or as probes on a biochip.

As will be appreciated by those in the art, all of these nucleic acid analogs may find use in the present invention. In addition, mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand “Watson” also defines the sequence of the other strand “Crick”; thus the sequences described herein also includes the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid contains any combination of deoxyribo- and ribo-nucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. As used herein, the term “nucleoside” includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, “nucleoside” includes non-naturally occurring analog structures. Thus for example the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

An CA sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the CA sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

The CA sequences of the invention were initially identified as described herein; basically, infection of mice with murine leukemia viruses (MLV) resulted in lymphoma, although many of these sequences will also be involved in other cancers as is generally outlined herein.

The CA sequences outlined herein comprise the insertion sites for the virus. In general, the retrovirus can cause carcinomas in three basic ways: first of all, by inserting upstream of a normally silent host gene and activating it (e.g. promoter insertion); secondly, by truncating a host gene that leads to oncogenesis; or by enhancing the transcription of a neighboring gene. For example, retrovirus enhancers, including SL3-3, are known to act on genes up to approximately 200 kilobases of the insertion site.

In a preferred embodiment, CA sequences are those that are up-regulated in carcinomas; that is, the expression of these genes is higher in carcinoma tissue as compared to normal tissue of the same differentiation stage. “Up-regulation” as used herein means at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably, at least about 200%, with from 300 to at least 1000% being especially preferred.

In a preferred embodiment, CA sequences are those that are down-regulated in carcinomas; that is, the expression of these genes is lower in carcinoma tissue as compared to normal I tissue of the same differentiation stage. “Down-regulation” as used herein means at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably, at least about 200%, with from 300 to at least 1000% being especially preferred.

In a preferred embodiment, CA sequences are those that are altered but show either the same expression profile or an altered profile as compared to normal lymphoid tissue of the same differentiation stage. “Altered CA sequences” as used herein refers to sequences which are truncated, contain insertions or contain point mutations.

CA proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins.

In a preferred embodiment the CA protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, for example, signaling pathways); aberrant expression of such proteins results in unregulated or disregulated cellular processes. For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

An increasingly appreciated concept in characterizing intracellular proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate.

In a preferred embodiment, the CA sequences are transmembrane proteins. Transmembrane proteins are molecules that span the phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors are classified as “seven transmembrane domain” proteins, as they contain 7 membrane spanning regions. Important transmembrane protein receptors include, but are not limited to insulin receptor, insulin_like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL_(—)1 receptor, IL_(—)2 receptor, etc.

Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted.

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. For example, cytokine receptors are characterized by a cluster of cysteines and a WSXWS (W=tryptophan, S=serine, X=any amino acid (SEQ ID NO:1613) motif. Immunoglobulin-like domains are highly conserved. Mucin-like domains may be involved in cell adhesion and leucine-rich repeats participate in protein-protein interactions.

Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell for example via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

CA proteins that are transmembrane are particularly preferred in the present invention as they are good targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, for example through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In a preferred embodiment, the CA proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. CA proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, for example for blood tests.

An CA sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology to the CA sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

As used herein, a nucleic acid is a “CA nucleic acid” if the overall homology of the nucleic acid sequence to one of the nucleic acids of Tables 1-112 is preferably greater than about 75%, more preferably greater than about 80%, even more preferably greater than about 85% and most preferably greater than 90%. In some embodiments the homology will be as high as about 93 to 95 or 98%. In a preferred embodiment, the sequences which are used to determine sequence identity or similarity are selected from those of the nucleic acids of Tables 1-112. In another embodiment, the sequences are naturally occurring allelic variants of the sequences of the nucleic acids of Tables 1-112. In another embodiment, the sequences are sequence variants as further described herein.

Homology in this context means sequence similarity or identity, with identity being preferred. A preferred comparison for homology purposes is to compare the sequence containing sequencing errors to the correct sequence. This homology will be determined using standard techniques known in the art, including, but not limited to, the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, PNAS USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.), the Best Fit sequence program described by Devereux et al., Nucl. Acid Res. 12:387-395 (1984), preferably using the default settings, or by inspection.

One example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng & Doolittle, J. Mol. Evol. 35:351-360 (1987); the method is similar to that described by Higgins & Sharp CABIOS 5:151-153 (1989). Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.

Another example of a useful algorithm is the BLAST algorithm, described in Altschul et al., J. Mol. Biol. 215, 403-410, (1990) and Karlin et al., PNAS USA 90:5873-5787 (1993). A particularly useful BLAST program is the WU-BLAST-2 program which was obtained from Altschul et al., Methods in Enzymology, 266: 460-480 (1996); http://blast.wustl]. WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span=1, overlap fraction 0.125, word threshold (T)=11. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity. A % amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the “longer” sequence in the aligned region. The “longer” sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored).

Thus, “percent (%) nucleic acid sequence identity” is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues of the nucleic acids of Tables 1-112. A preferred method utilizes the BLASTN module of WU-BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.

The alignment may include the introduction of gaps in the sequences to be aligned. In addition, for sequences which contain either more or fewer nucleotides than those of the nucleic acids of Tables 1-112, it is understood that the percentage of homology will be determined based on the number of homologous nucleosides in relation to the total number of nucleosides. Thus, for example, homology of sequences shorter than those of the sequences identified herein and as discussed below, will be determined using the number of nucleosides in the shorter sequence.

In one embodiment, the nucleic acid homology is determined through hybridization studies. Thus, for example, nucleic acids which hybridize under high stringency to the nucleic acids identified in the figures, or their complements, are considered CA sequences. High stringency conditions are known in the art; see for example Maniatis et al., Molecular Cloning: A Laboratory Manual, 2d Edition, 1989, and Short Protocols in Molecular Biology, ed. Ausubel, et al., both of which are hereby incorporated by reference. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, “Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-10° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes (e.g. 10 to 50 nucleotides) and at least about 60° C. for long probes (e.g. greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

In another embodiment, less stringent hybridization conditions are used; for example, moderate or low stringency conditions may be used, as are known in the art; see Maniatis and Ausubel, supra, and Tijssen, supra.

In addition, the CA nucleic acid sequences of the invention are fragments of larger genes, i.e. they are nucleic acid segments. Alternatively, the CA nucleic acid sequences can serve as indicators of oncogene position, for example, the CA sequence may be an enhancer that activates a protooncogene. “Genes” in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, additional sequences of the CA genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Maniatis et al., and Ausubel, et al., supra, hereby expressly incorporated by reference. In general, this is done using PCR, for example, kinetic PCR.

Once the CA nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire CA nucleic acid. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant CA nucleic acid can be further used as a probe to identify and isolate other CA nucleic acids, for example additional coding regions. It can also be used as a “precursor” nucleic acid to make modified or variant CA nucleic acids and proteins.

The CA nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the CA nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, for example for gene therapy and/or antisense applications. Alternatively, the CA nucleic acids that include coding regions of CA proteins can be put into expression vectors for the expression of CA proteins, again either for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to CA nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the CA nucleic acids, i.e. the target sequence (either the target sequence of the sample or to other probe sequences, for example in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by “substantially complementary” herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e. have some sequence in common), or separate.

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By “immobilized” and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can be covalent or non-covalent. By “non-covalent binding” and grammatical equivalents herein is meant one or more of either electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By “covalent binding” and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

The biochip comprises a suitable solid substrate. By “substrate” or “solid support” or other grammatical equivalents herein is meant any material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, Teflon™, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica_based materials including silicon and modified silicon, carbon, metals, inorganic glasses, etc. In general, the substrates allow optical detection and do not appreciably fluoresce.

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, for example, the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, for example using linkers as are known in the art; for example, homo- or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross_linkers, pages 155_(—)200, incorporated herein by reference). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, the oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5′ or 3′ terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In an additional embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Pat. Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affymetrix GeneChip technology.

In addition to the solid-phase technology represented by biochip arrays, gene expression can also be quantified using liquid-phase arrays. One such system is kinetic polymerase chain reaction (PCR). Kinetic PCR allows for the simultaneous amplification and quantification of specific nucleic acid sequences. The specificity is derived from synthetic oligonucleotide primers designed to preferentially adhere to single-stranded nucleic acid sequences bracketing the target site. This pair of oligonucleotide primers form specific, non-covalently bound complexes on each strand of the target sequence. These complexes facilitate in vitro transcription of double-stranded DNA in opposite orientations. Temperature cycling of the reaction mixture creates a continuous cycle of primer binding, transcription, and re-melting of the nucleic acid to individual strands. The result is an exponential increase of the target dsDNA product. This product can be quantified in real time either through the use of an intercalating dye or a sequence specific probe. SYBR® Greene I, is an example of an intercalating dye, that preferentially binds to dsDNA resulting in a concomitant increase in the fluorescent signal. Sequence specific probes, such as used with TaqMan® technology, consist of a fluorochrome and a quenching molecule covalently bound to opposite ends of an oligonucleotide. The probe is designed to selectively bind the target DNA sequence between the two primers. When the DNA strands are synthesized during the PCR reaction, the fluorochrome is cleaved from the probe by the exonuclease activity of the polymerase resulting in signal dequenching. The probe signaling method can be more specific than the intercalating dye method, but in each case, signal strength is proportional to the dsDNA product produced. Each type of quantification method can be used in multi-well liquid phase arrays with each well representing primers and/or probes specific to nucleic acid sequences of interest. When used with messenger RNA preparations of tissues or cell lines, and an array of probe/primer reactions can simultaneously quantify the expression of multiple gene products of interest. See Germer, S., et al., Genome Res. 10:258-266 (2000); Heid, C. A., et al., Genome Res. 6, 986-994 (1996).

In a preferred embodiment, CA nucleic acids encoding CA proteins are used to make a variety of expression vectors to express CA proteins which can then be used in screening assays, as described below. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the CA protein. The term “control sequences” refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. The transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the CA protein; for example, transcriptional and translational regulatory nucleic acid sequences from Bacillus are preferably used to express the CA protein in Bacillus. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, the expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art.

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The CA proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding an CA protein, under the appropriate conditions to induce or cause expression of the CA protein. The conditions appropriate for CA protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect, plant and animal cells, including mammalian cells. Of particular interest are Drosophila melanogaster cells, Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, Sf9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, HeLa cells, THP1 cell line (a macrophage cell line) and human cells and cell lines.

In a preferred embodiment, the CA proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral systems. A preferred expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter. Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3′ to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlytion signals include those derived form SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, CA proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the CA protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others. The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

In one embodiment, CA proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, CA protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

The CA protein may also be made as a fusion protein, using techniques well known in the art. Thus, for example, for the creation of monoclonal antibodies. If the desired epitope is small, the CA protein may be fused to a carrier protein to form an immunogen. Alternatively, the CA protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the CA protein is an CA peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In one embodiment, the CA nucleic acids, proteins and antibodies of the invention are labeled. By “labeled” herein is meant that a compound has at least one element, isotope or chemical compound attached to enable the detection of the compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the CA nucleic acids, proteins and antibodies at any position. For example, the label should be capable of producing, either directly or indirectly, a detectable signal. The detectable moiety may be a radioisotope, such as ³H, ¹⁴C, ³²P, ³⁵S, or ¹²⁵I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

Accordingly, the present invention also provides CA protein sequences. An CA protein of the present invention may be identified in several ways. “Protein” in this sense includes proteins, polypeptides, and peptides. As will be appreciated by those in the art, the nucleic acid sequences of the invention can be used to generate protein sequences. There are a variety of ways to do this, including cloning the entire gene and verifying its frame and amino acid sequence, or by comparing it to known sequences to search for homology to provide a frame, assuming the CA protein has homology to some protein in the database being used. Generally, the nucleic acid sequences are input into a program that will search all three frames for homology. This is done in a preferred embodiment using the following NCBI Advanced BLAST parameters. The program is blastx or blastn. The database is nr. The input data is as “Sequence in FASTA format”. The organism list is “none”. The “expect” is 10; the filter is default. The “descriptions” is 500, the “alignments” is 500, and the “alignment view” is pairwise. The “query Genetic Codes” is standard (1). The matrix is BLOSUM62; gap existence cost is 11, per residue gap cost is 1; and the lambda ratio is 0.85 default. This results in the generation of a putative protein sequence.

Also included within one embodiment of CA proteins are amino acid variants of the naturally occurring sequences, as determined herein. Preferably, the variants are preferably greater than about 75% homologous to the wild-type sequence, more preferably greater than about 80%, even more preferably greater than about 85% and most preferably greater than 90%. In some embodiments the homology will be as high as about 93 to 95 or 98%. As for nucleic acids, homology in this context means sequence similarity or identity, with identity being preferred. This homology will be determined using standard techniques known in the art as are outlined above for the nucleic acid homologies.

CA proteins of the present invention may be shorter or longer than the wild type amino acid sequences. Thus, in a preferred embodiment, included within the definition of CA proteins are portions or fragments of the wild type sequences herein. In addition, as outlined above, the CA nucleic acids of the invention may be used to obtain additional coding regions, and thus additional protein sequence, using techniques known in the art.

In a preferred embodiment, the CA proteins are derivative or variant CA proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative CA peptide will contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the CA peptide.

Also included in an embodiment of CA proteins of the present invention are amino acid sequence variants. These variants fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the CA protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant CA protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the CA protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed CA variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, M13 primer mutagenesis and LAR mutagenesis. Screening of the mutants is done using assays of CA protein activities.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the CA protein are desired, substitutions are generally made in accordance with the following chart:

CHART I Original Residue Exemplary Substitutions Ala Ser Arg Lys Asn Gln, His Asp Glu Cys Ser Gln Asn Glu Asp Gly Pro His Asn, Gln Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp, Phe Val Ile, Leu

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those shown in Chart I. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analogue, although variants also are selected to modify the characteristics of the CA proteins as needed. Alternatively, the variant may be designed such that the biological activity of the CA protein is altered. For example, glycosylation sites may be altered or removed, dominant negative mutations created, etc.

Covalent modifications of CA polypeptides are included within the scope of this invention, for example for use in screening. One type of covalent modification includes reacting targeted amino acid residues of an CA polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of an CA polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking CA polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-CA antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3′-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the a-amino groups of lysine, arginine, and histidine side chains [T. E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the CA polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. “Altering the native glycosylation pattern” is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence CA polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence CA polypeptide.

Addition of glycosylation sites to CA polypeptides may be accomplished by altering the amino acid sequence thereof. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence CA polypeptide (for O-linked glycosylation sites). The CA amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the CA polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the CA polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 Sep. 1987, and in Aplin and Wriston, La. Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the CA polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of CA comprises linking the CA polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

CA polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising an CA polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of an CA polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl-terminus of the CA polypeptide, although internal fusions may also be tolerated in some instances. The presence of such epitope-tagged forms of an CA polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the CA polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of an CA polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

Also included with the definition of CA protein in one embodiment are other CA proteins of the CA family, and CA proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related CA proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the CA nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art.

In addition, as is outlined herein, CA proteins can be made that are longer than those encoded by the nucleic acids of the figures, for example, by the elucidation of additional sequences, the addition of epitope or purification tags, the addition of other fusion sequences, etc.

CA proteins may also be identified as being encoded by CA nucleic acids. Thus, CA proteins are encoded by nucleic acids that will hybridize to the sequences of the sequence listings, or their complements, as outlined herein.

In a preferred embodiment, the invention provides CA antibodies. In a preferred embodiment, when the CA protein is to be used to generate antibodies, for example for immunotherapy, the CA protein should share at least one epitope or determinant with the full length protein. By “epitope” or “determinant” herein is meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller CA protein will be able to bind to the full length protein. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

In one embodiment, the term “antibody” includes antibody fragments, as are known in the art, including Fab, Fab₂, single chain antibodies (Fv for example), chimeric antibodies, etc., either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies.

Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-112, or fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes (“PBLs”) are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.

In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for a protein encoded by a nucleic acid of Tables 1-112, or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific.

In a preferred embodiment, the antibodies to CA are capable of reducing or eliminating the biological function of CA, as is described below. That is, the addition of anti-CA antibodies (either polyclonal or preferably monoclonal) to CA (or cells containing CA) may reduce or eliminate the CA activity. Generally, at least a 25% decrease in activity is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the CA proteins are humanized antibodies. Humanized forms of non_human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′)₂ or other antigen binding subsequences of antibodies) which contain minimal sequence derived from non_human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non_human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non_human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non_human immunoglobulin and all or substantially all of the framework residues (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522_(—)525 (1986); Riechmann et al., Nature, 332:323_(—)329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593 596 (1992)].

Methods for humanizing non_human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non_human. These non_human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co_workers [Jones et al., Nature, 321:522_(—)525 (1986); Riechmann et al., Nature, 332:323_(—)327 (1988); Verhoeyen et al., Science, 239:1534_(—)1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non_human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies [Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(1):86_(—)95 (1991)]. Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10, 779_(—)783 (1992); Lonberg et al., Nature 368 856_(—)859 (1994); Morrison, Nature 368, 812_(—)13 (1994); Fishwild et al., Nature Biotechnology 14, 845_(—)51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65_(—)93 (1995).

By immunotherapy is meant treatment of a carcinoma with an antibody raised against an CA protein. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen.

In a preferred embodiment, oncogenes which encode secreted growth factors may be inhibited by raising antibodies against CA proteins that are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted CA protein.

In another preferred embodiment, the CA protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the CA protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane CA protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the CA protein. The antibody is also an antagonist of the CA protein. Further, the antibody prevents activation of the transmembrane CA protein. In one aspect, when the antibody prevents the binding of other molecules to the CA protein, the antibody prevents growth of the cell. The antibody may also sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, INF-γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity. Thus, carcinomas may be treated by administering to a patient antibodies directed against the transmembrane CA protein.

In another preferred embodiment, the antibody is conjugated to a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the CA protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the CA protein. The therapeutic moiety may inhibit enzymatic activity such as protease or protein kinase activity associated with carcinoma.

In a preferred embodiment, the therapeutic moiety may also be a cytotoxic agent. In this method, targeting the cytotoxic agent to tumor tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with carcinomas, including lymphoma. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against CA proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane CA proteins not only serves to increase the local concentration of therapeutic moiety in the carcinoma of interest, i.e., lymphoma, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

In another preferred embodiment, the CA protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the CA protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

The CA antibodies of the invention specifically bind to CA proteins. By “specifically bind” herein is meant that the antibodies bind to the protein with a binding constant in the range of at least 10⁻⁴-10⁻⁶ M⁻¹, with a preferred range being 10⁻⁷-10⁻⁹ M⁻¹.

In a preferred embodiment, the CA protein is purified or isolated after expression. CA proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the CA protein may be purified using a standard anti-CA antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, R., Protein Purification, Springer-Verlag, N.Y. (1982). The degree of purification necessary will vary depending on the use of the CA protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the CA proteins and nucleic acids are useful in a number of applications.

In one aspect, the expression levels of genes are determined for different cellular states in the carcinoma phenotype; that is, the expression levels of genes in normal tissue and in carcinoma tissue (and in some cases, for varying severities of lymphoma that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a “fingerprint” of the state; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is unique to the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be done or confirmed: does tissue from a particular patient have the gene expression profile of normal or carcinoma tissue.

“Differential expression,” or grammatical equivalents as used herein, refers to both qualitative as well as quantitative differences in the genes temporal and/or cellular expression patterns within and among the cells. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, for example, normal versus carcinoma tissue. That is, genes may be turned on or turned off in a particular state, relative to another state. As is apparent to the skilled artisan, any comparison of two or more states can be made. Such a qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques in one such state or cell type, but is not detectable in both. Alternatively, the determination is quantitative in that expression is increased or decreased; that is, the expression of the gene is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip® expression arrays, Lockhart, Nature Biotechnology, 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, Northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e. upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably, at least about 200%, with from 300 to at least 1000% being especially preferred.

As will be appreciated by those in the art, this may be done by evaluation at either the gene transcript, or the protein level; that is, the amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, for example through the use of antibodies to the CA protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Thus, the proteins corresponding to CA genes, i.e. those identified as being important in a particular carcinoma phenotype, i.e., lymphoma, can be evaluated in a diagnostic test specific for that carcinoma.

In a preferred embodiment, gene expression monitoring is done and a number of genes, i.e. an expression profile, is monitored simultaneously, although multiple protein expression monitoring can be done as well. Similarly, these assays may be done on an individual basis as well.

In this embodiment, the CA nucleic acid probes may be attached to biochips as outlined herein for the detection and quantification of CA sequences in a particular cell. The assays are done as is known in the art. As will be appreciated by those in the art, any number of different CA sequences may be used as probes, with single sequence assays being used in some cases, and a plurality of the sequences described herein being used in other embodiments. In addition, while solid-phase assays are described, any number of solution based assays may be done as well.

In a preferred embodiment, both solid and solution based assays may be used to detect CA sequences that are up-regulated or down-regulated in carcinomas as compared to normal tissue. In instances where the CA sequence has been altered but shows the same expression profile or an altered expression profile, the protein will be detected as outlined herein.

In a preferred embodiment nucleic acids encoding the CA protein are detected. Although DNA or RNA encoding the CA protein may be detected, of particular interest are methods wherein the mRNA encoding a CA protein is detected. The presence of mRNA in a sample is an indication that the CA gene has been transcribed to form the mRNA, and suggests that the protein is expressed. Probes to detect the mRNA can be any nucleotide/deoxynucleotide probe that is complementary to and base pairs with the mRNA and includes but is not limited to oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a CA protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5_bromo_(—)4_chloro_(—)3_indoyl phosphate.

In a preferred embodiment, any of the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The CA proteins, antibodies, nucleic acids, modified proteins and cells containing CA sequences are used in diagnostic assays. This can be done on an individual gene or corresponding polypeptide level, or as sets of assays.

As described and defined herein, CA proteins find use as markers of carcinomas, including lymphomas such as, but not limited to, Hodgkin's and non-Hodgkin lymphoma. Detection of these proteins in putative carcinoma tissue or patients allows for a determination or diagnosis of the type of carcinoma. Numerous methods known to those of ordinary skill in the art find use in detecting carcinomas. In one embodiment, antibodies are used to detect CA proteins. A preferred method separates proteins from a sample or patient by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be any other type of gel including isoelectric focusing gels and the like). Following separation of proteins, the CA protein is detected by immunoblotting with antibodies raised against the CA protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

In another preferred method, antibodies to the CA protein find use in in situ imaging techniques. In this method cells are contacted with from one to many antibodies to the CA protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the CA protein(s) contains a detectable label. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of CA proteins. As will be appreciated by one of ordinary skill in the art, numerous other histological imaging techniques are useful in the invention.

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing carcinomas from blood samples. As previously described, certain CA proteins are secreted/circulating molecules. Blood samples, therefore, are useful as samples to be probed or tested for the presence of secreted CA proteins. Antibodies can be used to detect the CA proteins by any of the previously described immunoassay techniques including ELISA, immunoblotting (Western blotting), immunoprecipitation, BIACORE technology and the like, as will be appreciated by one of ordinary skill in the art.

In a preferred embodiment, in situ hybridization of labeled CA nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including CA tissue and/or normal tissue, are made. In situ hybridization as is known in the art can then be done.

It is understood that when comparing the expression fingerprints between an individual and a standard, the skilled artisan can make a diagnosis as well as a prognosis. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis.

In a preferred embodiment, the CA proteins, antibodies, nucleic acids, modified proteins and cells containing CA sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to carcinoma, especially lymphoma, severity, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, the CA probes are attached to biochips for the detection and quantification of CA sequences in a tissue or patient. The assays proceed as outlined for diagnosis.

In a preferred embodiment, any of the CA sequences as described herein are used in drug screening assays. The CA proteins, antibodies, nucleic acids, modified proteins and cells containing CA sequences are used in drug screening assays or by evaluating the effect of drug candidates on a “gene expression profile” or expression profile of polypeptides. In one embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, Zlokarnik, et al., Science 279, 84-8 (1998), Heid, et al., Genome Res., 6:986-994 (1996).

In a preferred embodiment, the CA proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified CA proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the carcinoma phenotype. As above, this can be done by screening for modulators of gene expression or for modulators of protein activity. Similarly, this may be done on an individual gene or protein level or by evaluating the effect of drug candidates on a “gene expression profile”. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, supra.

Having identified the CA genes herein, a variety of assays to evaluate the effects of agents on gene expression may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as aberrantly regulated in carcinoma, candidate bioactive agents may be screened to modulate the genes response. “Modulation” thus includes both an increase and a decrease in gene expression or activity. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tumor tissue, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4 fold increase in tumor compared to normal tissue, a decrease of about four fold is desired; a 10 fold decrease in tumor compared to normal tissue gives a 10 fold increase in expression for a candidate agent is desired, etc. Alternatively, where the CA sequence has been altered but shows the same expression profile or an altered expression profile, the protein will be detected as outlined herein.

As will be appreciated by those in the art, this may be done by evaluation at either the gene or the protein level; that is, the amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the level of the gene product itself can be monitored, for example through the use of antibodies to the CA protein and standard immunoassays. Alternatively, binding and bioactivity assays with the protein may be done as outlined below.

In a preferred embodiment, gene expression monitoring is done and a number of genes, i.e. an expression profile, is monitored simultaneously, although multiple protein expression monitoring can be done as well.

In this embodiment, the CA nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of CA sequences in a particular cell. The assays are further described below.

Generally, in a preferred embodiment, a candidate bioactive agent is added to the cells prior to analysis. Moreover, screens are provided to identify a candidate bioactive agent which modulates a particular type of carcinoma, modulates CA proteins, binds to a CA protein, or interferes between the binding of a CA protein and an antibody.

The term “candidate bioactive agent” or “drug candidate” or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic or inorganic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactive agents that are capable of directly or indirectly altering either the carcinoma phenotype, binding to and/or modulating the bioactivity of an CA protein, or the expression of a CA sequence, including both nucleic acid sequences and protein sequences. In a particularly preferred embodiment, the candidate agent suppresses a CA phenotype, for example to a normal tissue fingerprint. Similarly, the candidate agent preferably suppresses a severe CA phenotype. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

In one aspect, a candidate agent will neutralize the effect of an CA protein. By “neutralize” is meant that activity of a protein is either inhibited or counter acted against so as to have substantially no effect on a cell.

Candidate agents encompass numerous chemical classes, though typically they are organic or inorganic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.

In a preferred embodiment, the candidate bioactive agents are proteins. By “protein” herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides. The protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures. Thus “amino acid”, or “peptide residue”, as used herein means both naturally occurring and synthetic amino acids. For example, homo-phenylalanine, citrulline and noreleucine are considered amino acids for the purposes of the invention. “Amino acid” also includes imino acid residues such as proline and hydroxyproline. The side chains may be in either the (R) or the (S) configuration. In the preferred embodiment, the amino acids are in the (S) or L-configuration. If non-naturally occurring side chains are used, non-amino acid substituents may be used, for example to prevent or retard in vivo degradations.

In a preferred embodiment, the candidate bioactive agents are naturally occurring proteins or fragments of naturally occurring proteins. Thus, for example, cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of procaryotic and eucaryotic proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred.

In a preferred embodiment, the candidate bioactive agents are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or “biased” random peptides. By “randomized” or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, for example, of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

In a preferred embodiment, the candidate bioactive agents are nucleic acids, as defined above.

As described above generally for proteins, nucleic acid candidate bioactive agents may be naturally occurring nucleic acids, random nucleic acids, or “biased” random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate bioactive agents are organic chemical moieties, a wide variety of which are available in the literature.

In assays for altering the expression profile of one or more CA genes, after the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing the target sequences to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR occurring as needed, as will be appreciated by those in the art. For example, an in vitro transcription with labels covalently attached to the nucleosides is done. Generally, the nucleic acids are labeled with a label as defined herein, with biotin-FITC or PE, cy3 and cy5 being particularly preferred.

In a preferred embodiment, the target sequence is labeled with, for example, a fluorescent, chemiluminescent, chemical, or radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. As known in the art, unbound labeled streptavidin is removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise “sandwich assays”, which include the use of multiple probes, as is generally outlined in U.S. Pat. Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Pat. No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

The reactions outlined herein may be accomplished in a variety of ways, as will be appreciated by those in the art. Components of the reaction may be added simultaneously, or sequentially, in any order, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents may be included in the assays. These include reagents like salts, buffers, neutral proteins, e.g. albumin, detergents, etc which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used, depending on the sample preparation methods and purity of the target. In addition, either solid phase or solution based (i.e., kinetic PCR) assays may be used.

Once the assay is run, the data is analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

In a preferred embodiment, as for the diagnosis and prognosis applications, having identified the differentially expressed gene(s) or mutated gene(s) important in any one state, screens can be run to alter the expression of the genes individually. That is, screening for modulation of regulation of expression of a single gene can be done. Thus, for example, particularly in the case of target genes whose presence or absence is unique between two states, screening is done for modulators of the target gene expression.

In addition, screens can be done for novel genes that are induced in response to a candidate agent. After identifying a candidate agent based upon its ability to suppress a CA expression pattern leading to a normal expression pattern, or modulate a single CA gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated CA tissue reveals genes that are not expressed in normal tissue or CA tissue, but are expressed in agent treated tissue. These agent specific sequences can be identified and used by any of the methods described herein for CA genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated CA tissue sample.

Thus, in one embodiment, a candidate agent is administered to a population of CA cells, that thus has an associated CA expression profile. By “administration” or “contacting” herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e. a peptide) may be put into a viral construct such as a retroviral construct and added to the cell, such that expression of the peptide agent is accomplished; see PCT US97/01019, hereby expressly incorporated by reference.

Once the candidate agent has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, for example, CA tissue may be screened for agents that reduce or suppress the CA phenotype. A change in at least one gene of the expression profile indicates that the agent has an effect on CA activity. By defining such a signature for the CA phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as “CA proteins” or an “CAP”. The CAP may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of Tables 1-112. Preferably, the CAP is a fragment. In another embodiment, the sequences are sequence variants as further described herein.

Preferably, the CAP is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the c-terminus of the fragment is kept as a free acid and the n-terminus is a free amine to aid in coupling, i.e., to cysteine.

In one embodiment the CA proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the CA protein is conjugated to BSA.

In a preferred embodiment, screening is done to alter the biological function of the expression product of the CA gene. Again, having identified the importance of a gene in a particular state, screening for agents that bind and/or modulate the biological activity of the gene product can be run as is more fully outlined below.

In a preferred embodiment, screens are designed to first find candidate agents that can bind to CA proteins, and then these agents may be used in assays that evaluate the ability of the candidate agent to modulate the CAP activity and the carcinoma phenotype. Thus, as will be appreciated by those in the art, there are a number of different assays which may be run; binding assays and activity assays.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more CA nucleic acids are made. In general, this is done as is known in the art. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the CA proteins can be used in the assays.

Thus, in a preferred embodiment, the methods comprise combining a CA protein and a candidate bioactive agent, and determining the binding of the candidate agent to the CA protein. Preferred embodiments utilize the human or mouse CA protein, although other mammalian proteins may also be used, for example for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative CA proteins may be used.

Generally, in a preferred embodiment of the methods herein, the CA protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microliter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, Teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to “sticky” or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the CA protein is bound to the support, and a candidate bioactive agent is added to the assay. Alternatively, the candidate agent is bound to the support and the CA protein is added. Novel binding agents include specific antibodies, non_natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

The determination of the binding of the candidate bioactive agent to the CA protein may be done in a number of ways. In a preferred embodiment, the candidate bioactive agent is labeled, and binding determined directly. For example, this may be done by attaching all or a portion of the CA protein to a solid support, adding a labeled candidate agent (for example a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as is known in the art.

By “labeled” herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g. radioisotope, fluorescers, enzyme, antibodies, particles such as magnetic particles, chemiluminescers, or specific binding molecules, etc. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.

In some embodiments, only one of the components is labeled. For example, the proteins (or proteinaceous candidate agents) may be labeled at tyrosine positions using ¹²⁵I, or with fluorophores. Alternatively, more than one component may be labeled with different labels; using ¹²⁵I for the proteins, for example, and a fluorophor for the candidate agents.

In a preferred embodiment, the binding of the candidate bioactive agent is determined through the use of competitive binding assays. In this embodiment, the competitor is a binding moiety known to bind to the target molecule (i.e. CA protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the bioactive agent and the binding moiety, with the binding moiety displacing the bioactive agent.

In one embodiment, the candidate bioactive agent is labeled. Either the candidate bioactive agent, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at any temperature which facilitates optimal activity, typically between 4 and 40° C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high through put screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the candidate bioactive agent. Displacement of the competitor is an indication that the candidate bioactive agent is binding to the CA protein and thus is capable of binding to, and potentially modulating, the activity of the CA protein. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate bioactive agent is labeled, the presence of the label on the support indicates displacement.

In an alternative embodiment, the candidate bioactive agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the bioactive agent is bound to the CA protein with a higher affinity. Thus, if the candidate bioactive agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the candidate agent is capable of binding to the CA protein.

In a preferred embodiment, the methods comprise differential screening to identity bioactive agents that are capable of modulating the activity of the CA proteins. In this embodiment, the methods comprise combining a CA protein and a competitor in a first sample. A second sample comprises a candidate bioactive agent, a CA protein and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the CA protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the CA protein.

Alternatively, a preferred embodiment utilizes differential screening to identify drug candidates that bind to the native CA protein, but cannot bind to modified CA proteins. The structure of the CA protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect CA bioactivity are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc which may be used to facilitate optimal protein_protein binding and/or reduce non_specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti_microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding.

Screening for agents that modulate the activity of CA proteins may also be done. In a preferred embodiment, methods for screening for a bioactive agent capable of modulating the activity of CA proteins comprise the steps of adding a candidate bioactive agent to a sample of CA proteins, as above, and determining an alteration in the biological activity of CA proteins. “Modulating the activity of an CA protein” includes an increase in activity, a decrease in activity, or a change in the type or kind of activity present. Thus, in this embodiment, the candidate agent should both bind to CA proteins (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods, as are generally outlined above, and in vivo screening of cells for alterations in the presence, distribution, activity or amount of CA proteins.

Thus, in this embodiment, the methods comprise combining a CA sample and a candidate bioactive agent, and evaluating the effect on CA activity. By “CA activity” or grammatical equivalents herein is meant one of the CA protein's biological activities, including, but not limited to, its role in tumorigenesis, including cell division, preferably in lymphatic tissue, cell proliferation, tumor growth and transformation of cells. In one embodiment, CA activity includes activation of or by a protein encoded by a nucleic acid of Tables 1-112. An inhibitor of CA activity is the inhibition of any one or more CA activities.

In a preferred embodiment, the activity of the CA protein is increased; in another preferred embodiment, the activity of the CA protein is decreased. Thus, bioactive agents that are antagonists are preferred in some embodiments, and bioactive agents that are agonists may be preferred in other embodiments.

In a preferred embodiment, the invention provides methods for screening for bioactive agents capable of modulating the activity of a CA protein. The methods comprise adding a candidate bioactive agent, as defined above, to a cell comprising CA proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a CA protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, for example hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

In this way, bioactive agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the CA protein.

In one embodiment, a method of inhibiting carcinoma cancer cell division, is provided. The method comprises administration of a carcinoma cancer inhibitor.

In a preferred embodiment, a method of inhibiting lymphoma carcinoma cell division is provided comprising administration of a lymphoma carcinoma inhibitor.

In another embodiment, a method of inhibiting tumor growth is provided. The method comprises administration of a carcinoma cancer inhibitor. In a particularly preferred embodiment, a method of inhibiting tumor growth in lymphatic tissue is provided comprising administration of a lymphoma inhibitor.

In a further embodiment, methods of treating cells or individuals with cancer are provided. The method comprises administration of a carcinoma cancer inhibitor. Preferably, the carcinoma is a lymphoma carcinoma.

In one embodiment, a carcinoma cancer inhibitor is an antibody as discussed above. In another embodiment, the carcinoma cancer inhibitor is an antisense molecule. Antisense molecules as used herein include antisense or sense oligonucleotides comprising a singe-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for carcinoma cancer molecules. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen, Cancer Res. 48:2659, (1988) and van der Krol et al., BioTechniques 6:958, (1988).

Antisense molecules may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host, as previously described. The agents may be administered in a variety of ways, orally, parenterally e.g., subcutaneously, intraperitoneally, intravascularly, etc. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1_(—)100% wgt/vol. The agents may be administered alone or in combination with other treatments, i.e., radiation.

The pharmaceutical compositions can be prepared in various forms, such as granules, tablets, pills, suppositories, capsules, suspensions, salves, lotions and the like. Pharmaceutical grade organic or inorganic carriers and/or diluents suitable for oral and topical use can be used to make up compositions containing the therapeutically_active compounds. Diluents known to the art include aqueous media, vegetable and animal oils and fats. Stabilizing agents, wetting and emulsifying agents, salts for varying the osmotic pressure or buffers for securing an adequate pH value, and skin penetration enhancers can be used as auxiliary agents.

Without being bound by theory, it appears that the various CA sequences are important in carcinomas. Accordingly, disorders based on mutant or variant CA genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant CA genes comprising determining all or part of the sequence of at least one endogenous CA genes in a cell. As will be appreciated by those in the art, this may be done using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the CA genotype of an individual comprising determining all or part of the sequence of at least one CA gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced CA gene to a known CA gene, i.e., a wild-type gene. As will be appreciated by those in the art, alterations in the sequence of some oncogenes can be an indication of either the presence of the disease, or propensity to develop the disease, or prognosis evaluations.

The sequence of all or part of the CA gene can then be compared to the sequence of a known CA gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the CA gene of the patient and the known CA gene is indicative of a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the CA genes are used as probes to determine the number of copies of the CA gene in the genome. For example, some cancers exhibit chromosomal deletions or insertions, resulting in an alteration in the copy number of a gene.

In another preferred embodiment CA genes are used as probes to determine the chromosomal location of the CA genes. Information such as chromosomal location finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in CA gene loci.

Thus, in one embodiment, methods of modulating CA in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-CA antibody that reduces or eliminates the biological activity of an endogenous CA protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a CA protein. As will be appreciated by those in the art, this may be accomplished in any number of ways. In a preferred embodiment, for example when the CA sequence is down-regulated in carcinoma, the activity of the CA gene is increased by increasing the amount of CA in the cell, for example by overexpressing the endogenous CA or by administering a gene encoding the CA sequence, using known gene-therapy techniques, for example. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), for example as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, for example when the CA sequence is up-regulated in carcinoma, the activity of the endogenous CA gene is decreased, for example by the administration of a CA antisense nucleic acid.

In one embodiment, the CA proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to CA proteins, which are useful as described herein. Similarly, the CA proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify CA antibodies. In a preferred embodiment, the antibodies are generated to epitopes unique to a CA protein; that is, the antibodies show little or no cross-reactivity to other proteins. These antibodies find use in a number of applications. For example, the CA antibodies may be coupled to standard affinity chromatography columns and used to purify CA proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the CA protein.

In one embodiment, a therapeutically effective dose of a CA or modulator thereof is administered to a patient. By “therapeutically effective dose” herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for CA degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.

A “patient” for the purposes of the present invention includes both humans and other animals, particularly mammals, and organisms. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, and in the most preferred embodiment the patient is human.

The administration of the CA proteins and modulators of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the CA proteins and modulators may be directly applied as a solution or spray.

The pharmaceutical compositions of the present invention comprise a CA protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. “Pharmaceutically acceptable acid addition salt” refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p_toluenesulfonic acid, salicylic acid and the like. “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non_toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. Additives are well known in the art, and are used in a variety of formulations.

In a preferred embodiment, CA proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, CA genes (including both the full-length sequence, partial sequences, or regulatory sequences of the CA coding regions) can be administered in gene therapy applications, as is known in the art. These CA genes can include antisense applications, either as gene therapy (i.e. for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

In a preferred embodiment, CA genes are administered as DNA vaccines, either single genes or combinations of CA genes. Naked DNA vaccines are generally known in the art. Brower, Nature Biotechnology, 16:1304-1305 (1998).

In one embodiment, CA genes of the present invention are used as DNA vaccines. Methods for the use of genes as DNA vaccines are well known to one of ordinary skill in the art, and include placing a CA gene or portion of a CA gene under the control of a promoter for expression in a patient with carcinoma. The CA gene used for DNA vaccines can encode full-length CA proteins, but more preferably encodes portions of the CA proteins including peptides derived from the CA protein. In a preferred embodiment a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a CA gene. Similarly, it is possible to immunize a patient with a plurality of CA genes or portions thereof as defined herein. Without being bound by theory, expression of the polypeptide encoded by the DNA vaccine, cytotoxic T-cells, helper T-cells and antibodies are induced which recognize and destroy or eliminate cells expressing CA proteins.

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the CA polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are known to those of ordinary skill in the art and find use in the invention.

In another preferred embodiment CA genes find use in generating animal models of carcinomas, particularly lymphoma carcinomas. As is appreciated by one of ordinary skill in the art, when the CA gene identified is repressed or diminished in CA tissue, gene therapy technology wherein antisense RNA directed to the CA gene will also diminish or repress expression of the gene. An animal generated as such serves as an animal model of CA that finds use in screening bioactive drug candidates. Similarly, gene knockout technology, for example as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence of the CA protein. When desired, tissue-specific expression or knockout of the CA protein may be necessary.

It is also possible that the CA protein is overexpressed in carcinoma. As such, transgenic animals can be generated that overexpress the CA protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of CA and are additionally useful in screening for bioactive molecules to treat carcinoma.

The CA nucleic acid sequences of the invention are depicted in Tables 1-112. The sequences in Tables 1 (SEQ ID NOS:1-460) and 2 (SEQ ID NOS:461-952) depict mouse tags, i.e. the genomic insertion sites. The sequences in Tables 3-112 (SEQ ID NOS:953-1612) include genomic sequence, mRNA and coding sequences for both mouse and human. N/A indicates a gene that has been identified, but for which there has not been a name ascribed. The different sequences of Tables 3-112 are assigned the following SEQ ID Nos:

TABLE 3 (mouse gene: Fscn1; human gene SNL) Mouse genomic sequence (SEQ ID NO: 953) Mouse mRNA sequence (SEQ ID NO: 954) Mouse coding sequence (SEQ ID NO: 955) Human genomic sequence (SEQ ID NO: 956) Human mRNA sequence (SEQ ID NO: 957) Human coding sequence (SEQ ID NO: 958)

TABLE 4 (mouse gene Map3k6; human gene MAP3K6) Mouse genomic sequence (SEQ ID NO: 959) Mouse mRNA sequence (SEQ ID NO: 960) Mouse coding sequence (SEQ ID NO: 961) Human genomic sequece (SEQ ID NO: 962) Human mRNA sequence (SEQ ID NO: 963) Human coding sequence (SEQ ID NO: 964)

TABLE 5 (mouse gene Fosb; human gene FOSB) Mouse genomic sequence (SEQ ID NO: 965) Mouse mRNA sequence (SEQ ID NO: 966) Mouse coding sequence (SEQ ID NO: 967) Human genomic sequence (SEQ ID NO: 968) Human mRNA sequence (SEQ ID NO: 969) Human coding sequence (SEQ ID NO: 970)

TABLE 6 (mouse gene cmkbr7; human gene: CCR7) Mouse genomic sequence (SEQ ID NO: 971) Mouse mRNA sequence (SEQ ID NO: 972) Mouse coding sequence (SEQ ID NO: 973) Human genomic sequence (SEQ ID NO: 974) Human mRNA sequence (SEQ ID NO: 975) Human coding seguence (SEQ ID NO: 976)

TABLE 7 (mouse gene: Ccnd1; human gene: CCND1) Mouse genomic sequence (SEQ ID NO: 977) Mouse mRNA sequence (SEQ ID NO: 978) Mouse coding sequence (SEQ ID NO: 979) Human genomic sequence (SEQ ID NO: 980) Human mRNA sequence (SEQ ID NO: 981) Human coding sequence (SEQ ID NO: 982)

TABLE 8 (mouse gene: Ccnd3; human gene: CCND3) Mouse genomic sequence (SEQ ID NO: 983) Mouse mRNA sequence (SEQ ID NO: 984) Mouse coding sequence (SEQ ID NO: 985) Human genomic sequence (SEQ ID NO: 986) Human mRNA sequence (SEQ ID NO: 987) Human coding sequence (SEQ ID NO: 988)

TABLE 9 (mouse gene: Wnt3; human gene: WNT3) Mouse genomic sequence (SEQ ID NO: 989) Mouse mRNA sequence (SEQ ID NO: 990) Mouse coding sequence (SEQ ID NO: 991) Human genomic sequence (SEQ ID NO: 992) Human mRNA sequence (SEQ ID NO: 993) Human coding sequence (SEQ ID NO: 994)

TABLE 10 (mouse gene: Baff; human gene: BATF) Mouse genomic sequence (SEQ ID NO: 995) Mouse mRNA sequence (SEQ ID NO: 996) Mouse coding sequence (SEQ ID NO: 997) Human genomic sequence (SEQ ID NO: 998) Human mRNA sequence (SEQ ID NO: 999) Human coding sequence (SEQ ID NO: 1000)

TABLE 11 (mouse gene: Irf4; human gene: IRF4) Mouse genomic sequence (SEQ ID NO: 1001) Mouse mRNA sequence (SEQ ID NO: 1002) Mouse coding sequence (SEQ ID NO: 1003) Human genomic sequence (SEQ ID NO: 1004) Human mRNA sequence (SEQ ID NO: 1005) Human coding sequence (SEQ ID NO: 1006)

TABLE 12 (mouse gene: Notch1; human gene: NOTCH1) Mouse qenomic sequence (SEQ ID NO: 1007) Mouse mRNA sequence (SEQ ID NO: 1008) Mouse coding sequence (SEQ ID NO: 1009) Human genomic sequence (SEQ ID NO: 1010) Human mRNA sequence (SEQ ID NO: 1011) Human coding sequence (SEQ ID NO: 1012)

TABLE 13 (mouse gene: Myc; human gene MYC) Mouse genomic sequence (SEQ ID NO: 1013) Mouse mRNA sequence (SEQ ID NO: 1014) Mouse coding sequence (SEQ ID NO: 1015) Human genomic sequence (SEQ ID NO: 1016) Human mRNA sequence (SEQ ID NO: 1017) Human codinq sequence (SEQ ID NO: 1018)

TABLE 14 (mouse gene Bach2; human gene BACH2) Mouse genomic sequence (SEQ ID NO: 1019) Mouse mRNA sequence (SEQ ID NO: 1020) Mouse coding sequence (SEQ ID NO: 1021) Human genomic sequence (SEQ ID NO: 1022) Human mRNA sequence (SEQ ID NO: 1023) Human coding sequence (SEQ ID NO: 1024)

TABLE 15 (mouse gene Wnt1; human gene WNT1) Mouse genomic sequence (SEQ ID NO: 1025) Mouse mRNA sequence (SEQ ID NO: 1026) Mouse coding sequence (SEQ ID NO: 1027) Human genomic sequence (SEQ ID NO: 1028) Human mRNA sequence (SEQ ID NO: 1029) Human coding sequence (SEQ ID NO: 1030)

TABLE 16 (mouse gene Rasgrp1: human gene: RASGRP1) Mouse genomic sequence (SEQ ID NO: 1031) Mouse mRNA sequence (SEQ ID NO: 1032) Mouse coding sequence (SEQ ID NO: 1033) Human genomic sequence (SEQ ID NO: 1034) Human mRNA sequence (SEQ ID NO: 1035) Human coding sequence (SEQ ID NO: 1036)

TABLE 17 (mouse gene: Nmyc1; human gene: MYCN) Mouse genomic sequence (SEQ ID NO: 1037) Mouse mRNA sequence (SEQ ID NO: 1038) Mouse coding sequence (SEQ ID NO: 1039) Human genomic sequence (SEQ ID NO: 1040) Human mRNA sequence (SEQ ID NO: 1041) Human coding sequence (SEQ ID NO: 1042)

TABLE 18 (mouse gene: Myb; human gene: MYB) Mouse genomic sequence (SEQ ID NO: 1043) Mouse mRNA sequence (SEQ ID NO: 1044) Mouse coding sequence (SEQ ID NO: 1045) Human genomic sequence (SEQ ID NO: 1046) Human mRNA sequence (SEQ ID NO: 1047) Human coding sequence (SEQ ID NO: 1048)

TABLE 19 (mouse gene: Sox4; human gene: SOX4) Mouse genomic sequence (SEQ ID NO: 1049) Mouse mRNA sequence (SEQ ID NO: 1050) Mouse coding sequence (SEQ ID NO: 1051) Human genomic sequence (SEQ ID NO: 1052) Human mRNA sequence (SEQ ID NO: 1053) Human coding seauence (SEQ ID NO: 1054)

TABLE 20 (mouse gene: Tcof1; human gene: TCOF1) Mouse genomic sequence (SEQ ID NO: 1055) Mouse mRNA sequence (SEQ ID NO: 1056) Mouse coding sequence (SEQ ID NO: 1057) Human genomic sequence (SEQ ID NO: 1058) Human mRNA sequence (SEQ ID NO: 1059) Human coding sequence (SEQ ID NO: 1060)

TABLE 21 (mouse gene: Pim1; human gene: PIM1) Mouse genomic sequence (SEQ ID NO: 1061) Mouse mRNA sequence (SEQ ID NO: 1062) Mouse coding sequence (SEQ ID NO: 1063) Human genomic sequence (SEQ ID NO: 1064) Human mRNA sequence (SEQ ID NO: 1065) Human coding sequence (SEQ ID NO: 1066)

TABLE 22 (mouse gene: Wnt3a; human gene: WNT3A) Mouse genomic sequence (SEQ ID NO: 1067) Mouse mRNA sequence (SEQ ID NO: 1068) Mouse coding sequence (SEQ ID NO: 1069) Human genomic sequence (SEQ ID NO: 1070) Human mRNA sequence (SEQ ID NO: 1071) Human coding sequence (SEQ ID NO: 1072)

TABLE 23 (mouse gene: Ly6e; human gene LY6E) Mouse genomic sequence (SEQ ID NO: 1073) Mouse mRNA sequence (SEQ ID NO: 1074) Mouse coding sequence (SEQ ID NO: 1075) Human genomic sequence (SEQ ID NO: 1076) Human mRNA sequence (SEQ ID NO: 1077) Human coding sequence (SEQ ID NO: 1078)

TABLE 24 (mouse gene: Rasa2; human gene RASA2) Mouse genomic sequence (SEQ ID NO: 1079) Mouse mRNA sequence (SEQ ID NO: 1080) Mouse coding sequence (SEQ ID NO: 1081) Human genomic sequence (SEQ ID NO: 1082) Human mRNA sequence (SEQ ID NO: 1083) Human coding sequence (SEQ ID NO: 1084)

TABLE 25 (mouse gene: Gata1: human gene GATA1) Mouse genomic sequence (SEQ ID NO: 1085) Mouse mRNA sequence (SEQ ID NO: 1086) Mouse coding sequence (SEQ ID NO: 1087) Human genomic sequence (SEQ ID NO: 1088) Human mRNA sequence (SEQ ID NO: 1089) Human coding sequence (SEQ ID NO: 1090)

TABLE 26 (mouse gene: Fkbp5; human gene FKBP5) Mouse genomic sequence (SEQ ID NO: 1091) Mouse mRNA sequence (SEQ ID NO: 1092) Mouse coding sequence (SEQ ID NO: 1093) Human genomic sequence (SEQ ID NO: 1094) Human mRNA sequence (SEQ ID NO: 1095) Human coding sequence (SEQ ID NO: 1096)

TABLE 27 (mouse gene: Rel; human gene REL) Mouse genomic sequence (SEQ ID NO: 1097) Mouse mRNA sequence (SEQ ID NO: 1098) Mouse coding sequence (SEQ ID NO: 1099) Human genomic sequence (SEQ ID NO: 1100) Human mRNA sequence (SEQ ID NO: 1101) Human coding sequence (SEQ ID NO: 1102)

TABLE 28 (mouse gene: Icsbp; human gene ICSBP1) Mouse genomic sequence (SEQ ID NO: 1103) Mouse mRNA sequence (SEQ ID NO: 1104) Mouse coding sequence (SEQ ID NO: 1105) Human genomic sequence (SEQ ID NO: 1106) Human mRNA sequence (SEQ ID NO: 1107) Human coding sequence (SEQ ID NO: 1108)

TABLE 29 (mouse gene: Bmi1; human gene BMI1) Mouse genomic sequence (SEQ ID NO: 1109) Mouse mRNA sequence (SEQ ID NO: 1110) Mouse coding sequence (SEQ ID NO: 1111) Human genomic sequence (SEQ ID NO: 1112) Human mRNA sequence (SEQ ID NO: 1113) Human coding sequence (SEQ ID NO: 1114)

TABLE 30 (mouse gene: Runx1; human gene RUNX1) Mouse genomic sequence (SEQ ID NO: 1115) Mouse mRNA sequence (SEQ ID NO: 1116) Mouse coding sequence (SEQ ID NO: 1117) Human genomic sequence (SEQ ID NO: 1118) Human mRNA sequence (SEQ ID NO: 1119) Human coding sequence (SEQ ID NO: 1120)

TABLE 31 (mouse gene: Il2ra; human gene IL2RA) Mouse genomic sequence (SEQ ID NO: 1121) Mouse mRNA sequence (SEQ ID NO: 1122) Mouse coding sequence (SEQ ID NO: 1123) Human genomic sequence (SEQ ID NO: 1124) Human mRNA sequence (SEQ ID NO: 1125) Human coding sequence (SEQ ID NO: 1126)

TABLE 32 (mouse gene: Nfkb1; human gene NFKB1) Mouse genomic sequence (SEQ ID NO: 1127) Mouse mRNA sequence (SEQ ID NO: 1128) Mouse coding sequence (SEQ ID NO: 1129) Human genomic sequence (SEQ ID NO: 1130) Human mRNA sequence (SEQ ID NO: 1131) Human coding sequence (SEQ ID NO: 1132)

TABLE 33 (mouse gene: Fyn; human gene FYN) Mouse genomic sequence (SEQ ID NO: 1133) Mouse mRNA sequence (SEQ ID NO: 1134) Mouse coding sequence (SEQ ID NO: 1135) Human genomic sequence (SEQ ID NO: 1136) Human mRNA sequence (SEQ ID NO: 1137) Human coding sequence (SEQ ID NO: 1138)

TABLE 34 (mouse gene: Nfkbil1; human gene NFKBIL1) Mouse genomic sequence (SEQ ID NO: 1139) Mouse mRNA sequence (SEQ ID NO: 1140) Mouse coding sequence (SEQ ID NO: 1141) Human genomic sequence (SEQ ID NO: 1142) Human mRNA sequence (SEQ ID NO: 1143) Human coding sequence (SEQ ID NO: 1144)

TABLE 35 (mouse gene: Flt3; human gene FLT3) Mouse genomic sequence (SEQ ID NO: 1145) Mouse mRNA sequence (SEQ ID NO: 1146) Mouse coding sequence (SEQ ID NO: 1147) Human genomic sequence (SEQ ID NO: 1148) Human mRNA sequence (SEQ ID NO: 1149) Human coding sequence (SEQ ID NO: 1150)

TABLE 36 (mouse gene: Dntt; human gene DNTT) Mouse genomic sequence (SEQ ID NO: 1151) Mouse mRNA sequence (SEQ ID NO: 1152) Mouse coding sequence (SEQ ID NO: 1153) Human genomic sequence (SEQ ID NO: 1154) Human mRNA sequence (SEQ ID NO: 1155) Human coding sequence (SEQ ID NO: 1156)

TABLE 37 (mouse gene: Znfn1a1; human gene ZNFN1A1) Mouse genomic sequence (SEQ ID NO: 1157) Mouse mRNA sequence (SEQ ID NO: 1158) Mouse coding sequence (SEQ ID NO: 1159) Human genomic sequence (SEQ ID NO: 1160) Human mRNA sequence (SEQ ID NO: 1161) Human coding sequence (SEQ ID NO: 1162)

TABLE 38 (mouse gene: Tbx21; human gene TBX21) Mouse genomic sequence (SEQ ID NO: 1163) Mouse mRNA sequence (SEQ ID NO: 1164) Mouse coding sequence (SEQ ID NO: 1165) Human genomic sequence (SEQ ID NO: 1166) Human mRNA sequence (SEQ ID NO: 1167) Human coding sequence (SEQ ID NO: 1168)

TABLE 39 (mouse gene: Stat5b; human gene STAT5B) Mouse genomic sequence (SEQ ID NO: 1169) Mouse mRNA sequence (SEQ ID NO: 1170) Mouse coding sequence (SEQ ID NO: 1171) Human genomic sequence (SEQ ID NO: 1172) Human mRNA sequence (SEQ ID NO: 1173) Human coding sequence (SEQ ID NO: 1174)

TABLE 40 (mouse gene: Sema4d; human gene SEMA4D) Mouse genomic sequence (SEQ ID NO: 1175) Mouse mRNA sequence (SEQ ID NO: 1176) Mouse coding sequence (SEQ ID NO 1177) Human genomic sequence (SEQ ID NO 1178) Human mRNA sequence (SEQ ID NO: 1179) Human coding sequence (SEQ ID NO: 1180)

TABLE 41 (mouse gene: Mdm2; human gene MDM2) Mouse genomic sequence (SEQ ID NO: 1181) Mouse mRNA sequence (SEQ ID NO: 1182) Mouse coding sequence (SEQ ID NO: 1183) Human genomic sequence (SEQ ID NO: 1184) Human mRNA sequence (SEQ ID NO: 1185) Human coding sequence (SEQ ID NO: 1186)

TABLE 42 (mouse gene: Prlr; human gene PRLR) Mouse genomic sequence (SEQ ID NO: 1187) Mouse mRNA sequence (SEQ ID NO: 1188) Mouse coding sequence (SEQ ID NO: 1189) Human genomic sequence (SEQ ID NO: 1190) Human mRNA sequence (SEQ ID NO: 1191) Human coding sequence (SEQ ID NO: 1192)

TABLE 43 (mouse gene: Top1; human gene TOP1) Mouse genomic sequence (SEQ ID NO: 1193) Mouse mRNA sequence (SEQ ID NO: 1194) Mouse coding sequence (SEQ ID NO: 1195) Human genomic sequence (SEQ ID NO: 1196) Human mRNA sequence (SEQ ID NO: 1197) Human coding sequence (SEQ ID NO: 1198)

TABLE 44 (mouse gene: Dusp10; human gene DUSP10) Mouse genomic sequence (SEQ ID NO: 1199) Mouse mRNA sequence (SEQ ID NO: 1200) Mouse coding sequence (SEQ ID NO: 1201) Human genomic sequence (SEQ ID NO: 1202) Human mRNA sequence (SEQ ID NO: 1203) Human coding sequence (SEQ ID NO: 1204)

TABLE 45 (mouse gene: Fli1; human gene FLI1) Mouse genomic sequence (SEQ ID NO: 1205) Mouse mRNA sequence (SEQ ID NO: 1206) Mouse coding sequence (SEQ ID NO: 1207) Human genomic sequence (SEQ ID NO: 1208) Human mRNA sequence (SEQ ID NO: 1209) Human coding sequence (SEQ ID NO: 1210)

TABLE 46 (mouse gene: Tk2; human gene TK2) Mouse genomic sequence (SEQ ID NO: 1211) Mouse mRNA sequence (SEQ ID NO: 1212) Mouse coding sequence (SEQ ID NO: 1213) Human genomic sequence (SEQ ID NO: 1214) Human mRNA sequence (SEQ ID NO: 1215) Human coding sequence (SEQ ID NO: 1216)

TABLE 47 (mouse gene: Nupr1) Mouse genomic sequence (SEQ ID NO: 1217) Mouse mRNA sequence (SEQ ID NO: 1218) Mouse coding sequence (SEQ ID NO: 1219) Human genomic sequence (SEQ ID NO: 1220) Human mRNA sequence (SEQ ID NO: 1221) Human coding sequence (SEQ ID NO: 1222)

TABLE 48 (mouse gene: Zfhx1b; human gene ZFHX1B) Mouse genomic sequence (SEQ ID NO: 1223) Mouse mRNA sequence (SEQ ID NO: 1224) Mouse coding sequence (SEQ ID NO: 1225) Human genomic sequence (SEQ ID NO: 1226) Human mRNA sequence (SEQ ID NO: 1227) Human coding sequence (SEQ ID NO: 1228)

TABLE 49 (mouse gene: Vdac1; human gene VDAC1) Mouse genomic sequence (SEQ ID NO: 1229) Mouse mRNA sequence (SEQ ID NO: 1230) Mouse coding sequence (SEQ ID NO: 1231) Human genomic sequence (SEQ ID NO: 1232) Human mRNA sequence (SEQ ID NO: 1233) Human coding sequence (SEQ ID NO: 1234)

TABLE 50 (mouse gene: Nfatc1; human gene NFATC1) Mouse genomic sequence (SEQ ID NO: 1235) Mouse mRNA sequence (SEQ ID NO: 1236) Mouse coding sequence (SEQ ID NO: 1237) Human genomic sequence (SEQ ID NO: 1238) Human mRNA sequence (SEQ ID NO: 1239) Human coding sequence (SEQ ID NO: 1240)

TABLE 51 (mouse gene: Syk; human gene SYK) Mouse genomic sequence (SEQ ID NO: 1241) Mouse mRNA sequence (SEQ ID NO: 1242) Mouse coding sequence (SEQ ID NO: 1243) Human genomic sequence (SEQ ID NO: 1244) Human mRNA sequence (SEQ ID NO: 1245) Human coding sequence (SEQ ID NO: 1246)

TABLE 52 (mouse gene: Gnb1; human gene GNB1) Mouse genomic sequence (SEQ ID NO: 1247) Mouse mRNA sequence (SEQ ID NO: 1248) Mouse coding sequence (SEQ ID NO: 1249) Human genomic sequence (SEQ ID NO: 1250) Human mRNA sequence (SEQ ID NO: 1251) Human coding sequence (SEQ ID NO: 1252).

TABLE 53 (mouse gene: Ccnd2; human gene CCND2) Mouse genomic sequence (SEQ ID NO: 1253) Mouse mRNA sequence (SEQ ID NO: 1254) Mouse coding sequence (SEQ ID NO: 1255) Human genomic sequence (SEQ ID NO: 1256) Human mRNA sequence (SEQ ID NO: 1257) Human coding sequence (SEQ ID NO: 1258)

TABLE 54 (mouse gene Tnfrsf6; human gene TNFRSF6) Mouse genomic sequence (SEQ ID NO: 1259) Mouse mRNA sequence (SEQ ID NO: 1260) Mouse coding sequence (SEQ ID NO: 1261) Human genomic sequence (SEQ ID NO: 1262) Human mRNA sequence (SEQ ID NO: 1263) Human coding sequence (SEQ ID NO: 1264)

TABLE 55 (mouse gene Irf2; human gene IRF2) Mouse genomic sequence (SEQ ID NO: 1265) Mouse mRNA sequence (SEQ ID NO: 1266) Mouse coding sequence (SEQ ID NO: 1267) Human genomic sequence (SEQ ID NO: 1268) Human mRNA sequence (SEQ ID NO: 1269) Human coding sequence (SEQ ID NO: 1270)

TABLE 56 (mouse gene Morf; human gene: MORF) Mouse genomic sequence (SEQ ID NO: 1271) Mouse mRNA sequence (SEQ ID NO: 1272) Mouse coding sequence (SEQ ID NO: 1273) Human genomic sequence (SEQ ID NO: 1274) Human mRNA sequence (SEQ ID NO: 1275) Human coding sequence (SEQ ID NO: 1276)

TABLE 57 (mouse gene: Runx3; human gene: RUNX3) Mouse genomic sequence (SEQ ID NO: 1277) Mouse mRNA sequence (SEQ ID NO: 1278) Mouse coding sequence (SEQ ID NO: 1279) Human genomic sequence (SEQ ID NO: 1280) Human mRNA sequence (SEQ ID NO: 1281) Human coding sequence (SEQ ID NO: 1282)

TABLE 58 (mouse gene: Bcl11b; human gene: BCL11B) Mouse genomic sequence (SEQ ID NO: 1283) Mouse mRNA sequence (SEQ ID NO: 1284) Mouse coding sequence (SEQ ID NO: 1285) Human genomic sequence (SEQ ID NO: 1286) Human mRNA sequence (SEQ ID NO: 1287) Human coding sequence (SEQ ID NO: 1288)

TABLE 59 (mouse gene: Arhgef1; human gene: ARHGEF1) Mouse genomic sequence (SEQ ID NO: 1289) Mouse mRNA sequence (SEQ ID NO: 1290) Mouse coding sequence (SEQ ID NO: 1291) Human genomic sequence (SEQ ID NO: 1292) Human mRNA sequence (SEQ ID NO: 1293) Human coding sequence (SEQ ID NO: 1294)

TABLE 60 (mouse gene: Ptprk; human gene: PTPRK) Mouse genomic sequence (SEQ ID NO: 1295) Mouse mRNA sequence (SEQ ID NO: 1296) Mouse coding sequence (SEQ ID NO: 1297) Human genomic sequence (SEQ ID NO: 1298) Human mRNA sequence (SEQ ID NO: 1299) Human coding sequence (SEQ ID NO: 1300)

TABLE 61 (mouse gene: Mcmd5; human gene: MCM5) Mouse genomic sequence (SEQ ID NO: 1301) Mouse mRNA sequence (SEQ ID NO: 1302) Mouse coding sequence (SEQ ID NO: 1303) Human genomic sequence (SEQ ID NO: 1304) Human mRNA sequence (SEQ ID NO: 1305) Human coding sequence (SEQ ID NO: 1306)

TABLE 62 (mouse gene: Matn4; human gene: MATN4) Mouse genomic sequence (SEQ ID NO: 1307) Mouse mRNA sequence (SEQ ID NO: 1308) Mouse coding sequence (SEQ ID NO: 1309) Human genomic sequence (SEQ ID NO: 1310) Human mRNA sequence (SEQ ID NO: 1311) Human coding sequence (SEQ ID NO: 1312)

TABLE 63 (mouse gene: Tnfsf11; human gene TNFSF11) Mouse genomic sequence (SEQ ID NO: 1313) Mouse mRNA sequence (SEQ ID NO: 1314) Mouse coding sequence (SEQ ID NO: 1315) Human genomic sequence (SEQ ID NO: 1316) Human mRNA sequence (SEQ ID NO: 1317) Human coding sequence (SEQ ID NO: 1318)

TABLE 64 (mouse gene: Itk; human gene ITK) Mouse genomic sequence (SEQ ID NO: 1319) Mouse mRNA sequence (SEQ ID NO: 1320) Mouse coding sequence (SEQ ID NO: 1321) Human genomic sequence (SEQ ID NO: 1322) Human mRNA sequence (SEQ ID NO: 1323) Human coding sequence (SEQ ID NO: 1324)

TABLE 65 (mouse gene: Fish; human gene: N/A) Mouse genomic sequence (SEQ ID NO: 1325) Mouse mRNA sequence (SEQ ID NO: 1326) Mouse coding sequence (SEQ ID NO: 1327) Human genomic sequence (SEQ ID NO: 1328) Human mRNA sequence (SEQ ID NO: 1329) Human coding sequence (SEQ ID NO: 1330)

TABLE 66 (mouse gene: Egr2; human gene EGR2) Mouse genomic sequence (SEQ ID NO: 1331) Mouse mRNA sequence (SEQ ID NO: 1332) Mouse coding sequence (SEQ ID NO: 1333) Human genomic sequence (SEQ ID NO: 1334) Human mRNA sequence (SEQ ID NO: 1335) Human coding sequence (SEQ ID NO: 1336)

TABLE 67 (mouse gene: Sos1; human gene SOS1) Mouse genomic sequence (SEQ ID NO: 1337) Mouse mRNA sequence (SEQ ID NO: 1338) Mouse coding sequence (SEQ ID NO: 1339) Human genomic sequence (SEQ ID NO: 1340) Human mRNA sequence (SEQ ID NO: 1341) Human coding sequence (SEQ ID NO: 1342)

TABLE 68 (mouse gene: Pou2af1; human gene POU2AF1) Mouse genomic sequence (SEQ ID NO: 1343) Mouse mRNA sequence (SEQ ID NO: 1344) Mouse coding sequence (SEQ ID NO: 1345) Human genomic sequence (SEQ ID NO: 1346) Human mRNA sequence (SEQ ID NO: 1347) Human coding sequence (SEQ ID NO: 1348)

TABLE 69 (mouse gene: Mef2c; human gene MEF2C) Mouse genomic sequence (SEQ ID NO: 1349) Mouse mRNA sequence (SEQ ID NO: 1350) Mouse coding sequence (SEQ ID NO: 1351) Human genomic sequence (SEQ ID NO: 1352) Human mRNA sequence (SEQ ID NO: 1353) Human coding sequence (SEQ ID NO: 1354)

TABLE 70 (mouse gene: Map3k8; human gene MAP3K8) Mouse genomic sequence (SEQ ID NO: 1355) Mouse mRNA sequence (SEQ ID NO: 1356) Mouse coding sequence (SEQ ID NO: 1357) Human genomic sequence (SEQ ID NO: 1358) Human mRNA sequence (SEQ ID NO: 1359) Human coding sequence (SEQ ID NO: 1360)

TABLE 71 (mouse gene: Fgfr3; human gene FGFR3) Mouse genomic sequence (SEQ ID NO: 1361) Mouse mRNA sequence (SEQ ID NO: 1362) Mouse coding sequence (SEQ ID NO: 1363) Human genomic sequence (SEQ ID NO: 1364) Human mRNA sequence (SEQ ID NO: 1365) Human coding sequence (SEQ ID NO: 1366)

TABLE 72 (mouse gene: Cbx8; human gene CBX8) Mouse genomic sequence (SEQ ID NO: 1367) Mouse mRNA sequence (SEQ ID NO: 1368) Mouse coding sequence (SEQ ID NO: 1369) Human genomic sequence (SEQ ID NO: 1370) Human mRNA sequence (SEQ ID NO: 1371) Human coding sequence (SEQ ID NO: 1372)

TABLE 73 (mouse gene: Lmo2; human gene LMO2) Mouse genomic sequence (SEQ ID NO: 1373) Mouse mRNA sequence (SEQ ID NO: 1374) Mouse coding sequence (SEQ ID NO: 1375) Human genomic sequence (SEQ ID NO: 1376) Human mRNA sequence (SEQ ID NO: 1377) Human coding sequence (SEQ ID NO: 1378)

TABLE 74 (mouse gene: Itpr1; human gene ITPR1) Mouse genomic sequence (SEQ ID NO: 1379) Mouse mRNA sequence (SEQ ID NO: 1380) Mouse coding sequence (SEQ ID NO: 1381) Human genomic sequence (SEQ ID NO: 1382) Human mRNA sequence (SEQ ID NO: 1383) Human coding sequence (SEQ ID NO: 1384)

TABLE 75 (mouse gene: Sell; human gene SELL) Mouse genomic sequence (SEQ ID NO: 1385) Mouse mRNA sequence (SEQ ID NO: 1386) Mouse coding sequence (SEQ ID NO: 1387) Human genomic sequence (SEQ ID NO: 1388) Human mRNA sequence (SEQ ID NO: 1389) Human coding sequence (SEQ ID NO: 1390)

TABLE 76 (mouse gene: Dpt; human gene DPT) Mouse genomic sequence (SEQ ID NO: 1391) Mouse mRNA sequence (SEQ ID NO: 1392) Mouse coding sequence (SEQ ID NO: 1393) Human genomic sequence (SEQ ID NO: 1394) Human mRNA sequence (SEQ ID NO: 1395) Human coding sequence (SEQ ID NO: 1396)

TABLE 77 (mouse gene: Pap; human gene PAP) Mouse genomic sequence (SEQ ID NO: 1397) Mouse mRNA sequence (SEQ ID NO: 1398) Mouse coding sequence (SEQ ID NO: 1399) Human genomic sequence (SEQ ID NO: 1400) Human mRNA sequence (SEQ ID NO: 1401) Human coding sequence (SEQ ID NO: 1402)

TABLE 78 (mouse gene: Blm; human gene BLM) Mouse genomic sequence (SEQ ID NO: 1403) Mouse mRNA sequence (SEQ ID NO: 1404) Mouse coding sequence (SEQ ID NO: 1405) Human genomic sequence (SEQ ID NO: 1406) Human mRNA sequence (SEQ ID NO: 1407) Human coding sequence (SEQ ID NO: 1408)

TABLE 79 (mouse gene: Blr1; human gene BLR1) Mouse genomic sequence (SEQ ID NO: 1409) Mouse mRNA sequence (SEQ ID NO: 1410) Mouse coding sequence (SEQ ID NO: 1411) Human genomic sequence (SEQ ID NO: 1412) Human mRNA sequence (SEQ ID NO: 1413) Human coding sequence (SEQ ID NO: 1414)

TABLE 80 (mouse gene: Ptp4a2; human gene PTP4A2) Mouse genomic sequence (SEQ ID NO: 1415) Mouse mRNA sequence (SEQ ID NO: 1416) Mouse coding sequence (SEQ ID NO: 1417) Human genomic sequence (SEQ ID NO: 1418) Human mRNA sequence (SEQ ID NO: 1419) Human coding sequence (SEQ ID NO: 1420)

TABLE 81 (mouse gene: Mcm3ap; human gene MCM3AP) Mouse genomic sequence (SEQ ID NO: 1421) Mouse mRNA sequence (SEQ ID NO: 1422) Mouse coding sequence (SEQ ID NO: 1423) Human genomic sequence (SEQ ID NO: 1424) Human mRNA sequence (SEQ ID NO: 1425) Human coding sequence (SEQ ID NO: 1426)

TABLE 82 (mouse gene: Jak2; human gene JAK2) Mouse genomic sequence (SEQ ID NO: 1427) Mouse mRNA sequence (SEQ ID NO: 1428) Mouse coding sequence (SEQ ID NO: 1429) Human genomic sequence (SEQ ID NO: 1430) Human mRNA sequence (SEQ ID NO: 1431) Human coding sequence (SEQ ID NO: 1432)

TABLE 83 (mouse gene: Fus1; human gene FUS1) Mouse genomic sequence (SEQ ID NO: 1433) Mouse mRNA sequence (SEQ ID NO: 1434) Mouse coding sequence (SEQ ID NO: 1435) Human genomic sequence (SEQ ID NO: 1436) Human mRNA sequence (SEQ ID NO: 1437) Human coding sequence (SEQ ID NO: 1438)

TABLE 84 (mouse gene: Rassf1; human gene RASSF1) Mouse genomic sequence (SEQ ID NO: 1439) Mouse mRNA sequence (SEQ ID NO: 1440) Mouse coding sequence (SEQ ID NO: 1441) Human genomic sequence (SEQ ID NO: 1442) Human mRNA sequence (SEQ ID NO: 1443) Human coding sequence (SEQ ID NO: 1444)

TABLE 85 (mouse gene: Pik3r1; human gene PIK3R1) Mouse genomic sequence (SEQ ID NO: 1445) Mouse mRNA sequence (SEQ ID NO: 1446) Mouse coding sequence (SEQ ID NO: 1447) Human genomic sequence (SEQ ID NO: 1448) Human mRNA sequence (SEQ ID NO: 1449) Human coding sequence (SEQ ID NO: 1450)

TABLE 86 (mouse gene: Braf; human gene BRAF) Mouse genomic sequence (SEQ ID NO: 1451) Mouse mRNA sequence (SEQ ID NO: 1452) Mouse coding sequence (SEQ ID NO: 1453) Human genomic sequence (SEQ ID NO: 1454) Human mRNA sequence (SEQ ID NO: 1455) Human coding sequence (SEQ ID NO: 1456)

TABLE 87 (mouse gene: Tle3; human gene: TLE3) Mouse genomic sequence (SEQ ID NO: 1457) Mouse mRNA sequence (SEQ ID NO: 1458) Mouse coding sequence (SEQ ID NO: 1459) Human genomic sequence (SEQ ID NO: 1460) Human mRNA sequence (SEQ ID NO: 1461) Human coding sequence (SEQ ID NO: 1462)

TABLE 88 (mouse gene: Nek2; human gene NEK2) Mouse genomic sequence (SEQ ID NO: 1463) Mouse mRNA sequence (SEQ ID NO: 1464) Mouse coding sequence (SEQ ID NO: 1465) Human genomic sequence (SEQ ID NO: 1466) Human mRNA sequence (SEQ ID NO: 1467) Human coding sequence (SEQ ID NO: 1468)

TABLE 89 (mouse gene: Nr3c1; human gene NR3C1) Mouse genomic sequence (SEQ ID NO: 1469) Mouse mRNA sequence (SEQ ID NO: 1470) Mouse coding sequence (SEQ ID NO: 1471) Human genomic sequence (SEQ ID NO: 1472) Human mRNA sequence (SEQ ID NO: 1473) Human coding sequence (SEQ ID NO: 1474)

TABLE 90 (mouse gene: Dad1; human gene DAD1) Mouse genomic sequence (SEQ ID NO: 1475) Mouse mRNA sequence (SEQ ID NO: 1476) Mouse coding sequence (SEQ ID NO: 1477) Human genomic sequence (SEQ ID NO: 1478) Human mRNA sequence (SEQ ID NO: 1479) Human coding sequence (SEQ ID NO: 1480)

TABLE 91 (mouse gene: Lck; human gene LCK) Mouse genomic sequence (SEQ ID NO: 1481) Mouse mRNA sequence (SEQ ID NO: 1482) Mouse coding sequence (SEQ ID NO: 1483) Human genomic sequence (SEQ ID NO: 1484) Human mRNA sequence (SEQ ID NO: 1485) Human coding sequence (SEQ ID NO: 1486)

TABLE 92 (mouse gene: Git2; human gene GIT2) Mouse genomic sequence (SEQ ID NO: 1487) Mouse mRNA sequence (SEQ ID NO: 1488) Mouse coding sequence (SEQ ID NO: 1489) Human genomic sequence (SEQ ID NO: 1490) Human mRNA sequence (SEQ ID NO: 1491) Human coding sequence (SEQ ID NO: 1492).

TABLE 93 (mouse gene: Anp32; human gene N/A) Mouse genomic sequence (SEQ ID NO: 1493) Mouse mRNA sequence (SEQ ID NO: 1494) Mouse coding sequence (SEQ ID NO: 1495) Human genomic sequence (SEQ ID NO: 1496) Human mRNA sequence (SEQ ID NO: 1497) Human coding sequence (SEQ ID NO: 1498).

TABLE 94 (mouse gene: Map2k5; human gene MAP2K5) Mouse genomic sequence (SEQ ID NO: 1499) Mouse mRNA sequence (SEQ ID NO: 1500) Mouse coding sequence (SEQ ID NO: 1501) Human genomic sequence (SEQ ID NO: 1502) Human mRNA sequence (SEQ ID NO: 1503) Human coding sequence (SEQ ID NO: 1504).

TABLE 95 (mouse gene: Cd28; human gene CD28) Mouse genomic sequence (SEQ ID NO: 1505) Mouse mRNA sequence (SEQ ID NO: 1506) Mouse coding sequence (SEQ ID NO: 1507) Human genomic sequence (SEQ ID NO: 1508) Human mRNA sequence (SEQ ID NO: 1509) Human coding sequence (SEQ ID NO: 1510).

TABLE 96 (mouse gene: Sept9; human gene Msf) Mouse genomic sequence (SEQ ID NO: 1511) Mouse mRNA sequence (SEQ ID NO: 1512) Mouse coding sequence (SEQ ID NO: 1513) Human genomic sequence (SEQ ID NO: 1514) Human mRNA sequence (SEQ ID NO: 1515) Human coding sequence (SEQ ID NO: 1516).

TABLE 97 (mouse gene: Fzd10; human gene FZD10) Mouse genomic sequence (SEQ ID NO: 1517) Mouse mRNA sequence (SEQ ID NO: 1518) Mouse coding sequence (SEQ ID NO: 1519) Human genomic sequence (SEQ ID NO: 1520) Human mRNA sequence (SEQ ID NO: 1521) Human coding sequence (SEQ ID NO: 1522).

TABLE 98 (mouse gene: Calm2; human gene CALM2) Mouse genomic sequence (SEQ ID NO:1523) Mouse mRNA sequence (SEQ ID NO:1524) Mouse coding sequence (SEQ ID NO:1525) Human genomic sequence (SEQ ID NO:1526) Human mRNA sequence (SEQ ID NO:1527) Human coding sequence (SEQ ID NO:1528).

TABLE 99 (mouse gene: Ncf4; human gene NCF4) Mouse genomic sequence (SEQ ID NO:1529) Mouse mRNA sequence (SEQ ID NO:1530) Mouse coding sequence (SEQ ID NO:1531) Human genomic sequence (SEQ ID NO:1532) Human mRNA sequence (SEQ ID NO:1533) Human coding sequence (SEQ ID NO:1534).

TABLE 100 (mouse gene: Rac2; human gene RAC2) Mouse genomic sequence (SEQ ID NO:1535) Mouse mRNA sequence (SEQ ID NO:1536) Mouse coding sequence (SEQ ID NO:1537) Human genomic sequence (SEQ ID NO:1538) Human mRNA sequence (SEQ ID NO:1539) Human coding sequence (SEQ ID NO:1540).

TABLE 101 (mouse gene: Mbnl; human gene MBNL) Mouse genomic sequence (SEQ ID NO:1541) Mouse mRNA sequence (SEQ ID NO:1542) Mouse coding sequence (SEQ ID NO:1543) Human genomic sequence (SEQ ID NO:1544) Human mRNA sequence (SEQ ID NO:1545) Human coding sequence (SEQ ID NQ:1546).

TABLE 102 (mouse gene: mCG10516; human gene N/A) Mouse genomic sequence (SEQ ID NO:1547) Mouse mRNA sequence (SEQ ID NQ:1548) Mouse coding sequence (SEQ ID NO:1549) Human genomic sequence (SEQ ID NO:1550) Human mRNA sequence (SEQ ID NO:1551) Human coding sequence (SEQ ID NO:1552)

TABLE 103 (mouse gene: Rorc; human gene RORC) Mouse genomic sequence (SEQ ID NO:1553) Mouse mRNA sequence (SEQ ID NO:1554) Mouse coding sequence (SEQ ID NO:1555) Human genomic sequence (SEQ ID NO:1556) Human mRNA sequence (SEQ ID NO:1557) Human coding sequence (SEQ ID NO:1558)

TABLE 104 (mouse gene mCG15938; human gene BAT1) Mouse genomic sequence (SEQ ID NO:1559) Mouse mRNA sequence (SEQ ID NO:1560) Mouse coding sequence (SEQ ID NO:1561) Human genomic sequence (SEQ ID NO:1562) Human mRNA sequence (SEQ ID NO:1563) Human codina secuence (SEQ ID NO:1564)

TABLE 105 (mouse gene: Iqgap1; human gene IQGAP1) Mouse genomic sequence (SEQ ID NO:1565) Mouse mRNA sequence (SEQ ID NO:1566) Mouse coding sequence (SEQ ID NO:1567) Human genomic sequence (SEQ ID NO:1568) Human mRNA sequence (SEQ ID NO:1569) Human coding sequence (SEQ ID NO:1570)

TABLE 106 (mouse gene Zpf29; human gene: hCG27579) Mouse genomic sequence (SEQ ID NO:1571) Mouse mRNA sequence (SEQ ID NO:1572) Mouse coding sequence (SEQ ID NO:1573) Human genomic sequence (SEQ ID NO:1574) Human mRNA sequence (SEQ ID NO:1575) Human coding sequence (SEQ ID NO:1576)

TABLE 107 (mouse gene: Kcnj9; human gene: KCNJ9) Mouse genomic sequence (SEQ ID NO:1577) Mouse mRNA sequence (SEQ ID NO:1578) Mouse coding sequence (SEQ ID NO:1579) Human genomic sequence (SEQ ID NO:1580) Human mRNA sequence (SEQ ID NO:1581) Human coding sequence (SEQ ID NO:1582)

TABLE 108 (mouse gene: Ppp3cc; human gene: PPP3CC) Mouse genomic sequence (SEQ ID NO:1583) Mouse mRNA sequence (SEQ ID NO:1584) Mouse coding sequence (SEQ ID NO:1585) Human genomic sequence (SEQ ID NO:1586) Human mRNA sequence (SEQ ID NO:1587) Human coding sequence (SEQ ID NO:1588)

TABLE 109 (mouse gene: mCG910; human gene: hCG27579) Mouse genomic sequence (SEQ ID NO:1589) Mouse mRNA sequence (SEQ ID NO:1590) Mouse coding sequence (SEQ ID NO:1591) Human genomic sequence (SEQ ID NO:1592) Human mRNA sequence (SEQ ID NO:1593) Human coding sequence (SEQ ID NO:1594)

TABLE 110 (mouse gene: mCG2257; human gene: PRDM11) Mouse genomic sequence (SEQ ID NO:1595) Mouse mRNA sequence (SEQ ID NO:1596) Mouse coding sequence (SEQ ID NO:1597) Human genomic sequence (SEQ ID NO:1598) Human mRNA sequence (SEQ ID NO:1599) Human coding sequence (SEQ ID NO:1600)

TABLE 111 (mouse gene: mCG17918; human gene: hCG23764) Mouse genomic sequence (SEQ ID NO:1601) Mouse mRNA sequence (SEQ ID NO:1602) Mouse coding sequence (SEQ ID NO:1603) Human genomic sequence (SEQ ID NO:1604) Human mRNA sequence (SEQ ID NO:1605) Human coding sequence (SEQ ID NO:1606)

TABLE 112 (mouse gene: Lfng; human gene: LFNG) Mouse genomic sequence (SEQ ID NO:1607) Mouse mRNA sequence (SEQ ID NO:1608) Mouse coding sequence (SEQ ID NO:1609) Human genomic sequence (SEQ ID NO:1610) Human mRNA sequence (SEQ ID NO:1611) Human coding sequence (SEQ ID NO:1612).

TABLE 1 SEQ ID NO: MUTATION SEQUENCE CLONE CLASS. GENE 1 IM000619 GATCAAAGCAATCTCTATGTCTTTCTCTG p000632 A Spr CTGTCCTCCTCAGACATCTCCAGAGAGC TGGGATATTTTTCTTTCCCATTTGAGATT ATGAAGTTGTTTCTAGAGTGCATGACGC AGGTTGAAGGATAAGTACACAGGTCCCA AGGAACCAAGCGTTTTCACTGACGGTGA TGAGTCTTGTTCGTGAGATTGTTGTGATT CTCAGCCTTTCTCTTCCCCTGTGTGTGCT CTTCATTTTCTGGTTCTGTCTGCCTAGCA CCTCCTGGGGAAGCTGCTGTGCTTT 2 IM000620 GATCTTTGGAGCCCAGTTGTTAATCATAA p000633 D — GAGCTGATATTTTGAAAGAGTGTGTCAA CCTAGATGCACAGGGAAGCCAAAGCATT CAGCC 3 IM000621 ATATGACCACAAGGAAATAAGATAAAGT p000634 C — GTTCATACTGAATTTATAATGAAAAGTGA TC 4 IM000622 GAACAGGCATGGCTTTACTTGTACAATG p000638 D — AGGAAACCAAGGCAGAGATTGCAAAGCG GGTCCTACACGTTTGCTCCATGCCCTGC TTCTCTGACCACAGTGTACTGAGAATATG CTGAGCCCTAGTTCCTGGGGAGGAGGC AGAAGAGAGCAGCATCCTGCCCACTTGA AGGCGTGCACACATAGTTCCTGTCTGAT C 5 IM000623 GATCAGGAGACCACACCCAGCTAGCCTT p000639 D — CTCTGACTGGGTATCCTTGGTCAGCCAG CCTTTCTTCACCTCATGTTCTCATTTGCA AACTCACATGAACACTATTTGACCTACAC ACTTCATAAAGCTGTTTTTAGAAAGACGA GATAATACAGGAGGAACGCTACAATATT AAATGATATGTATTTATAT 6 IM000624 AGTGTTTAGGTCAGCTGGTGCAGGAGAA p000640 D — GCTTCTTGAGGAAGACGACCATCTGGCA AGGCCTGATGGTAGAAAATAATGGACTT CTCTCCAACTGAGTAGGAACTTGATGAT C 7 IM000625 ATCAGTAAGTTAATCCTAAGAATTACTAT p000641 D — GCATTTTTCCCCTCTTTTTTAACAACATTC CTCCTTAGCTTATATGAGGCTCTAGTGC CCGGAGACTTTAATACTGCCCTAACATG ATGGTGGCTCTTTGTCCCTCTTTCTCAGC CACTGAAATCTGACAGTTTGGGGAAGAA TAATAAGAATTTAAGAAACTAGATGGTTT TAAATATAGATATAAAAACAGTTCTTCGA CTATTCTCAATAAAGAAATTCAGTCAAAA GAATTTCAGTCCTAACACAATGATC 8 IM000626 GATCATCAGAGTCCTGCATCTTATGTGT p000642 D — GCAGTGTTTTCAGCAATACAGGCTTACC TTCTTACCTCTAACAGGCAACCAGATGCT ACAATAGCTTATATTGTTTTAGAAATCAC TTGGACTACTCTAAACAACAACTTGAGTG AAGGCTCTTTGTATCTGATACTGGAGTTT GTTAGTCTATGACACTTGTGGGGAGACA TGTCTGCACAAGTAGCATATGTGTGTAC ATGTATATTGTATACATATATAGTTTTGCT CTATGTATGTATGTGTATATGTATGTATG TATATGTATATGTATGTATATATATAG 9 IM000627 AAGGGACCTGATAATCGTGTTGGCAACT p000643 D — GGGCTACAATTAGTTATCAATTGCTTGCT TGCCACCTGCCCTGCTCCATAGAGAATC ATAGTCTGGGGAGTGTGGAGGAATAGC GGAGTCATCTAAACACATCACTGCTGCC CCCACCATTTGCCTGCCACCAGGCCCCT GCCTTTCATTTTGCATCTCCCTCTTAC AAGCAAATGGCGCTCACTGATC 10 IM000628 GTTTGGGGATTGTACAGAATGCACAGCG p000644 K Myc TAGTATTCAGGAAAAAGGAAACTGGGAA ATTAATGTATAAATTAAAATCAGCTTTTAA TTAGCTTAACACACACATACGAAGGCAA AAATGTAACGTTACTTTGATC 11 IM000629 GATCTCATTACAGATGGTTGTGAGCTAC p000647 R — CATGTGG 12 IM000630 GATCTCAGGAGGCACCGAGAGACTCAG p000649 K Gfi1 CATGGACTCAAATGAGTACCCTGGCAGC CCGCTACACCAGCTGTGTAACACTACCG TGAGGGATGTCTTCCCTGCCTCCCTCCA GCCCCTTCTCAGGCCCTGAGTCCAGTGT GCAAAGCTCATCATGGTTAGTCCCCTTC ACCT 13 IM000631 AGAGCACCCGACTGCTCTTCCGAAGGTC p000650 R — CAGAGTTCAAATCCCAGCAACCACATGG TGGCTCACAACCATCCGTAACAAGATC 14 IM000632 GATCAAATCCTGTCAGGGAGAGGGGCTC p000651 D — CTCCCAGTAGTGCCATCCCATAATAATAA GAAGGACTCCTGGGCCTCAGTGAAGTCA GGCTGACCACTACTGCAGGTTAGTCATG ACCAGTAGCCAGAATGGAACGAAGGGT GACCCAGTGTGAGGACACAGCCCCAGG CAACTGCTTCTGCTTTGAGCCAAGTTGTT ACCCCAAAGCTCGTCATTCCGCTTGGTT TCTCATGTGTGTGAGCTGCACATATGGA GGTCCCCCTTTGTTCCCTT 15 IM000633 GTGAGGAAGGTCCCTCTGCATTCTAACC p000652 D — TTCCTCAACTCCACCAGCCTCGGCGTTT AAGGGAGAAATATTACCGTTCCCTTTGG GCCAAGTTGGAGCCAGTGAAGTAGTCG GAAATGTACAGTCACAGGAAATTGCTGC TACCAAGGCTGGAGGAACAAAGAGAAGA CTTGTCACAAGAGGCCAGAGAGGAAGTC ACCCAGTACAAACTGAAGCGCGCGCGC ACACACACACACACACACACACACACGC ACACACACACACACACGATC 16 IM000634 TGGCCGCCTAGACAAGCTGACCATCACC p000654 A — TCCCAGAACCTGCAACTGGAGAGCCTTC GCATGAAGCTTCCGAAATGTGCGTGCTC CACCTGTCCCTCACCTCACAGACATCAT TTCTCCATTTAGCCCCTCCCGATC 17 IM000635 GATCCCCTGGAATTTACAGTCGGTTCCA p000656 C — ACAATCATGTAGATG 18 IM000636 GATCGGCTATAGCATTTGTCAATGTTTAC p000659 A Cr2 CCAGAAGAATAGCACAGATATATTTGCA CATCAATGCTTATTGCAGTATTATTCACA GTGGCTATGTAATGGAACCAACCTACAT GGCCAGCAACTGAATAGATTAAGAAAAT ATATATACACAATGGTGCTTTTTTCGGCT ATAAAGAAGAATGAAGTTATGTTGTTTGT TAGAAGATGGATGAAAGTGGAGATGATA ATATCAAGTGCACAGTCAACCTCTCTCTC TCACCTCCCCCGCCCCGCTCTTTCTCTC TCATATACATTTGAGAGTAGCAGTAAACT GTCTGAGAACAAAGGGGATTAATGGGAG GGGAGAAGATTAAGGAGCGGAAGGGTA GTAGGTAGTAT 19 IM000637 GATCGGCTTCTATGGACTGAGTGTGTAA p000661 D — GAAAACATT 20 IM000638 TTAGGAGGGTAGAGAACATTCAGGAATC p000662 D — AAGAACAAGCATTTTAACACCCACTGAG CTATCCTGTGGATGGTGGTGGTTTTGT GTTTGTTGGTTTTGTTTTAGGAAGTCAGG GATGGGGTGGGAATCTCACTCTGTGGCT TAGACTTGCAACAATCCCAAATTCTGGAA TGATAAGCAAGAGAGCTGTCTAGTCCCA GTCTCAGATACATGCTGTTAATTTTCTAC TACTGCTATAACACATAGGCTCAAATGC GGTGGCTTACCTAACACACCCTGTGCAG TTCTGAAAGTCGTAACTCTGGCACGATC 21 IM000639 ATGCTAAGCTGTGACTCCTGTCGATACG p000663 D — AGACCCTGGCTGCCCTCCTTTCCCGATC 22 IM000640 GATCGTCTGGAAGAGCAGTCAGTATTCT p000665 R — TAACTGCTGAGCCATCTTTGCAGCCCCC AGTTCTTTGGGGTTTTTTGTTTGTTTGTTT GGTTGGTTGGTTGGTTTGGTTTAGTTTG GTTTGGTTCAAGACAGGGTTTCTCTGTG TTGCCCTGGATGTCCTGGAACTCTCTTT GTAGACCAGGGTGGCCTTTAACTCACAG AAATGCGCCTGCTAGGATTAAAGCTGTG TCCCACCACTATATATATATGTGTG 23 IM000641 GTCACAGTGTTAGAGCCACAGACGGGG p000666 D — GAACCTACTGGCTGTCCTGGGTTCCTGT AAACTAGGGGACAAAGCTGCCACAGCCA GACTTAGCTGCGATC 24 IM000642 GATCGCTGCTTCTGTAAATCCGCAACGA p000668 R — CAATTGTTATCTTCTCCTTTTCTTTCTTTT ATGTTTTATTCTATTTTATTTTTCAGAT GAACTCTCATGTAGCCCAGGCTGGTCTC AAACTCCCTCTGTAGCTGACGGCAACCT TGAAC 25 IM000643 TTCCTACACCATAGCATTTAGTTGTAGGC p000669 D — AGAAGCGATC 26 IM000644 GATCGGCTCAAGGGCTCTAATTTAGTCT p000672 D — AGGAAGTCCTTAGGAAACATGAAAATCT CCGAGATAAGACCCGGGGTAAAAAGCTT GAGCCACGGAGTTAGACATGCCCAGGG TGGAGTCATGTTCAGAGGTTCAAGACCC GAATCAGCTACGTAAATAAAGCATTTGAG GCCTACCTGGGCTACAAGAGAGTATCTT TAAATAAATAAGATGATTTAAAAAAAACT GTTTTCCCCTTAGATGGATTAAAAAAACA AGACAAAACAAAACAAAACAAAAACCCG TCTTTCCTTCTTAA 27 IM000645 CTGTCCGTGTGGGAAACGTTTAGCAAGT p000673 K Nmyc CCGAGCGTGTTCGATC 28 IM000646 ATGCGTTCGTATGACAGTTCTCCTAATGA p000676 C — CTGTCCCAAAGTCCCAGATTCCTGGAAA CAGTAAAGACTGCCTCAAACTGTAGTCA CTAGTCTATTATCTTAATCATAGTAACCA TTTGGGTTTGACTTGAAAACCTGTGACA GGGAGATAAATTTCTGCCACTGTAGGTG AAGCTTGGAAGGGCTAACCCAATGAATA TGCTCAGTCGATC 29 IM000647 AGATGAAGCTATCCCCAGTCCCTAAGCT p000678 C — GAGTTCTGCCTGAGACTATTTGAAACAG GGTACCCCTGGGTCCCAGTTCAGTTGAC AGGTAGTGGACGCATGAGAACGCCATAC CTGGTGGCCGTGCCCGAGAGTGCTGTC CCTGACCTGCCACTGTGTTCTCCAGAGC AGCTCCAATCTGCCTGCTCCTGTCTC CCCTGCCTGTTGGCACCAGGCAGCCAG AATTCCATTTGTGTTTGCTTCGCGATA GGCTCTTGCCATGTAGTCCTTCCTGGCC TAGAACTTGATATGTAGACTTCCCCCCTT GGATC 30 IM000648 CCGTGTCCGTGGGCATGTGCGTGTACA p000679 D — GACAGACATACATGCCCCCGCATGAGTG TGAACACCAGAGGTCAACCTCAGGTGTC CTTTTGATGTTATCTACCTTGTTTTTTGAA GCAAGGTCTAGGATTGACCAATGAGCCC CAAGTAGGGATC 31 IM000649 GATCCATAGGCAGAGAAGGCAGTAATAG p000682 D — GACATTGGTCATTGTACCTCATTTGTGAG GGGTCACCTTGGAAATGTGCTGAGACTA GGTTCTAGGAGAAGCTCGCCA 32 IM000650 CTGGCACTGTGTGGCAGAAACAGTGAAC p000684 D — AGTGTAGCGGTGCAGAATGTGTGTGCTG TGGGTTTTAGCACCAGGGCTGCATGAGA CTGCAGACATGCTTATGACGCAGGAAGG CTCAGGACACAGCACACATGTGTGCTAA CATACATGTTTCACCTCAGACTCAGCTCC CATTTGACTTTTAATTAATTTTTGGCCATT CCACAACAGAACCTTTTCTTGCTCCCTTT TTTCAATCTTATGTATATATCTCCTACATT TAGTTACAGGACTGTGACCTACAGTTTAA AACTCGGGGATC 33 IM000651 GATCCCTCCCCTCCCTTCTTTETCCCGC p000685 K Myc CAAGCGTCGGCGAAGCCCTGCCCTTCA GGAGGCAGGAGGGGAGCTGAGTGAGGC GAGTCGGACCCAGCAGCTGAGAGCAGC GCAGCCCAGGGGTCCTCGGCCGCGCAG ACCCCCGGAATAA 34 IM000652 CTACCACAGCCCCAGTGCTCTGGAGGG p000686 D — ACTCTAGTAGCCAGGGCTGGCAGCTTGG TTTGGGCCAGCATCTCACTATGTAGCCT AGTTGTCCTGGAATTTGCTATGTAAATGT GGCTACCCTCAAACTCATAGAGAGCCTC CCACCTCTCCTGAGATTATAGGCACATG CTACCATGCCCTAAGTGGATC 35 IM000653 GGAGCAGGCCCTTCTGAATCAACTTGGC p000687 D — AGAGTGAAGGAGGCACTCTCCACACAAA CAGGAAAAGGGCAGTGGTGACTTTCTAG GCAGGGAACTGGTTACATTTTGTTTATTT GAAGGTGAAGAGTCGTGACATTCTGGGA AATAGGCAAGATGGCCGTTTCCCCTCAG CTACAACCAGCCATGCAGACCTCCTTGC AGGGACCTGGCTATCTACACTGGAACCA GAAAGGCACGCCCTGCTTTAGCCTCAGG CAGAACGATAATAACAGCGTGCTAGCTC GTAGTCTGTGTGCTGGAAGGGTTTATG AGGAGGAAGTCCGCTATTACATATTTCT GGGCAAACATTAACCAAGATTGAAACCT AGATTTGAAGAGAAGTAGCAGGCTGGGA TC 36 IM000654 AGATGAACTTATAAATGCATCTGCAGTCC p000688 B Mm.1313 TCTAATAAAGATGAATAGTAACCCAGAG 36 GCGTGGTAGTGCGCTCTTCAAACCCAGT GCTCAGAAGGTGCAAACAAAAGGACCG GGAGTCCAAGGCTAGCCTTGACTAGAAG GGGCCATGTCTCAAAGAACAACAACCAA GAGCTGCTTATGGAGGTCAGTCTGTGTT CCCAGGGGGACAGCATCAGTCTAAGTTG GCGGTTGTTGTTGGCTGAGCATGCACAA ATCCCTAACAGCACATAAAGCAAGTTGT GTCACACACTCACAGTGCCCAGATTCAC TGGATC 37 IM000655 GTCCATTGTGTACTGAGAGAGGAGTTAG p000689 D — GTTTAGAAAGCCTTCCTCAGATGTCCCT CAAAGAAGCTGCTACAACTGCCCTCATC CCACGTTGCCAAGGATC 38 IM000656 AGCTGTAGGGAAGCCCAAAGCACAGAC p000694 K Gfi1 GACTGCTGCTGCTGCTGCGGTTCCCACT CTGGGTTGACCTTAGAAACGGGGGTTCA TCTCCTCCAGCAGCTCCGGGAAGGAAG GTGAAGGGGACTAACCATGATGAGCTTT GCACACTGGACTCAGGGCCTGAGAAGG GGCTGGAGGGAGGCAGGGAAGACATCC CTCACGGTAGTGTTACACAGCTGGCGTT GCGGGCTGCCAGGGTACTCATTTGAGTC CATGCTGAGTCTCTCGGTGCCTCCTGAG ATC 39 IM000657 GATCGCCCCAGTTACCTCAAATTGTGTG p000695 D — AGTGTGTGTGTGTGTGTGTATGCATATAT GCATACAAGCATATACATGCATGCATATA TATAATACACATAGACATATATACACACA TATAGACGCATACATGCATTTGTATGCAT GCATCTATGTATGTACATATCCACAACCA AATATACCAAACACGCAGACACAGCACA CATAGGACAATAGTAATTGTGAATCTAAC TGGTGGGGTTTATGGGTCAAGAGCCAG GGTAGAGGAAACTGGCTAAGGCTCTAAC CATCCTAGAGCAGGCACATCTACCAGGA AAAGAAACAAGGAAAAGAGCAGAGTTGA GGGTTACTTAACATG 40 IM000658 ACAGAATCTGTGGGTCATTATTACGTTTA p000700 D — TAGGAACAGGATTTTCTTTCCTTTCTGAC TCTACCTTCTAGAAAGGCCGACTTTTAAA TCCTCATGCTCTTGTCTATTGACAGGAAA AGATGGGCTTCCACACTGATC 41 IM000659 GATCAGGCTGGCCTTGAACTCACAGAGA p000702 C — CCCACCTGCCTCTGCCTCCTGCATGGTG GGATTAAAGGTGTGTGCCACCACTGCCC AGCTCACAAAGTAGTAGTAGGACTAGTA CTAGTACTAATTATAACAAACATTACAAC AATCTTAATTATTTTTGTTTCTACCTAA AATCTCCCAACTGTCTTTTTATATTGCCT CAAGTCTTCCCTCAGTCCCTGGCCTTCA TAGCTTGACTTTTTTGCTAGAGGTTATCA GTGGCTCATCTCTCTCCTGAGATTGAGC TGGCTAAGACCACTATTCAGAGGGAGAA TGTAATGTCTCAGACATCATAGCCAGTC CTCAGTTCTCCTTTTGCTGACTGACCACT TTGCCAAACTAGTTTTCCTAAGCCATACC TTTTCTTTTTAAAAAATAGTCTTTCTTATA GTGGGTGCTGGCTTTGAACTTCTGTCCT CTTGCCTCACCTTGCACTGGTAGTAGAG GCTTGCAATTTCACCG 42 IM000660 GATCAAGAACGAAACCCCTGAAAACATA p000703 D — AAACAGTAAGATAACAATAGCGTGCCTG ATTTTGTCCAAACCTTCTTGTCACCTGTC ACTGAGATTGTCAACTCCTTTTCACCACC CTACATACGTTAGTTAGCTCAGTTTACGA GAGTTTGCAAAGGCCCCCACCAGTACCC TGCAACTTTACCCACCCCTGCATGGGAC TGTGAGAAAATGGGACTGGAGAGTAACC CTCTTCAGGCTCACAATCTGAGCTAGTC AGAGCATCTCACGGGTCCCGGGACTTTC AGTGTGCTCCTCTTGGGTATTGGACTT TAAACAATGTGTACCGATATGGGTGAATA ATACAACATCCATGGAGAAATAAGCCAA ATCAAGACACTTCTTCAGAGG 43 IM000661 GATCAAAAACATCAACGTAAGGAGCCCT p000704 D — TAATGACGCTTTGTGACGGTTTAGAATG GTCTACCCAAACCTAGCCAAGTCTAACT ATGTTATGGAGGTGGTAAAAGCAGTTAA CCTAAACATCTGGGACACTCACAGAATG TAGGTAGGTAGGTAGATAGATAGATAG ATAGATAGATAGATAGATAGACAGACAG ACAGACAGATGTTGAATAAAAAGTGACG TTTACAGTGATGTTAGCTCAAGGCAGGG CTTTTCAGGCCATTTCCCCTGGTCTCAC CC 44 IM000662 CTACTAAGTCCAGAGCAGAGAAGGAGGC p000706 D — GCCGCCTGTGTGCACAGCGGAGTCTGG GAGAGACCACCGGCCCAAACCAGTAAAC ACAGGGCACCCACCGTGCTCCGATC 45 IM000663 ACAGTAATCTGATTATCTTGGAGTAGATA p000708 D — ATTTGTCTACCTGTTAATGACTCTGCTTC TTGAACTACGTCCCAGTAGATGCCATGC TCAGCCTGGTAAGTGACACTAATACTA CCTCCAAACTGTCACTTGGATTGTCAGG GTTTTGGTGTGGTGATGATACAGGAGAA ATGTAAAACACGGAGTTGATGATAGAAA GGAGTCACTAATACATTTTCTTAGGAAAA GTCAAGTGACACACAGCAGAATCTAGCT GAAGGAGCTCCGCCAATAGGGCTGGAA GATAACTCTCGCACTAACCTGCTTTATTA GGAACTGTAGGAAAGGCAGGTCTGCAG CACAGTTGAAGTTTAGGTTGCTGAGAAA GTTTCTGCTCATATTTATTCACCAGTGAT GATC 46 IM000664 GTTTAGCAAGTCCGAGCGTGTTCGATC p000709 K Nmyc 47 IM000665 AGGCAAACCCATGTGAGGCCTTCTCACA p000710 C — TCTTTCCTTGGATGCCTGCACACACCTG ACTTGACAGACTTCAAATCAGACTTATCA ACTCACCTCTTCAGTCCTGGGCCTCTTC CTGTATTTCAATCTTAGATAGAAAATTGG TTCCACTGTCTACCAGCCTTGAACCAGG AATGCAGAGCCAACCACCCCTGGGGTGT CCCAGGCAGCTGGGCTGGATGCTACCT GTCATGCTCTTGATC 48 IM000666 ATGTATGAGTGTGGGGCTGGGTTTGAAC p000711 C — CTGTGTCACCTTAGGACTCTCTGAACCT CGGTTTCCTATTAGACGGAGGGGCTATT CGGAGTCCTCATCTAATGGAGACACTTT GTGGGTATCAGAGGGCAACACTGTGGTA TTGGGGGTGGGGGGTTGCTGCTTAGAG CTCAGAGAAGAGGAGTTTGGCTTGCTCT ACAGAACATGCAGGCTGAGGTGTGGGT GCAGGGTTTCCCTGAGGCCCCGGCTCT GACCCTCTCCCCACTCCATTTCCTGCGC AGGTGAGCGACAAACGTTCCAACAGCTT CCGCCAGGCCATCCTTCAGGGAAACCG CAGGCTGAGCAGCAAGGCCCTGCTGGA GGAGAAGGGGCTGAGCCTCTCTCAGCG GCTCATCCGCCACGTGGCCTACGAGACT CTGCCCCGGGAGATTGACCGCAAGTGG TACTATGACAGCTACACCTGCTGCCTCC GCCCGGTTCATGATC 49 IM000667 GATCATTTTTCTCTCGAGATGGATTAAAG p000712 R — CTATGCTGCAGAAGGACCCGTGTGTGTC CTGTGTGTGTGTGTCCTCGCCGGCGAGA CTCCTTATCACACATGACAGCTTCAAAGC CCCCAGATTCAATAGGTTCCAGGAGTTC ACATTTAACACTCATGGGGTCAAAGTGC AGGCAGATGGTGGAGCCTGTGGAAGGT CATCAGACAAACAACCTGGTGGTTGCAG CAGAAATCACCAGGCAAGTAG 50 IM000668 GATCTGGCTAGCAGGGAGCCATTTACAG p000713 D — CTCAGACATCTATCATCCTTA 51 IM000669 GATCATTGTACCTCACCTGTCAGTTTGAC p000714 C — AGGTGGGAGGTGATATCTCTTTTCATTCA TGTATTCTTTGAAAGTTTGTTCATGCATA TAATACATTCTGGTTCAATTCACCACTCC ACCCTTTTGTATCCCCTGCGTACCGAGC CCCCATTTTCTCACCAAGTCTTACTGTTA TCTCAGTTTTGGGGCTTAGTTTTTTGTTT GTCTTGTTTTGTTGTTTTTGAAACAGGGT CCCGTTATGCAGCCCTGGCCCTGAACTT GCTAAATAAACCAGGTTGGCTTTGAATTC AGAGTTCTGCACACCTCTGTTACCCAAG TGCTCAGATTAAAGGCGTATACTACCAC 52 IM000670 GATCAATTCAATCTATTGCAATAACCTGG p000715 D — TTTTTTTTTTCCGCAACTCCTAGATGGGG GGGGGGGGGCCCAGTCAGGAGAGGTTT CAACACAAACGCACTAGTATTTACACACA GAATCTCCTCCACTGTTCTTCTTCTTTGC TTTAAAAGTCTTTGTTCCGGAATCTATAG ATAGGGAGACAGATGGCTAGCTCCCCAA GGCTGAGAGCAGAGGAGAGTATAAACA GGGAAGTCTAGGGGTCTGGGAGGGCTA GGTAAGGAAGCCACAG 53 IM000671 CAATGCCTTCCCCGCGAGATGGAGTGG p000716 K Myc CTGTTTATCCCTAAGTGGCTCTCCAAGTA TACGTGGCAGTGAGTTGCCGAGCAATTT TAATAAAATTCCAGACATCGTTTTTCCTG CATAGACCTCATCTGCGGTTGATC 54 IM000672 TAGTATTCAGGAAAAAGGAAACTGGGAA p000718 K Myc ATTAATGTATAAATTAAAATCAGCTTTTAA TTAGCTTAACACACACATACGAAGGCAA AAATGTAACGTTACTTTGATC 55 IM000673 GATCAGAAAAACAGCCCATTATTCAAGAT p000719 D — TCAGGT 56 IM000674 TAACTTCAATTTAATAATTATCACATGCTA p000720 D — GGAACTAAAGAGGTGCACAAAACAAACC AACAGTGGTTCCTATCCTGTCTAACAGAA GAAACTACAATTGTGGTTTGGGATGCCA CATAAATGACAGCAACGGGACCTACAGA AAATTAAGTCACAGAGAGTATGGACCAT TTCTGCAGAGACCTGGAAAACAGACAAG GGAAGAAACATGGTGTGTCTAAGTGATG GGGCAGGTGGTGCAAACGCTAGAGGCA AGCAGAGGGGATATGAAACTGTGCTGCA CAGCTGGACAGAAGGGAGGCTGGAAGG GAAGAGAGGACCCTCTGTTTTGACTCAA TGGCTAGATGCCATGTGCCAAATAAGAA AGCACTTGGGGGGTTCTGTGGGAAATCG GAACAGAGGGACTGGAATCAAACCTCAA CGTTCCTTGCATACTCCAGATAAGAACC AGGCTTTGAGCCAGGGCCTGGGAAGAG GGCTGGCCTACATATCTCATTTTAGAGAT GAGCAAACAGGACTGGGAGCTCTAGGT CTTCAGTGACACGCTTGCTTGGCCCGCA GGAGACCCTGGGTTTGATC 57 IM000675 GATCATGTCATGGGTCAACAGAAATAATT p000721 D — CTGAAAGGCTAAGTCATTTCTTCTACCCC CAAGAAAAATCAAGAACACCCCACATTA CAAACCTTCCGTAGTAAACTGAGAATGG AGCCATGGCCAGAGCCCCTCTGCTCTCC CATCCCCCAACCAAGAACCAAAC 58 IM000676 ATATAACTTCTTTTTTTTTAAAAAAGAATT p000722 R — ATTTATTTTATGTATATAAGTTCCTTATAG CTGTATTCAGAGACGCCAGAAGAGAGCA TCTGATC 59 IM000677 GATCATAGCACACTGGGGTGCCATCTGT p000724 D — CACCCCTAGACAAACATCTTTAACCNGC ATCTCTTCCTGAAGCCCACTTGGACCAC CCTTTGGAAAACCATCACCAAGGCCAGT AAGGTACCCGTGGTGACTCACCTCAGCC AGCCCACCATAGACGCTTAGCAGAGCA GGTGTGTGTTAGTCAGAGCCAGACAATC AGAACACTCTCCCTGCTCCAAAGTAGCA ATGTAAAAAATTGAACCCAAAGTTG 60 IM000678 GATCAAAGTAACGTTACATTTTTGCCTTC p000727 K Myc GTATGTGTGTGCTAAGCTAATTAAAAGCT GATTTTAATTTATACATTAATTTCCCAGTT TCCTTTTTCCTGAATACTACGCTGTGCAT TCTGTACAATCCCCAAACGTATACATACA CACTTTATATATACACGATAATCTAGCTT ATTAACCAACCAGAAACATGAGTCTTTTG CTCTGTGCATTGGTTCTAGATTTATTATA TAATGCATATTCCCTCGGGATGCTTAT CC 61 IM000679 GATCATTTGATGCTTCAGATAAATATGTA p000728 B Mm.1278 AATGGTGAC 81 62 IM000680 GATCAAGATAATCCCCCACAGGCATGCC p000729 R — CAGAGGCCCATTTCCTAGGTGAGACTAT AGTCTGTCAAGTTGACAATGCTAACCATT GCAGTGAGGGAGAGAAAGAAGGCCAGG ATGGTGCCTCTCTGTTACTCTGCTTACCC CGGGGTGCAAGGACAGTGGGGGATGG GCCTGAGCTTCCTCATGAACACACACAT GAGAGCAGTCAGCACATGGCCTCTTCCT CTAAGCTTCACAGTGGCAGCCGCACCTC TGCTGTTAAGACCTAACATGTGGCCGGG CAGTGGTGGCACACGCCTTTAATCCCAG CACTCGGGAGGCAGAGGCAGGTGGATT TCTGAGTTCGAGGCCAGCCTGGTCTCCA GAGTGAGTTCCAGGACAGCCAGGGCTA CACAGAGAAACCCTGTCTTGAAAAACCA AAACCAAAACCAACCAACCAACCAACCA AACAAACCATCTAACATGTACATCCTATC CATGTGCACGAATCATAC 63 IM000681 AGACCAGTGCCGGAGCCGTTCCTGGCT p000730 A Cmkbr7 GAGGCAGCCCAAGTCCTTGAAGAGCTTG AAGAGGTCGCTGCGGAACTTGACGCCG ATGAAGGCATACTAGAAAGGGTTGACGC AGCAGCGGACGGAGGCCAGGCTGTAGG TGACGTCATAGGCAATGTTGAGCTGCTT GCTGGTTTCGCAGCTGCTATTGGTGATG TTGAAGTTGGCCACCGTCTGAGCCAGGA CCACCCCATTGTAGGGCAGCTGGAAGAC TATGAAGACTACCACCACGGCAATGATC 64 IM000682 CCCTCTCAAGCCTTCCTTGTTACTTAGCC p000731 D — TCTATAGGTCTGTGCATTATACCATCATT CTTTTAATACAGCTAATATCCATATA TATGATTATGTACCATATTTGCCTTTTGG GGTCTGGATTGCCCTACTCAGGATGACC TTTTCTAGTTTGATC 65 IM000683 GATCATGATGTTTGTTGAAGCAACAGAAA p000732 D — CTATAAGACAGTGCCCAAGAGCCTCTCT GGAGATAGCC 66 IM000684 GATCGTGTTAGACACAAGTAAGAAATGA p000734 D — ATGAGTCTTCCTGATTTTTTAAATTAACTT CTCCCCATATTGGCTGTCACTACTTTTTA TCAGAAAGGAGAATCTGGACGGTTCC AGGCCTGCAGCGCCATGCTTGCAAAAG GTTTACAGAATCGCTCTGGACAACT 67 IM000685 CTACCACAGCATCTTTTGAGTGTATATAG p000735 D — TCAGTGTGCTACATGTTATCTATGAACAT ATGCAAATGAGGTTTGAGAATTAAAGTTG CTGATAGACTCATGGGTTAGGGGTTTGA TTGCCTGCTAATGATC 68 IM000686 GATCACGAAACGGTTGACTAAAGCAAGA p000736 D — CTGAACCACAGGCAGATACCAAACCCAA AGCTCTATGTCTAGTGTCTAGAATACATA GGTTTGGGTAGCCATGCCCCTGTGACCC TGCCACCTGCAGCACACATAAGACAATA CTATAGACAACCACTTCTGAGTCAGAATT GCAATGATGTCTTTGGCAAACTACTCTAG TCTCCTTTGGCCAGGAGCTGCTAAGTGG TTCAGGCTGAGGTACAATCAACCTAGGT AGGTGGGACTGTGTGCCCCTGTGCTCCT GGGTGGCCTTCATGTCTGCTATGCTTGC CCTTT 69 IM000687 GATCATGTCAACTATACCTGGACACGGA p000737 C — CCTTCATCCTTGCTGGTTTCACTACCTCT GGCACCCTGCAAGATCTTGCAGTTTTTG GAACCCTGTGCATCTATCTCCTCACACT GGCAGGGAACTTGTTCATCATTGTCTTG GTCCAGGCAGATTCAGGGCTGTCCACTC CCATGTACTTCTTTATCAGTGTCCTCTCC TTCCTGGAACTCTGGTATGTCAGCACCA CAGTGCCCACCTTGCTGCATACCTTGCT CCATGGGCCTTCACCCATCCCCTCGTCT GCATGCTTTGTCCAGCTGTATGTCTTCCA CTCCTTGGGCATGACCGAGTGCTACCTG CTAGGTGTCATGGCTCTGGACCGCTACC TTGCTATCTGTCGTCCACTGCACTACCAT GCACTCATGAGCAGACAGGTACAGAAAC AGTTAGTTGGGGTTACATGGTTGGCTGG TTTTTCAGCTGCCTGGTGCCTGCAGGTC TCACTGCCTCTTTAGCTTATTGTTTGAAA GAAGTGGCCCATTACTT 70 IM000688 CTGTCAATTCATCCAGCTCTAGGCCGCT p000738 D — GTCTGGCTCGATGCTTATTGGTTTAACA GTGCCGATGCATAGGATTCTACAGTCAG AGTGGCCTAAGCAACAGCTAAATATTGTT TTCTTGCTGTTCTGGGAACTAGATGTTCA AGGTCAAGGCGTCAGTAGCTCTGTTATG AGACCTCTCTGCTGTCGGGCTGTGTCTT CAAGTTTTTTCCCCCCTCTGTGCATGTGT GTTCCTATTTCCTCTGCATGAAAGACCAG TAGAGCCAAGTGGTGGCACACACCTTTG ATC 71 IM000689 GATCATGAGAGGCGAGAAACCCAGACAT p000739 D — CTCTAACTCTTCTTGCCAACTCAGGAGC CACCTGTGGCCCCAGCTGGCCACCAGC CGTTCCTCCCTCAGAGGCCTCCATTTCC ACAAAAGGCCTTCCTGGTTGTTCAGGAC AGAGCCTGGTTTCCCTGATACCCCTTCT CTCAGTGGCCACTGAAGTTACAGGGATG CAGCCAGCCGTGGTTGCCATGTCTGTAT ATGCTAATCTCCGAATTCCACTTCCTGTT TAGATTCTCAG 72 IM000690 GTTTGTCCGCATGAGTCCCAGGGACCAC p000740 D — TCAGAGTGGCTGGCAGGCATTGTGGAGT GGAATGTGGGAAGACACATTCCCAGCCT TGTTTGCAGCTTGGGACTGTCTGTGTTTT GGGATGATC 73 IM000691 GATCACCTGGGAAGGGGGAAAAGGACA p000741 D — AGTCTGAGCTCCCAGCCCACATTCTCCT AGGGTAGCAGCTCCCTCACTTAGTGT 74 IM000692 GATCAGTTCTTATTAAACAATACAGACTT p000744 R — AGGCAAAATGAGTCAGAAATAAGGATAT CGCATATCCCGAGACCATGAACTCTA AGAAGTATTTTCTATTATTAAAGTAGTTCA CCAGGCAGTGGTGGCACACACCTTTAAT CCCAGCACTCGGGAGGCAGAGGCAGGT GGATTTCTCAGTTTGAGGCCAGCCTGGT CTACAGAGTGAGTTCCAGGACAGCCAGG GCTACACAGAGAAACCCTGTCTGGACAA ACCAAAAAAAAAAAAAAAAAAAAAG 75 IM000693 GATCATCACAGATGACATAGAACCAAAC p000745 D — TGTAACTTTCTAGACTACATGTAGCAGAC 76 IM000694 GATCATACATGAATACAAGCAGGCTTCT p000746 B AA65702 GGTATACTCTTAAGTTGAATTCTGTTTTC 8 TGTAGTCGTAGTCTTGTCTTTTCCAGTTT TAAATTCTAGAACAGGTATACTGTAGAGC ACCCGCCTCCCCTTGCTCTGGAGGTAGG GTAGAGTGGGAGTTAAGGTCAGTTCC 77 IM000695 ATTTCTCTTGTAAAACTCACTTTCTGTTCA p000748 D — CCCATTTTGTCTGTGTCCTTACTAAATTA TTTCTATATAGGAATCTTTGTATCTTCTGA TATAAGCTAGCGCATGGGTACCACCAGC ACCCTAGTCATCTGCTGAGGTGCTTCTA ACCTTGCTTGATTCAGTGTCTTCAACAGA AGGTGGAGTAAACAGGTCATTTTTTACC CTAGAGAGTTCAGATC 78 IM000696 GATCTCCGGGTGCCAGACTTGCCCAGCA p000749 D — AGCACTCTTACCTGCTGAGCCATCCTGA GGGCCTGGATTTAAAAAAAAAAAATATTG ACATATTGTTC 79 IM000697 GATCTCCTAAAACTCCCTGTGTCAGGAA p000752 D — ACTTTCTGTGCTTTTGTATTGCGTTCCTG TGTTCGTGGAAGGCCCCCACGCCTTCAT CCTTGCTAATTCTTTTTGGATAGCTTGTT GCTTTAACTAGATTGGCCCTTTCTTGGCT GTATTTTCTGCTGTACCTATGAGTGGTG TGGGAGAACTGTGCAGACTTCCAGGAAG CGCAGCCATGAAGCTACATGTGCCTATG TGTAGACACATCATGGATTTTCTTACTAG TTTACTAGTGGGTGATAATCTGTCCTTTT GAGCTCTCCAGAACGTTCTAGAAGCTTA AGGAGAGAAATCACTTAAGAGAG 80 IM000698 ATCTGATAGTAAGTAAAAGGACAGCTAAA p000753 D — GATGAAGGGAAAGCAGGAGAGTCCTGG AAGAAGAAACTAGTGTTTCTAAGAGTTCA TCATTGATAAAATGCAAAAGAAGTCAATT ACATACATGTTTAGGAAACTGAATCCTCT TGTTTTGGGGGATGTTTGTTTTGAGGCA AAGGCTCTCTTACAGAGCCCTGGCTGTT CTGGAGTTCTGTATATCAGGCTCTGGCC TCAAACTCAAGAGATC 81 IM000699 ACATCAAGAGGAAGTTGGAAATGTCATC p000755 D — TTTAGCTATCTTATATCCTGGTAGCTTTA AGATTTCCTTTGTGTGACTTTATAGTTCT CAAAATATTTTTAAGGGTCAGGGGAGGA AGCACTTTCAAGAAATGAGATGGGAGAG GGAATGTCTTTGTGTTGGCCTGGAGATC 82 IM000700 AGCTATACCTGAAATTTGGCCAAGAACA p000756 D — GAAGCTCAGSAAATAGTGTGATTTAAAAA CCAAAACCAATTTACAAAAGGAAGACTGT GGTGTAGATC 83 IM000701 CCACAACTGAAAGCAACACACACAGTAT p000757 D — TTTTCTGTGGGTTTTAGGATGTATCCACA CTCCCGAACTTCCTTTCCCTGAAGCACC CCTCAGTTTACTCTGAAGCATGGTTTGA GTCCCAAGGCCAGTGTCAACTTTCTGCC AAGTCTCAATGGCAAAAGTCTGTTTTAAT CTGCTCAGGCTAATGTAGATC 84 IM000702 CTTCCAGTCTTTTTAGCTATTTATTGATAT p000758 D — GAATTCCCTGCCTTATGTATCATCCAAGA TTCTACCTAAAATACTTCCAATAAGTATC AAGGACCACTCAAATATTCACTATTGGAC TTAGAAGCTCCACTCTTAAAAATAGATTC TATAGAAAGAGCCTGAAATGGGGGCATG AAATGGGTCCATCTCCACCATCACGCAC ACATGAACAAAGAAAAGGAGGAAATGGT GTTAAGAAAACTTACATCATACTATTTAA AAATAAGGAGGAAGGAGGGAGGGAGAG AAAGAGAGAAAGCTCAATGCTTAGGCAA GAGTGCTTAAGAAAATTACAGTTAACAGA TC 85 IM000703 GATCTCCTAAAACTCCCTGTGTCAGGAA p000759 D — ACTTTCTGTGCTTTTGTATTGCGTTCCTG TGTTCGTGGAAGGCCCCCACGCCTTCAT CCTTGCTAATTCTTTTTGGATAGCTTGTT GCTTTAACTAGATTGGCCCTTTCTTGGCT AGTATTTTCTGCTGTACCTATGAGTGGTG TGGGAGAACTGTGCAGACTTCCAGGAAG CGCAGCCATGAAGCTACATGTGCCTATG T 86 IM000704 GATCTGAGTGCTGGGAACCAAACCTGGG p000760 R — TCCTCTGCAACAGTTTGTGCTCTTAGCTG CCGAGCTTT 87 IM000705 GTACGGCGATGGGCACAGGCTTCGGGA p000761 B Mm.2739 CAGTCCGCGCGACGCTCAGGCGGACAA 3 CGGGAGGCGGGCGGGGAAGGCAGGGG CTGCAGTGTCAAGTCCCTGACCCGGGA GGCTCGGAAACTTCACTGCCTCTGCGCA TCCGGCATGGCCCCTCCCACTCGGACTT CGTCAAAAAACCGCCACCGTGGAGTGTC CCAGTATGTGCGGTGTGGGACAAACTAT CGCACTGTTGCCCTGGCTCTTCTCCTAG ACCCCCTTTGTGAGCCAAAAGAGAAACG CTGGGCAGATC 88 IM000706 GATCTCGTTACGGATGGTTGTGAGCCAC p000762 R — CATGTGGTTGCTGGGATAA 89 IM000707 CTGGGTTGACCTTAGAAACGGGAGTTCA p000763 K Gfi1 TCTCCTCCAGCAGCTCCGGGAAGGAAG GTGAAGGGGACTAACCATGATGAGCTTT GCACACTGGACTCAGGGCCTGAGAAGG GGCTGGAGGGAGGCAGGGAAGACATCC CTCACGGTAGTGTTACACAGCTGGTGTT GCGGGCTGCCAGGGTACTCATTGAGTC CATGCTGAGTCTCTCGGTGCCTCCTGAG ATC 90 IM000708 GATCTCAGGAGGCACCGAGAGACTCAG p000764 K Gfi1 CATGGACTCAAATGAGTACCCTGGCAGC CCGCTACACCAGCTGCGTAACACTACCG TGAGGGATGTCTTCCCTGCCTCCCTCCA GCCCCTTCTCAGGCCCTGAGTCCAGTGT GCAAAGCTCATCATGGTTAGTCCCCTTC ACCTTCCTTCCCGGAGCTGCTGGAGGAG ATGAACTGCCGTTTCTAAGGTCAACCCA GAGTGGGAACCGCAGCAGCAGCAGCAG TCGTCTGTGCTTTGGGCTTCCCTA 91 IM000709 GGAAGAAGTGTGTGCAGGCCATGGTCAA p000765 B Mm.1535 GTCCTGCATGGCTCCCATCTGGGTCCAG 12 CAGCACCCAGCCTCCAGTGCTTGCTCCT GATGTCCCAGTGAACTCAGGTCCTGAGC AGCAAATCCCAGGGGCCAGTCCTAGGG AGAAAAAGAACACACTGCCATCTCAGTG CCTCAACAGAAGCAAACCTAGGCGTCAG GTCATGTCCTTGTTACCCACATCACACCT AGACTTCCCTGGGTATCATGCTCTGTGT GAGATC 92 IM000710 GATCTAAGGATATATCATTCCTAGGAGAA p000766 A Mtm1 AATGAATATATGACCTTGGATGTCA ATGTTTTTTTAAATATGGCATTAAGCCAC AGAGATAAAAATAAGAAAATAGATACATC GAATTTCAGTAAAATGAGGAAGTTCTTGT GATTCAACAGAAAC 93 IM000711 GAGGTAAGTCTGTTCAGTGTAGCTATCC p000767 D — TTAGCAGCTAACAGTCCTCAAAACTTTTT AGAGATC 94 IM000712 CTACAGATGCATTATTAATATTACTTTTTA p000768 D — AAAAAACCCAGTATACTGCTTGAAAACAG TGAATGCAATGGGTTCTCATTCACCTTCC TGCTCTCAATCAATCTCCATCTCTAAAGC AAGAAGTGGGGGCCCTTCTGGCTGAGC GAGGGGTGAAGGGAGGGGAAGAGATG 95 IM000713 GATCTGGAGAAGATGTCAAGTTTTAAAAT p000769 D — GAGGCAG 96 IM000714 GAGTGAAGCAAGAATTTGGAGCCCAGCT p000770 D — GCCGCAGCCTTTTTCCTTTCAGCAAAGC TCGGGAGTGATAGATATGCATGAACCAA AGCAAAGGCTTGAGAGTGCCACTTGGCC CTGCCTCCTGAGGGTCTCAGGGCATCAG CTGGAGACCACCCTGTGACCCACACATC ACCGACTATGAAAACAGCTCATCAGAGT AATAAAGATC 97 IM000715 CAATGAACAGGACACATGCTTCACACGA p000771 D — CAGTCCAAAAATGCAAAGTGTGGAAGAA TTCCACAGCCATAGCCTTCATTACTAGAT C 98 IM000716 ATGCCTTCCTGGTAGAAGAGGGCCATGC p000773 D — TGTGGCGGGGAGGGGCCACTCAATTTTT CCTGCTCCCTTTCCCTGTCCCATATTCTC AGGAGCTTCTAGAAGCGTAGCCTGCATC TCATGCCCTGACTTGGCACCAAATGCTT GCTTTGTATCAACACCGCTTTCTCTTCTG CTCTTTCCAGCTCGCAGCCATTCAAATAA TACCACCCGGTACCCGTGGAATCAGGAG CAGAGATTCCAAATTGAGTCCTAAAATCA AATCCAAATGGGCCCGTCAGCTAGATC 99 IM000717 AGGCGAGCGGATTACTAAGGACTGAAAG p000774 D — ACTCCTAAGACTTGTCTCCTGCTCCCTG GCCAGCGGTGGAGCTCAAGCAGAATTG CAAGCTCAGCTCAGGTCTCAGTGATGCA AAGCACCCTCGTTACTCCAATGTGTGTTA CTCCTACAGGTGGGCTGCCTTCCACTTT CAAACACCCGCACAAACAGACCTCCCAC CGTATGCCAGAGCATCTGTTCGATGCTT TCTGGAAACTATGCAAGCCCAAATTTAAT ATCCAATCAGATC 100 IM000718 GTGTGTGTGTGTGTGTGTGTGTGTGTGT p000776 R — GTGTGTTACAAGGTCTCATACAGAATCC AGGCTGGTCTCAAACTACTGGAGTCAAG CCATCTTCTCACCTGGCTTAGCTGGGGT CACAGACTTGTGCCATCATGCCCAATGG AATGCTGTTCCTTTTGGAAAGCCTGCTAC TGTCATATACTGTCATAGGAGTTAGCGA CTGCTGGCTTATTCCTTCGCTTTGCTTGG AGATC 101 IM0007T9 CCCCCTTCCTGTCACCTCCTGACCCCTT p000777 D — GCGCAAAGGAGGCTCGTGGCCCGCTGT CCCACTGGGGGATGGGGCTGGGGTTGA GAAGGCTAGTGAGCGCCTCTAACGCTCA GGAAGTGAAGTTTGTGGTTTTGGGGGCT GAGCTCCGAAGGAGATTAAAAAAAAAAA AAAAAAGTCAGAGAGACAGATC 102 IM000720 CTTTGTATAAGCAGCAAACAAAAAGCCA p000778 D — GAGGCAGTCCACAGATC 103 IM000721 ATACAACAGGAGCAAAGCTGGAGGGGA p000780 A Rab37 ACAGATATAGAGGACAGTTCAGGGCATC TGCAGAGGTGCTGTGGAATGGGGAGGG GACAGTGGATAAGGGGACTTACCCTGAG CATCTCGGTAATAAGCATGGGTCACACT GCGGAAGCGCTCCTGTCCTGCAGTGTC CCAGATC 104 IM000722 GATCTATGTCATCTTCCAGGACTCAGAG p000781 D — TTAAGAGAGTTACCAAGTGAGAGCTCTC ATCACCTTCTGAAGCAGTTGAGAATTGG AACCCAGAAAGATGCACATGCACGGGCA CACACACACCCACGGGCACACACCCAC CCACCCATGCAGAGAGAGAGAGAGAGA GAGAGAGAGAGAGAACTCACACTGGTAC TGCAGTAAACGGGAGCTTGTTT 105 IM000723 GATCTTCTTTCTCTGCTCAATTAGTTCAC p000782 D — TTCTGCTTTCATCTCCTTTTCTTTTGATAA ACCATGAGTTTCATTAGGGCTATTACAAT CACATGCAGTTTTTCCTTATAGTA 106 IM000724 GAATTAGGCCTAGAAACATTAGAATCCA p000783 D — GACCACGGAGCTCCCCAGATC 107 IM000725 GATCTTGTTCTAGAACGACCCTGAAGGC p000784 C — AGCAGAACAGAGCAGGACTGAAGGCCA CCAAGGGGATTTCAACTCTTCAGAAAAA ATAAGTGACTCACCTTCTCACAAAGAGC AAGAATCACAGAGGTCAGATTGTCTCCT CCTGCCCATCAGGGACAGAGTCCCCCAT CTTTGCCTTGCTCCATCTGGCAGGTAAG AGATGGGAAGTCTCCTCCCTCGGTCT GCAGCATCCCTGGCATCCCTGGGGAGT GTTGGCACAGAACCCCCCTCCCTTA 108 IM000726 GATCTGTGTGGGCAAAGCCCATGTGCTG p000785 D — GAGTGTGTCTGGGTAGAAATGAGTTGTG TGGTGCTGAAATGTAAATGAAGTCCCTG TGTT 109 IM000727 GATCTCATTACAGATGGATGTGAGCCAC p000787 R — CATGTGGTTGCTGGGAATTGAACTCAGG ACCTTTGGAAGAGCAGTCAGTGCCCTTA ACTGCTGAGCCATCTCTCCAGCCCCCCA CCTTTTTTTTTAAAAGATTTATTTTATAGT TTTTGCTTTTTTAACAGTACTGGAACATC TCAGTAATTGCTAAGTTGTCCTTGCTCCA GGTGAGCAGTCATATTTTCTCCAATTCTG GTTTCCTTACTTGTGTCAGAGACCAAAAT AGCTTGTTTAATCAGTTAGAGCTCTTTAG TTACCCATATCTGTGTAGTAA 110 IM000728 TAAGAACATAAAAGCAAAATTTGGAGGCT p000788 D — CAAGATTCAGTTTAGTTGCTAGAGGGCT CACATAGCATGCCCTCCCCACCCGGGAT TCCATTCTCATTTATCGAGGCATAAGGCC AGGTGTGGTGGGATATGTGCTGGGATG CATAAGATC 111 IM000729 GAAAGGCACACTGGTGAAGGCTGAGGA p000789 D — CCACCAAAGCTGCATTTCTGCTAGGCTA GGTAGAACAAGAATGGTGCTCCACTAAG AACTCAAAAAGCCACAGCCCACCCCTGA GGCCCTCCATCTGACACATGCCGGTCAC CTGTCCTCCCACAGCCCAGCACAGAGAA GCCACCATCCCTCCCCTTCCCACCTCCT GCAGCTGACAGTGTGCATCTTTCCGCAC ATTCCTCTCTCCTCAATCAGGTCAGAATG TATTCCAAAGATC 112 IM000730 CACTGAAAATGGCTAGAATTCTGGTGAT p000793 D — GGGTGAGCCGATC 113 IM000731 GATCGGAGTCCCTCGTTTCAGAGGCCCC p000794 D — ACTTCTATGGCTCCTGCCTTCCTTGGCTA CATCCATTCCTGCTGAGCTCCTGGAAAC CTGTGTATCAAGTCTTTTCCAGTTAGTGC GTTCTGAGTGGCTCTAGAAACCGCTTGC CATTACAGCGAAAGACCCGTATAAACCA TGTTCTCTTCCTCTGTGACAAGAGACAAC GACACCGCACAAAGGACTGTCTGGCCT GGGGGGGGGTCCCTGGTTCACAGCTTC AGTCCTGA 114 IM000732 GATCGCTCAATATAACAGCAACATGCCA p000795 D — AGTGCCACTTGTAAAATTTGnGTTGAGC AGTCTCATTATCAACTGAAGCACAATGTC AGGCTAGCAAGAGGCAGGTTCAGTTGTT GATTAGCGATAGCACACACAAGCCAGCA CATGCTTTTTCTGTGAGTTCTAT 115 IM000733 GATCGCTGAGTTTGTTTACAGAGCAGGG p000796 A Cited2 ACGCCTCAGCTCGGATGCCAAAGCTACC AAGAGCTGCAAACGCAAACTTAGCAGTA GCACACGTACTCCC 116 IM000734 GATCGCACAGGTAAAATGGGGACTCACT p000797 D — TTAGCTAAAACAACAACAACAAACAGCCT GATGAGTCGAAAGTCTCTTTAGGTTGCC CTCTGTTCTCCAGCCCCACATCCTGAAG GCTGTGCATTCCTCCCACAGCAGTCTCA AAATAACCATAGTGCTCAAGTCCCCTGTA TCAAATGGTGGTATCTGCATCCACCCTA CAGGTGTTCTTTGATTCTTTCTTTTCTG TAAGTGTGTCTGGGTGTTTTGCCTGAGC GTATGTATGCGCCTAGTACCTGCAGAGG CCAGAATAAGGTGTCAG 117 IM000735 GATCGTGAGAGGCGAGAAACCCAGACAT p000798 D — CTCTAACCCTTCTTGCCAACTCAGGAGC CACCTGTGGCCCCAGCTGGCCACCAGC CGTTCCTCCCTCAGAGGCCTCCATTTCC ACAAAAGGCCTTCCTGGTTGTTCAGGAC AGAGCCTGGTTTCCCTGATACCCCTTCT CTCAGTGGCCACTGAAGTTACAGGGATG CAGCCAGCCGTGGTTGCCATGTCTGTAT ATGCTAATCTCCGAATTCCACTTCCTGTT TAGATTCTCGG 118 IM000736 ACTGTCCGTGTGGGAAACGTTTAGCAAG p000799 K Nmyc TCCGAGCGTGTTCGATC 119 IM000737 ATTTCTTTTTGAGTACTTCATATAAGAGC p000801 D — TTCGCATGTACACCACTCTTGCTCGCCA CTCCTCTTTTCTTCTTTCATTAACTACTGT CCACTCTCCAAACTTCATAATCTCTCTAA TTACTATTGTTATTTACACACACACACAC ACACACACACACACACACACACACACGT ATATGTAACCTACTGAATCTTACTAAATA GCTTTACTATCTTCCAAGTAACAGGCACT TGATAAATCTTCTGTCAATCTCCCAGAAC AGAAGCCTTAAGAGTCATTTAAGTTCT TATCTCAGGCTGTTCTGTTCTATGCCTTT TGCTTTTAATCCATCACCGATC 120 IM000738 GAATGTCTAGATGGAGACTGGACAGAGT p000803 C — TGGATTCCTAGACACCTAACAGAAGCGA AAGCAGGGGATGGATAAGGTGGGTGCC TCGTCCTACAGCAGGTTCTGAGTGTCCG CAGAGACTCCCATGGCTTGGCACCATGG TTGAAGCTTTCCATCGATC 121 IM000739 CTATTTTCGTTCTCTCCGATC p000804 D — 122 IM000740 GATCCTCATGTCAAGGCAGGGGCAGAC p000806 D — CAGGGTCAAGGGAAAAACACCTGCTTTC CTGGGTTGTAAATGCCAGAAAGGGAAGG CACGGGGTGGGTAGGGTGGAGAACATG GCCCAGACCCCTGTCTCTTCTCT 123 IM000741 GCACCTGACTTCCTCATATAAGACACAAA p000808 R — CATCTTGAGTGCTGCGCAGGTGTACCAG GATACAGGTGAATCCAATCTGGTGGAGA TTTGCCCCTGCTGCCCTGATTAGCTGAA GCTGCGTGCCTGGTGAGGTGGCATGGC CTGCTGTGCGTGGATGGGAACTGAGAGT ATAAAAGAGCGAGAGGCCCGGGTTAGA GGAGGATTATTATTCGAGAGAGGATTGT TATTATTGGGAGATATGAACAAGGGAGA TATTTAACAGGGGAGATATAAACAAGGGA GATATATGGAGAAAGAAGAAACAGGACT GAATAAATGTGTGCAGAAGGATC 124 IM000742 GATCCTTCTCCTGTCTTCTCTTCTGGAAG p000809 D — GCTGGGCTACATGCCTAACATGTCAGAGT TTTACCTGGGTTCCTTCCAGAGGTTTGAA CTCAGGTCCTTGTACTTACACAGCAGCT ACTTTGCCTATTGAGTCAATATTTTGTGT GTGTTTGTGTAGGTGTGTTCATGTCTGTA TACTTG 125 IM000743 GATCGTGCATGCATGGGTGTGTTTTGGG p000811 D — GAGAGGTTCTGTCCTTGCTAAG 126 IM000744 AGCTCAGCTTGTCAGGCCTGATTGTGAA p000812 D — CACTTCACCAACCGAGCCATCTCGTCAG CACAGCCCTGTTTTTTATTCCCATTTTCT TTTCTGTATTTCTGTTGAATTTCTCACATA CTCTCCTTTCTCTTCTGCCTTCTTCTGGT TTCTGCATCATTTCTATATTGACATTTAAA CAACCCCCAAAATTCAAGATACATCAACA AAAATTTATTCAACTAGTCTTTCTTACTTC CATATCAATAATGAAAGAAAATTAAAACC TTTCAAATTCAACAAATCCCTACACTACA TATAATCACTTTCCTCTATGCTAAATCCA ACTTGAAATTATATCCTCAATACCCTGCT GGTATTTTTACTGTCTACATCACTGCCTA GTCTTCGATC 127 IM000745 CTGGTATATGAACGAAGTTGGTCTCTAAA p000815 R — GGCCGTCTAGAACAACGGTTCTCAACCC GAGGGTCGCACCGGGGTCACCTAAGAC TACTGGGAAAGCACAAATATTTACATTAC GACTCATAACAGTAGCAAAATTACAGTTA TGAACTAGCAACAAAAAATAGTTTTATGG TTGGGGATTACCACAACATGAGGAACTG TATTCAAGGGTCGCAGCATTAGGAAGGT TGAGAACCACCGATC 128 IM000746 TTCTAACCTGCTAGGGTTTTCTCACGTG p000819 D — GGTTCTTCTTTGAGGGCTCTCTGGCTTC CCTACTGAGCTGTAGCTGCCAAAGTTGA AGGGCTGCGTCTCCCTTGCGTCTCCCCA GTCTTTACAGCTCCTGAAACACACTAAG GTATTTATTCAAATCCCTGTTTTGTGTGC GATC 129 IM000747 AGGGCCCTTCCACCTCTTCTAGAATTCG p000820 C — GTAAGCTAAAAGTACATGTATCCGATTAA TCTGAAATAATTTTGTAGACAGTTTGGTG ACGGGTGGAGGGTGTGTGGTTGCGCGA TC 130 IM000748 GATCGGCGAGACCACGATTCGGATGCAA p000823 R — CAGCAAAAGGCTTTATTGGATACACGGG TACCCGGGCGACTCAGTCTATCGGAGGA CTGGCGCGCCGAGTGTGGGGTTCGGAC CAA 131 IM000749 TTGGCTGTGGAGATGAACGTGGGAACC p000824 D — GTGGAAATGACCCTAGAATGGGGCTCAA ATGTGAAAGGCATGCCAGAGGTTGCTCT GTTGTTTTAAGTCCCTGGCGAACATTAGA ATTTAGCCTCAGTTTTAAAAGCTGTTACT GCCTAGTTGGGTGCTTCTTTCTTAAAAAG CAACCAAAAAAAAAAAAGCCGTTTTCACT CTGAAATGTATTAGAAATTTGCATTAGCC CAATGGCTAATAAGCGATC 132 IM000750 GTTATAAGGATTGCATACAAATGGCATCA p000825 D — GGACTGGATGTGGTGGCACATGTCTTGT ATCACAGCACTTGGTGAACAGAGGCAGG GGAATCTCTTTGAGTTACAGGCTAGCCA GCATGACACGGTGAGACTCTGTCTTAAA CAAACAAACAAACAAAAAAACAAACTAAG GTAGCATAAGAGCGATC 133 IM000751 ACCTGAATCTTGAATAATGGGCTGTTTTT p000827 D — CCGATC 134 IM000752 ACTAATACCTTTCCTTCCGCTGCGATGT p000831 D — TTCATGAGACTCTGGGTTAGTGCATGGT CAGGGGCCCAGGCAAACAGTGGCAGTT CTGCCCAGGATC 135 IM000753 GTTTAAAGAGCCGGTTCGACCCGCTTTC p000832 D — CGTTTCGCTCCGGGTCAGCTAGTACTGT GAACCGCTCGGTCGGGTCCGGCGCTGC TGCGCACCTACTCGCCGGGACCCTGAA GCCCCCCAACTACATATAGGGGTCTTCC CGGAAAGTACGCAGGAAGTCGCGTTCG GCCCCCTCCCCCCAGCACCACACCCAG TCCCTTCCACCCCCCGGGATC 136 IM000754 GATCCCAGTAGAGACAGAAACAGTGCCT p000833 D — TTGGTTAAGAATTCCAGGCAGGATGGTA CAGGATTGCAATCTCAGCATGGGAGACA GAGGCAGGATTTCCAGGCCAGCCTGGG CTACAGTATAAATGGGACCCTGTCTCAA GTTATTGAAAAAAAAACAGAGAAAGAATT TGGAGACTGTGACTATAGCTTGGTGATG GAGTCCGTTTGCCTAGCAGAGTGAAGCA GCTGTGCTCCTGTGTTCACACCACTAAA TAA 137 IM000755 GATCCAGTGAATCTGGGCATTGTGAGTG p000834 B Mm.1313 TGTGACACAACTTGCTCTATGTGCTGTTA 36 GGGATTTGTGCATGCTCAGCCAACAACA ACCGCCAACTTAGACTGATGCTGTGCGG CTGAGAACACAGACTGACAA 138 IM000756 GATCCTCCCTACCGGTCCTCGGGCAGAC p000835 D — CTCCAGCCCTTCCCCAGACACTGTTGGA AAGCAGGCACGCCTTCCACAGTATGGTC TGAGGTTAACCCATGACAGCACTCTGGG TGCCTGGTGGTGTTCCTGGTGGGGACG TCAGTAGCTGTAGCTCTGTCATTGGTCC TTGCAGCGTCTCATTCCAACTATTCTTCC CATCACTCCTCT 139 IM000757 ATATGTGTTTGTGCGTGTGTGTACATGTG p000837 D — CATGCATGGCATGTATGTACCCATATAAA TATGTGTATGTGTGTGAAGTGCTGATGTA TTTCACACAGCATTTTGGATTTAATGGAG AAGGTAGCTCAGATGTCAAGTGTGCCCT CCTGTCAGGAGAGGAAGCCTGATGTGC CTGCTGTCATAACTCTGGTTTTGATAAAT ACAGCACGAGTGATTTTTGGCTGTTGGG TTTGCCGTGTATGGATC 140 IM000758 GTGCTTGCAACATTGTCATAGCTTAGT p000838 C — GAACAGTATAGCATTGTTCTGGCTCAAG AAGCCCTGGTTCTTCAAAGCTCCTACTTA GATGAAATTATTTGCATCACTAACAAAAA TTGTTTTGCATTTTTTAGATAATGAAGGA TC 141 IM000759 GATCCTAGGCCAGTCAGGGCTACCAATA p000839 D — AGAACCTGCCACACACACAAAAGGAAAG CAAATTTTTGCAAAAACTCTAGTCTCATG GTGTCACGGTCTAAACATCTTGAGGG GCTCGAACTGGTGAGGTGGCTCGGAGG TAAAAGGGCTTTGATGCACAACCTGAGT TCAACCCCGTGTTTTAAAGACTTTCTGCA TGATTCTGGTCTGCAGTCCTAGCCCAA GCACAGTCAAGGAGAGATTGAGGCTGAA ACGGAAGAATGGAAGTTTGCATAACAGC TCAGTGGCAGAAATAACAGGAGAGACCT GACCTTAAAAACAGGGTGTAAGGTGAGA AATGATGACAAATGACATCCACTTCAACT GTGCTACGAACAGCTACCTGTTTGCACA CCCCAAACACACACACACACACA 142 IM000760 GTAAGAGGGAATGTACTCTCTGCCATCG p000840 D — GGACACCCAGTGGAACTGCTCACCTGGA GTCTTGCCTCCACGAAGACTAGGATC 143 IM000761 GGGACTTCAGGGCATAGAGCTTAGTTCC p000842 D — AGACAAAACCAAAGTTAGCAGTCGCCTC TCTCTTAAAGACGTTCTCTCTAGCCGCA GATGACCTCAGAAGGGGCTCTGGGAGC CGACTCCCACCCTTCCTTCTCTGTTTACA GAATCTGGTTGGGCTGTGAGGAGCGAC CCACGAGACGGGCTCCCTGTAGTGAGTT AGGCCAGTGGGAACCAACGAGGATC 144 IM000762 ACACACACTAACACACACTCACTCACAC p000843 R — ATACTCACACACACTCACACACACTGTCA CACACACACACACACACACACACACACA CACACTTTTCCACCAGGATC 145 IM000763 GATCCCTGGATATGGCAGTCTCTACATG p000844 R — GTCCATCCTTTAGTCTCAGCTCCAAACTT TGTCTCTGTAACTCCTTCCATGGGTGTTT TGTTCCCACTTCTAAGGAGGGGCATAGT GTCCACACTTCAGTCTTCATTTTTCTTGA GTCATGTGTTTAGCAAATTGTATCTTA TATCTTGGGTATCCTAGGTTTTGGGCTAA TATCCACTTATCAGTGAGTACATATTGTG TGAGTTCCTTTGTTCAAATTTCATTTCTAT CACCATTGTGTGTATATGTGTGTGTTGTG TGTGTATGTATATGACGTGTGTATGTTGT GTGTGTATATATAACGTGTGTATGTTGGG GGTCTAAGGCATGCTCATGCCACAGTGA ATGAGTAGACATCAGAGGACAACTTTCA GGACTCAGTTCTCTTGTTCTACCCTGTG GTTCCAGGACACTAACCCAGGTCATCAG GCATGGTGACAAAGGTTTTGACTCAAGG AGCCATTTTACATGCCTCATAAGAAGGG CC 146 IM000764 GCACTAGGAAGGAAATTGACCCGTGTTG p000845 R — TTGGTTTGTGTTCTGGTTTTGTTGGTGGT GCTTTTTGTTTTTTTTGTTTGTTTGTTTTT TTGTATCAGGATC 147 IM000765 GATCCTGCTTTCTCTTTTGACACAGAACA p000847 D — CTTCTCCTGATTGACTCTGGTCCAGACAT TTCTTTCAAAGGCAGAGGACTCTGGCTT AGCTGTGGATGACTTCTCAGATGAAGTT CATTGGTTGCGATTGGAAACGTAATCAG AGCAGG 148 IM000766 GATCGCATTAGGGTTTTTTTTATGGTTTC p000852 R — TCATCTTCTCTTCAAATTAGCATAGAAGC CTCTTCCTAAAGAATGGATACTTAATTCT TAACTTGAAATATCTTTTCTCTGTGTGTT TTCCTCTCCATTGACTGTTCGCTCTATCT ATCTATCTATCTATCCATCTATCTACTGA AATTAAAAATAAGGGAACGCCTTCTTCTC TTCATTCTTGTTTGTTGTTTGTTTGTTTGT TTGTTTTTGAGACAGGGTTTCTCTGTGTA GCCCTGGCTGTCCTGGAACTCACTTTGT AGACCAGGCTGGTCTTGAACTCAGAAAT CTGCCTGCCTCTGCCTCCCAAGTGCTGG GATTAAAGGCGTGCACCACCACCACCTG GCTCTCTTCATTCTTTTTAAAACGATTTTT GAAACCTTTTTAGTGAGGTCAACATTGTG TACTCCAGTCCCACTCATCTTCCTGTCCC TTCCCTCTTAGGCCTGCCTGTCTGGTAC CTCACTCATGTTTGTGTATTCTCTGTGCT GAGCCTCTTCTGTGCTTTCCCAGCACAT GGCTGCTGGCTCCAGTCATTCCAGTC CCTTGTGATGTGAGCCTAGTTCAG 149 IM000767 CTCTCATGGCATGGGTCTCAAGGTCCTG p000854 R — CCATTTCTGCTCCATCTTTACCCCAGCAC ATCCTGTAGACAGGACAAATTGTAGGCC GGAGGTTTTGTGGCTGGGTTAGAGACCC AGTTTCTCCACTGGAAGCCCTGCCCGGT TACAGGAGGTGACCAGTTTCTGGCTCCA TGTCCCCCATTGCTAGGAGTCTTAGCTG GGGTCATTCTCACAGATTCCTGGGAGAT TACTCTATTTTATCTCCTTGTTCAAAGTGT TCCATCAGATATTAATTATTCTCAAGATT CAATATTCTCAAATATTATTCTCAAGCTAT GGACCCTTCAAATTACAGATAGATTTTAT GAATGAAAAGTTGTGTGGTTTGAATATGT AGTTGAGGGTGACTTTGAACTTCTGGTTT TCCTGTGTCTACCTTCCAAGTGCTGGGG TTACAGGTATGAGCCATCACGCCAGTTT CTGTAGCACTGAGGCTCAAACACAGGGC TTCTGTCTGCTAGGCAAGCACTCCACCT ACCAAGCCAAATCCCCGGGCTTTACTGC ATCTTTGTGTGTATATGTATGGTATGTGC GTGTGTATGTTAGGATATATGTACCTGTG T 150 IM000768 GATCAACACCTGAAAAGTCGCGCCGCCT p000858 D — ATACACATCCCTAATTGAGAAGTATGTGG AAGATTCCATCCGTGAAATTCAATTATCA TGCAAGCCAAGTGGAAGCGCTTCCCTGG GGAAGGAACCCAGCAGCCGCATCAAAA CGACCCCACCTGTCTATTTTCATGTCAAA AGAGTGAGAAGTCTGGGTGATGTAATAG AGAGCATACATCAGCTTAATGAAAATTTC CAGGGGTCCCTGCCTGTAATGGGAGTC CCAT 151 IM000769 GATCACCACCAGGGTGTTGAGAAAAAAA p000860 D — AAAAGCAAGTTAGTAGATGTTAG 152 IM000770 GATCTGACAAAACCTACCTGTTTTTGAAC p000861 D — ACATGTGGGACAGCAGTCTGAGAGAATC TATGAATAAAATTCCTTTCTGAGTCTGGC ACATTGGTACAC 153 IM000771 GATCATTATACCCCAAATGGTACTGTATC p000863 D — TATATATACCTCAAACATGTCATGTTAAA GAAAATACTCTGTTGAACTAATTCACTTG TTT 154 IM000772 GATCACAGGACTGAATCACATTTATGCC p000864 D — AT 155 IM000773 GATCATTTATTTACTTGTTTTGGTGTTTCA p000865 D — TGTTTGTGGCTCCTTATGTAGTCTAGATA TTAACTTGAAGTCTGAAGTGGAACTACCA AAGATTTTCTTCCATCCTCATCT 156 IM000774 GATCAACCGCAGATGAGGTCTATGCAGG p000866 K Myc AAAAACGATGTCTGGAATTTTATTAAAAT TGCTCAGC 157 IM000775 GATCATCATGTCAAACCTGACACGTGAC p000867 D — GAGACAAATCTGTGTGCACAGAGGTGTG ACATCCTAAAAGTACTAACAATACCGCTG GGCAGGGACACACGCGGCAATTCCAGT CCTGGTATCCATGGCTCAAGCTCTGCAC GGAGAGCCCGGCACACGGCAGGAGGGA GAGCCACAGGCTAAGGAGAGCTATGCTA ACTAACATGGCACCCGTGTTAG 158 IM000776 GATCTGGCTTCCAAGGGCCTGTACTCAT p000868 D — GTCTACAATGCTCCTACACAGATATAT 159 IM000777 GATCAGCCTTCCTCCAAAGCTACGTGCA p000870 R — TAGAAGAGACCTCTGCTCTCACCTACTC TCCTCTACAGTTCAGCCCATATGGCTTCA CCTGCATCCCCTACACACAGACACACAG ACACACACACACACACACACAAACACGC ACACAGCACACACAACACACACAACACG CACACTCACAACACAAACACACACAACA CACACTCACAACACACTCACACACACAC ACAACACACACACACAACACACACTCAC AAACACACTAGTACACAAAGACTCCAAC ACACACATTCCCATGCACTACTCCCTCA GTATCCGCCGCATTTGTGTTCACACTCAT CCACACTCTCACACATGTAGCACACACA CATCATTCCTACACAGGCATGGACACAC ACATGCTCCTATACAGGCATGCCCAGTA CTCTCACATGCATGTTTGCACGTTCCCAA ACAGGTTCCCACAAGGGTTTGGCAAAGT ACATGCATCCTCACACGCTAATGCAAGC CGTCACACCCCATACCACAAGCATGCAC 160 IM000778 GATCAGATGTGGAAATTAGAGAGAAGTT p000871 R — TTTAACGGCTCATGCACATTTCTGAAAAC TCTTTGCGAGGTATACTGGTAGATAAATG AACATTGGTCAGACTCCTCTAGTTTAAAC CACTCTCTTCCCCGCTATGGGGGGAGG CGAGAGGCATTTCTAAAGCTTATATGTAG TTGCAAAGTGTGTGTGGTGTGTGTGCAT GTATGTGCATGTGGTGTGTGTGTGTGTG CATGTGGTGTGTGTGCATGTATGTGCAT GTGGTATGTGTGTGAGTGGTGTGTGTGC ATGTGTGTGCATGTATGTGCACCGTGTT GTGTGTGTATGTGTGCATGTGGTGTGTG TGCATGTATGTGCATGTGGTGT 161 IM000779 CTAACATCTACTAACTTGCTTTTTTTTTTT p000872 D — TCTCAACACCCTGGTGGTGATC 162 IM000780 GATCATAAGGACTGTTAGCAGGCAAAGG p000874 D — CGCGTGCCCAATTAAAAGATGGCTTTCG TTCCAAGAGGAATACTCTGGCAAAGTCC CAAGCGCTTCGGAAGCCCCTCCCTTCGC TCTCCCACCCCAGCTGATGCTCTGATT ATCCTAA 163 IM000781 GATCAGGCTGGCCTTAAACTCAGGGAGA p000875 B Mm.8363 TTCATATGGCCCTGCCTTCAGGGTGCTG 5 G 164 IM000782 CTTTCTTTCTTTCTTTCTTTCTTTTTTTTC p000876 R — TGAGACAGGGTTTCTCTGTATAGCCCTGG CTGTCCTGGAATTCACTGTAGGCCAGGA TGGCTCAGTCTGCTTTCTTATAGAACTCA GGACCACCAGCCCAGAGATAACACCACT CACAGTGGGCTGGTCCTCCCCACATTGA TC 165 IM000783 GATCACACACTTCACTGTGGCTTGTCAA p000877 D — CTGTGATTTGCTGATACAAGGGCTGTTTA CAAGTCAGCTATAGCTCCGCATTGCAGC TGCAAC 166 IM000784 GATCACTAATTGAGAAAATGCCCCACAG p000878 A CcT5 CTGGATTTCGTGGAGGTACTTCCCCAAC TGAAGCTCCTCTCTGTGATAATTCCAT CCTGTGTCAAGTTGACAGAAAACCAGCC AGTACACAAGTCGACACAAAACTAGCCA GTACACAAGTCAACACACAACGCGCACA AGCTGAAGGCAAAGAGAACCAAGCATCT ACCAGGCCTCAGTTGCTATGTCCACTTC TGCAGCCACTCCAAAACACCTGTCAGAA ATTCGGTTTGATAGAGAACTCACCGAGG GATTTCCCTAACACCAGGTCAACCAGGG CACCTCAAACCTGGAGGCACGACTGGCA CAATACAACCTAA 167 IM000785 GATCACTTGATAAAGATGCTCTGAGCAG p000879 B Al615991 AGGCTCACAGGAACCCAGCCCTGTGTG CTCCCCAGGAGCGAGATTCAGCAGTCAA CAGTGCAGTGTTCACGTGACCGTGCGCA GGCCATGAGCACTAC 168 IM000786 CTCCTTTTCAGCAAGCTCCTCACATCACA p000881 B MMU767 GGCCTTCTCTTGGGATGGCAGCCGCCTT 54 CTATCTGGAAAGTATGTGACAGCTCACA CAATCCTGTAAGTCTTCCATGTAATCACA TTCCACTGCCTCTCTCTGAACGTGCTCC ATGCCAGGGCCATGTGGAGGGAGCAGC AAGACTTGAGCTCAGCTAGTCTATGAAG ATGGTGGCAGAACAGGCTCTGCTGCCTT GATC 169 IM000787 GATCAAGAGTTCAAAGTCATCTTCAGCTA p000882 B Mm.1388 CAAATGAAGTTGGAGACCAATCCAGACC 09 CTCTCTCAGAAAAAAAGGAAAAAGGAGA AAGCAAAAGGAAAGGAGGGGGAGACCG AGAAAGAGAAGAGGGAAGGAAAGGGAA GTCAACAGAACTGAAGGTCAGCCTGGGA GGGTGAATGAGGCATTGTTGTCT 170 IM000788 GATCACCTCCACTTTATGGTGGACAGAG p000883 R — GATGGCAGTAGTAACTGCCCCAAGGAAA CAGAAACAACAACTACAACAACAACAAC ACCTCCAAAAAGACCAAAGCAGTAAGCT GTAGAACAAATGCAAAGAGCCAAAC 171 IM000789 GTTCCACCTATAAGGTTGCAGACCCCTT p000884 R — TAGCTCCTTGGGTACTTTCTCTAGCTCCT CCATTGGGGGCCCTGTGATC 172 IM000790 GATCACATGGACCGATTGCCGCGGGAC p000885 K Notch1 ATCGCACAGGAGCGTATGCACCACGATA TCGTGCGGCTTTTGGATGAGTAGAACCT GGTGCGCAGCCCACAGCTGCATGGCAC TGCCCTGGGTGGCACACCCACTCTGTCT CCCACACTCTGCTCGCCCAATGGCTACC TGGGCAATCTCTAGTCTGCCACACAGGG CAAGAAGGCCCGCAAGCCCAGCACCAA AGGGCTGGCTTGTGGTAGCAAGGAAGC TAAGGACCTCAAGGCACGGAGGAAGAA GTCTCAGGATGGCAAGGGCTGCCTGTTG GACAGCTCGAGCATGCTGTCGCCTGTG GACTCCCTCGAGTCACCCCATGGCTACT TGTCAGATGTGGNCTCGCCACCCCTTCT TCCCTCTTCATTCCAG 173 IM000791 GATCATACGCAATGATTTCTTACCTTATG p000886 C — TATAATTATGTTTAGAGGGAAAACTTTT TTTTAAATTGAAGTTCATTTATTGTATGTA ATTATTTCATAA 174 IM000792 GATCAGCATGGTCTACAGAGTAAGTTAC p000887 R — AGGACAGCCAGGGCTCCGTGGAGAGAC CCTTTGTCAGAAAACAAACAAACAAAAAA TTAGAAAGAGACCCTCTCTCTGATTTGAC CAATCACCCGTGTCAAATCTTGCCACAA CCGAATCACCACCAAATTGCCAGACAAG CGGCTATGCTGGGTTTCTGAGGTTGGAC TCCTCAGGTAGCCCGTGTCTAGGCAGAA TGATGCCAGCAGCTACACTTTTGAGAAC AAGGTCAGGTCAGGACTTGCCGCCAAAC CTAGGAATGCAGC 175 IM000793 GATCAGTCATGTCCTTTAGACGTTTACTT p000888 D — TCATCCCAACTTGGAACATTTCAAGC 176 IM000794 TTACAAAGGCAGAAATATCAGAAAGAGC p000890 D — CTGAAGTAGCAGCTGTTAACCTGTACCA GGAACTGGCCGAAGTACACACGGGTTAA CTCAGCCCTAATTATTCTCGGGAGATAC AGTTGATTATCATACACATGTCAAAATGG AAAATAAATGGGTAACTAAAAATTGAGGA AAATAAGATTAACACTTAAACAACCTAGT TCATTATGCCACGGTGATC 177 IM000795 GATCACAGTGGGACAGATTAAATGTTA p000891 D — 178 IM000796 AAACAAATACAAAGTGATAATTGTGTGAC p000892 D — ATCTGAACTTGTCAATGAGATAGGTAATT ATCTCTGGGCAATGGGTAAATGTGCTGG CCAGCAAACCTCACAGCCAGAGTTCAAT CTCCAGGAACTTAGGTGGGGAAGGAGAT AACTGACTTCCAAATGCTCACCCCCAAAT ATACAATTAAAATAAAAATCTTCCTTTTAT GAGTAGCAACTGATC 179 IM000797 TACCCCTGGTCCTCCAACACTCCGATC p000893 D — 180 IM000798 GATCATGACATAGACTTGAGTCACTTCTC p000894 D — TGCAGTTTGTCAATAAAAGCCCCTAAGG GACAGTGTGGACTTTAGAGATAAC 181 IM000799 AATGCCAGCCATAGTGGCACACACTTTT p000895 A — AATCCCAACACTCAGGAGAAGTTAAGTTT CTCTTAGCTCAAGGCCAAGTAGCTTGGT CTACTCCGTGAATTCCAGCCCAACTACA TAGTAAAACTAGCCTTAAAAAAAAAGGCA CAGGCAGAGGGAGATAACAAAAATGCCC AACTCCTAGCTACAGTAACTGTAGGAATT AAGATAGAATCTGTAGTTTGTTTATCATT ATCGTGATGATC 182 IM000800 GATCATGGCTTGATTGTAACATTATCAAA p000896 D — GCTTCCTTGGCACACTGCAGGGCTGTCT TCGGGAAACTGCGTATTGTGCTCTTCAG GTACAAAGCATAGAGCCCTTACATGACA AACGCTGGGGTTAACTTCTTCTAGTTCC CTCTGCCCCACTTGTGGCGCTTCCCACT CATGACTTCTTCAGTGTGTATTCACTT 183 IM000801 GATCATGCTGAACTCTTGAAAGTATTCTA p000897 D — GCAAAATGTGGCTTAAAAGAAAGAACAA ACATTAACTAGGTATGCTTTGAAAAATTA CCTGTGGTAAAATTTCCACAAGCATGAG AAGTTGTTTCTTTTGTTGAACCTTCAGAC 184 IM000802 GATCATATATCAATTTTATTTTTAACTTTG p000898 R — TTTGTTTGTTTGTTTGTTTGTTTGTTCGAG ACAGGGTTTCTCTGTGTAGCCCTGG 185 IM000803 ATTGTGTATCCAGAGTGTGACAAGGTAT p000899 D — ATATGGTTGTGTGATC 186 IM000804 GATCTTCTGTCTGGAAGAGTGCTTGCTG p000900 R — GTTCCGACTACTTTTTTTTTTTTTTTTTT TTTTTTNGCTTGGGTTTCANATTGGCTTC AGGTTCTGGGCCCTCGTGGGTTGTGCTG CANAGCCCCANACAATGTCTTGGG 187 IM000805 CAGGAAACCAGGGGAAATGGGACACAG p000902 C — TGACATCTGAGTCCTTAGAAGAGGTCCC ACAAAGGTCTATATGACCTAGCAACGTC ACTTCTGAGTTATTTCTCAGACACAGTGG ATGTTTGTCACAGCACACTGTAGGACAT CCCAGAACAGCACCATGGGAGACCATG GTTGGTGCAACAGAGAACATGCACACTG AGACAGTACAAGAGTTCCCAAGCAAGCA GACACAAACAATGGACTCAATACACATA CAGTGGCAGATC 188 IM000806 GATCTGCTCACCAAAAATCTTGTCCTAG p000903 D — GGAAGTTGAGTTTGAACTGCGTGCTTAC GGCAAACACGCGGTGCCCAAATTTAAA 189 IM000807 ACAGTTCCCCCTGGAAATGGTCCCTGTA p000904 D — CCAGAGGAGCAGATC 190 IM000808 CTGGGGCCCAGACTCCAATCCCGAAATA p000905 B Mm.2179 TCATTAGCTGCTGCGCACTTCTCCGAGG 8 AAGTTTACACCAGTACCCTAAGTTCAAGT CTCAGAAGCCTCCAAATCCTCGTTGCAC CCCTATATTTCACTTGGTCATCCGACTGT AACTCACTCACCGACAAGACAAAGAATA TCTTAGGCTCCGTCGTAAAAGAACGAGC CCGGTTCACCGCAGCTCCTTTTATAGTC TCCTTTGTGCGAGATC 191 IM000809 GATCTGAAGATATTTTGACAACAGCTAAA p000906 D — AAAAAAAAAACCAAAAAAACCCCTTATT ACTAACCAAGGGAAAATGCAAAAATAATT AAAAGTTCCTCAATTTTAAGTAAATATCC AAAAAGATTGGTTGTATAACAAAGTTGAA GAGTCAAACAGTATGAATAA 192 IM000810 AGCTCATTGCCGTTAATTTTCCTCAGCCT p000907 C — AATGAGAATCTAAGCCTTGATTTGTATGT CCATAGCATCTAGATC 193 IM000811 CCTTGAACCTAGTTCAGGGAATAGGCCA p000909 D — CCTGGGTGGGACTAGTGCTGGTTGGGG ATGAAAAGACAGTTGGCTCAGGTGAACC CTGCTCGCACCCTGGTCATCCTCTGAGA CTGCTTTGATTGCTGACCCCAGTGCTCC GCAAGAACTTGCGTTCTTGTTCTCTCCA CTCAAGCCGGAAGAAATCTGAGGAGAG GGTGTGAATCCTGAGCCAGGATGTCCAA AACAACGGAGTTGAGCCAGAAGGACGTC TAGTTGGGCAGAGTTAGCTCAGTCCCCT GACCCCCAGTCCGTGCAAGCTCGAGGG GTTATATAGTGATACAGATC 194 IM000812 GATCTCTTCTTATCTCTACCTTTTGGGGC p000912 R — ACAATCTTATCTGGGGACACCACAGAGC CCAAGAATTGTCCTGTATCAGAAATTTGG ACCTTTTCTGTGGCTATCTGTAAACCCCA CTGACTTAAAGTTTTAAGTAGAAAAGGAT ATGCCTTATGTAGCATGGTAAGGTCTTTA TGGCACAGGAGGATGTCATCCATGT 195 IM000813 CTTCCTTTCCTTTTTTGAAACAGGGTC p000913 R — TCTGTGTAGCCCTGGCTGTCCTGGACCT CAATCTGTAGACCAGGCTGGCCTCGAAC TCAGAGATC 196 IM000814 GATCTGCTCCACTTTACACAGCTGACCA p000914 D — TGAGACCATGTNCACATAG 197 IM000815 ACATGACATATCACCCTCATTCAGAGTTC p000915 D — AGAGTCTTCAGAAAACTGGGCGCCTGAA CCTGACCTTTTAAATTTTCGTCCATA GTTTCTTCTGTTGAATGAATATTCATAA AAGCTTCATAAATGCCTAGATC 198 IM000816 GATCTTCACAGCGCACCCAGGGATC p000916 D — 199 IM000817 CTTTTTCTTGGTATTTAGGGAGTCAGGAA p000917 D — AAGAAAAACCATTGGGTTTTTACATTAGC TTTCAGGTAGGGTTGTGGCTTTTGAGCA ACAATAACGTATGACCTTGTGGTCGGTT CTAGATC 200 IM000818 GATCTTCTTATATCTGGTTTCCTGGGCGG p000919 D — TTCCTGGTAT 201 IM000819 GATCTCTGACAGGGTTTCAAAGAACTGT p000920 C — TACTGATGTTTAGATTGCCTCTGAAGACA TCACATATACTGTGCTACTCTGCCTTGTC AGAGTCCCGGGCCCTGGGCACCCCAGA CGGCAGCAGAGGAAGAGCGGGGTATCA CTTTCTATACTTCGGTAAAGTCATTGGGA TATGTGCCCT 202 IM000820 GATCTCCTCTATCATTTATCTTTCTTCCTT p000921 D — CCTTCCATCTGTTTGTTT 203 IM000821 GATCTGCTCACCAAAAATCTTGTCCTAG p000922 D — GGAAGTTGAGTTTGAACTGCGTGCTTAC TGGCAAACACGCGGTGCCCAAATTTAAG GAGTGCCTACGACTTCGCGGGCCAGCA AGGTGAAACCGGAGCGCGCACGAGTGA GCAGTGGCCAGGAGGCCTGGCCAAGAG GCCAGGGTCCCTGAGCATGACCGAGAG CTGGCGTGCTCTCTGTAACCCCCAATCA GTTCACCTAATCTCGGGTCGAAACCTGA GCCCTGCAGGAGGCGGGGCTGAGACTG CATCCCAGCTCCTGGCCCGCTCCAGGG GCGACCC 204 IM000822 CCAGGCATCTCCATTCTTAATCCAGATC p000923 D — 205 IM000823 CATAGACTCTTTCATTTAGAATAAAGTGT p000925 D — TCCACCTAACATCCTGTAGGAAGTGATG AAACTAAAAAGAAAAATAAACGCATTTTC TCTTTCTCTCGTTACTTTTTCCATTCACTA AACAAAATTGACTTTTTTTTTCCATGAGA GTTCACACTGGGTCTGCCTCAGTAAGAG TCACACTGTTCAGCCCACACACGCTGTG ATATGTTATTTACTCATTCTCTTCTCAGG AACCACTCTCACATGTGAACCCTGAATA CCAGCTCCCTCCCTCTTCAGATC 206 IM000824 ATAGGTTCTGTCTCAAAACAAACAAAAAA p000926 D — CCAAAACATGTCCACAGGGTCCAACAGA CACAGTCTCCGCCACTCACAACTAATGG GTACACTAATACACACCTCAGCCTTACAT GGTTACAGAGAGAAGCAGGACCACAAG GTAGGCAGGCACCTAACACTTGCTTCTT GGAAGTTGGAGCACACACACACACACAG AAACACACACACACTTTCTCACACTCACA CACACATTCTCTCTCTCTCACACACACAC CATGCACACATGGTCTTGTACAAGCTC CTCCTGGGATGGGCACACACAGGGGTA AGAGGACTCCAGATC 207 IM000825 GATCGAACACNCTNGGACTTGNTAAACG p000928 D — NTTCCCACACNGACAGA 208 IM000826 GATCGTCTGGCCCGACCGCGCCTCAGT p000930 D — AGATGGGTCCTGGTCTGAGCAGCCGG GCTGGTGCGGGTGTCCTCACTAGGATAA TGAATACAGCTCCACTACCTATACTACCC AAGACGACCCCTCACACGCTCTGCGAG GAAACCGGTCTTCGGAC 209 IM000827 GATCGACCGCAGATGAGGTCTATGCAGG p000933 K Myc AAAAACGATGTCTGGAATTTTATTAAAAT TGCTCAGC 210 IM000828 AGTAGACTGAGATTTGTGAGCGCTAAGA p000934 D — TAAAGATGAGCAAAGCTTTGGCAGCTCT TAGGTATCTGAGGGCCACCGTCCTCTAC AAAGCAACGAGAGGCACGGCGGATTAG GATAGACTGGTTGCATCCAAACACTACC TTGCTGCCTCAAAGGCTTATTGGACACC ACAGAAAGACCTCTGCTGGAGGCAGAAG TCACAGGACTCCTCGTCACAGACGATC 211 IM000829 GATCGGCCTCCTCCAAAGCTACCTGCA p000937 R — TAGAAGAGACCTCTGCTCTCACCTACTC TCCTCTACAGTTCAGCCCATATGGCTTCA CCTGCATCCCCTACACACACACACACAG ACACACACACACACACACAAACACACAC ACAACACACACAACACACACAACACACA CTCACAACACAAACACACACAACACACA CTCACAACACACTCACACACACACACAC AACACACACACACACAACACACACTCAC AAACACACTAGTACACAAAGACTCCAAC ACACACATTCCCATGCACTACTCCCTCA GTATCCGCCGCATTTGTGCTCACACTCA TCCACACTCTCACACTTGTAGCACACAC ACATCATTCCTACACAGGCATGGACACA CATGCTCCTATACAGGCATGCCCAGTAC TCTCACATGCATGTTTGCACGTTCCCAAA CAGGTTCCCACAAGGGTTTGGCAAAGTA CATGCATCCTCACACGCAAATGCAAGCC GTCACACCCCATACCACAAGCATGCAC 212 IM000830 ACACCACATGCACATACATGCACACACA p000938 B Hs.17043 CCACATGCACACATACACACACAACACA 4 TGCACATACATGCATACACATGCACACA CACCACTCACACACATACCACATGCACA TACATGCACACACACCACATGCACACAC ACACACACCACATGCACATACATGCACA CACACCACACACACTTTGCAACTACATAT AAGCTTTAGAAATGCCTCTCGCCTCCCC CCATAGCGGGGAAGAGAGTGGTTTAAAC TAGAGGAGTCTGACCAATGTTCATTTATC TACCAGTATACCTCGCAAAGAGTTTTCAG AAATGTGCATGAGCTGTTAAAAACTTCTC TCTAATTTCCACATCCGATC 213 IM000831 GCTGGACCCCGGTGACAGACTGTGCAG p000939 K Pim1 ATGGATC 214 IM000832 TTAGCAAGTCCGAGCGTGTTCGATC p000941 K Nmyc 215 IM000833 ACTGCACACATTGCCGGTTGTCGATC p000943 K Notch1 216 IM000834 CAAGTGTAGACATTGCAGGAAAAAAATAT p000944 B AW32146 GGTGACAGTGAACAAAGCCCGTGAAGGT 8 GACAAAAGCCAGTTAAAGTAGGACAAGG CAGAGCGAGGCCCATGACCGGGACCAG GCCCAAGAAAATAAACGAAGGCCACGAT C 217 IM000835 GTCGGAGGAGCTGGCTGGACCGGTACA p000946 R — TGCCCTGGCCATCCAGGCGAAGACCCC CGCCCAGTGGAGAGAAAACCCACAGTTG GACATTAGTCCCCCCTGCCTAGGTGGGA GCAAGAAAACTCGAGGGACCTCTTAATA AATACCTGGATTGGGAGAACGATC 218 IM000836 GATCGCGGGGCTATCTATAGAGTCCCCG p000950 D — GGATGTCTGAGAAATCAGCCCTAGAAAT GACTAGAAAGAAAATCGAAGTATTCTTG GCTCCTGGAGACTTCCGCAGCGAGAAGT CACAGATTCAGGACACAGATTGACAGGA GCTGCGGGCGCTGGTAG 219 IM000837 GATCCCAGGATTTGGGAGGCAGAGGCA p000953 R — GTTGGCCCCA 220 IM000838 CAGGCTGGCCTCAAACCTGCAGAGATGC p000954 K Lck TCCTGTCTCTGAGTGTTAGATTTTATAAA GGGGTTCACGATC 221 IM000839 GTTGCTGGGCCCTAAGCGCCCACATTTC p000955 D — ACAGCTCCGATGCTCATCAGCATGACTC TCCTGAGCACATTATCTGGTGGTGGCTG ACACTCTCTTCAGTACCCCCCCCCCTCC CAAAAAAGAAAAAAGAAAAAAAGGACTG GTTGCTAAAAGAAGTAAAAGTCAAGTCAT CAAAAACAATGTAATATCCTGTGTGAAAG TCACGAAGCCTTGCGGTGAGTCCCTC GATC 222 IM000840 GATCGGCCGGCTGTCCAGCGACCGGAG p000956 D — AAAGGAGAGCACTCGAATCGCAGAAGCT ATCAGGTGAGTCCGACCTCTCTCTGAAT GAACGCTTTGGGGAGCCTGCCAACGGT GACCAAATTTAGCCAGTTAAAAGTACAG GCTGCCCAGCTGTAAACGTACATCAAAC AATGTGCGATTTTATTTTTAGTGTGAA 223 IM000841 ATAGTAACACTTGGGAGGAGCCATTCCC p000957 D — AGTGAGGCTCGTATAGCATAGCCCTGTC CAATAGAGCCTCTGTTGCACTCTGTGTA CACTTAGCTCCTTGCTTAGGGATTTTTTT TACATGGGTGACTACAGCACCCCAATTT CACATTGGACAGACTCCAGGACACCCCT CGGTGTCCTGTGACGCATACAACAGCCC CCCACGGGGCTGCACCGAAAACGCCAC AGTACTGAGGCTGCACCTCACTCACTCA CACACACCTCTATGGCTCAACGTCCTGG AGAAAAGGCTGCGACAGATTCCCACATC TGGGAATGCAGTGAAAAAGCACTCACAC TGGGGGTGGGGTGGGGCTGGGGGGGC ACCCTGTCTTCCCGTCTTCCCATGACCC TCTTCCCTTCCAGGAGACCATAGCCAGA GCTGACAGGAGATTCAGTCGCAGCTGCA CACGCTGCTGCCTTGCCGATC 224 IM000842 GATCGGGCAGGACACACATTGGGGAGG p000959 D — CCCATCAAGCCCGAGCCTGCCTTGTGAG CCCCCGGATTGGCAGGGCAGAGAGGAA AGCTGCTGCGTGCTTTATAGACTTTGGG GAAGTCACAGGCTCCGCTTGCTTGGGG GAGGCAGGAAACCCCCTCCACCTAGGC GTCTGCCAGAGCACCCGCAGGCTTCCTC TTGTCTCTGTCCCCCTCCCCAGCACCTC TTCCCCTGAACAGCTTCCCTCTCCTGGC CCTGCTGTCCCTTTAAAGGAACTTGAATC AGAGTTGAGAATGATGGTGACTCAGGGT GGAAGGGGTGGTCACTTG 225 IM000843 CCAGGGCTACACAGAGAAACCCTGTCTC p000960 R — GAACAAACAAACAAACAAACAAACAAACA AACAAAGTTAAAAATAAAATTGATATACG ATC 226 IM000844 GATCCAGGACATGGCAGAATATGGTCAT p000976 D — CTTCTTTGCTTGCATGTCACACGAATGG CCTCTGGCTCCACCCCTGATTGCTTGCT CCCCTTGGAAGCCTCTTGAGCCTAGCTA ACTTTTCCTGTTCACCTTTGTATTATGTG CTCCCACCATGGCCCACCAGGCTCTGCT TGCAGCACTGCAGCCTGCAGCTCCAGC GGCCTTTACATGGCTCCTGTAAACAAGT CCCAGAGGCCTCAGTGTCATCATTTCAG CAACCGCCTCACTTCTTGGTGCCGCCTT CCTTTATTACTTTCATATTTCTGTGACCG AAATACCCCCAAAGAAGCTACTCAAGGA AAGCAGTATGTGTGGGCTCACCATTAGA GGTCAGTCCCCTGCAGCAGTGGAAGCAT GTGCTGGTGACGC 227 IM000845 GATCGCTACTTTTTCAGAGACGCCTTCAT p000983 C — TAAGGGGAGAATGGAAAGATGCTGGTTG ACTTGAAAGATTTCTCTCTGATTTGTTTTA CAGGAAGTGCATTCTGTACACATGAGAG ACTCCGGGTGGAGAGGCATTGTGGCGG TTGAGATGCACCTGGGAGTGCCAACTGC CCCCGCTTCTACCACAGCTCTGCATAGC AGGCTGGAGCAAGCAGCCAGCCAACCA TTGTGCCCTAGCCTCATCTCCTCCAGAA GAGGTTATCTGGGCTCTGTGTAACCTCT GCTCTTTGGCTATGGTATTCCTTCTTGGT GCTTTCTGTGGTCAACCTCCAGGTACAC TTAGGGCCTATCCTAGACAGACTGGGAA GAAAGTATGACATTCCCATTGACCTCTGT TTTTATTTCCTGGAAATCCAGACCTTGTT CCAGTTAGTGGAGCATGGGGTTAGACCA ACCACACTGCTAAGAGTTTTGGCCTGTA GACATATCTGG 228 IM000846 TAGCAAGGTAAGTACTTGTCTCAATTTCC p000988 D — AGGTAGTATAGAAGAAACATATATGTTAC AGCTTTAACACCAGAACTATCACACAGT GTTGTATTTTAGCTAAAATATGACTCTGT GGTTTTCAAATGGCATAGTTGTGGACAA CTTAATTAAGCACGCTCTTATAAGACGTG ATAGAGTATGTGCCATCCAGATACTAAG AACTGTGTCCAAAGAGCTTGGGACACAC ACTAAGGGGCCTGCCTCTTTCATAACGG GGATGAAAATGACTGAGGCTTCACATTT GCACAGTACGATC 229 IM000847 AAGCCATCTGGGTCTCAAGTTGCTAAAA p000991 D — CTTAATAACTCCCTCCCTGTGTTTGTCCT TTATCTAATGGTAAAATATGACCTAATGA AATAGGTTCCTAAGGCTTTCATATAAGGC ATGATGTTGAAGGATGGAGGACAGAGTG GGATGGAAAATCAGAGCCTGCACAGAAA ACCACAAGCAGCTAACAAAAGTCCACAA CCAAAGCCTGTGCCTGAAATGTCACCTA CAATGCAGTGGACTATTCATATGCCAGC CTGGTCCTCATGCGATC 230 IM000848 CCAAGAACAGAGCCCCAAACTAATAGG p000992 R — ATGGTTTGTTGCACGTGTACATGTGTATG CATGCGTGCATATACGTGTGTGTGTGTG TCTGTGTGTGTACACCCACACGTGTGCA TGTGTGTTGTGTGTTTTTTAAGCAAACCT CAGTGTGTCATACATACTCTCCTATACTT CCCCTCCCTTGTTCCATATGAGGGTGCC TTCTTATCTCACAGGGTTGTTTTGTTTTTT TTCTATAACAGAATGCCGCTGATGCTCTT TTTTCTATATGAACCCTACATTTAATACTT ATCCATAAGCAAAGGAACAGTATCTTATC TTGCGGATC 231 IM000849 CTGGGGGCTCTGCTACGCGTCAAACGC p000993 A Saas CTGGAGAACCCCTCGCCCCAGGCGCCG GCACGCCGCCTCCTGCCTCCCTGAGCG GTGCTGCATCCTGCACGCCCTGGAACCC AGGAGCGCCCCAGCGACCCTGACTCCC TGCCAGCACGTCCAAGGCTGCTTACCCC AGCAACCTCCCATCCCCTGAGCCCTCAG TAAATGCCATCTGTAGCAGCTGTTTGTCT GAGCGCCCTGTACTAGGGGGCCGGTGG GCTGGGTGACTATGATAATGGAATAGTG GCTGTCCTACTGAGGACAGCACAGTACT GTTTGGGACCTGTACTGGTAAGGAATAC ATGCCTGCTTCCTCTGGACTTTGCGGGT CTCACCGGGTGCCTGGGCTACCCTTCTA GGCTTCACTGAGGCGGGTTCCCTGGGA GGCTCTGAGGTTACTTTCAGCGTCTGCC GGGGTCCACAGCACTTAGCCAAGGGG CTATGGATTCACTCGTGGTCTGCCAGGA CCAGGCTTGTTGTGAGGGCCCCAGGTG GATC 232 IM000850 GTGTTTCTTTTCTCTTTTTTCTTTTTTCT p000994 R — TTCTTTTCTTETCTTTTTTTTTAAATCTAA GTAAGGTGCAACAATGTAATTCGAAGGG GCAGTGTCTTCCCTTCCTGTAGTCTCTG CTTAATTCCTGAAGTTTGCCAAACCAGGA GTTAGGAAAAGTTGGAAACCTGCAGAGA GAGCGTTTGAGAGGTTTGAGATGTTATA CGAGAGGGTTTGGCAATGTGTGGAGTAC AGGTAACTTGCGGTTATTGTTTTCTTGGC CCTCTATCTTCATCCTTTGTGCTTGCTAT TTACCTTGCTGTCGGATC 233 IM000851 GATCCTTGAGTCTGTACTTAGCCTGAGA p000995 D — GCGCTATAACACTATATACAAAGTACCGA CTAGAAACTCCACACACATTTGTTGACTG ACTTAATGTGTAGCCCTGCAATGGTTGA CAGTTGGGGGTCAGGGGGCTCTTGCAC GAGGGTAGTGTATAGCCTAAAGAGATA TCAAGATGATAAGTACATCCACACTAG GACAGGAGCTTTAACAAGAGCTTTTAGT GAAGGGAACTTTCTGGGAGCCTCAAGGA AGGCATAT 234 IM000852 AGCAACACCTCATGTGGGAATTCATACA p000996 D — TTGTAGGTAATCAGTCTACTAGCTGAACT ATATCTCCAACCCAGGAGGTCAGGTTTG TTTGTTTGTTTAACAATCTAGTTTTGAAAC AGTCATATCCTAGGCTGGCCTCAAGTTA TGTAGTCAAAGATGGCCTTAAAAGATGA CTCTTGGTTATTTTCCAAGTGCTGGGATT ATAGATATGCACACCACCACACCTCATTT GTCTCGGGGCTGGACTCAAATCCAGAGC TTCATGCATGTGAGGCAAGCACTGTACC AACTCGACTTTTGCATACTCCATTGAAAG TCATTTTTATAACAGGATC 235 IM000853 CTACTTATCTATCATCTATATGTCTATCAT p000997 R — CTATCTATCTATCTATCTATCTATCTATCT ATCTATCTATCATCTATCATCTATCATCTA TCATCAATCATCTATCTAGCATCTATCTT CCAGAGCTCATGTTGTGGCTTGGGCTTC TCATTTCACCATCATCGAAGGTAGTTGCA TTTTTTCTATTGGCTTCTTAGAAGCAGGA GGCACATGAAACAACTTGCTAACCCTTT CCTGGTCTTTTGTTGTTGTTGGTGGTGG TGGTGGTGATGGTGGTGCTGGTGGTGG TGGTTGATGTGCACAGGAGACCTGTCCG GTATGGAGATATGGAGAGCGTCTACGTC CTCATGGGATC 236 IM000854 GTGGGACGCGGAGGGTGGAGATGAATT p000998 R — GAGAAGCAGTTGTCGATTTCCTCCTTCTT CCAAACATCAAAGGCAGCGGTGGATGAC AAACTGAAGGACAGAGGGTTTGATGATG CAAGAGGAGCCAGCAGCAACCAAGGCC AGCCTCTTGCGGGTGTGGGCAGGGCCT TCTTTACAATGAGTTCACACACACACACA CACACACAGAGAGAGAGAGAGAGAGAG GAGAGAGAGAGAGAGAGAGAGAGAGA GAGACTGCTCTTTCAGAACAGCCCTAGG AGGTTAGCTTCAGACTAAGACAGGAGAC AGAGAGTCCTTGATTTTGCCAAGGTTGC ACAGCTGGGGAGAAACCCAGCTATGGCT TCACCTTGGCCCTTGTTAGGACTCCTTC CTAGTCCGGTTGCAGTCTCCTGGATC 237 IM000855 GTATTAGAGGCCAGGCCATTCAGAAGAT p000999 C — GTGGCAAGATTGTCATGTGGAAAATATTT GAAACCATTGTAACCTAGTCATTCCATCA TCAATAATAATAATAATAATAATACTACTA AAATGAAAAAACCTAGATATTTTGAGACT GTACTGCTGTATTTTAAGAAATACACGGA AATTTAGCACTGAAATTTAGTGCTAGTTT TAAGAATACTTTGTACCGTTACTTGGACC CACAATTGCTTAGAGCAAGGGATC 238 IM000856 GATCCTGAGACAGTACAGGAACTTTAGAA p001000 D — GCCCTGGGCAATTTGCAGTGTGCACACC CAGCCTGAATTTGCCTGGTTCTCACCAG CCTACCAATAGAGCATTGTAGTGGCAGG GATGTCTGCTGGTGTCTCGCAGACAACT TTTGAGGTCCTGCTTCTCCAGAAGTGTG CAGCTGGCAATTAGCAGCCTGGTCTTTT CCTGTCCCCAAGACCAGTGCTTCCACCA ACCTGGTCTCTTCCCACAGCCCAGCCCT TTCTCTTCCTCTTTGACACCCACTTCCTC TAAATGGTGGTCACATGCTTTGTCTCTTG AAAAAAAGTTGTATGAGTCAGGGTATTTT CAACGCCGGGACAGAAAAATTGACTCAA CCTGGCTTTTTCAATTAACCACTAATGGG TTTCACTTACAGTCCTGACAAATACCAGG CACAATTCATCCAGGACAATAGTGAAGA ATTTCATCTCTTCCCCCCAAGCCAGTCA GTCTGGTTTTAATATGCACGGTGGATAG CCCATAGCATGCAATGAACTGTGAGCAC CCCTCTGGGAGTCAGCAGAGACACACAC ACAGGCACCCATACCACACACTGTGCTT TGTATCA 239 IM000857 GATCAAAACAATATTCAAATAATGACATC p001001 C — AGTCAAAGTATGATTTGATGGCCATCACT CATGTCAATAGGCAACACATAAGCCTGA GAGTAAGTTAAGGAGAAATTCAGCAATA AACTAATTGACATACTATGTCCACTATGA GTAAAACCTGCCTCTCTTAAAACGTTTTA CTGTACTCCATGGCTCTCCCCCAATGTG CGTTCGTGAGAGTCCCCACCCCTGTGAC TCCATCTGTGTGTGGGTTCAGGAGAGAC TCCTGTGTGTATTCAAAAGAGCCCCCCA TGTGTGTACACACAAGAGACCCAGTGTG TGTACATGAGAGGCCCCACCCCATGTGT GTTCATGAGAGACCCAACCCCTGTGCGT GTACATGACTCTCCCCATGTGTGTTCATA AGAGACTTGTGTGTATGGGAGACTCCAC CCTGTGTGTGTACATGAGAGACTCCTGC CTCTCCTGTGTATATGGAATACCTTCAGA GTATCAAATATTTCACCCACTGAGCCAT CTTAGAACTTCTCTCCCTT 240 IM000858 ATACATATGTACACACACACTCACAAACA p001005 C — CACATATATACACATACATACATACTCAC ACATATATATACACACTAGTACACACATA CGCAAATACACACATGCATATACACGTA CTCACACATACATACCCATACTCACACAA ACACATATATACACACATACTCACATATA CATTCATACATACACACACATATATACAT ACACACACTTGCATACACACAGCACACA CTCACACACAGAGACACACAGACACACA GACACACACACAGAGGAACCCAAAGGAT TGGAAGAATAATTTCCTGTGCTCAGTGG GAAAGTTTACCAGAAAGACAAGTGGTCA TGTGGGATGATC 241 IM000859 GATCAGGGACCCTGTACCCTCCCCCGTG p001006 C — CAGCCTGTGATTC 242 IM000860 GGACTGTAACCAACTCGGAGAGGAAAG p001007 D — GGCTTATTTCATTTTAGTCTTTACAGTCC ATCATTGACGGAGGTTAAAGCAGGACGC TGCTTACTGACTTAGCTCCCCGTTGCTTT ATCAGCTACTTTCTTAATACAACGCCACC CCCGCGGCCGCCACCTCCCTAGGCAAG ACCCACAGGTCAATCCAACAGAGAGGAT TCCTCAAGTGACACTCCTATGTCAACGC TATCAATGGCAAAGGTATATTGAGCTAAG AATTGATC 243 IM000861 GATCTCAGGCTGCCCGTGGGCGGGGCT p001009 B Mm.7675 GACGGAGGGAAGCAGACTAGGCCTCTA 3 CCATATCCGTGGGAGGGACTTCCAAGGA CCGAGACTGAAGAAACAGCGCGAAACA GGAGACACTGGGAGGAGAGGCGGAGAC CGACACTTAGTAG 244 IM000862 AGAGAAAAAGACTATCTTGACCTTTGGATA p001011 R — TGCGGGTGCAAAAATGAGAAGACCACAG TGCAGCTGTGTGCCCTGCACGGGGCAG CGAGAGGAGAAAGAAGCATTTTACATGA AGCACAGAACACGCCTGACAGTTCTCAA CAGCAGCACGTCAGACCACCGCAGCAC TGCTCGTTTTTCTCAGCAGACCCCCAGG AAGCACCACCCAGGATGGACATGTAGG GGTGCATCCGAGAGAATCAAAATCACAC AGGGGCCATCCTTTTGGTTCGGCATGAA TGATGGGGGCCGCCTGCACTGGCCTCC ACCTTCTATGGTTGTTCTTCCTTGTATCA ATGTTTCAAAAAAAATCCTTGGGCTCACA ACTGCCTAATGACATCTTCAGGAGTCAA GTCAAGAAAGAGAAAAGTAGCCGACCTG GCACGTGGTAGATAAGACTCAAGGGTGC AATAAGCAGATGAACTGGCTTAGTTGGG CTTTCTATTGCTGTGATAAAACACCATGA CCAAAGCAACTGGGGCGGGGGGCGGG GGGTGTCATCTTACACTTCCATATCACAG TCTATCACTGAGGAAGTCAGGGCAGGAT TCAGGCAGGAACC 245 IM000863 GATCGGCCAACACAGGATAGATACCACA p001013 D — CAGGATAGGAGGTACAGTGTCTGGAAGA TTATTATCGAGCCCCTGAACGTAGTAGA AGCTGGCTGTCGTTCCAGTGCAAGCTGA GCAGATGGTCC 246 IM000864 GATCCACATGAAAGCCAAGCTGCACATT p001015 R — TGCTTCATATGTATGGAGAGGCCTAGGT CTAGCCCATGTATGTTCTTTGGTTGGTG GTTCAGACTCTAAGAGTCCCAAGGGTCC AGGTTAGTTGACTTTGTTGGTCTTCCTGT GAAGTTCCTATTCCCTTTGGTGCCGTCA ATCCTTCCTCCTATTCTTCAATAAGAGCC CGCAAGCTCCATCCACTGTTTGCTTGTG GGTATCTGTAA 247 IM000865 GCCTCAGCTACATAGTCAATTGCCATCTA p001018 D — GCCTGGGTATGCGAGATGGCAGTAAAGA CACTAGCTGCAAAGCCTTACTGCCTGAG TTTGATC 248 IM000866 GATCCAGTCACAGGAGAGCAACTGGGG p001019 D — GAGGGAGCAGGACAGTAGCACACCATA GCCCTTTCAGGGGGCCGGGGGCGAGG GGTGGACAAGAGAAGACAGATTATGACT CACAGGATGAAGAAGCCTCCCACAGCCC CTCCCTGAACTGGCCATCTGTTCTGGGG CCCCAGAGCAGGCGAGTACCGTGAAGC TTGGGGACTAGCAGCCGGACCACTGAA CAAGGTCAACCAGCCAGTTGTCCCACGA GGGGAGAAGCTACCATTGAACTGTCACT TTGGAAAGTAGCCAGAGCCCATCCCTGG TCACCACCCAAC 249 IM000867 GATCCCTAGAGCTGCTGGTCAGCTGGCC p001020 R — TGGCTGAAACTACTTCTGTGCAGTGAGA GACCCTGCCTCAAAACACAGATAATGGA GACAGATAAATGACATCGTCCGCTGTGT CTGCGTGTGTATATGTAACACAACACAC AGTATACACACATACACACCACACTCATA CCGTCACACATGCACTCTCAGTGCATGT GCTACACAACACAGTGTACACACATACA TACACACCACACACATACACATACCACC ACACACGCGCACACACACACATAA 250 IM000868 GATCCTTGTGCATCACTGAGCCATCTCC p001021 R — CCAGCCTACAGTGTAAGTATTCTATACAT ATTAATTTAATCCTGCCGGGTGGTGGTG GCGCACGCCCTTAATCCCAGCACTCAGG AGGCAGAGGAAGGTAAATTTCTGAGTTT GAGGCCAGCCTGGTCTACAGAGTGAGTT CCAGGACAGCCAGAGCTACACAGAGAAA CCCTGTCTCAAAAAACCAAAAAAACAAAA CAAAACAAAACAAAACAAAAATCCTATGG GTATTCTAAAAGTAAAACCGTATCATTA GCACTGCCAAATAACAGAAAGGAAGACC GCAAA 251 IM000869 GATCCTCTGAAAATGGAGTTACAGATGG p001022 R — TTGTGAGCTGCCATGTGAGTGCTGGGAA CTGAACTCGGGACCTTTGGAAGAGCTGC TGGTGCTCTTAACAGCTGAGGTGTCTCT CCAGCCCCTTTGGGTGTGTTTTGTTTTGT TTGTTTTGTTTTGCTTTTTCAAGACAGGG TTTCTCTGTGTAGCCCTGGCTGTCCTGG AACTCACTCTGTTAGACCAGGCTGGCCT CGAACTCAGAAATCTGCTTCCCAAGTGC TGGGATTATAGGCGTGCGCAACCACTGC C 252 IM000870 GATCCAATATATTCATATGGAGATACATG p001023 D — TATATACATAA 253 IM000871 GATCCAGGTCCTTTCCCCCTTATGGTCC p001024 D — TATACACCCCTGGGTACTTAGAGGCTTT CAGCTCTGACTGGTGGTGTGGGGAGAA GTGAGGGGTTACACATGTGACACAGGTC CTAAAAGCTGTCGCCATTGGCACATGAC CATCCTAAGTCTGTGGCAGAAGGCTGCT CAGAGCCTCTGTCCAGGAACAACCCAAC ACATTGCAGAAATAACTGTGCATCTGGG CAATGGGGCAACTACTACCTGTCCATCC AGATAGCTCTTCTAGAGGCATTCGAAATA ACACGTAAAGTGGGGTGGTGATGAACAC ATATAATCTCAGCCCCTGGGAACCGGAG ACAGGGGAGTCACAAG 254 IM000872 GTCACAGTACTTGCTCACTTGCCTCTCTC p001026 D — ATGGTTTACTCGCCCCTCCTTCTCGTAC CCCCTTTCCTCCTACAATCCTCCTCGTCT ACTTTCATGCCGTATATGTCAAACACCGT CATATATAACAATGTATGCATGCAGCATT TCTTTTTCTTTCCCATCAGCCTCCCTTGC TCCCCATCCTCCCGCCCTTCCTCCTTCC TCCCAGGATC 255 IM000873 AGTTATGCTTGCAGACAGGAATGTAGCA p001027 R — TGGCTATCCTCTGAGAGGTTCCACCCAG CAGCTGACTCAGACAGATACAGATACCC ACAAGCAAACAGTGGATGGAGCTTGCGG GCTCTTATTGAAGAATAGGAGGAAGGAT TGACGGCACCAAAGGGAATAGGAACTTC ACAGGAAGACCAACAAAGTCAACTAACC TGGACCCTTGGGACTCTTAGAGTCTGAA CCACCAACCAAAGAACATACATGGGCTA GACCTAGGCCTCTCCATACATATGAAGC AAATGTGCAGCTTGGTTTTCATGTGGATC 256 IM000874 GATCGTGGTCTCTTCTCTTTTTTCCCTCT p001028 R — ACTTCTTCTTCTTCTTCTTCTTCTTCTTC TTCTTCTTCTACTGTCTTCTTCTTCTTCT TCTTCTTCTTCTTCTTCTTCTCTTCCTCTC TCTCTCTGTCTTTCTCTGTCTGTCTGTCT CTGNCTCTCTGTCTCTCTCTATCTCTGTC TTTCTCTGTCTCTCTGTCTCTGTCTCTCT TTCTCTGNGNCTCTCCCTGTCTGTCTGT CTCTCTCTTTCTCTCTCTGTCTCTCTCTC TCTGNCTCTCTNTCTCTGNCTCTCTCTGN CNCTCTGNCTCTGTCTCTGTCTNTGTNTN TCTCTCGCTCTCTNACACACACACAGAT GTACATGCAC 257 IM000875 GATCGGCGGTATCATATTTTATGTGTTTT p001029 C — TTTCTGTGTCAGTAAGTTTAAAAGGCCT CAGATTGGAAGTCTGGTTTGCATGGAAT GCATATGAGCTTTTTCATCTTATTGCCCA ACAGATTTAGTCTAAGAACCACCTCTATT ATATAGGGTATGATAAGTAATATAGGTAA GGGAATGCATCCCATTTGATAAGTGAAA GTTGAACACACATAGAGTTGGCTCACCC CGGGGTCTAGGCTCTAATCCCCTGGGG ATACCCAGGCCTACTAAACGCTATAGCA ACAGGCATTGGGGCATGAAGATACTTTT TGTTGTTTGTCTTGAATTTATATAGGGGC TTATATCTCATTACAATTAATCATGAGTTG CAGTCAATAAATCTTCATTGCTCAACATA TTTGTACCCTCAAATATTTTTTTCTTTTTT TGTGTGATAT 258 IM000876 CTTGTAAACACGATTATTTTAAAGATATA p001031 D — AATGGCTCTTTACTCTGTTTAAAAATTGT TTCTTTACCAGTTCTTCGTGTACATTGGT CTCCATTTCACATGAAATAAAATATTTTGT TTAATGTTAGATTTTCAATACCAGCTGAG TGTTCGATGTGTGCCTTTTGGACATATAT GTTGTAAAGTGGTCATTTGGGATC 259 IM000877 GATCAGATTCAACTCCCGCATTTCTAGC p001032 D — CCCAGCATCGTGGAAGGGCTACTGTGTC TTTTCAAGCACTATGGTGGATACACATAA TGCCAGCTTCCCTCATTACTGGTGATGT GAGCTGTTTGCCTAAGGTCCTCTGCC AGGCTTCTCTGCTGCCAAGGCTCTGAAT TTCCCTTTGTAGCTAATGCGTAGCCCTAT TGGCAGACTCTTCCCGTGGCTGACTTCT GCCTCCCGTCACACAGCAGTACCTTGTT TGTTCTCACCTTGATGTTTCTTATATGCA TTGATGATGGTGAACAGCCCAGCAAGTG CGCCTGTTTCTTCCCTTCCTCCCACTTTT GTTCTCAGTTGTACATGGCAAGGAAAAC CAATTCCTTCTCATATTTCTCCCAGAA AAAAAATCCTCTTTATAAGAGTTCACATC CTTGAGCACACATGATAGGAGCTGGTAG CCAG 260 IM000878 GATCATGATATTGTACTGCTGAAGACAAA p001033 D — CATATTTAAGATATAAGACTTGGAGAAAT CAAGETGGTATTGACATTGGAGATTAATC TCTTTTGGCTAGCTTTTGTAGAGCTAGAA GTTGGTATGTAAGCTATAAGGAAGAGAA GTATTCATAAGACTTACCCAGTTGTCTCT CCTGTAAGCTAAGACCAGCCTAAGAAGC TAAAATTATCTTTAATGTAGAACCACAGA GAAAGAAATTGTGGTATGAATTTTGCTTG TTCGTGGACATTAACCATTAACTCAATGA TAATCAAATGACAATACATAGAGACAAAG ATATGCATACTAGTAAAATAGTGATAA 261 IM000879 GATCGTGCTAGAGAATGGTACACTTGGG p001034 R — TTATATTAAGAAATCTTGGTTGAGTGGTG GTGGCACCCTCCTTTAATTCCAGCACTC AGGAGTCAAAGGCAGGCAGACATTTGAG TTTAAGGCCTGCCTGGTCTACAAAGTGA GTTCCAGGAAAGACAGGGCTATAAAGAG AAATCTTGTCTTGAAAAAAACAAAAAAAC AAAAAACGAAACAGTAACTGAAACCGAA AAAAAAAAGAAAGAAAGAGAGTAAGAAA GAAAATCTTACAATGTGGGAGCTGGAGA GCTGGCTCAGTGGTTAAGAGCATTGGCT GCTCTTCCAGAAGACCCAGGTTCAATTT CTAGCACCCACATGGTGGGTCACACCTG CCTGTGGCTTCAGTTCTAGAGTCTGA CACTCACACACAAACATACATTCAAGT 262 IM000880 GATCETGTATTTCTTCTTGGCTTGTCTCC p001035 B Mm.1388 ATAGGAACAGGCAGCACAGCAGAGGTCT 34 GGGAGATGGCTCCGAGGGTAAGGGACC AAGCAAGGTCACCTGCGCTCACTCCCTG GAACCCACACAGTGGACAAGAGAGAAAG ACTCTATGGCCTCCACGTGCGTGCGTGC GTGCTGTGGTGTGCACGTGCCCCTCCC CCAAATAAAGAAAACTTAACGAAAAATAA TTAAAAGTAAAAAAACAGCACTGCAGTAG CTCCAGGAATCAACTGGTCAATCAGTGT ATCACATTTGACTATCCGATGATGGTTTT ATTTTACATGTATGCACGTGTTTGCATGT ATGTGGGTGCACATGTACAAACACATGT GCCAAGGCCAAAGGACAACTTTGGGTGT CCTTTCTCAGGAGTCATCGACCTTATTTT CTGAGACAGGGCCTCTCACTGGAATCTG ACTGGCCAGCAGCCTCCCAAGGATGCTC CCCAACCTCAGAAGGATGCGCCTGTCTC TGCCTCCCAGCCCCGGGGGTTACACTG GTGGACCACTGGGCTCTTTTCACCTGGG TG 263 IM000881 GATCTCTTCTTAAAATTACATTACAGTAG p001036 D — AAAATGTTTATGAGGCCGTTTTTATCTCT TATATTAWTATTACCACTCTCCTACCCC CAGAGTCTTACAGGCATCAGGGAGTGGA CAAAGGCCGGCGGTACTGAATGGTGAT GTTATTTTTGAAATAATGAAAAG 264 IM000882 TACCTGTTGCTCCAACATGGTCAGAAAT p001066 D — CAGTTTGTTTCAATTTTAAGATACAATGA GAGTAACACCCTAAAGACTTCACATTTTA TGCATATGCTACTCTGTGAGCACATGA ACGCTTCTCCTTGGGCACGATC 265 IM000883 GATCGCAGATACTGCAGGTATGTAGTAA p001067 D — TGAAGTCTGTAAACATACAGAATGGAGA AGGCCAGAGAGGAAAGTGCAGGCATTG GGTAGTCAGTAGGTAAAATAT 266 IM000884 GATCGCAGCTCTTCCTTGGTGCTTTTCC p001069 B Mm.2811 CCTCAGTTCAAGTGCTGTGGCGGGGAG 2 GACTACAGAGACTGGAGCAAAAACCAGT ACCATGACTGCAGCGCCCCCGGGCCCC TGGCCTGCGGGGTGCCCTACACCTGCT GCATCAGGAACACGGTAACTGCATGGGT GCTGGATGTGAGGGTCACCCAGTTTGCC AAACACTGCCCTCACTCTGCCCAAGTGG AGCAGGCAGTGGGAGTGGGTGGGACGT GGTGGCCGGGGCTGAGCTTGCCTTAGA CCAGGGGCCCTAGCAATGGGAGATGAG TGGGCAGCTTCCTCTGGGAGTGTGTCAG TGAGCGTGTGCGTGTGTGGGCCTGGCC CAGGCGCTTTGGTTGTAGTTACTTGGTT CTTACAACAGCTTTGGAGGGTCTCAATT GGGGTAGTGTTGCTTTAGCCACTTAGGG GGACTTGCCCAAGGTTGGCAGGGCTCTT CCCAGCAACAGAGAGCCAGAGTGCCCG GCAGGTGCAGCAGGCTCTACCCAGTCA CTGGAGGCAGAGTACAGTGCAGGTGCT GTGAGCACTGGCAGCAGAGCCCTGGGC AGCGGCATGCGGTAATGTAAATG 267 IM000885 CCATGTCAGGTGATTAACCTGTGAGTCT p001070 D — AACTTCCAGGAATGCAATGCCTCTGGCA TCTACAGGCATAAACATACTTGTGGCTTA CACTCAAACTGACACACCAACACATATGT GCACGCGCACACACACACACACCAAATT AAAAATAAAATAACCCTTTTTAAAAAAAAT ATAGAACCTATAGATAATTGCTTTACTGC ACTCACAAACATTTTAGGATC 268 IM000886 GGGGCACATAGTGAGTTCTAGGATAGCC p001072 D — AGGGTTATAGAAGCTATAGTGTGAGACC CTATCTCAAAAAAACAAAACAAAACAAAA AAACAAAAAAAACCTAAGCCCGTGTGGT GGTGTGTCTCAGTCTGAGCGCTTGGAAG ACAGAGGGAGGTGCATCTCTGAGCTTGA GGCTAGCCTGGTCTACATAGAGAGCTCC AAACCAGTCAAAGTAACAAAATGAAACTG TCTCAACAATGACAACAACAAACAAACAA GCACTAGAATAAAAAGAAGCCAGCATGG TGTCATGTGCCCGTCATCCTACCACTTG GAAGGAGAGAAGCCAGTGCAGGAAAATT AGGGATC 269 IM000887 GATCCCAGGCTTCCTGTAGGCTAGGCAA p001075 D — GCCCTCTCCCCACCCTGTCCTGGTAGAA TTCATCCCGAATGTCAGCATTCCTTCAGT TAAAGGAATGTGCTCCCTCAGGCTCTCT CCCATGGTGCATTGCTTCAGCACGCAGG CAGACACTTGTCCAAGCTAGGCTCCCTG TCTCCCATCTGTAGGAAATGCTTGGTAT GAAGGCCCTGGTGGACCTGGCTAGATG GGCAGCGCCCAGTGAAGGGCTGTGTCT GGAGCCTGGGCTGTAATTAGTGGTGA ACTGGGTGCTCTGGGGAGAGGCAAGTA AGAATTTGCTTTCTGTTTTTAGAGCAGGA GGAGCTGGCGGCTGGCTGTGCCTTAGC CGGCTCCTCGAAGAGCATGAGGTGTT CGCCATCTTAATGGGTTAAGACTCTCCT GTGCTAATCTGGTGGGTTGCTTTTAGGC ACGGTGGTCCCACTGTGGTTGTGTGAAC AGTACCTTAATGCCAACACTTTGGAGGC CTAAGGTATCCCCATCTGCAGGAACTGG GGTGCACA 270 IM000888 GATCCTCACACAAATTGAGTAGTACTAAC p001078 B AA79335 AAGAGTGTGATTCACATAGTCAATAAAG 6 GTATAGGCCATCTGTGCCCTGGCTTGAC CTCCGCAGACCAGAAGCTAACAAAACCA AAACAGACTCAGTTTCTGCATGCTAACTT AACCATGATTTTCCAGACTATTTCTTTTAT CCTGTGAAAAATATATTAATCTCTATTCT GCAGAGTATCCCTTCTTTAAGAGAACAT GATTTCACTGTTTTTGACAATATGCCTAG ACACAGAAAAAAATCATTTAGTTT 271 IM000889 TTTTGAGTGCTCAGTGAACTACTTAGGG p001079 A Edar CAGCCTAAGGAATACAGTGACCCACCAG GAAATGCCTTGTGTTTTGGCAGTCTGATA GGATCACTCACAGCTGTCGGTCGTGACT TCATTGGATC 272 IM000890 GATCCAGGGACAAAGAGCCCATTCTCCT p001081 D — GTTCCTTCGTAT 273 IM000891 ACTTTCAGGCTAGCTCTTTGCTCAGTGA p001082 R — ACCTGCTACCACACACAGACTCCTCCTC CCTGTTCCCGTCGTTAAAAAAAGTTTTAT TTGAGGTTTAGAGCAATGGCTCAGTGCT CAAGACTACTTGCTGTTCTTACAAAGGAC CTGGGGCTAGTTCCAACACCCACATGAT GGCTTACAATTCTCCAGTCTCAGGGGTT CCAGAACTCTTTTTCTGGCATTGAATGCA CATGATGCATATATAGACAAGCAGGCAC ACACACACACATAAAATAAAACAAATCTT TTGAATGTAATTTTAAAAAGATTTATTAAT TTTAATTTTATGTGTATGAATGTTTTGCCT GCATGTATGTCTATGCACTGCATGTGTG CCTGGTGCTCAAGGTGTCTGATAGCCTG GTGCTGGGCTTGGTTCACTCAACAGCTG GCCCTATGAAGGCCAGCCGTGAGGACA CCTATCCATGCTGACAGACACAGATGCT CAAATGAGACAGCCCCTTCTCTATGAAT GCCCTCTTGAGAATGAACAACCTCCCTG CAGCAGACCTCCTTCTGGATACCCTGCC CTTCCATACTTTCTGGGTGTCTAGTTCTC TTCC 274 IM000892 GATCACACGCTTCACCTAATTACAAATGA p001083 D — TTCTTTAGAGGGGTCTGTATATAACAGA GATGATAAAATTCAACGGCAGCCCTCCA ACTGCATTGATATACAGGAAGTACTCATG AAATTGGAGACACTGATTATCTCTTTGTG TGGTGTCCACATATGTGCCATCATATCAT ATTATTATTATTACATGGCTAAAAAATGG GGTCATAGGTTTCATGACCAGAACCAAA ATATCCCCTGTAATTTACACAGGATTGA TGGTAAGAAATGAAAACAGTTTACATTTT TGATAATTACTTACTTGACATAAAATGT GACTTCATTTCCTTGCATTCCTTTTCAC AGGTAAGGCTACGACAATAGATTCTCAG TTCTCCACCTCTCTCTATCTTGTCTACTC TATCAGCAGCAATAGCAACAGTTTTCCAT GGTCCTTCCATCTGTAAAAGCAATAAAAA TAACAAAGTAAACCATACAAACCATTAG AATATGAGTTGGTATTCACAACTCTCCTC TCAATACTTCATATTTAAAAATTACTAGA TATTCATCAATAATATTTCATTTGTTAG CTCTAGATAATGTTTCCAGG 275 IM000893 GATCATGGTTATTTTTGTAGGGTTTATTT p001085 R — ATACATGTCTACATGAATTTATGTGCACC AGATGTGTGCAGGTGCCCATAGAGGCCT GCGAGGATGCCAGATACAGATAGTTATG AGCCACCTAATATAGATGTTGGGAATTG AACCCATGTACTCTGCAAGAGCAGCAAG TACTCTTAACTACTGAGTCATCTGTTTAG CCCTCCTGTTGGGATTTAATGGTCAGTG TGAAATACTATGAAGATAGAAGGGTTTCC TAGACTCTGGTGTGTAGGGGTGGGGTAT CTGTGAGATGGGTAAGCTCTGTTGGCTT TCTAAGAAGGAGAATGAGCAGAAGGCAC ACATAGACATTCACACTTTCACACACATG CATGCCAAACACCACACATGCACACCAC ATACCACACGCGCCCTCCTGTTTCTTACT ATGTAATAATGTTCTTGTAATAACTTAGTA CTCTGCTAATGAAAAGGTCACCACTAACT AGATGCTAGCCTTCAACTTTGGACCAGA ACTATGAGCCCAAATAAACCTCTTGCATT TATAATTTAGCCAGCATGTAGAACTGTGT CAATAACAATGGAATAGTGTTG 276 IM000894 GATCATCTGGCTAAAATTTTATAATATGA p001086 R — CTCTTTAAATTCCTTAAGAATTCACAAGG ACCTTTATGTTGAAATTACTCATATGTAA GCTTACTGGAATGAGATGGCTCCCCAGT TGAAAACACCATTCTTAAAATACTCAGAA AATAAGAACGAGGCCAGCCCGGTCTACA AAGTGAGTTCCAGGACAACCAGAGCTAT ACAGAGAAACCCTGTCTCAAAACAAAAA CAAAAACAAAAACCTAAAAAAAAACAAAA AAGAAAAAACAAAACAAAACAAAAAGAAT GTAGATATAAAGAAAGAATAGTGTTTGCT GGAAATAAATAGTAATATAAACTTAACAG CAGCCTGTCAATTGCAGGGTTTTTGCAC TTGCAGCTCAGAAAGAAGTGACCCTCCT CAGGAAGTAG 277 IM000895 GTGGGTTGTGTGACTCAGAGAGCAAGCT p001087 D — TCTACCTCCACAGGCAAGGATGCCTGTG CACACAGAAATGAGATGAAGTCATATGT GGGGACTGGAGTTGCAGTGGCTCCCAG AAGGAGGTGTGCAGAGTTCAGGCTGGA GTCCAGATGAGGAACATCAAATAGAGAG GCCTTTGGAGGGAGTGGGTTCTCTTGAT AAGTAGGACTGCCACCCATATCAAGTAT AAGACTGCCAATCATACTGAATCTCAGG TTATTTCCCATGTAGCATTGGGAACATAT AGCATTTGTCACACTGCTATAGCAAAGAA TCTGTGATGAGGTTGGGAGTGGAGGGG AACGCCTTTGGTCCTAGAAAAAGAACCA AAGGTAGGCTGATC 278 IM000896 CCTGCCCTTGCCAGACCCGACCGCAGC p001088 R — TCATCGAGGAGGTACCCTCTAAAGTCGT CACCTTGAGGAGACAAGCTCTGTCATAG TGCTCGCAGCCCCGCGGCCCCTGCGCC AGGTTGCGGACGCCATCTTCCCGCGCC GTCGCCGCCATCTCCTCCTCCTCCTCCT CCACCACCTCCCCCTCACCTGCCACTGA ACCTTTCCCCCAGCTTGGAAGCCACGCC TTAAGGAAGCAGAGTCGGTCGGACACCC GCTCCTCCTCAGAGCAGCGGCCACCAG AGTCAGGAAGGGGGGGTCCAATCACGT GATC 279 IM000897 GCTCAATTAGTTTATTTAAATTCAAAACA p001089 D — AAGCTAAAAGCCTGATGTGTCAGTTGCCT TCAGCAGAGCTGTTTGGGGCCCATTGTT ATGTTGTGAATTAAGTTCTGATGTAAGT AACCAAGCCACTCCCCACACTCTTACTT GCAAGAGTTCCAGGCAGATGTTAAGGTC AACCCACCTGACTCTGATC 280 IM000898 GATCACAGTGTTTATCTCAGCAACAGAAA p001091 C — GCAAATGAGGACACACCTGGGTCTCACT GATATACTTGGTGATATGTGTAGTTATTA TGTCTCACAGTAATTGGACAAGGAAGAG AGTTCATTGTTTTAGAATGTTGTTACTGG CATTGTTCTTCTCTCTCTTGTTTTCATAAA ATCTCACAATATCTACAGCTGTGAGGTC CAAGGGGCTCATTGGTGATACCCACTCT TTCTACTTTGTGTGACCAACCTCTTTTGG ATGTCAAGGGT 281 IM000899 GATCAGTTGCTATTGCTTGATTGATTGCG p001092 C — AGACTTTCTTAACAAGAGTCTTTGTCTCC TCTCACTCCCTAGCTTCATCTTAGAACTT AAACCCACAGCCCAAATGAGTAGTTGTA TGTCATATGCCTCGGCCAAAGCACGACT GAAAGGAAAAGAAAGGCAGACACTGGA GTGCAGGAAGAAGACACAAGGCAAAGC CCAGAATTCAAAAGTAGAAGCACAGATT GTTTTCTTTGTTT 282 IM000900 GTACCCTGCATCCCCGGTGTGGCCTTGG p001093 D — AGTCTGATGCCAGCACTACAGAGCCAAG CCATAATACTAACCAAATAGAATTAACAA GAGCTCCATATGATC 283 IM000901 GATCACCTTCCTAGGATGAACGAAGAAG p001094 C — GATGGCTGGAGGTTAGGGACCCAAGGG ACTTCCCCCTAGAGCTGGCTGTGTACCC TAGGCATGTGTGACTGCAGCTGTACAAG CAGGGTATTCTGGGATTCACAGTCCTCA GGATAAGATGACACTACAGATTCTAAGC TTTATACCCAACATGGTGGAACCCCATG GTCACACTCTTTCACAGATGGTCACTCC CATTGCCCGAAGCCCAGCCTTTATCCAA G 284 IM000902 GATCAATAACAGCAAAAGAAAAAAAGAA p001095 C — GTACTTTTCATGTAGCAATGTGGATAA TTCCCATCCAGAGAAACAAAACCAGTTC CAG 285 IM000903 GATCAGGGAAGATGTCACCTCCAACCCA p001096 D — GCCTAGACATGGTGCTGTGACCA 286 IM000904 GATCAAGGAGCAACCCAATAGCTTCTAT p001097 R — TCCCCCCCTACTAAAATATGACCCACTG ATGGATTCTGGGGATGCACAGATGTTCT CAGAAGTTACTGATGAACACACCATGCT CTAACAAATAGTATCAAACCCACAGTCAC AGATGGCCCTAGTTAAGCACAGTGCATC ACAAAGCAAAGCAAAGAGCCTTGACTGT GGGAAAGGTACTTGTGGTGAGGACTAGT GGGGTATGAAAGAAATTAGAGAGGATGA AGGTAGTGATATTCAGTGTGTGTGTGTG TGTGTGTGTGTGTGTGTGTGTGTGTGTG TGTGTAAGACTATTAAAGAACACCCTTTT TTAAAGAAAGGCTTTCTTGAGTGTCACC 287 IM000905 GGTTAATAAGCTAGATTATCGTGTATATA p001098 K Myc TAAAGTGTGTATGTATACGTTTGGGGATT GTACAGAATGCACAGCGTAGTATTCAGG AAAAAGGAGACTGGGAAATTAATGTATAA ATTAAAATCAGCTTTTAATTAGCTTAACA CACACATACGAAGGCAAAAATGTAACGT TACTTTGATC 288 IM000906 GTGAACGACAGCAGAATCGGGTTGTACC p001099 D — TCAAAGCACTTACCTTTCCCAATACACCT GATC 289 IM000907 GATCAGTGACAATGTAGCTTTGCCTGGA p001100 D — AGGATACTTGAGTC 290 IM000908 GATCAGCAAAATGGGACATCGAAGTTGA p001101 D — ACCAAAGTCATTATAAAACATCCTGAGGT ACATAAACACTCTGTAATAGACTAATACA GTTCCTCCAGGCACCAACAGAAACCTTG ACTACTTCCCTTGACTACTTCAGTCAAAT CTTCTGATAAAACCAGACCCAACTTGGA AACGTCCATGTATACTATG 291 IM000909 GATCATCTGCTTCTACCCCCAATTAAAAG p001102 D — ACGGACTAAGAACATAAAAAGAATCCAG GCACCTAGGTTTGCAGAAATCTAAAGGT TGAGTTCCTTT 292 IM000910 GATCACAAGTTATAGTTGAATAACAAGTC p001103 D — CTGTGTGTGTCTATGTATCCGTATATCAT ATTTTCTTTATCTGTTACTCTATTCATGGA AACTAGGTGGATGTGTTAACTTGGCTATT ATGAGTTTTGCTGCTAT 293 IM000911 CTACAATGGTTCAGGCTTTGGAATATCAC p001104 C — TCTATAGGCTGTCTGCCGGCCACCACCC TTCAGACTGCCACTCACAGGTGCCCGTG AAGGCTGCCGAGAGGCAGTCCCCATCA GCCTGTCTCCTACACCCACACACTCTGT GTGGAGACCACAGGCGCCCAAAGGGTA TGCTAGTCTCTGCTCTACCGCGTACCCT CTCCTGAAGGCAGGCATTTCAGAGATTC CAGTTTCACCAGGAAGCTCAGATC 294 IM000912 GATCTTTTCCCCCTTTGTAGTATCAGAGA p001105 R — GAAAAGCCATGGCATGCATGGCACATGC TAGGCAAACACTCAAGCATCCTACTCTG TGATGCAGTTTGAACAACTTTTTTTTT CTTTTTCTTTCTTTTTTTCTTTTTTCTT TTCTTTTTCTTTTTCTTTTCTTTTTTTTT TTTTTGAGT 295 IM000913 GATCTCTCCCCATCCTCCTGTTGCCTCTT p001106 A Gata1 GTCTGTCATACCTCTACTACTCCATCAGT TTGCTGCCTCTGAGTCCCTCTTCTTCCTC TCCTATCCCTCCTCCCATCTTCCTCATCT CCAGGTCTCTCCAGGTCTTCCTTCTTCC CTCTTTTCTTCCCCTTTTCCTCTTTCCACT GTCTTGTATTCCCTTCCTTTCTCTGTTGG TCCCTTCCCTCGCACCTCTTTCCTCCTGT CCCTCCTTTTCATGTACCATATTTCTCTT CCTCTTTCTGTGTCTCCTCTTTCCTTCCT CCTTTACTTTCCTTCTAACCTTCCTCTTTC TCCTCCTCCGGCAAGCCTTTGCTT 296 IM000914 GGTTGTTCCAGTTAAATTGGCTCTCTACA p001107 D — GGAACATGGCTTAGTTCTCCCTTAGCCT TTCATGACCCTACACCTCAGACACTAGT CAAAGTCTAGCTTAATAAAGTGTTCAGGA TGTTGGTGGAGGGGGGGAGATTGTTAAT ACAGATC 297 IM000915 GGACCACTTTAGTATGGGTCATATGTTCT p001108 D — AACTTTCTTTCATTTTCTAATTCTTTCCAT CTGCATTGATTGTGCCCAGTTATCATTAG TGACTTATTTTAGTAACTTAAGGGAAAGT TGTCTATGCTCTACTTAGTGTCGATTTAA CTTACTCTCCAGACATGGGAGTGCTTATT TTTGTTTGCCTTACCTCATCCAGGAGCTT GTAGATC 298 IM000916 GATCCGATTATGAAACCGGTTTTGAAC p001109 D — 299 IM000917 GATCTGTGGAATGCTATCCAGCTCTTCC p001110 D — AACAAATAC 300 IM000918 TTAGTATCTGCATCTGACTCTTTCAGCTG p001111 R — TTCGTTAGGCCTTTCGGAGGGCAGCCAT GCTAGGCTCCTGTCTGCAAGCACACCAC AACATCAGTAACAGTCTCAGGGGTCTGA GCCTCCCCTTGAGCTAGATC 301 IM000919 GATCTGTGGTAATGATTCTGTAAATACAG p001112 D — ATAAACAACGTACACATGGGAATTGTTCC CTGTGTGAAAGTGTTCATCATAAGGTGTT TTTATTTTATCTACAATATCTTTGGGTTTT TAG 302 IM000920 ACTGCCACATTCCCTAACACCTCATCAAA p001113 D — GAAAACAACACCACAGGTCTCAGGCTGC CACTCTAGACCTCCGAGTTGACTCTGGC TCCTGCTCTCTGCTAGCAAACACGCATC CCTCAAGTCTTCATGCTGGTTCTCTCAAG TCTTCATGCTGGCTCTCTGTAGTTCTGTA AGCTTACCCTTTCAGTGGTGATTTGGGG AGATC 303 IM000921 GATCTCCTGGCTTTGTAGATAAATGTAGA p001114 D — GAGTTCGTTACCAACTGAACTAAAGAGC GGCACAGGAAATTAAAAAAAACAAACAA ACTGATAGTTAACTCAATTGAGTAAGTAT GGAGTTTTGGGACCAAGACATATTAGGC AAACAGACAGTTTAAGGCCTAG 304 IM000922 GTTCCTGTACTTTATCATGTCTTACCCCT p001117 D — ACCTCCCTCCATTTTAATCATCTTTACTG GGATGTAATGCATTCCTTTGTCCATTCCA GGATGCTATAACAAGATACCTTCAGCCT GTAAGCTATAGAACAGTGTGGTCCTCAA CCTTCCTAACTGTGACCCTATAATATA GATC 305 IM000923 CCANCGTGCCANACTCANAANGGAATTT p001119 D — TATTCATAGATTCTNTCANACTGCTGTCC CACATGTGTTCAAAANCAGGTAGGTCTT GTCANAT 306 IM000924 GATCTCATTGCACAGAAGAGTTAGAAGA p001121 D — AAGAAAGAAAAGCAGACTGGGAAAAATT TTTGCAGCGAGCATTCAGAGATTGAACA TCTATCTAACTTATGCAAAATTCCTATCA AAAGAAAAAAAAAGCTTCAACAGCTGGG TAAGTTAAAATGTAACTATAAGGCAACAC AAGGCAAAGTGTTGTTCTTTTTGCTTGTT TCCGAGATGAGCTCAATTAAAATATCAAT AGCGACTACAATTCTGAGCTGGACTAAC GAGTAGTTACAATACTACCCAACGCT TGTGGTTAGGTAACCTTACACAATATTTT CCTAATGCTATTCGGCAATAATTGTCAAG AAAA 307 IM000925 GATCTTTTCCTACAAGACTTCTGGGTGAC p001122 D — CTTGCCAAGCCCAGCCACTGGCTGTGGT ACCTCACCAGGACACTCGGTGGACATTA GGTAGTGCTCCCCAAGTGCTAGGTGACA GTTTATGCTTCAAAGTGACTCCTGCAC 308 IM000926 GTGCTGACGCGCCCTTGCATTTGGGAGA p001123 D — GCAGTCAAGCTATCTGTACCTTCACCGT AAGACTACATTGTCACTGCTGGCTTCCC TCCTGTGCAAGGGACGCATTTGGGTCAG ACTATGCATGAAACAGGACAACAAAGGT AGGGCCATTGGTAGATC 309 IM000927 GATCTCACTGAATATAAAAAGACATCAGT p001124 D — CCAAGGGTGGAAATTTAACCAAAATAATA CAATTGTTGTTG 310 IM000928 GATCCTCCAGGAACTAGAGTTACAGACA p001125 D — ATGCCCGCCTTGTATT 311 IM000929 GTGGCAGTGACTGTCCGTGTGGGAAAC p001127 K Nmyc GTAGCAAGTCCGAGCGTGTTCGATC 312 IM000930 CAGGAGAGTGTCTCAAAAAGCAGCAAAG p001129 C — CACCCAGCACCTTAGGGTGAAGGACCAC TTCTGGAATGTATCCTCCCAGTTGCAAAT GTACACTGTCTCATTCACTCCTGTGACAT ACTTTGTTTGTGAATGCTAATATCACATA GTTCGATC 313 IM000931 CCAGCAGAGACCAAGCATCCAAAACATG p001131 D — AGCCCATTTCAGGCTTCAACCATAGCAG CTCCCATCTCAATCCTGTTCACCCCCCA CCCCACCCCCCGCTTCTCTATTTAAATCA CCACTCTCAGTGACCAAAAAGATGCTCA TGGCAAATGGACTCTTGGCTCTCTTTTAC CTAATACTGAAGGTAACAAGATAATCAAC TGTTTCCTCTCCTTCCCGGGGACCTCAT CATACAACATTCTCCCACATGAAATTATC ACCACGTCCTATACCCACATCCTCCCCG TCCTGTAGAGAAACCACATGCCTAGCAG CAGTGGTTTCCCACCTCTGTGCTCCCTT CCACCTCGATC 314 IM000932 GATCGCTGTGGTTGGTGTCTGTGTATAT p001132 B Mm.3669 GCACTGTACATACTAACCAGGTACACAC 2 TAAATATTTAATATATAAAAAATAAAGTG CTTTCTAAGAGGCCCCTAGGCAGGGACG ATAAAACATTTCACAAAGCAGCAAAAC TTGATACAATCAAAAAAACAACACT ATAACCAACATAGGTGAAAACAGCCAAA CACATAATGTACAATCTGGTGTTGCAGG ACAAACATCTGTCATATACATGGTATATA CATACATACTTTTTCACTCAATAA 315 IM000933 GATCGCTAAGTGTGCGCGGCCGCCGTC p001133 B Mm.1515 TGCAGAATGAATGGAGGGAATGAATGAG 28 GGTGCGCGCGCCCGAGGCCCGGCTTGC GTCAGCCATGCGTGCCCGGCATGGACA CGGCCTGGCCTTCCTGGGAGGATGGGA CCGGATGCAGTTAGTCCAGGCGTTCAGC ATCCCAGGGCCCTTCCTCTGTTGCGTGG TCTGAGTAATCTGTCTCGCAGAAGATAC CCT 316 IM000934 GGAGGTCTCTGTAGGTGCTTAGACTCAC p001136 D — GTTACAGTCATTCCAGAGGAGGGAGCTG CAGCTGCTAGTTTCTGTGCACACCGATC 317 IM000935 GATCGGCTGTCAAGACTGGGGAAGGGT p001138 D — CCTCCTAG 318 IM000936 AAGCAAGAGGTAATAAAATACATGTGGA p001139 D — TGGATGACTCAGGGGTTCAGAGCATACA CCGATC 319 IM000937 GATCGGGGACCTTGCATAAAGGGGTCCA p001140 B AA70964 GGGCTCTCAGTCCTTGGGAAGG 7 320 IM000938 GATCGTGATGACTTCATAACCATCACGT p001141 C — GTGAAAAGACTTAATGGCGCTGAATTCA CATGACACTTAAAATGCACAAAGTAACAA ATTTTATGTCACATGTATTAAACTACAGC TAAGTACATGGGGAAAAAGTTAGACTTA GAATAACTCATCCAGAGTCATATGGTAG 321 IM000939 GATCGAGGAGTAACCCAATAGCTCCTAT p001144 R — CCCCCCTTACTAAAATATGACCCACTGA TGGATTCTGGGGATGCACAGATGTTCTC GAAGTTACTGATGAACACACCATGCTC TAACAAACAGTATCAAACCCACAGTCACA GATGGCCCTAGTTAAGCACAGTGCATCA CAAAGCAAAGCAAAGAGCCTTGACTGTG GGAAAGGTACTTGTGGTGAGGACTAGTG GGGTATGAAAGAAATTAGAGAGGATGAA GGTAGTGATATTCAGTGTGTGTGTGTGT GTGTGTGTGTGTGTGTGTGTGTGTGTGT GTGTGTAAGACTATTAAAGAACACCCTTT TTTAAAGATAGGCTTTCTTGAGTGTCACC 322 IM000940 GATCGGGCCACATCTCAGACACTCCTAT p001149 R — AGCTACAGAGAGATACCGTTTCCTGTTAT CTGCAGACAACTTTATCTGTTACTCAG AGAAAACCTCCAGGTGCCCCTAAAGAAA CTGGGCCCTACATCACATACCCATACCA CACACATGCAACATGCAAAACATACACA CATACATAGACACACACACCACACGCAC ACAGACACATACAGACACACACACATAC TATACATACAGACACATATGCTACACACA TACAGACACACACAAGCACACATACTTC ACACACAGAGACACACACACCACACACA CACAC 323 IM000941 GCCTGCCTCTGCCTCTCGAGTGCTGGGA p001151 R — ATAAAGGCGTGCTAGAGCCTTCACTTGG CTCTCTCTCTCTCTCTCTCTCTTTTAACC TCCTTTTTCCTTTAATGAGTTATTTATTTT TATTTTATGTGCATTTGTGTTTTGCCTGT TCCGATC 324 IM000942 GCTTCAATATTCGAAAAGTATTAGTAAGA p001152 D — AAGGCTGTTCGATC 325 IM000943 CTACCAGGAAGTCAGGGGTTTCCAGGAA p001154 D — CCCACACTTGGCTTCCTCTGCACAGAGG GACCTCATACCAGTGAGATGGTGATATG CTCCCTTGTTCCTGAGCCTCAGTGGAAG CGACTTTCTATGGATACTCCCTCCCTCGT GCCTCTCCTTCTTTCCCTCTCTGCTCTCC CCCCCCCCCCTCGCCCTCACGATC 326 IM000944 ATACACACCATCAGATATACCTCATTCTG p001155 D — TATACCTACAGGTACACCAATCACACAC ACACATTTACTCACATGTACATGCACACA CCACATCGGTTAGAACCAAAGACCTCAC ACACACCCCTCACACATGTTTCATCTCCA TTATCAGTGCCGATC 327 IM000945 GATCGTCAGGTTATGAATGCCAT p001156 C — 328 IM000946 GTTCTCAGAACCAGCTACTGTTTACACA p001157 C — GGGCCTCATGCAGCCTTGCTGTCCTCCA TTCTGCAAGCACAGGATACACACCCCTG AAGGCCAGATTGTCAGGTCAGCCCGATC 329 IM000947 CTTCAAACCGGTCCTGCGAGGAGTCCAC p001158 D — AACCTCTGCCTGCCGATC 330 IM000948 GATCGAGGCCAGCCTGGTCTACAAAGTG p001159 B Mm.8136 AGTCCCAGGACAGCCAGGGCGATACAG 6 AGAAACCCTGTCTCAAAACAAACAAACAA ACAAGATTCCATTGAGGAACACCCAGAT GGAGACATGGGTGTTCTCCATAGAAGGG TTAGGGGCTTCCACACCGTTGACAC 331 IM000949 GATCGGTGTGCTTTCTGCAGTTTCAGCG p001160 B AA40894 AGGACTCTGGGCCCAAAATGTTTTAAAG 5 CAGAAAATTGGTAACACTAGAGATATTGT CAAAATACGATTTCCTCTGGTTCAGAAAT GGCGAGAGGGAGGGCTGGAAGGGTGG AGTGGGAAGGAATTGTCATCAAAGCATT GTTGATAC 332 IM000950 CTGTCTCAGGCATGAAAACACTAAAAGA p001161 D — TGACCAATTTCAATAAAGATGACCTGAAT GTCTACTCAATTCCCACCATTAGGTCTAC AAGATGTAAATGGGCCGATC 333 IM000951 GATCGTGGAAACAGAGCCTTGAATATAA p001162 D — TGAAGAAACAGAGGGCAGGCAGCAGCC GCAGCACAGCAGGGGCACTGTGAGCAG GCAGCAACAGGGGG 334 IM000952 CTCCCTACTACCTTCCCTTCCTGGACNT p001163 C — CCACTGAGATGAGGCAGGATAAAGGGTC AAAAGAGACCTGACCTTCTCTGCCAAAG CCAGGGATTTCTGGAAGAATAGAAATGG TTCTGGAATTCACAGATGCAGTGGTCTA GGATC 335 IM000953 GATCCATAGGTCTCTGCTTTCCCCATTCA p001164 D — GGGCTGGAGTTATAGATATCTGTCTATC ACCCAGCTTTTATGTAGGTTCCAGG 336 IM000954 TATGTATCTACAAGCCAGAAGAGGGCAT p001166 D — TGGATC 337 IM000955 GATCCGAGTTCTCTCCGGCCACGTACCT p001167 D — TCACATCCCATGCACCCTGGTATGTAAG AAGAGCCCAGCTCAC 338 IM000956 TCCCATAATATTTCCTCAGAAGGATC p001168 D — 339 IM000957 TATAGTTCTGCCTGTGGAGTGTGAGCAG p001169 D — AAATGTGTATCGTTTCTGGGTCAGAGCTT TCAGGAACTGAGCATGACTGCTCTACAG TGTCTTTCTCCTTCTGGCTGCTGTAGCC CTAGGGGACAATAGAACCACAGGATGAA AGGACTCGGGATC 340 IM000958 GATCCAATGGCAGCTAGCAGAGTCAGAG p001171 R — AGCCCTCACTCCAGTTAACTAGGGGACC CACATGAAGTTCAAGCTACATATCTGCTA CAAATGTTTGAGGGACCTCCTAGCTCCA CGCCACATGCTCTTTGGTTGGTGGTTCA GTCTCTGTGAGCCCCACTGGGCTCAGGT TAGTTGACCTACAGTCTTCTTGTGGTATC CTTGACCCCTCTGACCCCAGAGTTTAAC AATAGGCCTTCTGACTCTAGAAATCTACC TACATTTTTTCCACTTTAAATTCCTCGGC TCACATAATACCAATGAACT 341 IM000959 GATCCATCTGCACAGTCTGTCACCGGGG p001172 K Pim1 TCCAGCAAGTAGCAGCCTTTCTGCTGCT GTCTGTCAGACCCTCCAGGGAGGGAGA GCTTGTCTTCTGGCCTCCCAACAGGACC CTGCGTGACGATGCAGGGACAGCAATG ACAACTCATTCCAGACTCCAGGTCCCTG GAGGAGCCTCCCACAAGGGAAAGAGAC TACTTCACTGGTCCTGGGCCCCTCTTTG CGCGCCCCGCCCCCAGACTCAGCGTCT AGTGTTGCTGGGCTCCCCT 342 IM000960 GGGTAACAGGCTTAGTTTGGGGCCTTT p001173 D — CTGTTACAGGAAAACCATGAAATGTCCT GAAGTGCTCAACAAACAGGGAATATAGA TCATAATGGTTCCTCCCTAGCACAAG GAAGCATGTTTAAAAATTGCAGCAAAATA AAAAAGAACAGATTCTTAAGATTGAGGG ATTTTACGGGGTGGTACTTTTTCTTTCTC TTATAAACATTTATTTACTTTTGTTATTCA AGACAGGATC 343 IM000961 GATCCAGCTGTTTGCTAACATACGTAAA p001174 C — GGTATGGATGCTGAGAGAGTATCTATCG AAAGCGAAGGCACCCTCCCCAAATTCAA GAAAGCAGCTGTTTCTAGAACCAJAGAC ACCACCGCCGCCGCCGCCACCACCACC CGCGAGGGCCCGGACCCTGTTAGAGAG TGTC 344 IM000962 GATCCTGAAATTATCACATTTGAATCAAA p001175 D — TCATGCCCTGCCGAGGATAAATAACCCA AACGACCGAGAAAACCGAGAAAAAGAAC ATTTACTGACCATCCTTC 345 IM000963 GATCCAGTCCAGAGCAATGTTCACGTCT p001176 D — GTGATGGTAT 346 IM000964 AAAGGTGCTCTCAATACTTAACAATCCAT p001177 C — AAGCTTGTGCTCTCTTAGTCGTAAAGGT GGGGTCCATCAAAATCCCATGACACCAC AGCGAGACCAAACTCCTTTTCTCTTACTC CGAATCACCCATCCCATGTGGGAGACGA ATAAGAACACAAACTACATCTTCAGTGAC ATAGAGTAGCATCTGCAACAGAGGAAGT GGATGGAGACCTTGTCTCTGGTCATiAGA CAAAGCATGTGACAGCTGAGCCTGGCAC TTCCTACTTGGGTCACAGCTCAAACCCA CCTGAACCAACAGCAGAGCCCCACAGG GATGGGACTCACATGTTTCCCTCTTGCC CTGGAGCTTCGTGCATGTTGTTAGAAGC TAACTGGCTAACACGCACGGGAACAGGC AATGTAGTTGGAGTATGAATCGAAGTCA CTGGGCATGGTCCTCAGTCAGCCAGGAT C 347 IM000965 CTAGACTAGTATGGCAGAACCTATCTTCT p001178 C — TCTAATCATTTAGATGAATACTCCACATG AGAGAGCCCTGAGAATATCTGTAAAAAG TAATCCAGGTTCTGTTACTTCTAGCTAAT CTTATCTAGGTAATAATAGATAAGGAATC GGGATTCACGAACACAAATACCTGTACA AAGCATGTTGTCTCACACGGGACGAACA CTGTTTCTGCTGTGCTTTATAACGCTGG GACATACAAAACTAGACTCTGCCTAAGA AGTGTTTGGAAACATGGGTTAAATTAT AGTCAGATAAAACAACAACCATGAGTAAA TCGAAGAATATAAAACTAGGGATC 348 IM000966 TTTCCTGGACAATAATGTTTTCTTCATTAA p001179 D — ATTTACACTTAGAGCATTGTCTTAATCCA TGAATAATTCCCAGCTCCTAGCTCATTAC CTGTGACACAGCAGGGATTCATACATTT ATTGAATGAATGGATGAGTGAATGAATAA AAGAATGAGCATATCAAGAGGATC 349 IM000967 GATCCCTTCTGTCTTTGGTTATCTC p001181 D — 350 IM000968 GATCCACCACTGAGCCACTTCTTCAGCC p001182 C — TGTGACTGTCATTCTTAATCATCCACACA GACTTCTCCTTGGCAGATTTTGCCCACC TCTTAAGACTTTCACAAAGGTTTTTTTCTT CTGCAGGGCACATGAGAAAACAACTCTG TCATAAAGAAACCCAGGAAGAAAACCAG CAGAGGCAGGTGAGTTAAGCCTGTGGT GGACATTCCTTCTGGGGATGACCAGATG GGAACAGTAATTCACAGAGGCAGAGGG GTCTGCAGTCACTCTGCATGCCACATGT GTAACCCTTAAGAAGTGAGGAATGCTCT CAACAGGAAAAACACAGCAGCAAATGCT ATGATACCAAAGCCACAACTCCATGGGT CCCTGGAGCCTCTCGAACTAAGCTGCCA GCTAGGGAGCTAACACTAGCTTTGGATG AAACACAGCTCTGGTAGAGTT 351 IM000969 GCTGGGATTTGAACTCAGGGCCTTCAGA p001183 R — AGAGCAGTCTGCTCTTACCCGCTGAACC ATCTCACCAGCCCCCTTCCGTTCTTCCTT TCTTCCTTCCTTTTTTTTTTCCACATTGTT TTCAGACTGCACCTTGTTTAGTAGTCTAG GCTGGCTTCCAATTCCCCAATGATTGAG CTATGGGTATACTCTCTTCACCTACTTTG ATTTTTTGTTTGTTTATTTGTTTTTTTGTTT TTTTGAGACAGGGTTTCTCTGTATAGCCC TGGCTGTTCTGGAACTCACTTTGTAGAC CAGGCTGGCCTTGAACTCAGAAATCTGC CTGCCTCTGCCTTCAAAGTGCTGGGATC 352 IM000970 GCTTCATTTAATATACATCATTTACCAGA p001184 D — AACCACAGACATCTTTGTACCAACATATA GTAATATTAATCACAATAGCCATCACTCT TATGTAAGGATGAGAAGACTCCCAGCTA ATATGCTAATGTGTAGAAGATGCCAGAT GGATC 353 IM000971 GATCCCTGCTTCTGTAAATCCGCAACGA p001185 C — CAATTGTTATCTTCTCCTTTTCTTTCTTTT ATTTGTTTTATTCTATTTTATTTTTCAGAT GAAAA 354 IM000972 GATCCTCCTGCCTCTGCCTCCTTCAGCA p001186 R — AATCCTACCGGCGTGCGCCACCACTACC GGCGAAAAA 355 IM000973 GATCCCCCTTTCTCTCTGTCTACGGGCT p001187 D — CTGTCCTGTGTTAGCTGTAGGCCTACTC TGTATGAACAGACCTCAGCGGAGGGGTT TGGACTTGGGCTTGTGTTTCTTAAGAGA ATGGGGCTTCCATGACTGTCCCTCTGTC CCTTTCATCCTAACCCTGCCTCCCGCTA ACAGGCAGCCTGTATGTTTCTTGCACTG TTCCTTCCTCCTGACGGTCTGAGTCGTTT CCCTCAGAGACTGTTGCTGCTGCTTCAG CTTTCTCTCAGCTTCTCTCAGGGCTTCC GCTCTGGAGTTTCTCCTGCTTCTCTGTTT ACTTTTCAAAGCTCAGCCTCCATCTTCTG CACCTGCGGAGTCATCACTGATTCCCAG CTGTGGCCTGTCACCCTTCCCTTTGTTTC TTCCTCCTGTGCCACCACCATGCACCCT CCCCTTCTGTCTGTTGTGTTGTCCTAACC TTTCTTCTCCCCATGCACCCTCCCCTTCT GTCTGTTGTGTTGTCCTAACCTTTCTTCT CCTCTCTGTGCTCTGCAGGTTTTAGGGT CTCTGTATGATTTGTACCTGCATTTATTT GAACCTCCACTCTTCTCTTTCCCTCTCTT ATC 356 IM000974 GATCCTGCAATACCTCTCCTGGGCATAT p001188 R — ATCTAGAAGATGTTTCAACTGGTAATAAG AACACATGCTCTACTATGTTCATAGCAGC CTTATTTATAATAGCCAGAAGCTGGAAAG AATCCAGATGTCCCTCAACAGAGGAATG GGTACAGAAAATGTGATACATTTACAA 357 IM000975 ATCTAAACTATAATAGTTGCAGGGCTAGT p001190 D — TCATTGTCAGGTGCGTGGCGAAAGAGTG CAAATCCCGGGGGTTCTTTCTTCAGAAT CAACGAGGCAATACACTTGAACATGTAT GTTTTTGTAATCTGCGGGGCATCACCCG TCCTCCAGGATC 358 IM000976 GATCCCCCAGAAGTGATAGTTTAACAGT p001192 K lrf4 GAGGTGAATGCAAGCAATAAGCTACCTA TATCATTAAAACTTCCTATTTTATTAGCAT CTATTAGTTGCACACAGCAGTGATGGGT TTCATT 359 IM000977 GGACCTCTGTACAAATGTCGGGAGATAA p001194 D — GGGAAGAAAAAGACGACAGAGATAGCA GTCAGGATGTAATGTGTACTAGATGAGT GGTTCAAGCAATAGGATGGAAAGGGCTT AGCAGGAGAGATTTTTAAGGATGGAGGC AGTAGATTACATCTGGGAAATGTCACTG GAACTGGATC 360 IM000978 GATCACCAGGCTGGGCAGGCCACCTAA p001196 D — GGAAGTGGCACGGGCACGGGCACTTCC CCAGAGCACCCTCTGGGCACTCTGAGA GGGGCACAGATGTACTGCACTAGGCTG GGCCCGGAGGAG 361 IM000979 TATAAAATATCGAACGTCCTCTGGCTTG p001197 D — TAAATATCATGTTAACCTTCAAAGCGTTC GAAAGCGCAGGAAATCTGAGTCAACAGA ATAGTATGTAAGTATTTTTATAGAACCT GCCTGAACTGCAAGGGAGGGGCGGGGC GTGGACCCAGGCCTGCCTGCCAATCTG CGCTGCCAGTGAACTAAGCCTGATC 362 IM000980 GATCAAGTCCTGGTCAGTACCAAGTTAA p001200 D — AAAAAAAACTATATAAAAGCTATATTAGG GGACAGCTGTGGCTTTTGTAGAAAAGAA GGTCCTGGTGCTATGACCTGCAGATGCC CATGTGGAAGTCTTCAGATGAAGACTTT CTCATGGAGTAAACATACTCTGTTGTTTG ACCATGTGGACTTGGTTCAAAATGCCCA TGGATGCTCCTTTGGGTACCAGGCTTCA GTGGGAGTCCCAAGCCCATGTCTTTATT TGAGCATGAGCAGTACTGATGCTTACCT GTCTTATTCTTTCCTTGCCCCCTGCCTG GACCGTCTCTGGTTACAAGGATGCTGCA GTGGGAAGCGGTATGACCGTTACCTTTA TGGGACTGAGACCAACTAAGGGGAGGC TGAGGAGGCTGCAGTGAAGTTATTGTTG GGACTGTGGGCTAAGATGGAAGATAACA TGTTAACAAACTCAAGTGCGGAGGTCTC AGAAGTAAAATTGCCTGGTTAGTA 363 IM000981 GATCAATTGGTAACCAAGCCTTGAACTG p001201 D — AAGAGTCGTGAGGTGGGGGACTTTATAT 364 IM000982 GTATCTCCCACCTGGCTCAATATAGGCT p001202 D — CTTTTCAAAGGCTAAATTAAGACCAAGGA CACAGAAGGGTAGCTCGCTGGGCAAAC GTGATCCCTGCTGATAGTGTAG 365 IM000983 CTCTCGTGTGGAGATATTAAAGGTGTGA p001203 A Scp2 ACCACTAAGCCCTGATC 366 IM000984 GATCAAGCAGAGGGGTAAAATAAGGGCA p001205 D — AGCTCAGTGTTAGACAAGCTCATAAGCC AAAGCTGTGAACTCTCCAACGCCT 367 IM000985 GATCACTTCAACATGAAGAAGTTACCCA p001207 D — GCCCCGGGAAGAAGTACATTTCCAGGAA GCAGTGTTTTCATTTTTTGAGTCTGCTCC CATCCCGTTTCTCTGCAGCTGGGTAAAC TTGAAGCTGGGCTAGCCTCTGGGTAGAA GGCAGCTAATGACAACTACCTTGCCTGT CCCACGGAGCCCGGACAGAACCTGAGA TAACACACCTAGCTTGCTGAGTAAAGGC AGGTTACTGTGTGAATGACTCTGAGCTG TTCCAGCTCTGCAGAGCAGGAAGTCTGA CTGTGGAGATAAGAGATAT 368 IM000986 GTCATGATTTGTAATTCCCTGTCCAACTC p001209 D — TCATTGCTTAGGTCAAAATGGCTTAACTC CTAGCCTACTTCAGTGTAAAAGTCATGC GTAATGATC 369 IM000987 GATCAGGCTGGCCTCAAACTCAGAAATC p001210 A Hsc70t CACCTGCCTCTGCCTCCTGAGTGCCGG GATTAAAGGCGTGCGCCACCACTGCCTG GCTGCTTTCTTTTTTTTCTTTTTCTTTGTG TGTGTGGGGTAGTGGTGGTGGTGGTGG TGTTCGAACC 370 IM000988 ATGTGTGTGTGTGGCATGTGTGTGCCAT p001212 R — TGTGTGTGTGTGAGTGAGTGTGTGTGTG TGTCTGTGTATGTTGTGGAACAGATTCCT GTGTATGTTTCCTTCTTCACACATGTTTT CAGAAGTGAAACCAGGCTATGAAGACCG CCAGGCAGCTCTGCAAAGCAGTACTGAG AAGGTGGGACACTGCGGGGGTGAGAAC AGTATGCATGATC 371 IM000989 GATCACACTCCATGAAGCTTCTCTTCTGC p001213 D — AACAGGAAACAAATAGCAAGCAAAACCA CTGGTAATCATTATGTGGTGTCTAACAGA GAGCGGTGACAGGGGTGGAAAACTGAA TGACATTTAAAAGGAGCTGGAGATGTTG GTTTAAGGCGTGTGGGGGCAGCCTACA GCATGGAATTGGTCCATAA 372 IM000990 AACCATCATGGTAGCTTCTGCTTCTCTCC p001214 D — ACGAAGATGGTTGTCCACAGTTGCCC TCTCTACAGAGTGGTCCTGTATTAAGTCA CAGGTGCCATCCTGGTGATC 373 IM000991 GATCTTACCACCCGTTTCCTGCCCGGTC p001215 A Farp TTAGATAGACCTCTTGGCCCCCACGCAC CTAGACAATGGAGTAGACAAGACTTCGA GGGGAAAGAGGCTTCCCAAGATGACCC AGCTCATTGGCTTGACTCCCTACGCCAC CCACTTACACAGTGAGTATCTCTGGTCTT TGCTGT 374 IM000992 GATCTATGTCATCTTCCAGGACTCAGAG p001216 D — TTAAGAGAGTTACCAAGTGAGAGCTCTC ATCACCTTCTGAAGCAGTTGAGAATTGG AACCCAGAAAGATGCACATGCACGGGCA CACACACACCCACGGGCACACACCCAC CCACCCATGCAGAGAGAGAGAGAGAG 375 IM000993 TAGGTTGTGCCTGGCCTGTGCAGGACAT p001217 A Snn GCCTATGGGGTCTTCATCCCTCTCACTT ACTCTAATGTTCACTACTGACAAGCACTA GTAAGAAAGTAGGTGCCTGTAAGAGACT GGAGCAGCCTGCTGCTGACTTCAGCACC TGGGAGGCCTCAGTAGCAAAGCTTAGG GTTAGCTATCCTTGGGGCTGTGGCTGGC TGAGCTCTGGGGTACCGTTTAAGAGGAA AGCTGGAGTCCAGGTTCTCCAGGCCCTG GGTGCATCCCACAACCTCTCTCTCTCTC CTTTACCACTCGCAGCCTTGGCTAAGGA TGAGGACCGGGACCTGGAGTTATCTGAG ATC 376 IM000994 GATCTCTCCCCATCCTCCTGTTGCCTCTT p001218 A Gata1 GTCTGTCATACCTCTACTACTCCATCAGT TTGCTGCCTCTGAGTCCCTCTTCTTCCTC TCCTATCCCTCCTCCCATCTTCCTCATCT CCAGGTCTCTCCAGGTCTTCCTTCTTCC CTCTTTTCTTCCCCTTTTCCTCTTTCCACT GTCTTGTATTCCCTTCCTTTCTCTGTTGG TCCCTTCCCTCGCACCTCTTTCCTCCTGT CCCTCCTTTTCATGTACCATATTTCTCTT CCTCTTTCTGTGTCTC 377 IM000995 GATCTTAGATGGCCAAATGTTGTGAACG p001219 D — TTTCCTAGATGTGTCGTGAGCACTCAGG GTTGAGAGCCCTGGTTATTTAGCAAGTG AAGTGGATGTATACACAAGCAGAAGGCT GAAACTAGACCCCGGTCTCTAATCCTAT ATAAAAACCAACTCCAAATGGACAATAGA AATAAGTGCAAGACTAACTCCAGGGTCA CTGGAGGGATACAAAGGGAGATGC 378 IM000996 GAATGAATATATATATGGGACTAAATGCC p001220 D — ATGCCATAACCAAGAGAACTTAAAGAAG AAAGTGTTTAGTTATGCTTACTCTTTCAA AGAGTCCAGCTGCCAAAGGGATGCTGTC AGGAGTAGCTGAGAGCATACATCTGGAC CCATTAACAAAGAAGGGATGCTTCCCCA GCAAGATC 379 IM000997 GGAGGAGGGGCACCTTCTCAGAGATC p001221 D — 380 IM000998 GATCTTAAAGCTAATAGGTGTGTGTGTGT p001222 R — GTGTGTGTGTGTGTGTGTGTGTGTGGTC AGTGGTAAAATTGTCTACCAAGCTCTAG GTTCACCCCTCACAGAGCCGGAGAGAAA AGGAGAAATCAACTCAAGTCAACCCAAA CAAAACAAAGGACTCAACA 381 IM000999 GATCTGTTCCCAAATCCTCAGTTACTCTC p001223 D — TGGGAAATGGCTTCTGTATGTACACATG TTCTCTAGCTATGTAATAAAAGACCTCTC TTCCTTGGCAAAACTTAACTCTACCTTAG AAAACTCTGATGAGTACTAGAAAGATGA CATGTTCCACAAACGTCTTAAGTGATTCA GGGTTCACAACAAAGAAGGAGATGCTAT ATTGTCTTTCATGACATAGCGTCTAAGTC CCATAGCATAACTTCTATAACACACAAGT GGGT 382 IM001000 ACACTAGCTTCGAAACTTCTTAGTTGTCT p001224 D — GTCCCTGAGCCCTTTGTGGTACTTCCTC CTCAGAGCCCAGCTCCAGCAGTCCCCTT AGCGGCTGTTTTTAGCAACCACACCCTC TGACTGTGGGTTTGCTCTGCAGTGGCTT TAAGGTTTGAATACGAAATGCCTTCCACA AACAGACACTACAGAATCTTAGGTGTCG AGACAATGGGCATTTGAGAAGGAATTGG AACCTTCAGATC 383 IM001001 GATCTTAAGGGAAACCCTTGTCTTTTTGA p001225 D — ATCTGAGCCAGCACAATATTGTATTTCCT TCAATACGTGGTGAATGTTGTATTAGCAA CAATAAATGGAAGCAGGGAATCTCTCAT CTCATGAGTGATATTTACAATGTCTGTCT GGAAACAAACGGCTAATCAAGTTAGTCA CTTACTGTTCTTTAGAAAACACAGTACTT TGAAATGCATACCTAGCAGAGAATATAAA GTATTTACTGTTGGACTAGACTGGGCCC CCGGGTGTGAGGG 384 IM001002 GATCTATCTCATCCTGTTATAGCCGGAAA p001226 C — CATGATAGCAGGATTGGGCAACTCTCCA GTCCCTTTCTCTTGGGTAAAGTCTGAAA GCAAATCGCCCGGACCCATCTCCTGTCT CTGCAGCCTGTCCCAGTTGCCTCTGCCA CTCACTAACTTCACTCCTTAATTTAAAAA GCCAGCACATTTATTGACCGTCT 385 IM001003 GCATGTCTCCAGACTCTCAGCTGCTTCC p001227 D — TGTCTGCTCCTGCTGGATGCTTCATGAA GATGGAGTGAAGCAGTGGTCAGCTTGTC TGTCTCAGCTGTTCTATGTGCATGTGTG CACTTGCTGGAGCTTATGTGCACCACAA GCACGCAGGTGCACACAGAAGCCAGAG ATC 386 IM001004 GATCGAACACGCTCGGACTTGCTAAACG p001229 K Nmyc TTTCCCACACGGACAGTCACTGCCAA 387 IM001005 GATCGTGAGTTCAAGACCAGCCTAAAAT p001230 D — ACACAGTGAGCCTCTGTCTTTAAGAAAC AAACAAACAACAACAGCAAAAACAAAAAT ATTGCTCAAGACCCAATGTTCCTCGGAC TATTTATAGGAATCAGAGTTGCTGTTCTT CTCAGGGCATGCCAGTTAATTTGAAAGA CAAGGTGTAGAGGCAAAGGAAAAGTGAT TTTACTTGGATAACCACCTCATGGAGCA GTCAGGGGAACTCTAGCCTCAAAGCTCT TGCAGAAGTTATAT 388 IM001006 GTAGAAGCTTTTTAGAAATACGTTTCTTA p001233 R — TCTATCTATCCATCTATCCACCCATTATC ATCTATTATCTATATTTAACATCTATCTAA GTATCTGTTTATCTATCTACCTGTCTATA CCTACCTATCTACCTACCTACCTATAGCG ATC 389 IM001007 GATCGTGCATGCATGGGTGTGTTTTGGG p001235 D — GAGAGGTTCTGT 390 IM001008 GTTACTATTCATCTGAGGTTCTCTTTTGT p001239 D — TGTATTTGAACAGGAGGAAGGAACCAGG AGCTCAAGGATGTAGCTGGAAATGCTAT AAAACTGGGATGCCCTAGAGAATCACAC GGACAATCCTGCTAACCCATGGATTGTA CACTCCAATATACAAGATAACATGTTTGT GCAGGGATGCCACCATGATGTTCGATG 391 IM001009 GATCGACCGCAGATGAGGTCTATGCAGG p001240 K Myc AAAAACGATGTCTGGAATTTTATTAAAAT TGCTCAGCTACTCACTGCCACGTATACT TGGAGAGCCACTTAGGGAT 392 IM001010 CCAAGTATACGTGGCAGTGAGTTGCTGA p001242 K Myc GCAATTTTAATTAAATTCCAGACATCGTT TTTCCTGCATAGACCTCATCTGCGGTCG ATC 393 IM001011 GATCGTAGAGAGATGGACCCAAATATCA p001244 D — GCCAGAGAATTAGACCAGAAAATGGAAC CAAAGTACCTGTCAGTCCAAGGATGTAG TGGCACTAC 394 IM001012 GTCCCCAAATGTAAACAAAACTATCAAAA p001246 D — GAAATTGGGCATGCCAGAATTTTGTTCTT CACATTAAGGGAATTCTGAAATTGAAATC TTGCTAAGGGAAGGGTGGCTTGAGAATA TTTACAGAATCCTAGGTTGAAGGAGCAG GAATAGAGGATC 395 IM001013 CAGCTAGCCCATGGAGCTGCTGGGACA p001247 D — CGAGGCCGCAGGCTGAGCATAATGGGG AAGAGATGGCAGATTCATTCACCCACTT GAGGAGACCACAATTAGTCAGAGGCATG CTGGGCCTGGTCAGAGTGCTCAAATAAA CATTCACAGGACCAAAGTAATAAGCATT GGTGTTACAGAGATAAATCCTTTAGCAG GGACACGGGACCCCAGAAAACCGGAAG GACATCGTTCCCATCATGAGAACAAGGA CAGCAAACAGTCACTGAGGGTATACTAC TGACCAGTTCCAACAGGGATGGTCAGAA GTTGAACGCTGGATATATCATGAGCTCT GACCTAAATATTCTGAGTATTCCCCATGT TTGAATGGACTGAATACTCACATTTTCTA TGCTGAATACTGAATTTTCATAGCTAC CATCATAAGGCATGGTGGCAGAATAATA TCTCTCACTCAGAAAGCAAACTATTCTAA GTTGGGGATC 396 IM001014 GATCCCGTGGGGACTGAGCCTGCAGCT p001248 D — CAGTGGTAAAGCAGATGTCTAACGTGGT CAGGGTCCCAGATGAGATGACACAAGT ACCTGTCAGTACTCCGGGAACACTGGGT GGGACTTTTATATGTTTATTTGTATTCTTA 397 IM001015 AGTCCATTGTGTACTGAGAGAGGAGTTA p001249 D — GGTTTAGAAAGCCTTCCTCAGATGTCCC TCAAAGAAGCTGCTACAACTGCCCTCAT CCCAAGTTGCCAAGGATC 398 IM001016 AGATTGCGTGAGTTCTGATGCATGCTGG p001250 D — CCATGATGTGAGGCAGGGGCAGTGGTT GGATTCGGAGTCAGAAAACTTTCCCGTC TACTGCCGTAATTCCCAGCTAAATTCCTA TCCTCGTTGTAGCTGTTGGTGAGGATC 399 IM001017 GATCCTTCCGAATCTGCCATTTATTGAAT p001253 D — ATTTAAAACACACCTCACTGCAGACTAAA CACATTGCAAGCACTGGGAGCAGAGGT GGCTAGTGAGCACCACTCTAGATGGTCC TTC 400 IM001018 GATCCTCCTGCGTCTACCTTCGGGTGGG p001254 R — ATTGCAGGCATGCACCACCATGCTTGGC TTTGTGTGGTACTGGACATTGAACCCAG AACTCTTTGAGCACTAGGCAAGCACATC CTGAACACCAGTAAAACATTTTCAAAGAG AAAAGAAAATTTTAAACATACACCTATCT ACATCCATTTCCACCATGTTAGTAAACCA GGGACATTTTGAAGTGTGGTCTTTATAAA AACACCCGGGTGCTTATCTCCCACGCTCT 401 IM001019 CCAGCGGTGCTCACTACTGCATGTAACC p001255 D — AGCTCCAGGATC 402 IM001020 GTCTCAAAGAACAAAAATAAAAGAGGAA p001257 C — ATTAGTAACGAGTCCTGAGAGATAGAAG AGTATTCAGCCTGGGACCAGAGCTCTGT CTTACAGTCTTGCCATTCTGTGGGGCCT GGGACACAGCATCCTTGGTCTTTAGAAT GCCATAGGCCTCCTGAGGGAGCCTTTTC TGTAGGCACTTCTCCCACATTCTTGGAT GGATGCGATTTATTCTGTGTCAGGGGAC TAGGGTGCTGGATGTGTGGGTCGAATGA CTGTTGTTCTGTCACTTGGGAATTTGGG ATAGGAGTTATTCTGAGTGCAAGGCTAGT CTGCACTTGAACGTACATATCGGGTTTTA AGCCAGCCTCTGAGCTACCACAGTGAGA CTCTCTCTTAACTAAAATCAACATAAATA GTCTTAGTATGGAGAGGTTAGGGGATC 403 IM001021 CGTTTTCCTCGGAAAATGTGAAAAGAAG p001260 C — AAGCACGAGACGAAACCCCCTCGAGAAT GAGAAAATTAAATCTAGAACCCAAATGG CGTCCAACAAGAACATTAGCTCTTGAAAA TGAATATTGCGCCTGCGCAGCCACCGCC CGGCCAGCTGCTCAACTGCAGCTAGAG CCCGACCCCAAGCGATC 404 IM001022 GTGTCACATGTATGAACAGCATCACATG p001262 D — GTATGAATGGTATCATATGGTATGACGT GAATGTGTGCACCGGCACTGATC 405 IM001023 TACCACCCACTCCCTTAAGAAATGATC p001263 D — 406 IM001024 GACTGATATTAGTAGGTTGTTCTCTAAGG p001264 D — GCCGTGAAATTTTTAGCTAGAAGTTCTTG CTTTCATTAACAGTGCCAAGTATGAGTTC CATCTCATGGGGTGGGTCTTGAATACAA TCAGAAGGTGGTGAGTTATCGCCATAAC ATCTGTGCCGCTATTGTACCAGTGGACA TAGTTGCCAGGCAGGCCATTACTGTAGC TCTTAGGTCATTCCTGAAGCTCTCTGGG GTCTGTTAGGTGAGACTGATGATAACTC TTCTCTTCCGTTAGTGTACACAGCACCTT TTAGCACTATGAAAGCGAGGCAGTATTG ATC 407 IM001025 GTTCCGATGTTTGTATCTCGTTTGAATTA p001265 A Rad52 TCCATCAGTTGATTAAGTTGATGGTCATC TAGGCTGATTCCCCTACATGGCCATCTC AATATTGCTTCTTTAATAAGACCTGGACA ATTAACAGCACCAGTTGACATGCCAACTT GGATTGGGGGAGGGGTCTTAAAGGGCC CCGCCCTTAGATGAAGAGCTATACGCAA TTAATGACTGTCAGAAAGGGAGAATGGC TTTCCCAGAGATGAACCCCCTAATGGAT TACCCAGTACCAAGTGATC 408 IM001026 ATTCAACCTATGGGGCCGTTAGACCCCT p001266 C — GGTCTTGGGTGGGGTGGATATGTTATTC TTTTTTGCTGTGGTGGCAGCAATTTTGTT TGCTTTCTTGTTTTTTGATACAGTTTCTC GTCATGTAnCCTGGTTGCCTGGAATTCA CTTCTATAGACCAGAATGGCCTCAAATTT ACAGTGAACCCCCTGCCTCTGGCTTCAG ATTACTGGAATTACAGGTTTGTGCTATCT CACTAGTTGGTGTGTGATC 409 IM001027 GATCAAGTCCCCAGTTAAATGCTTTCTTT p001267 C — GATAGGTTGCCTTGGTGATGTCTCTTCAT AGTAATAGAAAAGCAACCTAAGACAAGA GGAGAGAGTGGGTTTAAGAACGAGGAG AGAGAGGAACTCAGAGGGTCCTGGAGG TCCCGGGAA 410 IM001028 CTCACACATACATTCATACATACACACAC p001270 C — ATATATACATACACACACTTGCATACACA CAGCACACACTCACACACAGAGACACAC AGACACACAGACACACACACAGAGGAAC CCAAAGGATTGGAAGAATAATTTCCCGT GCTCAGCGGGAAAGTTTACCAGAAAGAC AAGTGGTCATGTGGGATGATC 411 IM001029 GATCATCACCAGTGTAGTGTTGGCTTTAA p001271 C — CGGTGCACGCCTTTAATCCTAGCACTTG GGAGGTGGAAACAGGTAGGTGTGCTTAC TTCAGTGAGTGAATTCCAGGCCAGGCAG GGATACAGAGTGAGAACCTGTTATCTAA ATAAATAAATAAA 412 IM001030 CACCCACGGCTTGCTTCTTTTCTCTATGT p001272 D — GTAATTGAAGCACATACCCGGTGGGAGC CATGTTAAGCCTGTGTCCATGATC 413 IM001031 GATCATGTGTTAATGAAACTGTCAGGGG p001274 R — TTGGGTAAGATGGCTCAGTAGGTAAAGG CACTTGCCTCCTAGCCTGGAGACCTGAG GTTCCTCCTGGGGCCCACAGGGAAAAG GAGATAACCAGCTCTCTGTCCTCTGACC TCCTGGGCCCCTCCCTCACAAACAAACA AACAAACACACACACAAACGACCAGACC ATTTCCCACAGTAGCTGTGGTGCGTTAC ACTGTAACGGGCACCATGTGAGGGTTTG GGCTTTATCACATCTCCGCTAGTCATACT TGGTGTTTCCTGCGTCTTGCTTACAGTTG TTCTAATGGGTGGGCGGTGATATCGAAT TGTGGTTTTAGCATGTATTTCCTGTGCTC TGCTAAGACCACTTACAATTACAG 414 IM001032 CCTTAACGCTCCCTTGATGTCCACTCCC p001277 D — GTTTTCTCTGCAGCGATTTATTGCTTAGT CTATCTATAAGGTGTATGCAAGCTGCAAA GTCAAGTATTTCCTTTGTACTTGAGCAAG TCTCCTAAGTATTATGCTTCATAACGTTG TGATATGCTTGAGCAAATTTGAGTCTATT TCATAATTAAGCCACTGTTCTGATAAAAG ACCCTAGAGTGCTATATCTGATC 415 IM001033 AAAAGAGTGTCAGATGTCAGAACTGACT p001279 D — AGCTGGGCTGACACTGAGGAATGAAGGT TGGGGATATATGCACCTCCTGAAAACAG GAAGCCTTTTGTTGGTTGATC 416 IM001034 GATCAACCTTAGTACACAGCAGAGTGTT p001281 D — TTCTGGGAAGCTCATGGAGACCCACTTT TGTCATCCCATAGAGGTTACTACAAATCT GAGCATGAGAATAACTACTTGCTGTTTAA TACAAAGAACCATTAGCAGTCAATGCCC CAAGTTCTAAGGGCACAGACTTCATACG AGAAAAAAAAACAAAGCAAAACAAAAACT ATCACATGCTACTATCTGTACTGGGGAAT GCATACAATTTTGTAGGTAT 417 IM001035 GATCAGTAGAGAGCAGAGGGGTCTATGA p001282 C — GGGAGGTAGAGCAGCCTGGGAGGCCTG AGGAAGGAGGGACAAGGGCAGAGTCTT GGTCACTCTTTGGTCTAATTGCCTTCAGA AGGCTTGCAGACTCTGGTTTGGAGTTCC AGGTGGGTGGCTG 418 IM001036 CAAGTAGGGTTTGTGTGTGTGTGTGTGT p001285 R — GTGTAGCCAGTGTCTTTCTCAATCACTCT CCACCTTAATATnTTTTTTGAGACAGAA TCTCTCACTGAACCTGTATGCTGTCAATT TGTCATGGCTGACTGGCCAAGGAGCCC GAAGAATTTATCTCTATGCTCAATCCAAC CCCCAGATC 419 IM001037 GATCAGATGGACCGATTGCCGCGGGAC p001289 K Notch1 ATCGCACAGGAGCGTATGCACCACGATA TCGTGCGGCTTTTGGATGAGTACAACCT GGTGCGCAGCCCACAGCTGCATGGCAC TGCCCTGGGTGGCACACCCACTCTGTCT CCCACACTCTGCTCGCCCAATGGCTACC TGGGCAATCTCAAGTCCGCCACACAGGG CAAGAAGGCCCGCAAGCCCAGCACCAA AGGGCTGGCTTGTGGTAGCAAGGAAGC TAAGGACCTCAAGGCACGGAGGAAGAA GTCCCAGGATGGCAAGGGCTGCCTGTT GGACAGCTCGAGCATGCTGTCGCCTGT GGACTCCCTCGAGTCACCCCATGGCTAC TTGTCAGATGTGGCCTCGCCACCCCTCC TCCCCTCCCCATTCCAGCAGTCTCCATC CATGCCTCTCAGCCACCTGCCTGGTATG CCTGACACTCACCTGGGCATCAGCCACT TGAATGTGGCAGCCAAGCCTGAGATGGC AGCACTGGCTGGAGGTAGCCGGTTGGC CTTTGAGCCACCCCCGCCACGCCTCTCC CACCTGCCTGTAGCCTCCAGTGCCAGCA CAGTGCTGAGTACCAATGGC 420 IM001038 GATCTAACTCAGGCTGTTCAGCTTGGCC p001292 D — AACAAGCTCAAATATCCATTCCGCTGTCA CATCGGGCCCCATGTGATGCTTTATATA CTAAATAGAACAAGCAAATTGATACTAGA TGGGACAGTCTGCTTACCCAGTTTGGTG TTTGGTGGGGGAGGTGAGACATATCCCA CAGTCCCAGAGCAACTGTCACTGCAGGG TCCCAGGGGAGGAGCCAGGTGTGAAGC TGGCAGTGTGTGAGGTACCCTGGGGAA AATGAATGGTTACT 421 IM001039 AGGCCTGGTAGTGACCAGCAAGTACTGA p001293 D — ACGCTCGCTCTATGCCAGACACAGACCC TCTTCTTCCTTCGTCTTATCCTATTATCCA TACTGAACAGACAAGGAAATGAAGGCTT AGATGAGTCACCCGACTTGCTGAGATC 422 IM001040 GTGGGGCCTGAAAATCACATCTGGGCA p001297 K Notch1 CCCTGAGGCCTGCCAAGTCCTCATCA GAGGGATGCCCTCTTCATCCCAGGTGCT TTCTGACTATAAAATAAGGTGAATACTAC CTCCCCTGAGGTTACACCTCCAGGGTTA AGCTGGTTAGAGAACCCAGGGACACACT GGGAAACAGCCCACAACAGCAGGAGCT GGAGCACTCACCCACGGATGTCCATGG GGTCCAGCTCCCTGCGCTGGCGCCCAC CACTGGTACCAGGAAGCAGTGAAGAGGT GGCCCAACCCACTGTAGAGCGCTTGATT GGGTGCTTGCGCAGCTCTTCCTCGTGGC CATAGTACGGGAAGATC 423 IM001041 AGTGGAACCAGATTCCTCCTACGCTTTG p001298 B Al604147 CACTCCACTTTCGTTTTCTCTTCTGTACC ATTCTAATGGAGGCCAGAGTAGCAACTG TATAGACAAATCAAATCGTTTACTCTTCC AGTCTTGCCCCTTAACAGTCTTTCCTTTG TTCTTCCTCTTAGCCTCATTTTCTCCTTTC TCAGATC 424 IM001042 GATCTTCTGCTTCATCTGAGTAGGCTTAG p001300 R — ACTGGTTTGTATTATTATTATTATTACTTG TTGTTGTTGTTATTTTGGTGGGAGTAGTA GTAGCAGTAGGTGTGTGTGTGTGTGTGT GTGTGTGTGTGTGTGTAGATGTCACAGC ATGTATATGGAGGCCAGAGAACAGCTTC TAGCGGTTGCTTCTCTCCTTCCTTCCACT GTGGTCCAGGGAATAGAACTCAGGTCAT CAGGCTGGGCAGCTGTCACCTTTAATGC TCTGAGTTATCTCACCAACGTTAATAAAA GGCTTTTCAAACAGCAGTTTGGGCTGGG CCTGGTTGTGCAGACCTGGAATTGCAGC TTCTTAGGATGCTGAGGCAGGAGGACTG GAAGCTCAAGTTGTGTCGGGGAAACTTA GTAAGTCCCTATTCTCGTCCCGCACGCC CCCAAAAAGCCAAGACCAAGACCAAGCA GTTTGGTACAGCAGAAAAAGCACGAGAG TCTCCTCCTCCTCCTGCTCCTCTTTAATG TGCAGAACCC 425 IM001043 GATCTGTGCATTATTCTGTTGGAAATGTG p001303 D — ACAAGATTCTGTTGAGAATCTCATACTCT ATGAAGTCTTAAAAAAAAAAGGTTTCTGC TGTTTTGAGACAAAATTACTTATAAAGGT TTATGATGTAGTTAAGGCCCTGAATGTCC CCCAAAGACATGTGTGTTGAGGGTTTGG TCTCCACTCCGTGGTCTTTTGGGAGGTG TTTTATGTTAGCTGGTGAGGCATAGTGG CAGGGGAGGAGAGTTGGGTCATAGTCC TTTTGAAGAGGCTATTCAGGCTCTGGTG CCTAA 426 IM001044 GATCTGACTGTGATAGGAGGGTCCTGGG p001305 D — GCCACCCTGACATAGGCCTGGTCTATGA ATGCTCTCATGGACTGGGCCTGTTTGTC A 427 IM001045 CTGCCTCTCTCCCTGGTCCCTCTCTGAG p001306 C — GTTCTGGACCCTCAAAAGGCCCTTTCCC ACCCCAGCCTTCAGGCCTGTAACCCAGC CTCGGTTTCTCTCCCATTGCCAAAGCAC AATGGCTGTTATAATTAACGGATTATCTC AGCGCGACAGCTGCGCCCCTTTGAAAAT TAGGTTGAATAACAAGATC 428 IM001046 GATCTTGGACCACCACGTCAAGCCTCTT p001307 D — GTACATTTCTTTGAAAAACAAAGCTTGGT TCCCCCTAGTCACCACGGTGAAAAAAAC CCAGGACAGTAAAGGTCCCAA 429 IM001047 TTAGTACCTCTGGTGGAATCACCATGCC p001308 R — TGACCTAAAGCTTTACTACAGAGCAATTG GATAAAAACTGCATGGTACTGGTATAGT GACAGACAAGTAGACCAATGGAATAGAA TTGAAGACCCAGAAATGAACCCACATAC CTATGGTCATCGATC 430 IM001048 GATCGCACCGATTGCCAGTATAGTACCT p001311 D — AGAGTGTCAAGTTGGCCTCTCAGGGAAG AGAGAACATGTATTAGGGTAAGACGCAA GCCCCAGTAAAAACATGTGAG 431 IM001049 GATCGCTTCACCAAGTGTGAACTGTTGG p001313 D — TAGGGACAGAGCAGACCACAAGCCCCT CTTTGCATTTACATGGGGGCGTCCTAGT GTAGGTGGCTAGGGATGGTGGACAGGA GAGGAGGGAAGACAGTATCACATAAGAA CAATAGTGGAGGGCAGGGGAGGAAGCC TTCTCATGGCTGGGGTGAAGTCACTTCC GTAGCCAGAGCTGACTGAGAATATCACT GCTTTCCTAGTAAGGAAACACCGGAAGT CGGAAGATGATAAACGCGAAACTCACTA CATCATAGACACCATTCTGTCTTCATCAA CAGAGAAATTTATTA 432 IM001050 GATCGTCCACTTCTGTGTTTGCTAGGCC p001316 R — CCGGCATAGTCTCACAGGAGAGAGCTAT TCTGGGTCCTTTCAGCAAAATCTTGCTA GTGTATGCAATGGTG 433 IM001051 AGGGTACAGCGAAGCTTGAAAAAAGCAA p001317 D — GGAGTGCTCTGGGACCGGGAGTGATGG AGAAAGTCTGAAGCCCCTTTGCACACCC CTACAATGGGTTTGCGCCAAGAGAGGCG CCGGCAACTCTACGCGGCGTGGGGCTC TCCCCAGCGCTCTAGGTTCTACTGTGCT GAGCCACACTAGTTTCTCTCCCTAGACC TGAAGAGACCCCAGAAGTCTGAGAGTCC CTTTGGTTCTCCATCTCTCACCACCCCC CACTCTCGTGCTTTAACTCTGAGGAGGG CCACTCAAGTTCATTCATAAGAACAAGG GCTTTGCTCTTAAAGGAGCCGCATACCG AAAGCGTTTGTGTGACTGAGGGTTCACA TGCACAGAGCTCCGCGTGTCTCGACATC CTCTCTCTCCGATC 434 IM001052 ATCTCAGGAAACTCCTAGCAGCTTTAGTA p001318 D — CGCATCGTGCTGTTTCCAGCTGTCGGTA TTTTACACAGGTTTTGAGCGATC 435 IM001053 CCTTCAGGATTACTTTGGATGATTCATTA p001319 D — GAGAATCTTGTCTTTAGACTATAAAGCAC TTGTTGAACAAGGTTACAATGTAGCAAG CAACCTTGTTTTGGAATGTATTTTGCTAC ATTGTGCTCTTCCCTGGTCTGGTGCTTTC ATTTCACATATTTTGCTCTTAATAGAAGTA GGGTTCAGTGCTGGGGATTTCATTTGCT GTTTTCTCCATTGACCTCTTGAGCTGAAG TTATTCTTATTAGAAAGTCAGGGTAGGCG ATC 436 IM001054 CCAGCAGGCAGCGAGACGCATTTTCGC p001321 B Mm.1045 GTGGCGGTGGTGAGCTCTCGTTTCGAG 31 GGGATGAGCCCCTTGCAACGGCACCGG TTGGTCCACGAGGCACTGTCGGAGGAG CTGGCTGGACCGGTACATGCCCTGGCC ATCCAGGCGAAGACCCCCGCCCAGTGG AGAGAAAACCCACAGTTGGACATTAGTC CCCCCTGCCTAGGTGGGAGCAAGAAAA CTCGAGGGACCTCTTAATAAATACCTGG ATTGGGAGAACGATC 437 IM001055 GTTTTTCCTGCATAGACCTCATCTGCGGT p001322 K Myc CGATC 438 IM001056 AAACTAGGAAAGGGTATAGCATTTGAAAT p001324 R — GTAAATAAAGAAAATATCTAATTTAAAAA CAAAAAAGAAAGACAAAGGAAAATTAAAA AAAAAAAAAAAAGWCTTiTGCCACTG CAGGACTGCCCAACAGTCTACTGAAAAC TGTGAGCCTTATTCCTAGATGAGCCTCT GATGCCTCCACTTACAAGCTACCTTCACT CCTCCATCTATCTCCTTTTGTTATGTCCC GCGATC 439 IM001057 GATCGGACTCGAAGAGCAGAAGAAACAA p001325 D — AACTCAAAGCAGGGATTAGGTCAAAATT AAAAAGGGTTTGCACACAAAAGGAAACC ATCCSAAGAGACAACCTACAAAGTGAGA GAAACTTGTTTTGAAC 440 IM001058 GTCTGAGAAATTGTCTTTAATGTAGTGAC p001326 D — TGTGGAGCCTTGCAGGGATACCCACGAT GGGGGTGTCATTCATATGTCACTGCACC TGGAAGACCGATC 441 IM001059 GATCGCACAGCCTGCTTTCTCAACAGTA p001327 K Pvt1 GGTAGGACCAACAGCCTAGGTGGCACC ACCCACAGTGAGCTGGGCCTTCCACATC AATCATCAATCAAGAAAAATAGCACAAAA CCCTTTCCCGAAGGCCAATCTGCTGGAG GCATTTTCTCAGTTGAGATTCCCTCTTCC CAAATGACTGCATAATiACTTGTGTCATGT TGACATGAAACTAGCCAGCACAGGGTGT 442 IM001060 GATCGGGTAATTTAGTAATAGTTCATGAT p001328 D — ATTCATTACTCGGCGTAAATCAGGAAAAA CATTTCTAGATGAATGTGGTATTCTCAGT GCACAGTTTGTTTAGTTTAGAAAACAAAT 443 IM001061 GATCGAGGAGGGGAAGTCCTTCCTTCCT p001329 R — TCCTTCCTTCCTTC 444 IM001062 GATCGGGGGTTCAAGGTCCTCCTCGGG p001330 R — GTACCTATTAGGAGGGCAGCCCAGGCTA CGTGAGACTCTGTCTCAATAAAAATATAA ATAAAAAGCTGGGTGGTGGTGGCGCAC GC 445 IM001063 GATCGACCTGCCTCTGTCTTAAGCAAGA p001331 D — AGGGAGATAGATATGCATAGTATTTAGT GTAATGAAAGTTACGTTGTATTACGCTGA GGTTTATCACA 446 IM001064 ATCTAAGTAGTATAATGTTTAAGACGATC p001332 D — 447 IM001065 GATCGTCGTCTAACTTAGCTGGCTTTATA p001333 D — GTGATATAACAAAATATTAGAGGATGCTT TGGTTGAAAAAGAAGTTTATTTGCATCAC AGTTC 448 IM001066 GATCGAACACGCTCGGACTTGCTAAACG p001334 K Nmyc TTTCC 449 IM001067 GATCGTCATCATTTTTATTACAGTAGTGA p001338 D — GGAGATGTCCCCTGGGGCCGCCCTGGC TCTGGAGAGGGAAGCCACATGCTCCAAG GGGCTATGGTGAGGACCACAGCCTTTAC ATTTGGCTT 450 IM001068 GATCATGCACTGTCTGGGATAGTGATGG p001339 D — GCTGTGTCCTTTGTTGGCCAAGAGGAAG TGGCAAAAGGCAAAGTTGCTGTTGGCTC CAGGAGTCAGTCTGGGGACGGGGCTGA GATGCTGTGGGACAGACTCTGGAAAGG GCAG 451 IM001069 GATCGTGGCCACTGAGAGACCTTCTTCT p001341 D — GGCCACCAGATGCACACAGCTGCATGAA CATCTGCATACACATTTAACACATACAAA GTTGAAGAGAAGCACGTGTGTCTTGTGG TCTGACCACTTCCTGGGCACCACCAAGC TGCTCTGACAACGGATTCCCACTGGGTT CGGCCATCTTGCTTCCTCCCCTCAGAGT TTGCCCATGTCCTCTGTCTTTTCATAGCC ACAGCCTTGCCCAAGATAAGATACATCC AACTGTACAGTGCTCCAT 452 IM001070 GATCGTACCAGGAGCTCCAAGCGTACCC p001342 C — CTGATGCTACAACCTCATTCCTGAGCCTT GATTCTGTGGACTCTAG 453 IM001071 GAACAAGGAAGGAAATAAAGAATAAAGG p001344 D — ACATCTGACACTACCAAAGTTAGGTCAG GATGTGTCTTACAGATGGCCACTCAAGA GCCTATAGAAAGCACCGCACAGACCAGC ACGGTCTTTTTCTCCCAGGTGTCTCTGA GGTACTGCTTTCTTTCCAGGGATC 454 IM001072 GATCCCGAGTCCTTTCATCCTGTGGTTC p001345 D — TATTGTCCCCTAGGGCTTCAGCAGGCAG GGAGAAAGACACTGTAGAGCAGCCCC CTAA 455 IM001073 GATCCTGGGATTTTCTGGGCAATTGGAG p001346 R — GCCACAATTTAGATAGTTTCCGGAATCG ATGTCCCTTAAAGACCAGCGCCTGGACT CTACTGAGTAAACTCCCATTTCAACTTCC TCCTCTTCCTCTATTTGAACAACGTGTAT CATTAAATTATAAAATTGTTGTTGTTGTTG TTGTTGTTTCAAAAATTAACTTTATTGGG GGAGGGGCAGTTGCCCGAGGACTTACTT GTGAGAACCAGGTTTTGCCTTCCACACT TAGGGGTCCCTGGAATGGAACTTATGT 456 IM001074 AGAGGAGAAATGGGGGTGCGAGAGGAC p001348 D — AAAGTCTGTGCCCCACAGCGCTGGGGC CAGAGCCCAGGAGGGCCTCATGGGAGA GGTTGCCTGAAGGCAGTAAGAGAGGCA GAGGATGCTTGGGCCAGAGAGGTTCCC CACAATTGCTTGGATC 457 IM001075 GATCCCAAACAACTGGAACAGGGGTTAT p001349 D — CCCAAAAGCTGTTGCCTG 458 IM001076 GATCCAACTCCTCTTCACAAAGAGACTAT p001350 B Mm.1238 GTGCAGGATGGAGAAGAAGATGTATCCA 02 AGCATATCCTGTGAAATTTATGTCAATGC TGTGAAATTTGTCCCAGCACTCACAATCC AGATCTGCTTTTTAGGTGGCTTTTTCT ATTTCATTTCTTCTGGCTTCATAGAAGTT TGAGGTGACATTTTTAAGACCTGTGCCA CTAAAATTTCAGACCCTATTTG 459 IM001077 GATCGGTTAGTTTGACCAGCCATACTATA p001351 D — ACTTTAGTGCAACCCTTTACTTGGTGGGT GGTACTAGGAATTAATCCCAGGACCTTC ACATATACTACTATCATTGAGTTACATTT CTAGCCCTTTTAACCAATTTCCCTTTAAC CCTTTTTATCCTTTG 460 IM001078 CTCAAGATTCTGTTGTCTGAGAATCTCTC p001352 D — CCTCTGCTTGGGGACCCATTTATAATGA GGTGATACTTCATCTGAAGTAATGGCCA GGCCACGGTGTGAGACTCTTGAATGTCA CATGCTGGATC

TABLE 2 SAGRES # SEQUENCE SEQ ID # CLASS. GENE IM000127 CATGTGAGACTTGTTAATTTAGATTT 461 D — ATTCTGTAGTGTTTTTGATATGAGTAT AAATAAGACAATTAAATTCTATATTAG AAAGTGGCTTTTTACATTGAATATGC TTTCAGGATATGCGTGAGAATTTGGC GATGTGTAATC IM000128 CCTTACTGCAGAGATGACTCGGCCA 462 D — ACGGCTNCGAGCTCCTGACCACTTC CTCAGGTTTGGTTTTGTTAGTTTTTTC TCACAGCAATGGGAAGCATAATCAAT ACAACTTCCCAGAATGCGACCTGTG ACAAGACCAATGAGCAGACTCAAGG CTGGGCACATAAAAGCACCAAAAAA AAAAAAAAATTCCCTTGCAATTATTGT TCATG IM000129 GCTGCTCATCACCAAAGGAAGTCAG 463 R GACTGGAACTCAAGCAGGTCAGGAA GCAGGAGTTGATGCAGAGGCCATG IM000130 CATGGCAAGATGGAGACTTTGTCTA 464 K Fgf3/Fg CCAGGGCCACTCCAAGCACCCAGCT f4 G IM000131 GTGAAAGGGCAGAAATAATTCCTGA 465 C — AGGTTGTCCTCTGCCTTCTACATG IM000132 CATGACTATGTTTCTTTTAGGTATATC 466 D — TGAATAGTATGGATCTAAATGATGAA GTTACACCATTTTCTACAAATGGGCA CAGAACACAGGGCATAGATACAAAT GGCAAGGTGAACCCAGATCTCTGTG CTTATCTGCAATATAACAACACTAAG AAATATTAGGTCTCTCTGTGGTTTTC CTTAAATCTA IM000133 GTATTTCCTGTCAGAGGAAAAGAGTT 467 D — TTCAAAAAACTTTTAAAATTTTTATTT GTTAGCCTGGACCAGTTTCATAGCAA CCTGTCATCCATATCCTCAGATTCAC TTATGAGTTTGTCTGCCCATTAAGAT CTTTAAAATGGTTCTAACAGCTTACT TCATTGTTCATTAGTAAAGGGTTTAT ATCTACACTTTGATATTTGCTTACTCC ATACATG IM000134 CATGAGATGAAAAAGAACCTTTTGGA 468 D — CTTGAATTTTGTTGCTTCAAATGCGT ACTGCAGTTGATGGAAATT IM000135 AGGGTCCCTTCAACTTCCTCAGAGC 469 D — CAAGGCTGACTTACTACCGTTCCCC AAGATCTCATG IM000136 CATGCCTCTGGAAAGTACCTTAAACA 470 K AAyb TAGAATCCCCTCCCTAGTG IM000137 CCAGATCCCATTAACAGATGGTTGTG 471 K Wnt1 AGTCACCATG IM000138 CATGACTTCTTTCATTTCTTCTGTGT 472 K Braf GTCTGTCTTCCTGTGTTTGCCTGCCC CTCTCTTTCTCTTCTAACAGCCCCCT TGAACCAACTGATGCGCTGTCTTCG GAAATACCAATCCCGGACTCCCAGC CCCCTCCTCCATTCTGTCCCCAGT IM000139 CATGGGAATGTAATGTATTAATGAAT 473 D — ATTATATAAAAGAGGCTAAATAGCTT GGCTTTAATTTCTCACTTTGCCTACT CAATTGAGAAGTTTATGGATCACCAA AAGT IM000140 CATGTCCTTATTCTAGGAAGCCCCCT 474 D — TTTTTACCCCTGCCTCTGAGAGAAAC AG IM000141 CATGAACACCCAAATCCATATGAATA 475 D — CACACATAAAATATTTTATTTTCTCTA TAATTTATGCCCACC IM000142 GAAAGCATTGAAATATACTGGCCTTA 476 D — TTAATGGCACATG IM000143 CATGTGCACACACCCCACAAATGAC 477 D — CTCAGATGTCAGTGGTACTGAAACT GAGAAACTGATGATAGAGCCAGTAA AAATACTGAAAGTGCCTGTTTTGAGA GTTTATATTTTACAATACTTTAATATC TAACTACACACACATACACCTGAAAA GGGCTCAGAATACACAGGCCTGAGA TGGCTCTCAAGAACCAGCCTC IM000144 GGCCTTCCACTGCTCAAAGCTCAGA 478 K Wnt1 CTGCAGAAAAGGTTGATAGCCTCCC AGGGGCAATGACACCCTTTCTGCTT GAGCTTCCCCCCCCCCCCTCTCAGG ATGTAGTCATG IM000145 CATGCCAGTCCACATCTGCTTCTATG 479 D ACAPATGCCACATCCCAACGACAAA CTCACTCATTCTTCCTGTATCAATTTA CGCATACACATAATACTTTTGCTCAA GGTACATTCATATTTCCGGCAAACAG ACAGCTATAG IM000146 CATGTCACTCACTTGGAGAAAGAGTT 480 B AATTT.605 CTAATTATTTATCACGGCATTTTTCAC 52 AACTATAGAAATAAAGTTAATTTCTTT GGAAATAAAGTTGAAGTTGTAATTTC CAGATGGGCTCAGGTTGCTGTT IM000147 CTCCTCCTAAAAGAAAAAAGGAAAAG 481 D — AAAAGTTAAACCTGCAACAGCATCAG CAGAGCTCACCCCTCCTCACCTGCA GCCCTGGTTGCCTCTCTTCCTTTCAT G IM000148 GAAAACACTGTTCTGGGTTCAGGGG 482 D — TTACTTAGCCTTGGAATCAGAGTCTA CCCAGAGTCTACCTGCTTCTACCCAA AGCAGGTGGAAGAAGCTGCCCAGGA CGGGGCTCAGAGTCTACATTTGAAC TCCCTGTGCCAAGAAGTCTGGATAG AGTATAGTGTCTGTATATTCTAAACTT TCTGGAACAACCCCTGCTTACAATAC TCTTTCCAACTCTCAGGCCATG IM000149 ACCTCTGTGCCAGCTTCTCGGACATT 483 K Fgf3/Fg TAACAACTCTGGATCATG f4 IM000150 CTGGCAGTAACACACTTAAACTGCTA 484 D — GCACCTGGGAAGTGGAAATAAGATC AGGAGCTCAATCAAGGTCATCCTCA GCTAAACAAGACCCCCCCCAAAAAA AAAGAAGAAGATGGCCTAGAAAGAG AACTCAGCAGCTGCTGATCTTACAGA TGACTAGAGTTTGGTTACCAGCACC CACATG IM000151 CATGCCTGGTCCCTGCTGAGTGCAG 485 C — AAGAGGGTGTCAGATTCCTTGGAAC TGGAGTTATATACAGTCGTGTGTCAC TGTGGGTGCTGGGAACTGAACCTGT GTCCTCTGCAAAAACAAGAGGTCTT GGTTGTTGTTGTTTTGTTTGAAACAG GGTTTCTCTATGTGGCCCTG IM000152 GCAGGAGCCCTTGTGCAGGCCACAA 486 K Fgf3/Fg CCTGCACAGCTGTACAAGGCCTGCC f4 TGACTGCCTGAACAGATGTGTGGGA TCTTGCCCCCCTTGTGCAGGCGTAC AGATGCAGACTGCTCAGAGACACAC ATG IM000153 CATGGGCTAGACCTACACTGAGTTG 487 D — TGCTAAAGAAGTGAC IM000154 CATGTCCTCCACAGCTGAGCACCCT 488 K Fgf3/Fg CAACTGTCTCCCAGGGCCTCTGTTC f4 TATCCAGGGTCTGCAGGGTCTCTGC CCCACGCCTAGCCCCTGAGAAATCT TAAGCAGTCTGAAAACTACGCCACT GAACTGCTAAAACCCTGGAGTCACT GATGGAA IM000155 TAGTGCTAGACTCTGCCTTTTCACCT 489 D — GGCATAGATTCACCTTTTTCCAGATA TCCAGGGCACTTGCAAAGAAGCCAG GCATCATCAGGGGTTTGGACTTCCA GCCAGAGTCTGAGTTGTCACTTGAAT GTGCTGCATTTTGTTGGATTCAGCCC CAGTCTCCCGACTCTTTGTGAGTTTA GGATAATAATCACAACAGCACCCCTT CTTATTTGATGGCTAATAAGCTCTAG GCCAGTGTCTTAGCTCCATTCATG IM000156 CATGTATTCTGAGAGTAGAATTTATA 490 D — CCCAGAGAATACCTAAGAAGTGAAC TGACGCCGGGCGTGGTGCCGCACG CCTTTAATCCCAGCAGTTGGGAGGC AGAGGCAGGTGAATTTCTGAGTTTG AGGCCAGCCTGGTCTACAAAGTGAG TTCCAGGACAGCCAGG IM000157 GCCTGGTGTGGTAGCTCACACCTTT 491 K Fgf3/Fg AATCCCAGCACTCATCTCTGTGATTT f4 GCTAGGCCAGCCTGGTATACACAGT GAGTTACACATCAGCCATG IM000158 CGACATCCAACTTCTGGAAGGAGAG 492 K Wnt3 ATGGGAAGGGGCATTTGGGGTGCTA GGAAGGGATGGGAGGTGTCCCTAGA GCAGTGCTCATG IM000159 CATGAAATAATGCCTTCAGAACTGCA 493 D — TTAGAAATCACAAATAGCCCTGAATG CCCTCTAGATGCTTTTCTTGAGAACA ATTATGTGTTAAAGTCCTAAGGCCCT TGTCAGCCCACCATATGGAAAGGGA GAACTAACTGAAATGGGAGTT IM000160 ACTGACAAGAATAGAGAGAAGTTCA 494 D — GTCATG IM000161 GTGTCCTGCTCCTGTCTGGGTCAAG 495 D — GTCATAAAAGATGAGCCAAGGCTGA CTTCAGTGCCCACCTGGGGAGACTG ATGTCTTCACAGGAATGCTCACCTG GAAGGTGTCCTCTGGGTGCATCTGT GTCACATTCGGTATAGAAGGAAGAAT GCCAACAATACTCTAAAAATATTAGA GGCCTTGAGAGTCCTCAGTGGTATT CCACCAACATCAAAGCTGCATCGTAA TATGCCAGCCTGGTCCTCACCTTTCC TGCCCTTCCCAGGAAAACATCAGCC TTTAACCTCAGCCCATAGGGGACAT G IM000162 AGGATCTTATAAAAATAACAGTGACC 496 K Wnt1 CAAAACATAATTTTTGCCATCAAGAA TCTCAAAATCAAGTCTCATCCAAGTC TACTCTTCTTTATTGTATCTTAAACAC ACACACACGCACACATCACACAAGC ACACACACAAGAATTCACACACATAC ATG IM000163 CATGGTATTCTGATGATAGTACCAAC 497 D ATACTGCTGCAGCTAGCTGTATCTG GAAATCCCAACCTCAGCCAAGTATTT GTGGTTGAAATAACCTATACTTCTCA CATCAAACAC IM000164 ACTGTGACCTGAGCACTTCTTGTCTT 498 K Fgf3/Fg ATCAATAGCTCACGTGCCCAGGCCG f4 GGTGACCAGTCTCTAGGATGTTCTC CATG IM000165 CATGCACACAAACTGGCCCTGAACT 499 K Fgf3/Fg TTTGACTTCCAGGCCTCTGCCTCTCT f4 GCGCGCACACACACACTCGCACTCC TGTATATGAAGCGTATATGTGTTTCT CTGGGAACTGTTTTTATCAGGTGAAG CACTTCCTTTGTTCTTGCTACCCACC TCCAGGGCTCCAGGATCTCCAGACA GCCAACCCTAAGACAGGCCCAGCTT CCTCTGTATCTCTGTGATGAGAACCT TGGCATAGAGCTGCCCTCACCCTCG GGATAGGGCTTATGTTCCCCGGAAC GAGCCAGGCACCTCAACAGCTCCTG GGGAGGAATAGGGGACT IM000166 CATGGCACTATGAAGGAAATGAAGA 500 D — TACAAAAGATTTCCCATACAAAGGGT CAACTGTTCAATTTGGCATTTATT IM000167 CATGATAGAAGACCACGTCTGGGAT 501 D — GGGGTAAGGGTTTCTCAGAGTACCT TGCCCTGGGGCCACATCCTAAATCT ACAACAAAGCT IM000168 CATGCAAAAGAATTCCAAATGATTTT 502 C — ACAGATCTTAGCCCTCTAAGAGATAG ATATAGCACAAGTCCTGACTCCTGAG GTAGGTACACACTGACTTCCTTCCAC AAGCACTGCCTCAGCCCGGAGATGA AGGTCACATCAATAGAGACAAGTCA GGTTAACCGTGAGCAACCTCAAGAC AAGGAGGAGCACAGCATAGGTCGGT GGAAGTGTTTGCATAAGCCTAAGGC CTGGGCCCAGTCACCAGCATTGCAG AGGAAAAGGAAAAACAGATAGTAGG TGCCTTGGTGTGT IM000169 CATGCAGTTTACCAATCTTTTTCCAC 503 D — TCTTTAAAAAGACAAAAAATATTAGAA TACTGGGCTGAGGAATGGCTCATCA GTTAAGAGCGCTGCTCTTTTGAAGG ACTCCCGTTCTGTTCCAAATGCCCAC CTGGAGGCTATCCTGTAGCTAGAGG T IM000170 AGGAAGTGCTGAATAGAGAGGTTTG 504 K S100a4 GGGAGAGCCCAACAATCTGACCTAT TTATACCCTGCCAGGCCCTGCCCAT G IM000171 CATGGTGCTGGAGGATCATCCATCC 505 R — TGACATTCTGGGA IM000172 CTTTAACCCATTTATGGTGTGACCAG 506 D — AAACCACAGATCTTACCTAGGCTTCA GACACATCACCCGAGGAAAGCTCCA TTAAAATCCTCATTCATG IM000173 CATGTATTCATAAGTGGATATTAGCA 507 D — AGAAAGTACAGGCTAAT IM000174 CCTCTGGAAGTCAAGTGCAGCTTTG 508 D — CTTATTTGTTTAAGCCATCCACCATC CAGTTATTAGATCTGAATTCATCTTTT AGGGTCAGCTTTGTTGTAGATTTAGG ATGTGGCCCCAGGGCAAGGTACTCT GAGAAACCCTTACCCCATCCCAGAC GTGGTCTTCTATCATG IM000175 GTTTTCTTTCTTTTTTTTTTAAAAGAA 509 D — ACAGTCTCAAGTAGCCCAGGCAGTC CCTAAACTTATTATATAGCCCAGGAC AGTCTTGAATTCCTGAACCTCCCTCC TCTACCTCGTAGTCCTGAGACCGATT GCATG IM000176 AGAGACCCAGAAATACCAAGGTGAT 510 D — TTCCAACTGCCTGACCTGGGAGGCA AGCATG IM000177 CATGTAAGATCTTCACTTTTCCAGTG 511 D — TCTGTTTGTGCTGCCTTCAAACTGTT GACCTGATGTAAAAATGTTTGCATCA GCTCAGGTGTATAGAATTGGACTGAT TCCAGGAGAGTCAAATATACAGAATA TCTAGTGTCCAAGAT IM000178 CATGCTAATGGAGTTTATTCTTAGGA 512 D — CTGCCTCCTGCATCCATTGATTGACT TAAATATGTGCACACT IM000179 ACTAGGTGACTGTCTCAGGGTCTCA 513 R — CTGTGTAGTCCTGGCCTAGAACTCT CTATGGAGACCAGCCAGACCTCACA CTCAGATCCAGATGCCTCAGCCTCC TAAGTGCTGGGATTAAAGGCCAGTC CCACCATACCCTGCCCCTGTTTCTGA CATTTGAACCCCTCCTTTAGACAGTA GGGAAACTGAGGCCCTGAGATATGA CACTTTTAGGGGCATG IM000180 AAACTTTCAGAAAGCGGGGGCTACCA 514 D — AGGAGACTCAATTAAGATCTCTCCTC GATCTTGAAACCATCCCCAGCCCTTC GCAAAGCACATTTGACGGACAGGGT TCTCTTGTCTTGGGCAACACATCCCG GCTACGCTCTGCAGGGTGAAGCTGT TAAGAACGTTCCATG IM000181 GATAAGCCTCTACAAAGCTGGAGAG 515 D — GGCAGTCCAAAGAAACTTGAAAAGA TTAAAAGACAGTGCCTAAGGACACAA ACGTTTTTCCATAAAGAGCCTATGAC ATATTTTACTGCTGCTAATGAAACTG ACCTTGAAGGAACAAGTGTTTAGGG TTAGCCTAAACTTTGGAATTGGTGAA GGCAATGTGTCAGCTAGACAAATTA GAGAAAGAACTCAACAGATGAGTCA ATGAATTGTTCTAAACTAGCTTGACT TAGGATTTTCAGCACAGGAACAAAAG CACATACTGTCCCTCTGGTTGGCAT G IM000182 CATGGAAAATGATAAAAACCACACTC 516 R — TAGAACATATTAGAGGAGTGAGTTAC CCTGAAGAACACATTCGTTGGAAAC GGATATTGTGTAA IM000183 CATGCCCGGCTCTATTACTATTTCTT 517 D — TCTTTCTTTTTTGTTTCAGGATCCAGT TTCCTTGATAAATTTTTCTTGAATGTT GTTGTTGTTTTTTCTTTTGCTGAGTTT TTCTTCAATACTGCTGCTTTTTCTCTC CAGGTTCAGGATGAGA IM000184 CATGCTGTCACTAAGCTGTGCTCTTC 518 D — CAAGGAGATGAAGAGACTAGCTGGT ACCCTTGCTATGCCAGGCTTTCTTCT TGTTTATACACACCTAATG IM000185 CATGATCTAATCTGAACTTGTATCCC 519 D — AACCCTTTATAAACAAGTGAATGTGT AATCTAAACTAGTATAAGCTCTTGAA TAATAGCTGAGTGAATTGCCTTTGAT ACACGTTTCCAAATTAGTAGCC IM000186 GTCAACCACAGCAGTACTGTTACTTT 520 D — CTGTGGGGGAGACGTCTCCCCTCCT CATG IM000187 GGCAGTGAGCTTGCCCACTCTGCTAC 521 D — AGGACCTCGGTGACCCACTATATACAG CCCTCTTCACTACGGCTCACAATCGG AGTTTTGACCCAGTGAAGTAAACCCAG CAGGACCCTTTACAAAGCCAGGACATG IM000188 CTTGTCCAAACCAGCTTAGTCAACAG 522 D — CCTCCTATCTGGGCTCCATCTTACCC TCCTCATCTAGCTGATGAATGTACCT GCCTTCTGTTCCCTTCCTCCTGGTCT GAGCTGAGCCTTCTTGGGACTGAGA GCCTTCATCCACCACAGGCAGACTA TCTTTAGATCATCATAGCCCCAGGTC TTCATTGCAGTGCAAAAGTGCAGAC CTTACATTTCCATTTTTATGCTCCCTT TGTAACGGCTCCTTACCGGACTGCA GCATAAGTGGCTGAGTATCCAATCA CAATAGAACACTTAGTTGTTTGCTTG TCTAACTCTCTCAGTTACACCATTGA GTATGTTACACAGGGCTGCTTTGTAG CTGTCACTGAGGCCACAAGGCAAGG GGACTAAGGCAGGACTCAGATGAGC CTGTTTTTACTTCCCGTTGTCCCTTT CACTTTGGGTTGAGCATG IM000189 ATATAGACTCAATCAAGGTATTATTC 523 D — TGGAACAAACAACTAGTAACAAAAAT AGTGCAATTGCAAGTATGATAACACA AGGCAGCCTTTACCAGCTTTGTCGG AAGGAAATTGTTCTTTGAAATCTGAA TTCCAGAGAAAAAGTCAAATGTAAAC TAGAAGTGTTTGCATG IM000190 CATGTATGTGCGTGTGTGAGTGCAT 524 B BF1638 CAACACAAGTGCATAGATGCGTGTG 10 TGTTTGTGTGTCTGACTGTTTAAGTA GGTGGCATCTGTCCTAGTCCTGACT TTTGATAAGTCTACACGTTTGATAAG AGGATCTCTCTCACCACTCAGGTTCC TCCCCCCACCTCCACCCCAGTACAC AGCCATAACTATAAACTCCCCACGCA GATGAAGCCCCTCTGATCCCATTTTA GGGACATAACACCCCCCTCCCAGAC TGAGCTAATGCCTTGGACCCTCCAA AACTGATCTGAACCCTCTCTGACCCT GCCCTCCTCCCAGCACAGGGCAA IM000191 CATGATTTTCAGTTTTCTTGCCATATT 525 R — CCACGTCCTACAGTGGACATTTCTAA ATTTTCCACCTTTTTCAGTTTTCGTCG CCATATTTCACGTCCTAAAGTG IM000192 AAGTATGTCTGCTATGAGTCAAAAGT 526 D — CTTATTTTTGCATCACATG IM000193 CATGCCGCAGTGGCCAGCAGCCCTG 527 K Fgf3/Fg GTTCCAGCATTCTCAGAGATAACAAG f4 GAGCCAGTGACCCTTTCTTCAAGCA CCAAAGAAAAGCTAACCGACCCCAC AAAGACCTGAGTATGAATGGTTTCTG CAGCTAAGGCACTTCCTTTGAGGTC AGCGCAGTTCGGGGCTGAGAAAAGA GCTTGCCCTGGCTTAGAGCCTTTCT CTGGCTCACTGTCCCAGCCAGGACC CATCCATCAGCCCACAGTGGGGTGG CATAGTGCAATCCTAGAGAGATGTTC AAAGGGACATATC IM000194 ATTCTCTGGGTTTTCCTGTGGTGCTC 528 R — TGGACCCCTCTCGCTCCTACAATCCT TCCTCCCCATCTTCCACTGCTCTGCC TAGTATTTGGCTGTGAGTCTCTGCAT CTGTTTCCATG IM000195 CATGCCCCTCTCGACCCTGGGAGCA 529 D — TTCACCATCTTTATAAACTGATTCTTT CTGGGAAGATGATG IM000196 CATGAAACACACTTTTAACTTTCCAC 530 D — ATACTTTTTAAAAGTGTACCTTCCCAT TTTTTCGCCCCTAGACCCAAATTGGA TGTTTCTGGCTCCCTCTCGTTCGTAG CTTTCCTGTGATGTAGAAACCTCTTA GAAACCACACC IM000197 GTTTCCCACGGTGGAAGAGGCAAAC 531 D — AAGATCCCTTGGGCCTGCCTTCTTGT GGCACTAATCTTACTCATG IM000198 ATGTGGTGTTTAAATGAGAATGTGGC 532 D — CCATAGGCTCATATGTTGAATACNTA TTTTCCAGTACTTGGAAGTATTTGGG GAGGACTAGAGGTGTGACTTTTTGA AGGGGGTGTATTATGTGGATGTACT AAGAACCTTTAAATCCCTCTGACCAT G IM000199 GCATCATAGTTGTACCATG 533 D — CATGGGTTAACAGTGGGCCCTAAAC IM000200 TTGAACTAGAAAACTTAAAGATG 534 K Wnt1 CAAGTCTGTCTGTCTCCTTACTAGCC IM000201 TTTTGCTGTTCTGACTCTCAAATGGT 535 K Fgf3/Fg TCCTTAATTGGCCATTTGTCCCCTAA f4 ATTAGGGGCGATTAGGATCAACACT CAAGCAATGTTCCAGATGGGGTCTG ACGTTCCTCACTGGGGTCCCAGGGC TCCTCTGACTTGGTCACAGAAAGGT CAGCCCTCTGACCTGGCATAGATGT CTGGATGACCTCTGACCTCAGCTCA TAAACCTGACTGTGGAGATTGAGACT GGAGGGACTCAGGGCAGTGGCTCA CTGGACAGTGCCAGGGTGTGCAGTG GTAGGCAGACTTCTATGTCAGGTCC TCCTGTGCCTCCATG IM000202 GCACATATCTGAGCATCTCAAGAAG 536 R — CTGAAGCAGCAGAATCATCCGCTCG AAGCAAGTGTAAGCCAATAAGAAGA CTCTGTCTCAGAAGAAACTGAAACGA AGAGAGACAAAAACAACTTCTGGGG CTGAAGAGATGGCTCAGCAATTAAAA GCCCATTCTGCTCACTCAGAGGCCC TCTGTGAGCTGTCTCCAGATGTTTAA CAAGCACAGCTAACATTTGGCATG IM000203 CACATTCATTAAAGAGACTTTATTAAA 537 R — GCTCAAAGCACATATTGCACCTCACA CAATAATTGTGGGAGACTTCAACACA CCACTTTCATCAATGGACAGATCATG IM000204 GGGGAGAGGCTTCAATGAGCCCCCT 538 D — CACATTTGCATTTAAATAGCAGCATC AAGCGCTTCGCGTGCCACACACCAG TGGGCTCCCAGATGTCAAGCCGGAG TCAGTCAGATGGCCAGTGCCCAGCT GTCCTCCCTATGTCGTGCCGGAGCA GGCAGTGACCTTAAAGAGACAGCGC TCACCGCTCCTGGAGCCCGACTCTG GGTCCCTCATG IM000205 CTTGTCCGCCACCCCGCCTGCCTCA 539 K Braf TTACCTGGCTCACTCACTAACGTGAA AGCCTTACAGAAATCTCCAGGTCCTC AGCGGGAAAGGAAGTCATCTTCTTC CTCATCCTCGGAGGACAGAAGTCGG ATGGTAAGCATCTGTGCTGTGCTCCT CTAACTGTGACGCCGGGTTCCCATC ACATG IM000206 ATATAGTATGACTGCCTCAAAACAAA 540 C — ACAACAACAACAAAACCCCAAGATAT CTAAAGGAGGAACATTCCAAAAGAC AGAAATGTCCATAGACCTTGACAAAG GAACATG IM000207 GTCAAGTGGATGTTTCTCATTTTCAA 541 R — TGATTTTCAGTTTTCTTGACATATTTC ACGTCCTACAGTGGACATTTCTAAAT ATTCCACATTTTTCAGTTTTCCTCGC CATATTTCACGTCCTAAAGTGTGTAT TTCTCATTTTCCGTGATTTTCAGTTTT CTCGCCATATTCCAGGTCCTTTAGTG TGCATTTCGCATTTTTCACGTTTTTTA GTGATTTTGTCATTTTTCAAGTTGTCA AGTGGATGTTTCTCATTTTCCATG IM000208 CATGAAGTTAGAATAATTGGGATAAA 542 R — GCTTTTATCATTATCAATTGGTTTTGA AATTATTGTATTGATATCTTGTAAACT GAATATTTATTGGTACATAAGTCTGG TTATGGTTGACTACTTTAAGTTTTAAG AGTTTTGATTCTTCCAGGTAAATGGG TGTTGTAATG IM000209 CATGCAGCCGGGGTGGGATTTGAAG 543 D — ATTATGCCTAGTGAATATTTAATATTA AACACGGTGTGATCGAATTGATAGCT GTTGAAAACTAGAGCGAAACC IM000210 GGACAGGGTCTCTCTCTCTTGTTGTT 544 D — CATTGTTTCATATATCATCGTCGGCC TGCTTACAGACTGCATTGTGTTCCCC TGTCTCTGCCTCCCATCTCACTGTAG AAGTAATGGGATTACAGATAGATGCT ACTGTGTCTGAAAGTTAAATTCCTAG GCCCCATG IM000211 AGTGGGAGGGAGCGCCACTCTTGGA 545 K Fgf3/Fg GCTAGGCAGGAACTGTTGTTACTTCA f4 AAAACTAACAAGACAATCTCACATTC CTGAGCTGAAGACCAGATGCAGCCA GGGACAGGGTTCTGCCCTGGCCACT AGATGGGCTCTCTGGCCCTGCTAAA GCACTGCACAAAACTGGACGAGGTG CACCAAGAGTCCCGTGTTTGGCCCT CAGGGCAGACTAGAGAGCAGGACTT TCTCCTGGGAGCAGAAACTGAGCCT GGGGTCTTCATG IM000212 CATGCTCATAATTCTGCAGTGCCTTC 546 D — TCATAACACAGGATAAAACACTCTAA CCTTTAACATTATACTTGAAAACTTAT GTGGTTTTTTCCTACCAGAGTCATAT CAAACCAGTCTCCCTCTCCACTCACA AGGATCCAGTCACAATGGCCTTTTA IM000213 CTGTAGGACCTGGAATATGGTGAGA 547 R — AAACTGAAAATCACGGAAAATGAGAA ATACACACTTTAGGACGTGAAATATG GCGAGGAAAACTGAAAAAAGTGGAA AATATAGAAATGTTCACTGTAGGACA TG IM000214 CATGGCGAGATTCTGTGTCCAAGCT 548 K Wnt3 GCCTCTACTCGTGACATTCCAAGATG CCTCTGAGGTGGGAACTGTGAAATA GGACAGAGCCCCACAGTCCCCTCTT IM000215 CATGGGGGGGGGTACCAAGAAGGG 549 D — ACTGCTGTGATTGGGATGTAAATAAA TAAATAAATAGAATAAACAAAACCCA AAAACAAACAGAAACCTAAACTCAAT AACTGCAGAAATGACTCTTGCTCTTT TCTGGTAAGGTTAGAAGCAGGTTAC AAATCTATATTAGAGATGGAGGCATT TCACACCAGCATAGGTATAGGAAGT AGATGAAATGAGGACTACACTAGAG TCTGTTTGTCACAACCAATTCTGAGT GATTTCACTGAGATAT IM000216 CTCTGAGAAACCTACCCCATTCTCCC 550 D — TCCTTTCTCCCATAAGCAACCACCTC CACAGCATTATCAAAAGACTGCTGAC AGATTGGTGGCTCAGCAGGGAGAGT CAGAGCTGTTTCTTAGGTCTAAGTTG TAGCTCCACAGTAGTATGTTCTCCAT G IM000217 CATGGAACACTCAAAGCTGGCCAGG 551 D — GCCCATTTACCAGGTATCCTTTGCCT TCTCAGCTGATGGGCATCAACACATT AATTCACATATGACTCGTTTGTGTCA TATCAATAGTAT IM000218 GTGGTTTTTGTGGTAGAGAGACACA 552 D — GAAGAAACTGAAGTCCTTGGAACATA ATTATCACTGTGGTTGAATGTTTGTG TTCCTATAACATCCTATGTAGGAACT GAACCTATAAAAGTAGTGGCTCCGA AGGTGGTGTCCTTAAATGTGAACTG GGCTACAAGATTTTGCCCTTGTGAAT GGCTTTATGGAAGAGGCTGTCACTTT TCTGTCTCTTCCTCCATTATCTTGGA AGACACAACAGTTCAAGGTCTCATCT GGGAAACAGAGACCTTTACCAGACC CTAAATCTGCCAGTGGTGTCTTGATC CTGGTCTTTCTGTCCTTAGGAGCTAT AATGCATG IM000219 GGCCACAGCCAGTCCACCTGTATGC 553 K Fgf3/Fg AGCTGGGTGCTTGGAGTGGCCCTGG f4 TAGACAAAGTCTCCATCTTGCCATG IM000220 CCTTAGGGCCCAAAATCCTTCCTCC 554 R — CATTCTTCCATAAGAGTCCCCAATCT CCATCCACTGTTCACCTGTGGGTGT GTGTATCTGTCTAAGTCAGCTGCTAG GTGGAGATGCTCAAAGGACAACATG IM000221 GACAGTAAAGAAGACAAAGAAGTGA 555 D — GTAGAGCTGGATGAAAACTAGGAAG TTCAGACAAAGACTGCGGGAATGAN GTGTAGAGTCTAGAGCCCAAACAGT TAAACATG IM000222 CTGCTACATTCTTAGCTCTAGCTAAC 556 R — TAGCATCAATTGTCCCAACCCCTTCT ATGTATGACTCCAAAGCCAGTGTCAC ATG IM000223 CATGGTCTCTAGAGCTAAGAGATAC 557 D — CAATGCTGCGGCAGGCAGTTTTTATT ACAATCATTACAGTTTTGACAGTGTC TGGCCGTGTGCCAAGGCTGGCCTTC ATCCCTGAGCTCGGTGATGCTTCTG TCCTGGTCTTCTGGCTCGTCACAGC TTAAGAAAGTAGCTGCTTCTC IM000224 CATGGAAAATGATAAAAACCACACTG 558 R — TAGAACATATTAGATGAGTGAGTTAC ACTGAAAAACACATTCGTTGGAAACG GGATTTGTGTATATCAATGAGTAGTT A IM000225 CATGGAAAGATAATGTGTAAATTTGG 559 R — GTTTGCCGTGGAAAACTTTGGTTTCT CCATCAATGGTAATTGAGAGTTTGGC TGGGTATAGTAGCCTGGGCTGGCAT TTTTGTTCTCTTAAGGTCTGTATGAA GTCTGTCCAGGATCTTCTGACTCTCA TAATGTCTGGTGTAAAGTCTGGTGTA ATTCTGACAGGCCTGCCTTTATATGT TACTTGACCTTTTTCCCTTACTGCTTT TAATATTCTA IM000226 GGTAAGAGTGGGAGAAAATGGGGGT 560 D — GGGGGGTGGGGACACTGCAGAAAC CTGGGAGAAAAAAAATCCAACTAAAA TCAGGAAACACATG IM000227 CACCCCCATCCCGCAGTTCCCAGAG 561 D — GGAACAGTCCCAGCAAAAATACATG IM000228 CATGGAGATGCAATGAAAGCACACA 562 R — ATATTGCTGAACCAAACAGAAAGCTC AAAACTAGGCACAGAAAAGAGATAC AAACACAAATCTGAACAAATTGACCT TCTCCCTATAGCATAACTAATATCTC AGAGATAAAAGTGGTCTTTATATACC AGGGCGAAAGAGGTCTAAAAAGAGA GGAATAAAAAATATGGCATATTTCCT GTCATATGCAGAACCTATATGAGTCT TTTTGTTTGTTTCTTTCAATACAGCCT ATGTAGCTCTAGCTGTCCTAGAACTT ACTTTGTAGACCAGGCT IM000229 CTGTTCTACAATGCCGGTTTCCAACG 563 R — TATGTGTTTTTCAGTGTAACTCACTC ATCTAATATGTTCTACAGTGTGGTTT TTATCATTTTCCATG IM000230 GACAGGCTCCAATCAGATATACCAA 564 R — GGGCAGGAAGCACGTGACAAAATCA GATGCCTGGAGACAAGTGTAATAAA AGAAGCAACAGAAAACAAGGTTACTT GGCATTGTCACAACCCAACTCTCCC ACCATAGCAAGTGATGGATACACCAT CACACCAGAAAAGCAAGATATGGAT CTAAAGTCACTTCTCATG IM000231 CATGGGTCCCTGAAGGGTCTCTCCT 565 D — TTAGCAAACCCCTGTACAGTTGAAGT GANTTTTCAGGTACCCATTGGTCTTA GC IM000232 CCCCACTCCTCACAGGGCTCCCCAC 566 K Fgf3/Fg ATCTGCCCTGGGACACCCCACTCCT f4 CACAGGGCTCCCCACATCTGCCCTG GCACCCCTCCATTTTTCAGGCACCT GAAGTCCCTACTTTCTAAAGGCCATT CTTCTACCTCAGGTCTTGCTCTAGGA CTGTCAACATG IM000233 CAGGACAGCCAGGGCTACACAGAGA 567 R — AACCCTGTCTCAAAAAACAAACAAAC AAAAAAAAGACCATTATGCATTCCTG CGGCTCTGACATG IM000234 CATGGGCAGCACCTCGTGGAACACT 568 D — ATTATAAGTGTCCTCCAGTCAGGTCA ACAGCGTAAGAT IM000235 CCTGTACATTCTGTGTTAAGGACAGA 569 K Fgf3/Fg GGGCCTCCTGCATG f4 IM000236 CATGGAGGCGCAGGAGTTATTGTCT 570 D — AAAGTTGTGAAGATGAAGCCTAGATT GTATTGGAGATCCGGGTAT IM000237 GCAGATATTTCCACCTCTGCCTTCCA 571 C — CAGTCCTTCCTCCCATG IM000238 CATACGCTTACAATGTGTTGTTATTT 572 D — CTGGTTCTCGTCTGCCTTCTTTATAA AAACAAATCCACTAAGGTGGAGTAG CCAGCCTTTACTCAGGGACTGTCAC CATG IM000239 TTCTGTATATATTGTGTGGTCAGAAA 573 D — ACCGTGGTTTTCCTGGTGTCAAGAG TTAACACTTTCAGTAATCACTCATTCT AAACCAGACAAACCTTTAATCTTTCA TCTGGAAAGGTACTCATTCAAACCAA TGCTCTCTTAAAACCAGAGTATTTAA ACAGCCAACTGCATCTTCAGGGTTTC ATAGAAAATCAGCTTGATCTAAAATA GTCACTGAATTCTGATATCATAGACA TG IM000240 TCCACCCACCCACCCACCTGCCCAC 574 D — CCAGACAAATGTTCACTGAGCATTCA TATACTCCATTCACTTCTAAGTACAG AGCCTAAGAATATGAGAAAATCCTCA TAGCAAAGAAATGCCTCTTGCAACTC GAGTAAAAACTCGAGTATGGGATGG AAGAGTTGAGAAAACAGATGATAGTA TGAGAGCCTATG IM000241 AGGAGCCTAGCAGAATTGCCCTCTG 575 R — AGAAGCTCCACCCAGCAGAAACAAA TGCAGAGACCCATCGATAAACACTG GACAGAGCACAGAGTCTTGTGGAAG AGTTGGGGGAAGAATTGAGGAACCC AAATGGGATAGGGACTCCACAAGAA GAAAAAGAGAGTCAACTAACATG IM000242 CATGTCCTACAGTGGATATTTCTAAA 576 R — TTTTCCTCCTTTTTCAGTTTTCCTCGC CATATTTGAAGTCCNAAAGTGTGTAT TTCTCATATTCTGTGATTTTCAGTTTT CTCGCCATATTCCAGGTCCTACAGT GTGC IM000243 CATGTGGAGGCCAGAAGTCAACATA 557 D — TAGTCTCCTTCCCAATTACTTGTCAC TGGAGAGC IM000244 GTTCAGTAGCCAGCAGGGGGGATAG 558 D — GACCAGCCCAAATTCTCCCTTTGCTT GGCCTTGACTACTAGTCTGGGAAGG GATAAGTGGGCTAACCAGAAGTCTT CCACATCTCTAAGTGATTAAAAATGG AAGACGTGATCTCTGGTCATTCATAA ACAGGCATTTCTCAAAGTTGGTCTGT GCAGTTTGTGGGAAAAAATGAAATGT ACTCATG IM000245 CTACAGAGTGAGGTCAAGCTCGAGG 579 D — ATAGCCAGGCAGGGATGCACAGGGA AACCCTGTCTCAAAAATCAAAACCAA CCCAACAAACAAAAACAAAAATGGAA GGATAGAAGAGAGATAATCCATG IM000246 CATGTACTGAATCCCTGAAGTTGATG 580 D — CTGAGCACCATCTTGTGCTGTTCTAC CGCATTTACTGGGG IM000247 CATGTGTCACTCAAAGGCTGCTGAG 581 D — AATCAGGCTGTACCTGTATTCCTAAG CCATCCACAGCCATCCTGACCCACA GCAAATGCTGGCAGTCGCCCCACAG CTGGACTCCGTTCCTCCCTCCACTC CTATAGCCGAGGCTATCCACACAGG CTATTTCAGTGCCCTAAGCCTTGCTA CCCTTATGTATACATTGAGGACAATG AT IM000248 AGAAACCACTGCCAAATCAATACATT 582 C — TTAATTGGAAGTGTTTATGAAGCCCA GGAGAGATCCCTAAATGTATTAATTG CTTCCTGAGGAAATATAAAACTCACA GTTACTAAAGCCATG IM000249 ATCTTCTACACAGATGAAACTGACAA 583 K Fgf3/Fg AGTACAAATAAAGATTATATACCAAA f4 ATGAAAAAAAGTAAACAGCACACATT TATAGATGCATCTAGCATCCCCCAAA GCTCAACACCATCCATACTTGAAGAC TGCAGTGGTCCCTCTAGACAGTATG CTCCAGGTCAGCCCTCAGCACTTGA GAATAAACAGCTTCATTTACTCAGCC TGTTGTCAGGATCCATG IM000250 ACTGCCTCAAAACAAAACAACAACAA 584 C — CAAAACCCCAAGATATCTAAAGGAG GAACATTCCAAAAGACAGAAATGTCC ATG IM000251 CATGAGCTGTCGATAGTGACCTGCAGT 585 C — CAAGGAAATCTGAGGGCTTCCTAATTA ACAGAGGAGCTCTAAATGAGAGTAACG CGCTCCACAAACCCCCTCACACTCGGT AAGTGTCACGGTGCAGATAAT IM000252 GCCGCGTATGTGTTTCTTTTTCATAGA 586 D — AGAATTAGCACATAATGGAATGTGCGT ATCTGAAGTGCACTTCTGAGGAGTATT TATTATTACATACCTTTACAAGATATC TTTTCTCAGGGAGCAACCTGAAAACAT AAGGAGAAAAACATAAGAACTGCCACT CTAAGGGTTGGTGAAATGGCACAGCCT GGCGGTAGGACACACACATG IM000253 CATGGAGAAACCTGGGCTTATTCAAGC 587 D — AGTTTCCTTTGTTTACCCTGCCCAGGG TTGCCAGTGAAGGGGCTCCTCCATCAC TAACTAAAGGTCTTATCCTATGCTGGT TCCTCTCCACCCCACCAT IM000254 TATAGGAATAGAAATTCAGAACTTAT 588 C — CAGTTTGTTTTGCTTCAAATGTCAAC ACATAATAAATTTACAAACCCCTTGC ACATTTGCATG IM000255 GAAGACAAAAGATGTGTCAAATACCTG 589 K Wnt1 GGCAAAAGGGGGTGGTGGTGCTCTCTTT CCAACTCCTGAAAGACACCTCTGCTCA GCACACTAGTTTCCAGGTTCCTGGGTT AGGATTTGGGTGAGATTGGTCGGCGAT GGTTTGGTTCCTCCATTCTGCTGCTTC TCCCTGATACATTGAGTTACAGCAGCC CACGCGTACACACTCTCGCACATG IM000256 GAAGAGGAAATAAGGCAATAGCTAGAC 590 D — TGGAAAAACGAGCCAGCCTAAGAAGCT GCAGAGTAGTCTGTGGGGTTCTGCTTT GGTTAGCTGCCTTTAGTGCTCATG IM000257 CATGGATAGAGGATGGAAGTTGAAA 591 D — ACCTGCTATTAAGAACATAGCCCTGT CCATTAGTGAGAGTG IM000258 CATGTGGCCCAGGGGCACTTGGAGCC 592 K Fgf3/Fg TTAGATAGCTGCCTTTATGGCTCCTG f4 GTGGCCTTGGATGTGGGTGGGTGACA GGAAAGAGGAAGAGCTGGATAGTGGG GGGTCCCCAGGAGGAGCTAGCTGTGC TCTCTATCACTTTTGCTCTCCTGGGG CTACCCCCGTCTCAGGGGAAGGCCTG TGACTGGCTAAGCTACAAGTGTGGGC TGAGACCTTTCTCTGTGACACTCTGG TGCTACTCTGGCCATAGCACAGATCT CTAGGAACGCACTCT IM000259 TATATGGATATGTTTATGTGAGGGTA 593 D — GGCACTCCTGGAGGGTGGAGGCATTA ATTAGATCCTCTGCAGGTGAGCCACC TGACATG IM000260 ATATGTGGACTGTAGTCATCTTGAAC 594 D — ATCTGTAACAAAATATATAGATTAGG AGGTTTAGACAGCAGACATG IM000261 GTGCCTCTTGTCTGCCTAGCTGGTAT 595 D — TGTAGCATG IM000262 ATTTGTGACATCTTAGGAGCTTAGGT 596 K Fgf3/Fg TGGTCTTCGAGACACAGGGCTGTCCC f4 CTGTAAAGCAGGTTCCATCAGTGACT CCAGGGTTTTAGCAGTTCAGTGGCGT AGTTTTCAGACTGCTTAAGATTTCTC AGGGGCTAGGCGTGGGGCAGAGACCC TGCAGACCCTGGCTAGAACAGAGGCC CTGGGAGACAGTTGAGGGTGCTCAGC TGTGGAGGACATG IM000263 CATGACGACTTGAAAAATGACGAAAT 597 R — CACTAAT IM000264 CCTAAGTCTGACCGTGCCACTTCCCA 598 B AATTT. 102 GTCTTCCCTACAGTTCAATGCTTTTA 899 GGCACAACAAATTTGTACCCCTCATG IM000265 CCCCCCAGCCTGCTCCCTCCCCGGAG 599 D — GGAGTCCCCAGTGTGACATG IM000266 GTTTAGGTGATAGGGTACTTGCCCAG 600 D — CAGTAGGTGGTGCCCAGGATTCTATC CTCAAAATTGCACAAACAGAACATG IM000267 CATGTTGTGTAGATACCTACATAATT 601 D — ATAATTCATAACTGTAATTTGCTAC IM000268 CATGGGTTTGAGCCTTGTCCTGAGCT 602 D — GGAGGAAGAGAGTGACCCAAAGGGAC CTTGGTAGCAGCCAGGGATGTGTTGG GGAGCAGAGAAACTTTTATGAACTTC AGTTTCAGTACTGAAACTTCCCTTTC CCTAGACTTCCTTTG IM000269 CATGGGACAACTCCTTTTTCCTTCTG 603 D — GGTCAGGGGAGAGAGACCTCCTATCT AAACTGTATAGGCCATTGCTGTAGCC CTTAGCTCACTTCCGGGGCGGGGAGG AGGAGGTTAAGACCCTAT IM000270 CATGAAATGAAAGAACAGAGTAGCAA 604 D — TTTGGGGAGAAAAGCCTGCCGAGCGG ACTTAATCTTTCCCAAGTGCTATCAGT IM000271 ATGCTTGTCTTTCCCGCCCATTACCT 605 D — GCTTTTGTTTGAGATAATAGTTTTGT TACTTTATCAACTAGTAGCGACTAGT TTACATTTGGTTTCATAAATAAGATC CATTTTAATCTGAGTTTTCCATCCTT GATTTATTTTGATTCATATTTTAATT GTCTAGTTCCCATCCCTGGGCAGGAC TTTTTGGGAAAGTCTTGCAGGTGACT ATGTTGAGAATGATTTATGTTGTATT AGCACAGGTACATTCGACAGTGCTGG TTCCTTCTGGAGCGCCTCGGGTGTGG GTCCTTTTCCTCAGC IM000272 CATGAGTTTGATTATTTCCTGAATTC 606 R — TACCTCTCTTGGGTCTATTTTCTTCT TTTTGTTCTAGAG IM000273 GGGATAAGACTGGATAGTAAGCCGGG 607 D — CGTGGTGGTGCATG IM000274 CAGAAGGTAGTGTTTCACAACAGTCC 608 D — TCCCGATGATCAATTGTTTTACACTA AACCATATAGGAATTCACCCTGAGAG GAGTTCGAAAGCCTTTCAAAACCTGT ACTGATATAAAGCAAATCTCTTTTGG ATTCCCAATCAAAATGATTTGGCAGA ACTTTAAGGCCACAAAAATTGTGTCT GAACAACCCCTCTGAGCCCAGTTTTG TTAGCTTAAATTAAGGGCCATG IM000275 CCTCAAACTAAGAAGCATCCATTTCG 609 D — AAGCTGCTGGGATTAAGGGAGTATGC CACCACCACCAGCTATGGCATTTTTT TTCTTTAATTTTACTATTTTTTTGCT TGTATATTATGGTTTCCAGTTTTGTG GGTTTTATAAGCTTTGAGTGTGTTTC IM000276 GTCCACTTTAGGACGTGGAATATGGT 610 R — AAGAAAACTGAAAATCATG IM000277 CATGGTCAGCTCTCACTGCCCCATCC 611 D — CCTGTCTCCAGTTCACGCACTGTATC CTGTGTCTTTCTCTGTGGCTAGACTC TTCTCTTGGGGGAGGGGAGTCTTGTA TATCGATGTGTGCTCACGCACATAGA GGCTAAAGATTAATCTAGGTGTATTC ATTCATCGTCTCATTGC IM000278 CATGTGTCCTGATTTTAGTTGGATTT 612 D — TTTTTCTCCCAGGTTTCTGCAGTGTC CCCACCCCCCAC IM000279 ATGGTGTCTGTTCATAGCAGTAAAAC 613 R — CTTAACTAAGACACTGATATAACTCA CCTTTCCCAGCCTCAAAGTCTCTACC ATGTCAGGATCCACTCACTCATTCAC CAAACTTCATCAAATGCCCACTGTGC TATCATCAGTACAGAATAAATCATG IM000280 CATGAGACTGTCACAAGCTCCTGGGA 614 K Fgf3/Fg TGGGGACCTTACCAGAAAGCCACCAA f4 ATCAGAGGCATCCCTGTTTGGTGAGG GTACATTTGTTTTTCCCCAGGCCCTG AGTGCCAGGCAGGAGCAGGCAAAGTT CACCTGGGAGGATGCCCTGGAT IM000281 GTTTTGGTTCTTTTCAAAGAAAAACA 615 D — AAGGTCATTGCAGCTTTTTGTACCAT TGAGGTGATGGTAGGTTGAGATATAT AATCTACTTGAAGATATATATTATGG CATG IM000282 CCGCTGCTCTCTCACCAACCCAGTGT 616 K Wnt1 GTCTGCTTTTAGCCCAGACGGGGGAG GGGGTAAGGGGGTGGTCTGTCTCATG IM000283 GTGTCCCTCCTGTCGTTAGGCAGTAC 617 C — TTCCAAATCAAACCATG IM000284 AGCTGGTACAATGCTTAGAGCAGAGC 618 D — TGCAGAAGCAATACAAGAGATCCTGG CTCAGCTAGGTGCAAGCTGGAATAGA CTCCTGACAGTTGTCCTATGAACTCC ATACACAGGCATG IM000285 ATGGATCCCTGGGGGGCAGTCTCTGG 619 R — ATGGTCCTTCCTTCTGTCTCAGCACC AAACATTGTCTCTGTAACTCCTTCCA TG IM000286 CATGATGCACTTAGCAATTCCTCTAT 620 K Fgf3/Fg TGAGACTCAAGTGAGCCTAGGCTGTG f4 ACAAAATGACTGTTAAAACT IM000287 CATGTAAAGCTAGTTCAAAACATACT 621 C — AAATAATTCAGTTGTAGAAGAGGTGA GGTTATCTCACTGCCAGGATAAGCTA TTGAACAAGCAAGGGTTCTCACTTAC TGTTTAAGTGGAAGTGTTTTCTTACT TCAAAAAGTCATTAATGAATTTTAAG CTGCATAAATATTTAGTTATT IM000288 TAAGCTTTTCTCTTACACAATCCCCC 622 D — GGAAACCCACAGTAGGTCACAAAGAC CCAGGCACCTATTCCTAGGCCTGGTA AGTGGGCACCCACCATTTACAAAGAG CTCAGCATTTGGCTCACACATG IM000289 CATGAAGATGAACCGGGCTTGTTTCT 623 K Wnt1 CTGGCAACTAGGCTCAGAAAGGATAG GACCACCAGCCGAGTAGCTGTCAGAT GGAGCTGAAGACCTGAGGGAAAGAAT GCTTGTGGGAAGAAGCTGGCTCCTTT TGGTTTTGTTGTTGCTGGTTTTGTGA CCGGATCTTGCTGTGTGACCCTACCT AACAT IM000290 CATGGACTTAATTTTACTGCATTTGA 624 D — ATTATGGAAAATATATATGAAAAGTC TTTAGAAAAAGGCAGAGGACGAAATT AACCAAAGAACTTTAATTATCTGAGA CCAAGAPAACTCTTTAAGAAAAAGCA GTAGATTTAAACTACGTGTTGTTAAA ATAGTCCTGTATAGATATAAAGTCCC TCAGAGGGAAGAGATTTGTTGAATAA ATTCAGACACTCPAGAGAA IM000291 ATTAAACAGCCCAGTGCACTCAGAAG 625 K Fgf3/Fg TGAATGTTGAGAAGTGGGTTATCTGG f4 GGACAAACAGAGGGAAGAATAGTGCC CTTGGCACGTGCAAAGGAGTTTGGGA ACAAACATG IM000292 CATGTATGACAGTGAGGTCAGGAGTG 626 D — CCCAGGGAGCTTGCATTGGCAGAACA GCCTTTCCTGGCCAAGCCTAGTGTCA TCAAGTATATATTGGACCAGACCTTA TAAAACTTGGGTTCCACTCTGGCTGG ACCAGCCTCAAGGCGTCGCCTCTCCA GGCCTACCTCCCAGACGCAGAGGCAG CATTTGGAGGATTGAA IM000293 CATGGGAACTTGTTCCAAGCAAGGGA 627 D — CTCTGCTACACCTTCAAGGGACGCTG CTAATACTGGGTTCAACCTTGGGCAG CGTGCACAGCAGGAGTGGGAGGGCTC TGATGAGGAGAGCCACCCACACTGTG AGATCTAGGAGATAAGGTCACATCCAC IM000294 CCCTCCAGCAAATTGAAATACGAAAG 628 D — ACTCAAACACATTAGAACCATTCCAA TAAAAACTTGCATTGCCCCAGGCCCC TCCCACCACCATG IM000295 CAAGAGTATATATCCAAGAAAAATAC 629 D — AGCTGAGTTGACTGTTAGTTCTGTTT TGGCCTTCATG IM000296 GGTAAAAACTCTACCAGTTAAACTAC 630 R — ATTCCCAGCCTGCCTCCAATGAATTT AATTTGTGTTTTTAGGGTTTCTGTTAT TGTTGTTTTTGAGACAGGGATTCACA AAGATCTGCCTGCCTCTGCTTCCTGA GTGCTAAAATTAAAGGTATGCATG IM000297 GTTTAGTTACTGTTTTCTGTATTACT 631 D — TTTGTTGAAAATTAGATTGTTCCTGG TGACTTTGTGTGCTATATTCTCTGCATG IM000298 CATGTTTCTGCTTCTACTTTATCCAC 632 D — CCTGCACACACTGACTGCTATGTTCC TGTACCTTTTCCATCTCTCCATTGAA TATTCACTCCTACAGTGGCATTGGAA ATTGCAGTGGAGATACC IM000299 ACGATGGTCTTGCCCTTTCTCACACC 633 D — ATCAATAGTCACTCAGAGCTGTGGTT GTTATCTGAAGTGTGTTGCAGTCCAA CTTTGCCCGATG IM000300 GGAGTGTAAGCGTCGGTGTGTCACCC 634 K Wnt1 GTGAGATTAAGTCAAAGTGTACATG IM000301 TAGACCCAGTCTTGCACTGGCCTGG 635 D — GACTCGCTTATTAGGTTTGACTGTTA TCTGGCCAACAAACACCAGGAAATG GGGTGACAGGTGGTTGTGAGCCCTC TGAAATGGGCATTGGGACCTGAACC TGGGTCCTCTGTAAGAGACATG IM000302 TCACCCCAGCTGGGGCTGTGCTGAAGA 636 K Fgf3/Fg CTCTGAAGGGGAAGATAGGCCTATGG f4 TNACATG IM000303 GTTGGGCTGAGCCACTAGTACACCTC 637 K Fgf3/Fg CACTCACTGAGCCATCTAGCAGGTCC f4 CAAACAAGGTGACTTTTGTCATCCAG CAAGACATAGCCATCTATGCCAGTCA TCCTTGTCATG IM000304 TAACATATTTGCTTGTTATGAAGGAA 638 C — AATGTTGGATGTGTGTGCCTGTGGTT GAGTACTGCAAGTAGTGTCAGGGAAG AGAAACCTAGCTTGAACAGTCCCCTC ATCTCCTTCATATCCTCACTCCTTGT CAGGCCCTGTATTAGGTAGTGCTTCC CTACCTCCCTAATGCTGTGACCCTTT CTTTAATAGAGTTCCTCATG IM000305 CATGTGAGCACAGGTACCTATGGAA 639 D — ACCAAAAGTGTAGGATCCCTTAGAAC TGGAATTATAGGCAGCTGTACGCTAT TGATGTGGGTGCTGGAAACTGAACT CCAGGCTTCTTGAAGAGCATCAACT GCTCTTAGCTGG IM000306 CATGTAGAGACTGCCATATCCAGGGA 640 R — TCCACCCCATAATCAGCATCCAAACG CTGACACCATTGCATACACTAGCAAG ATTTTATTGAAAGGACCCAGATGTAG CTGTCTCTTGTGAGACTATGCCGGGG CCTAGCAAACACAGAAGTGGATGCTC ACAGTCAGCAAATGGATGGATCATAG GGCTCCCAATGGAGGAGCTAGAGAAA GTAGCCAAGGAGCTAAAGGGATCTGC AACCCTATAGGTGAAACAA IM000307 CATGTCCTAGAGTTGTTCCAGCACAG 641 D — AAGCTTTTGGGAGAGACCACCATTAC TGAAACGCAGCAGATGCTGCAGCT IM000308 CTGCTTGTTGTGGGGACCAGCCAGAC 642 K Fgf3/Fg ACCCTCCACAGGTGCAGTGGTGCAAC f4 ATG IM000309 CATGATGTTTGTGCAGGAATAGAAAC 643 R — CCTGACTAAGACAGAGGATATTCAAG ATCCAAACTAGCAGGTTAGCTGTGGT TCC IM000310 CATGAAGCACACATTACCCTGTGACT 644 D — TGCTTTTTTATTAAT IM000311 CATGTGTCCTCTTGTCTTGTAGTCTC 645 D — TATTCTTTGTGATTCCGCAGCTCTCC ATAGAGTGCAGTTCTATGTCCTGCCT GCAAGGTCCATTGGCTTACTAGGGTC TGCCCCTCCCAGAAGAGTAGCTCATT TAGAATGCATTACTGGTGTGCTGTCT TGCATCTTTTTTACCCAT IM000312 ATCTATGTATGCACTACTAATTACTG 646 D — TTTAGTTTATATATGCCCTAATAATT ACCCCATTGAAAACTTAAATTTTGTT TCAAAAGTGTGGTCTCATTGGAGGTG TTAATGTACPATGTCTTTCTCATG IM000313 CATGGCCAGCTGAGCGGGCTGGAACC 647 D — TGCCCTTCTGCTTCCTGTCCCTGCAC CTCAGCACCGCTGTGCACTTGGTACT AGACCTCAATCACCGCAG IM000314 CATGTGCGTCCCCCCCAAACACGCAA 648 D — GCGCACACCCACAAAGAGAAGAGACA GGG IM000315 CATGGCCACTTGGAGAGAAGGGGGAA 649 C — GGGAATGCGGAGAGAGCGGGAGCAAG AG IM000316 CTTAAGCACTGATCAATGGCCAAGGT 650 K Fgf3/Fg TTGCCGACTTGGGATCTGGGGTATAG f4 ACATCCACCCACTGAGACCCTCTAAC AAAACCAGATGTGGAGGTACGAAGCC TGGCTCAGGGGCCTGTCCTTTGTCAT CAGAATTCACCAGCTGCAGCTCCTGG GTCAGCTTTGTTTGGCATG IM000317 GTGTATTGATATGCAAATGTGTTAAA 651 D — ATATGATTTAAANTTCCCCATG IM000318 GCAAAGTGTCCACACTTTGGTCTTCG 652 R — TTCTTCTTGAGTTTCATG IM000319 ATAGCAGGTCCTGGATACCCCAACAT 653 C — ACCAGAAAAGCAAGATTCAGATCTAA AATCACTTCTCATG IM000320 CATGTCCTGGCTTTGTAAAGGGTCCT 654 D — GCTGGGTTTACTTCACTGGGTCTTAA ACTCCGATTGTGAGCCGTAGTGAAGA GGGCTGTATATAGTGGGTCACCGAGG TCCTGTAGCAGAGTGGGCAAGCTCAC TGCCTGCTACCAGCAGTTCACTATGT TTTATGGTCTGCTGCCTGCTGGTGGT TTATAGATGCTGTGTCGTAAGAGAAA AGTTGAGGGTAGCCTGGAGTGAATGG AGTTGGGGTATCAGGGAGGTCTTTGT ACACTGGGGTGAGCTAGGCCTCTGGA AAGCTTCTGGGGGTTCCCC IM000321 CATGCTCCCAGGCACCAGGCTTGCTT 655 D — TGCATAGGTGGGACAGGGTCCCAATA CTCAGCCTGGGGTGCCAATGAGGCTC AGGCCACACACCCTCTTGGTAGGAGT CACTGTAGTGGGGTCTGTGAGAGCCA GTAACTTGTGAGGGTGTGAACTTAGC TCAGGACAGAGGCCAGCAGGAAGCTT TCCCTACAGAGAGTGTTTTCGTCTTT TCCTTTTTCTGGTTTGTTTCTTGGGA AGGGAACAATTTTCGCTTTTAGTTGG CTTGTATTATTCGCTACTGAAACCTT AAG IM000322 CATGTATTAAGTCCCTCGTGAGGAA 656 D — GGGT IM000323 CATGAGTCAGAGGCTTCTACTCCAGT 657 D — TAAAACTGATCTGGGTATAGAATTGT GTTCTCAAGAAATAGTAAGTTATAAT CAACTAAGTCATCTCCTGTCTCATTT TTTTCTTCCAAATCGGGTCCTCGAAT TGTTATPAGAAGATTCAATCAATCAA CAGTATCCCTTTCCCAATTTGTGTGC TAAGTGGAAACAGGTCTTAGCACATC AATCACATAAAGTTCAATTAAGAAGG AATTTAAAGATCAG IM000324 GCTATGAGTCTCCACTTGTAAACAAT 658 C — TATACTCAAACATATTCAGGACACAC TTGGGCTTCCTCCATCAAGCCAGGC AGGTTTGTTTTCTTGTTTGTTTTGAG ATAGATGGATGGGCCAGCTTCATG IM000325 CCCACCCCTAGCAACCAGTTCCTCCT 659 D — CTGAATGGAAGACATCTGATACCAAC TGAGCTTTCACATG IM000326 ATCNNCGAATCATTCTAGGCTTGTGG 660 D — GACCATG IM000327 ACTATTCTCAACAATAAATGAACTTC 661 R — TGGGGGAATCACCAATCCTGATTTCA AACGGTACTGTAGAGCAATCATG IM000328 CCTAGGCACCCACCACAATAGTTAAT 662 D — CCATCTTTGAATTTTTGACCCAGTGT TGCCTAGTATTCATTGCAACAGCTTT TCAAATGTTTTATTCTTTCCCAAATA AATTCCATG IM000329 AGAGGCTACCCCTTCAAGTGGCTTGC 663 D — CTAGTATAGCTATTACAGACAGAGAA CTTCCAGTAATTTCCTCAAGCCACATG IM000330 ACTCTGAACTTTGCTTTGCCTGGTAT 664 D — TTTTGCCTCTCTTATCCCATTGACCC TGTACAGAAAAGCTGAGGAAGCAGGT GCAACCAGGCATCTCAGGCACCCAGT TAAGAAGTAGATGAAATACTGTAATG TACATG IM000331 CATGATTTTCAGTTTTCTTGCCATAT 665 R — TCCACGTCCTACAGTGGACATTTCTA AATTTTCCACCTTTTTCAGTTTTCCT CGCCATATTTCACGTCCTAAAGTGTGT IM000332 CATGAGACAGTCCCAGATCCCTCACC 666 D — ATAAAGAGCTACCATATAC IM000333 CATGCGACCATCCATCAGGAGTTGGA 667 K Fgf3/Fg GGTGCCATCGGCTCTGCCTTACAGAA f4 AAGGAATCTGAGATTTAGAAACCCCA GGTGACCCACTCAGGGCCACCGGGGC AGTAAAAAGAATCTAAGATCTAAAGT CAGTGGAAACTCCTCCCAACCAGCAG AGACTCCTCCCAGCCAGCTCTTGAT IM000334 GGGAAGCAAGAGGCAGTAAGAAAGGG 668 D — GAAACTGGGGAGGTAACCAAAGTCAC ATG IM000335 CATGCTAACAAAGAATGGGGAAAGCT 669 D — CTCTAGGCTTCCACCTTAAACPATGA GGAAGGGAAGAAGGAAAG IM000336 CATGTTGGTGGGACTTTATGGGTATT 670 R — GCTTCTGATATTACTAGGAGGCACAA TCTCACAGAAAACTCCCTGATCTTAC AATCCTTCTGCCCCCTCTTTTGCAAT GTTCCCTGAGCCTCAAGTATGGAGTT ATTTTATAGCTGTATTCATTGAGACC AGAATCCACAGGTATGC IM000337 CTCACACAGATATGCATG 671 D — IM000338 AGAAGTGATCTTTCTTCTGTGTGTCC 672 D — CTGTCACCCTGGGAGGCAATCAGACG GTCCCTCATG IM000339 CTTTCCTTTTGTTTTGGACGAATATT 673 D — ATTGAAATATGTAGTGTGCATG IM000340 CATGAGATATGATTTTAGATCTGAAT 674 B AT5970 CTTGCTTTTCAGGTGTCTTGGCATAT 62 TCAGAACTCGCTGTGGTGGGTGAACT GGGTTCTGATGATGCCCATTGGTGCT GGTTTC IM000341 CATGGAAAGGTATTTGGAAATAGGCT 675 D — GTTTTGTGTGTAACTC IM000342 CCCTAGGACTCACCTGGTAGGAAAGA 676 D — AGTAATTCTTCCAAGTTGTCCCCTGA CATCCACAAGCACATAGTGTCAGGCA TG IM000343 CATGCCATTCATACATACTGGCAATG 677 D — GATATATAGAAAATGAGACTCCTTCT AATATTGTGTGATGACAGAT IM000344 AGAAACCATTTACACTGCCAGGTTTG 678 D — GGGCCTGCCTATGCATG IM000345 GATCCCTTTAACTTCTTGGATAGTTT 679 R — CTCTAGCTCCTCCATTGGGGGCCCTG TGATCCATCCAATAGCTGACTGTGAG CATCCACTTATGTGTTTGCTAGGCCC TGGCATAGTCTCATAAGAGACAGCTA TATCAGGGTCCTTTCAGCAAACTCTT GCTAGTGAATGCAATGGTGTCATCAT TTGGAGGCTGATTATGGGATGGATCC CTGGATATGGCAGTCTCTAGATGGTC CATCCTTTTGTCTCAGCTCCAAACTT TGTCTCTGTAACTCCTTCCATG IM000346 AGGGTGGTCTCTGCAACCCAGGCTGG 680 K Wnt1 AACCCAGCACAATAAATAGTTTTATA CATAACCGAACGCGTGGCTCTGCGGC CACATTTCGGTGCAAATTATTTACAC AGTGATGAGGAGGCAGGACAGGAAGG GGTGGGAGGAGGCTGAGGGAGGCATG IM000347 CATGTGTGTTCTTTTGTGATTGGGTT 681 R — ACCTCACTCAGGATGATATTTTCT IM000348 CATGAGGCCAAGGGAGAGGCAAATTC 682 D — CTGTGTGAATCAATTATCATCTCACA GAGAACATACC IM000349 AGTAGTATGCCACAGGGAGAAAGGGT 683 R — ATTTATCAAAGGGACAGGAGCTAGTT GTGGTGACCTTACCTATCTGCTTGCC TCTGCCTCCACGGTGCTGGGATTGAA GGTGTGCACCACCACACCCAGCTTCA GATTGTTTTTATTTATTGNGTATTCC TGTTTCACCTGCATG IM000350 CATGCATATACAGGATATAACCTTTG 684 D — TAAGTAAGAATAAAGCACATAAAAAA TACTTTCAGTAATATTGTCCAAACCA CTT IM000351 CATGTGTGTGTTTGTGTTTGCGGAGT 685 K — GTGGGGGCGGCAGGGAAAGGTGGCCA GGCTGTCACTCAGAGATCAGGATGAC AGGCGCTCCCTCATCTAGGCGCGGGA GCTCTGATTGCAGATTCGAGGAAACA AAATAGCAATTG IM000352 CATGAAGATGAACCGGGCTTGTTTCT 686 K Wnt1 CTGGCAACTAGGCTCAGAAAGGATAG GTCCACCAGCCGAGTAGCTGTCAGAT GGAGCTGAAGACCTGAGGGAAAGTAT GCTTGTGGGAAGA IM000353 TCAGTTCCAAGAGATGACACAGCCG 687 R — CAGTCATG IM000354 CAGAGACTGAAGGAAAGACCATCCAG 688 R — TGACTGGCCCAACTTGGGATCCATCC CATTTGAAAGCATCAAATCCAGACAC TATTACTGATACCATG IM000355 CCCTACAGTGACACTTACTCCAATAA 689 R — GGCCACACATCCTAGTAGTGCCAGTC CCCATG IM000356 GGCCTCTATTCTCGGTTCAGATTAAG 690 D — TACCTGGCTTCACTGAGAGCGGCTCT ATCATTCCTAAAATGGTTCTCATG IM000357 AGTAGATGGCAGAGAATAATCAAACT 691 R — CAGGGCTGAAATTAACCATG IM000358 CCAACCCAACAGCTGGGAAGGGTTGG 692 C — AAGTAGCCCCGAGGCTGGTTAGTCCC CTTCCAGATGGGGAGGTTAGACTGGG GCTAGCCAGGCTGCTCCACATAGACT TCCGATTCGCNTTAGAAATGAAAAGA GGAGAGGAAAGGGAAAAGGAAGAAAG GCTACAAGCATG IM000359 CATGGGGTCTGGAGCGAGCTATCAAA 693 R — CCCAGGATTGTCTTAACTGTGGTGGC TTGGATGAGAATGGCCGCCATAGGGG CATAGATTTGAATTCTTGGTCCCTAG TT IM000360 ACGGTGGGCTGATATTTTCTAGATCT 694 C — CCTAGTGCCTATCCCCTATTATCATG IM000361 CATGAATTTTGAGATATTCTCTGAAC 695 D — CAAACAATATT IM000362 GGAGAAATTATGCCTTAAATTAAAAA 696 D — GCAAATATTGAAAAATTAAATATAAT TTCCATTAAATCATAATGGACCAACA ACAGAACACATCTATCTATGTATCTA TCTATGTATCTATGTATATCTACCTA TCTATCTGTAAAGCAAAAACTACATG IM000363 GCAAGGACAACTGAGAGTTTGAAGCA 697 D — ACTATTTTCATCTTGACTCTCACTCG GCTTTTAACGTCCATTCAGGAAACAG GCATG IM000364 CATGAGAAGTCACAATTCCACCACTT 698 D — AAAATCAGTGCTTGGAAGGATACTGT AGGCCAAGAGGTAAGTAGAGGGGAC AGCAGTGCACGTTTTTCAAAGTGTG GGTGTGTGTTTGTGGGTGTGTGTCT GTCTGCCTGTGCGTGTATGTGGGTC AGTACAGGAAAAGC IM000365 CAAGATAAACTCTTAATGGGATTCTA 699 D — GGGAGTCATTCTGTAGAGAGCACTTG ACTAGAAGGTTAAGTCTTAGATCCAG ATCCCAGCACAAACATAATACATCCT ATACTCACACACACACAGACACACAC ACACACGCAGTCCTCATG IM000366 CATGTCTCAAAAAAAAAAAAGAATCA 700 D — CTTGGATTGTACATAGTAGTTAATAA TATGTAATTAGTCTAACTGTGAAGGG GCACTTATTAGTTTCTACTATGTAGT GTAAATGAACTATGTTGCTATTAGAA ATTC IM000367 GAAGGTTGAAATCTGTAATCTATCTT 701 D — CTATGGCATCATTCACCTCTCTAATA CAGCTGTAGAGAAAAATGTCTGAAGA TTCGGTTCTACTCTCGTTCTTTGAGG TCTCCCAACCCATG IM000368 CATGGCTGGACTATAGAGCTCTAGCT 702 D — TCAGTTGCTGGGATGTTCAGTGCATC ACCACAGAGAGGGTTCTTAAGTGGTG ATGGTGGTAGTGGAAAGGTGGACCCT CCAGACAAAGGAAGCACTCACCACGA CCCTGCTCACCTGTGAACCTCCTTTC AGACTGATTCCTGAGATCAGCCAGGC AGGGCTACCAACCAGGGACTCGTAAT GAAAATTTAGGCATATGG IM000369 CATGGTCTGGTGAGTATGGCACCAGA 703 D — TAGGATGTTATGCCCGTTTCTTATCT CAAGAAACAAGGAATCTTGTTTCTTA TCATTAATAGGAAGAATAGAGCAGTC CTGGCTAAATGAAAGGTGGNAAAGTT GGTTTGAGTATCTCTTTCC IM000370 AAAATCCAATACACATTCATG 704 D — IM000371 CCCTTTGTTGTGCATTTCAGCTAATC 705 R — TCATCCCTGTTTGGGTCCTGGAACCC TCTTGCTTCCCTGGCATCTAGGACTT GCTAGTGGCTACCCCCAGCTCCCCAT TCCCCATTGCTACACACCTCTGTTCA AATTCCTGACCCTCTGTATATCATCC CAGTCTCTTCTAATACCTGACCTGAA CCCCCTTTTTCCCCTCCCTCTATTCT CTTCCTTGCAAGTCCCTCCCACCTTC TACCTTCCATG IM000372 CATGGGTCNTTTCTGATCTTTACCAA 706 D — GCAACAGTGATGAATCTATAAATAGA ACCATCAGTTCAAGAAACACAACTTT AGATTCCTTTCCATACCTTGCTTTTG TTTCTTACATCTTCCCCCTGCCCTGT GGTTTTTCTTTTAATCTTGTTTTTAC AATCCAAATTGTATCCCCTTCTCTGTC IM000373 TTGGGCCTTTGCATACCCTGTTCTGG 707 D — CTAAGACAATTGTCACCTGACTGGGC ATG TAA000374 AAGTGGATGTTTCTCATTTTCCATG 708 R — IM000375 TATAAGCAATCCCAAAAATTCTACCT 709 R — GGGAACTCCTAGAGCTGATAACACCT TCAGTGAGCCAAGTATCTGGGTATAG GATTAATTTTAAAAAAATAGAAAATC AGTATCTCTCTTACATACAAATAACA AAAGGGCTGAAAAAGAAATTAAGGAA ATAAAACCCTTCACAATAGCCATAAA TAATATAAACTATCTTGGGATAACTC TAACCAGGCAAGCAAAAGACCTGTAT GATCAAATCTTTGAAGAAGAAAATTG AAAAAGGTATCAGAGGAGGTAAAGAT CTCCCATG IM000376 CATGGGCTCTGCTTAAGAAACCCCGG 710 C — AG IM000377 CATGCTTTTAGGCCTTTTCACGATCT 711 A TTTDal1 TANNGGGGACCGNGAGAGNTNGCTGC TGGATGATCTCTGAGAGAGCTTATCG TCCTCAAACTGCTGATATTCAAGCTG TTTCGCAGCTGCAGCAGCAAAGTCCC GGTCTTTGTCACCGATCTGTGAACAG CAACAATGAGCACCTTTCATAACAGA CAGGAAATGGATGCT IM000378 GGCGTACCTGTGTATATGCATGCATG 712 D — IM000379 GTGCTAGGCTCACTCAAGATAAAATT 713 D — TGCTATTTCAGCTCCCTGGATAATAA AATCTATCCTCTCACAGCTGTGACTC TCACAGGGGTGCAGGCAGGACGAC ATCAAGAGAGTGATGGCCTCTAACA AGTGTTCTGCCCACTTCCTCTTCCGG GTCAAAGACTAGATCTAGACTGGTG GGGCTGTTGATTCACTATGAATGTGC CTGACACCATCCCACACTTAGCATCA TAGACACTTGGGGGACTGGTGATAC ACTATGATGCCTGACACCATCCCACA CTTAACATCATG IM000380 CTATCCCGAGGGTGAGGGCAGTTCT 714 K Fgf3/Fg ATGCCAAGGTTCTCATCACAGAGATA f4 CAGAGGAAGCTGGGCCTGTCTTAGG GTTGGCTGTCTGGAGATCCTGGAGC CCTGGAGGTGGGTAGCAAGAACAAA GGAAGTACTTCACCTGATAAAAACAG TTCCCAGAGAAACACATATACGCTTC ATATACAGGAGTGCGAGTGTGTGTG TGCGCGCAGAGAGGCAGAGGCCTG GAAGTCAAAAGTTCAGGGCCAGTTT GTGTGCATG IM000381 GGGGTTGACTAGAAGAAGGAGGCGAT 715 D — TAGGGTGTATCATATGAGAGAAGAAT AAATAAAGGAAAAAATAAAAAACAAG GATTAAAAAGTAATTACATACATACA TACATACATACATOCATACATACATA CATACTAGTTAAACTGTTATGGTAGC ATG IM000382 AGGATGATATTTTCTAGTTCCATCCA 716 R — TTTGCCTAAGAATTTCTTGAATTCAT TGCTTTTAATAGCTGAGTAGTACTCC ATTTTGTTAGTATACCATATTGTCTG TATCCATTCCTCTGTTGAAGGACATC TGGGTTCTTTCCAGCTTCTGGCTATT ATAAATGAAGTTGCTATGAACATAGT GAAGCATG IM000383 CATGCCTGCAGGTCACAGCCTTGCGC 717 D — GCCTCCAGTGCCCAGCGTTCAAAGTG ACACAGACTCTGTCAGGATGGTTCAA ATGCAAATCTCTGCAACTGCGTTAGC CGCTTCTAACCAAGACAGAAAGCTGC CGTCCTGTCCTTCGTGTCTGTCCCCA TACCCCATATCGGGTAGCTTTTCTTT CAGCATTGTCCAGACACCATCATATG CCTACATCGCACAAGTTCTCTGAGGC CAGATAATTGGCAGCACTCCTGTTGT GTGCCGAGAGTGCAGAAAAGGGCTAT CCCGAAAAGGTGTGATCTGGAAAGAA GGAAAAAAC IM000384 ATCTTTTGGCCAGAGCAAGCAGGGAC 718 C — TGAGTGAGCAGAGGTGACAGGAGCGA GCAAGGCTGACAAAGTCTTCCATATT CCTACTAGGATGACCCATTAAGCCCC ATAAAGCATTCCATTGCTTTCCAAAT ACAAAGTCCCAAAATCCACATTCTTT CAAATAAAAGCATG IM000385 TTAACATATGGTTTTTAAAAATCCAT 719 D — AATGAGCATATGATAGAGAAGTCATC AGAGCTCTTCAGCTCCACATCATCTG TCCCCAGAAGTATTACTACTCCTAAC TTGCTGAGCCAAGGCACAGATATTCT TTGTGTAAGCATCTCTTCTATCCTGT GTTGCCACGCAGGAGCACGCACACTG CTTCCTGTCTGAGGTTGTTCCATATC AGCATG IM000386 CATGCCAGGGCTTGAATTAACACAAG 720 D — TGCCCCAGAT IM000387 CCTGTCTGTATATGCACATG 721 D — IM000388 CATGGAAAATGAGAAACATCCACTTG 722 R — ACGACTTGAAGAATGACGTAATCACT GGAAATCGTGAAAAATGAGAAATGCA CACTGTAGGACCTGGAATATGGCGAG AAAACTGAAAATCACGGAAAATGAGA AATACACACTAGTACGTGAAATATGG CGAGGAAAACTGAAAAAGGTGG IM000389 CATGAAGGTAAATTATGACCATCAGG 723 R — GTTCAGACCTCAGCTCGACCGGAGAC CAGCCTGCAANTCCCCACAGCCCTCC CTTAAGTGGGTTAAAAGACAGAAAAG AATTAAATATCTGA IM000390 CATGCACTAGCAAGATTTTGCTGAAA 724 R — GGACCCAGAT IM000391 GACACATACACACACATG 725 D — IM000392 GTAAATGTATTAGGTTCAGAACTGGC 726 D — ACTGCTCACTTATGTTCACAGTTGTT TGGGTAAAACTAGAACCAAACACAAA AGCAAAAGAGCCAAGCAGCAGAGCAG GGAGCAAGGGGCTTGGGGAAAACACT CACCTCTGTTGTGTCTTCTTCTAGCT GTCAGGGCATTGAGTGGCAAGGAGTG GAAAGGAACTTTGGGCATTCCGAGTC AGGAAAAGTGTACCAAAATAACACTA TGGAGGTTAGCAAGTGTTCTAGAGGG CAGAATAAATACATG IM000393 GTTTAGGTCATTGGTGGTACACTCTC 727 C — CAAGGACAGTATAAATTGATTTTTTT CTGTATCCTTCTTTGTTCTTGGCCAT AAGGCACTTGGAGTGCATTAATATGT ACTTATTATTACTATGTCTTTTCTTG TCTTTGGCTTAAAAGAAACAGGGTCA AGTGACCATG IM000394 AGTTTTCTTTTAAAAAAATAAAGTAG 728 D — GAATGAAACTGGAACAAAAATGCAAT AAATTTTAAACCATCACCGCTAAAAC ATG IM000395 CATGATTTTCAGTTTTCTTGCCATAT 729 R — TCCAC IM000396 GAGAGGAGCCTGGGGAAATGAAGGT 730 R — CCAGCAACAGGCCCAAAGTGGGATC CAGCTTAAGGGGAGGCCCCAAGGC CTGACACTATTACTGAGGCTATGGA GCACTCATAAAAATGGACCCAGCATG IM000397 CATGGCAGCCTTGGAGTATCAGGCT 731 D — GCTGTTCCCAATGTGGGATGCAGAG GGCACTGCCAGCCTGGTTATCACGC ACCACTGTCACACAGGGAAGCGCCC CCTTCCC IM000398 GGAGTTCTTCTCTTCAATAACAGAGT 732 D — AAATTCTCCCTCAGCAGTTCTCCCAG GAAACCCATAACCTAGCCATG IM000399 CCTTAGATGTTTGTCTAATCGACAAA 733 D — ATACTTTATATGTGAAAAGGAAAGCATG IM000400 AATAATCAGATTTCCAGAGCTCCCAG 734 R — GAACTAAACCAACAACCAACGAATAC ACATG IM000401 ATCCAGTAATCATTCATCTTATTGTT 735 D — TCCACACAGGAAAACCTGTAATAGAT GGTTCATCAGCTTTATTTATAACTTT CTATCTTGAAAGCAACTGGAATGCCC TTCAGTAGGTAAGCAGATACACTAGG CTCACCTCAACTATAGGCACAATGAA AGGAATGAAATGTCAACTCACGAAAG GTAAGTACACATG IM000402 CCTCGCCATATTTCACGTGCTAAAGT 736 R — GTGTATTACTCATTTTCCGTGATTTT CAGTTTTCTCGCCATATTCCAGGTCC TTCAGTGTTCATTTCTCATTTTTCAA GTTTTTTAGTGATTTCGTCGTTTTTC AAGTCGTCAAGTGGATGTTTCTCATT TTCCATG IM000403 CATGCAAGAACAGGACTAATGTCTGT 737 K Fgf3/Fg GAAGAAAATGAGTGAGCGTGAACAGG f4 AGGTCAAGGATCCGGTCCCAGGCAGC TCTCAGTCTGGGCAAGCATTTCTAAA CTTTGCCTTCCTTCCTGTTGGGGGTG AAGGTCTG IM000404 AATAGGAGTAGATGAGAATGAAGATT 738 R — TTTCAATTTAAAGGACCAGCAAATAG CTTCAGCAAAATTATAGAAGAAAACT TCCCATACCTAAAGAAAGATGCCCATG IM000405 CATGCAGCCCCATTAGTGATTGATCC 739 D — TGTTCCATATAA IM000406 CATGGGCTCTCTGCTGATAATGCTG 740 R — AGGCTGTTTGTGCTGTAGTCTGCGC TTTTTGCCCCCTCTCAGAAAAACTGT ATGTCATAGGAGTTGCTGGCTATTG GGTACATAAGCAAAGCCACCCTATT GTGCCAGTGCCTTAGACAGTGAGAC AAGAAAGGCCCCTGGTTAGAAATCTT ATCAGGACTGGGAATGTAACTCAGTT GATAAGAGTGCTTGCTTAGCGTGCA CACAGCCCTGGGTTCAACCGCCTAG TACTACAGAAACTGAGTGTGGCTTCA CACACCTGTAATCCCAGCACTTGGA GAGATAGATGCAGGAGGATTAGAAG TTCAAGGTTATCTTTAGTCACATAGT ATTGGTAGCCAGCCAGCCTGGAATA CTTGAGATACTTACAGGAAGGAAGG AAGGAAGGAAAGAAGGAGGGAGAG AGGACAGGAGGAAGGAGATAGATAT ACACAGAAAGAGACAGAGAAACAGA GATTCAGGAGACACAAAGACATACG GAGACACAGTGAGA IM000407 CATGTGGTTGCTGGGGATTGAACTC 741 R — AGGACCTCTGGAAGAGCAGTCAATG CTCTTAACCGCTGAGCCATCTCTCC AGCTCCCTTTTAGACTTCTTAGTAG CAGCATTAATTCTTGCTTGGTTTCA GTTCTGACAACCACAGCAGTCAGGA GTTTGAGTAAGAGG IM000408 CCTCATAATGTTTGTTTGAGCATTTTT 742 D — TTAAAACCTAACTTTGTCTTTTGCTTA TCTATTGTGGTTTTTTAGTGTGTGTGT GTGTGTGTGTGTATGCGCGCGTGTG CTCTGGTCTTCGTGCACATG IM000409 ATTTGTGACATCTTAGGAGCTTAGGTT 743 K Fgf3/Fg GGTCTTCGAGACACAGGGCTGTCCCTG f4 TAAAGCAGGTTCCATCAGTGACTCCAG GGTTTTAGCAGTTCAGTGGCGTAGTTT TCAGACTGCTTAAGATTTCTCAAGGGC TAGGCGTGGGGCAGAGACCCTGCAGAC CCTGGCTAGAACAGANGCCCTGGGAGA CAGTTGAGGGTGCTCAACTGTGGAGGA CATG IM000410 CATGTATGCACAACCAAAACTTATAA 744 D — ATATGAGAATTCACTTATAGTCCTAG TCCTTTAATACAGAATTTAGCATTCC GATATAAAACAACAGATTAAACCCCA ACAGTTAGAATAGAGCAG IM000411 AATAGGAGTAGATGAGAATGAAGATT 745 R — TTCAACTTAAAGGGCCAGCAAATATC TTCAACAAAATAATAGAAGAAAACTT CCCCAACCTAAAGAAAGAGATGCCCA TG IM000412 CATGCACACCCTACTCCTGGGTGATC 746 K Wnt1 GTACCAGCTCCAGCCTCTGTTCTGCA CGCTGTGCCTTCAACCTGGCAACCTCC IM000413 CATGAAAACCTGTCTCAGAAAACAAA 747 D — AAACACGTTGAGAGCCAGCATAGAAG CCATAGGAGGTAATGTGTGTGTGTCT GTATATATGACAAGAGCAGACCTGTG CTGAACCAGTTAACTACTTTTG IM000414 CATGCTACTAACCAGTTGAGGCAGTA 748 R — CCAGTTGTTGAAGATGCTGTCTTTTA TCCAATGGATGGTTTTAGCTCCTTTG TCTAAGATCAGGTGATCATAGGGTGT GAGTTTATTTCTGGGTCTTCAGTTAT ATTCCATTGATCTACTGGCCTGTAAT TGTACCAATAC IM000415 GGTTAGGAATTCTGGACAGTTGGTAC 749 C — TTGGTTTGAATATAGTAGGTGACAAG CTGTGCCTTGTAGTGGGGTGGCAAGC AGGGTTCTCTGCAGCAGGATGCAGTG TACATG IM000416 CATGAAAATGTTAAGTCCTGACAGAC 750 D — AGGGTGCCATCTGCCAAGAATTTGAG TAATCTAGAAACAGAAAT IM000417 CATGGGGTTTTGTGGATCTG 751 D — IM000418 CAGAACAAATAAGCTGGAAAGGATGA 752 D — AGCAGCCACAACATAACTGCTGTTGG CTTCTATGTGTACATTTTAAACCTTC CTCTGAAAGAGTGACCAATGCTTTTA ACTGCTGAGTTATCTCACCCGACTTA CTTTCTCTCTCTCTCTCTCTTTTCCT TCTTCCTAAAATTAATTGTGTGTGTA TGTGTGTGTGTGTGTATGATTCAGAA ACCTTTTATGTGGTGGTAGAAGACCA TCTGCAGGATTCATG IM000419 CATGGTCCCACAAGCCTAGAATGATT 753 D — CGTGGAT IM000420 GGGGTCCAGGAGAGAAACTTGAGTC 754 D — ATG IM000421 GGAAAGAGATACTCAAGACCAACTTT 755 D — ACCACCTTTCATTTAGCCAGGACTGC TCTATTCTTCCTATTACTGCTAAGAA ACAAGATTCCTTGTTTCTTGAGATAA GAAACGGGCATAACATCCTATCTGGT GCCATACTCACCAGACCATG IM000422 GTCCTTCCCAAAGAATAGTGTTAACT 756 D — GAGCTCTTTGGGTGGCAATAAATGAA TTGCTCTGGTGGGACAGGCAGTGCAC ATATGGGGAGGGGGAGACACATG IM000423 CATGTTCTTACTTCTTGTTG 757 D — IM000424 GGGTATATGAATTATATATATATGTG 758 D — TGTATATATGTATACAGGCATG IM000425 CATGCGCCCTAAGACTCATCTCCACG 759 R — AATGACGTGACGACCTAATTGCATTC CTTCTAACCCACTGATTAGGCAAACC ACCCTCCAAAGGGCTCGCTGAGTTCC TCTTCGGGAAGAGGTGTGTTGAGTAC GCTGGAATGGATATTCGAGGGCTGAGG IM000426 CATCTCTCGAGCCCTTGCCCAGCCTT 760 D — TTTTCTTAAAATTGTATTTTTAAAAT TTATTTTCTGTACACAGGTGTGTGAG TGTGAACATG IM000427 CATGTGGACCTGGGGGCTAAGTCAGG 761 K Fgf3/Fg GTGAAGCTTCCACAGCTAAGTGGCTG f4 GAGGCTGCCCTAAAAGCTCAGGAGGC ACCGCAAGCAAGCCTTGAAAAACCTT ACCCACCAGCTTGACCTTAGACTTCT GGCCTTCAGGCTGTGACAATACATTC CTGCTGTTTAAAGAACCATATGGTTG GTGATGTTTTGTTTGTTTCTGGTTCT TTTGTGTTGGTGTTTTTTGTTTGCGG GGTGTGTGTGTGTGTGTGTGTGTGTG TGTGTGTGTGTGTGTTGCAGTGCTAG AGATAAGATCTGA IM000428 GTCTAAAGTTTTCAAATGATGGATAA 762 C — GTTGTTAAACCTCCTTTAAGATCTCA AGCACAAAAAGAAAGACATCAAATAC GAATAGTAGAAAGGAAAGGAGATTTG GAACTAGAGGCCCCAAGAGTCATAAA GAGAAGAATTTAAACAACTGTACCCA CAAATTCATTAGCATAGATCAAGTAG TCCATTTCTTCATG IM000429 CATGTATGTTCTCGATGCCTTGGCCT 763 D — G IM000430 AAAGACATTAACTCTTGAGAACCAAG 764 D — GGGTAGGACAGTATAGACTGAATTTT GCCTCCCCTCTTCATAAGTTGTCACT GCTAACCTCATTTCAGAACTTAAGCA TATAACCTTCATG IM000431 CATGGAGAACTAGCAAGAGCAGGATG 765 D — GCGTTTCTCTAGAATGCCGTATAG IM000432 CATGGTGACTTTCCATCTTTAGAACC 766 D — ATAATCANGTTTAAT IM000433 CATGCTTATATCCCTCAAAAATTTTA 767 D — CAGTTAAACTGAAAATGCTTACTTAC TTTTTTTCTTACTTATATCTAGTATC GATAAGAACTGTCCCAAAGGACAC IM000434 CTGGGTCTTAGTCCTCTGAGGTCCCT 768 K Fgf3/Fg AGCACATCAGAGGTTCATCAGTTCCA f4 AGAGATGACACAGCCGCAGTCATG IM000435 CATGGAGAATGCACAGTCAAAACGCT 769 D — TGCATCCT IM000436 CACCCCCTCCCGCCTTACATCAATC 770 K Fgf3/Fg CTGGGTGCACAATGGGACTGTGGAT f4 GACTGATGTCTGCGCAAACAACTTG CGGGGAAGTCTAGCTGACAAACGCT CATG IM000437 ATGTATCCAATGGCAAAGCACGGGG 771 D — GAGGCTTCATCTTGAAGAGAAGAGT GCTCTTGGTAGGCTATCCTTTTTTT GAGACAACTAGAAATAGGAGCATTT CAACAATCTGGACATATGTCCTCCC ACAAGAACTTGTTGAGAATGGGTCT GAATTAACTGGAAATAAAAGTGAAC ACATTCTCCTATACACATG IM000438 TCACTCCATTTTAGTTCAAATGCTAC 772 C — AACTCCTTTGAGCACCACTGTCATTT CAAGACCTTATTCTGTGAATACCATG IM000439 CATGCTTAGCCCAGGGAATGACACTA 773 R — TTCGAGGTGTGGCCTTATTGGAGCAG GTGTGGCCTTGTTGGAAGAAGTGTGT CACTCACTGTTGGGGTGGGATTTGAG AGCTTCCTCCTAGCTGCTTGAGGATG CCGGTCTT IM000440 CATGAGCTGGGTGAACGACAGCAAAG 774 B AATTT.202 GTTTGTTTCTCTTTTAAGGAAGACAA 45 TGGTGTGAAATTGGTTGATCCTTTGG GGGAAATGTTGGCCCCTT IM000441 CATGATCTCACTGTGAGGGCTGGCTA 775 D — CCTTGGAGCTCACTGTACTGAATATT CTGGCCGATTGCCTCTTCGCTGGGTT TATGGGCACACACAGTACTTGTCTAT GAGTCTTTGTTAGGCTGAGCCTAGTG GTGCAGGCCTGTCATCTCCCCTACTT TACTTTAGGCTCTGAGGCAGGAGGAT IM000442 TCTGGTAACTTGGGGGTCTGATAAAA 776 D — CAGTTGGGGGATTTCTTTTCTTTTCG CGTCTGAAGCCAATGTTATTACAGGT GTGTGCTTGTCTCTCCCACACCCTGC CCCTGTTGCCTAACACACGCGGCACA CACATG IM000443 CATGACTCTTCCTCCAGAGTTAGAGG 777 D — TGGAGCCAGGACAAACTCTAAAGAAA AGAAACCCCAATCAAAAAGGGAAGCT GGTATCATCCAACCTTTAAATTACTC CACATCCCTCCAGAG IM000444 CATGTCTGTCCCAAAAGGAAGTTCCT 778 D — TCCTCTGTCCTCCACATCTGACCAGC ACCATCATTCAATCTGCAACCCAAAC CAGACATTTACATCATCTATGCCTCC TTTCCTGCTTGTCTCCCCTCAACCAG CACCCAGCAAGCTTTCAGGTATCCCC TTAGTGTTGTCAGGATCTCTCCAGTT CTCCAGACCCCAATTCTGTTCTCACT CTACACTGCTAGC IM000445 AAAGCTAACTTCTCATCACCTACCTA 779 C — ATAGCCTGAGAGCCCTGTGTAGAAAA ATTAAGGAGTTTAGTTCCTTCATG IM000446 CATGCAGACAAAGTAAATAAGAAAAC 780 D — AAATTAAATGTAGGCTGGACGGATAG ATGGT IM000447 CTCAGCTCCTAGGCAACACTTGTAGA 781 K Wnt1 CCCACAGCCCCTTCACACACACACAC ACACACACACACACACACACACACAC GGCTGGGGATCCAACCCATCTCGTCC TTACACGTGCTCTACCATCACACCAC ACATTTCCAGCACTTTTATCTGAAGT GTTTCCTTTTATTTGTGCATG IM000448 CATAACCACTATAACCAGCCTGCTTA 782 C — CTTGGCTTTGTTTCGAGGGCTTTTGT TTTAGAGCTCTTTGTTTTTACCCTTC TCCGTGTGTGTGTGTGTGTGTGTGTG TGTGTGTGTGTGTGTGTCTGTCTGTC TGTCTGTCTGTCTGTCTTAGTGTTTG TACATG IM000449 CATGTGGTCCACGGTTTTACTTTACT 783 C — AGGGAGCTACCTGTACCACAGGGAGA GAGGCCTAAGGACAGGAAAGGAGCTG ACCCAGAACTGAAAAGGCACACACCA TTCTGCCAGCACTTCCC IM000450 CATGTCCTACAGTGGACATTTCTAAA 784 R — TTTCCCTTCTTTTTCAGTTTTCCTCG CCATATTTCACGTCCTAAAGTGTGTA TCTCTCATTTTCCGTTATTTTCAGGT ATCTCGCCATATTCCAGTTCCTACAG TGTGCATTTCTCATTCTTCACGTTTT TCAGTGATTTCGTCATTTATCAAGTC GTCAAGTGAATTTTTTCATTTTCTCT GATTTTCAGTTTTCTCGCC IM000451 CATGTTGCCTCAAGACAGATCTCCAC 785 R — TAAAGACATACCTAAAGGCCTGGAAG CTTAGTCAATTAAGCTTTCCTGCCCA GACACTCCTCCCTGAAAAAGGTATTT AACCTCAGGCCCACCCTGAGAAGTGG GGTATGATTTTACTCATCCACTTTC IM000452 CATGGTTTCTATTACTGTGTTGAAGC 786 R — ACCCTGACCAAAGCCAATTGGGGGAC GAAAGGGTATTTGGCTTAAACTTCCA AATCAGTGTTTATCATTAAAGGAAGT CAGGGTAG IM000453 GCAAGTGTCAGACGGCTCTCAGGGAG 787 D — ATACACATAGCTTTATTGGATAACTG CAGCTTGAAGACATG IM000454 CATGTACCTATGTGTGTGTAACATTT 788 D — GCCTATTTTCACACAGTTAAGAAAGC ATCGTTATGAAAATCATTACAACTTT CCAGATAAACAGATCCACTCAGCCAC AGAT IM000455 GCCCTTCTCTCTGAACTTTTCAGTTC 789 D — CTGGATAAAGTCAGTGTTCCACCTCT ATACCTGACTAGTTTTCCTAAATTCT GAGTCAAGCATATTTCATG IM000456 GACCTCGTGGGCGGGCCTGAGGAGAC 790 D — AGTGCAGATGAGGTGTCAGTAAGGAG GATGCAAGCAAGAAAGATGCAGGAGA TGATGGAGAAGCTGAAGAAGGCACTG AAGAAGGCACAGGGAAGAAGAGTGCA TG IM000457 CTTGCCGTTGAGAGCGTCCAGATCCC 791 C — CTGACTTGAGTGGGTCCACCTTGTTT GGTTTGGTTCGCAGTGTCGGCTGTGG AGCCCCAGGCCTTGCATG IM000458 TTCTTATCCACTGAGCCACACTGCTA 792 D — ATACTGTGATGTCTTTTTTAAGACTC ACCATG IM000459 GGGTTCAACACATTTTTGGAGATTGA 793 D — TCAAAATTAAAACATG IM000460 CATGAAGGAGAGTCTGAGGCTACATC 794 C — CACCAGGCTCTATGATCTCCCTCTGC TGCATCCAGGACATTCTCCTTCTGGA TGAAGATGATGCTGGCGCTGGCGCTG GCGCTGACGCTGATGCTGCTCGCTTC TGCGTCCT IM000461 CCTTGTCCTCAAATTACAAAACTCCC 795 B AT4269 TAGGGTCTTTTCTCTGGGCTACAAAA 08 TTCTGCAAATGGACTCAGGAGGAAT CAATGTGGAAATTTCACTTTGCCTTC CCAATCAGCAAAATAATGTTTGCCAA AATCGTTAGATTTCTTTCCCCTAAGT AGGCTACTGCCGACTTGAAAGCAGT GGTTCCAGAACCCGAGCCCAGGGG CTGCCACTTCCTATGCATG IM000462 CCCTTGTCCTCAAATTACAAACTTCC 796 D — TTAGGGTTTTTTTTTTGGCTNCAAAAT TTTNCAAAGGGCTTCAGGAGGAATA ATGGTGGGAAATTTACTTTTGCTTTC CAATCAACAAAAAAATGGTTGGCCAA ATCGGTAGAATTCTTTCCCTAAATAA GCTACTGCCGACTTGAAAGCAGTGG GTTCAGAACCCGACCCAAGGGCTGC CCTTTCTATGCATG IM000463 CATGTATCTTAAGAACAGAGCCAGTG 797 D — CTCTCCCTCTCCCACTTGAT IM000464 CATGCAGANTAAAGTACATATATGTA 798 D — AAAAATTAAAATAAATCTTT IM000465 GTGCTCTCCCTTGCCTCTCCTCTCCT 799 K Fgf3/Fg GAGTTTCTCTGTAGGTGTAAGGGCT f4 GGAGGTGGGCCCAAGAACCAGAGAT CAGAGGAGGGAACTTCCGGAGCAGA GGCCCTGGGAGCAGTGTTAAGCAGG CTTTGGCCAGGTCTGGAGGTGTCCA GGCAGGGAGGTGGAGCTGGAAGAG ACCAATTAGTCAAACGGCTGCAATTG GCCATTTGGAAGCAATTAACAGGGT CTCCATTACCATATTATGCCCCTCCA CCCCCTCCACACTCTACTAGGCTCT GCTCTGTATGGAAGGGGGAAGGTGG AGGCTCANCTCAAGCCAGGGAGACT ACAATGGAGGCCCAGTGCTCGCCAG GATGCACACACTCAGGCACCCTCCG TGTGAGGAGGGGAGGGCAGGGCAG CATCTGAAGCAACCTGTCATTCACAG CCTGANAGANGGTGGGAACAANGGC TTNCAAAGCCAAGAANGCANGTGGN TAGAAATGCANGAAAACCTCTCTGGT AAGAAAGGCTGAANGAAGCAGCTAG GGTTGTAAAACAAGANCAT IM000466 CTCCCTCTCCCTCTAGCTGGCCTAGC 800 B Al5500 AGGGGCCAATACAACTGCAGGGAATC AAGGAAGAGCCTTTTCCTGAACTGTC CTGGATGCCCCAGTCCAACAGCAACT CCCACTTGCCCTGGCTTGGTTTGCTC CACTGTCCTGAAGGCACAGTGTGATA TCCCAGACCTCCAGCGAGACAGCCCA ACCTGCAAGCCCTGATGGGAGGGGTG GCCTGAGACAACAGTACCTACATG IM000467 CATGGACTCCAGGGTCAGGGTGTAAG 801 K Fgf3/Fg AAAAAGGTGGAGCCTGCTAGGTGTGG f4 TGACACACACCTTTAACCCCAGAACT CAGAAAGCTGAGGCAGGTGACTAGCC AGGAGTTCAAGGTCATCTAGTTCATC AGATCTATAGAGTGAAACAGCCAGGC TACATTTGAGATC IM000468 GCTCAACACTTAAAAGCGCCTGCAGA 802 D — GGGGTGGGGGTTTAATTCCCAGCACA CACATAGTGGCTCAGGGAATCTGAAG CCCTCTTCTGGCCACTGCGTGAACTG CATG IM000469 GTGGGAAGCTATACGAAAGTAAAACA 803 D — CACTCTAAGAAAGAGAACAGGCTGCC TGGGAGAGGGAGGTGCCAGGGGCTTA GACAGGAAGGTAGTTTTCAAAAACTG AAAACTTAAGCTATCTGAATGAATGA TACAAAATAAAAGAAGACACAAGAAT TTCCAGTCACCTGAGATATCTCACAC TCCTGTTCTTTCAACCTTCTAGCTGA AAGGAGAAAGAGCCATG IM000470 CATGGAAGGAGTTACAGAGACAATGT 804 R — TTGGAGCTGAGACGAAAGGATGGACC ATCTAGAGACTGCCATATCCAGGGAT CCATCTTATAATCAGCCTCCAAACCC TGACACCATTGCATACACCAGCAAGA TTTTGCTGAAAGGACCCTGATATAGC TGTCTCTTGTGAGGCTATGCTGGGGC CTAGCATACACAGT IM000471 CATGCTTAGATTGACCGCAATATGTG 805 D — TGGTACTCTTCAGACTTTTAAAGATT TGCTGAATATCCTATTCCCCTTAAAT TGTGATCACCCTAGCTAGATCTAATC TTAGATCTCGAAAGTTCTACAATTTG CCTCAATTTGATTACTGTTTTCCTCC TTGAAGAC IM000472 CTTGCCTTGGGAAGTGAGGGGTTCTA 806 K Fgf3/Fg ATGAAGGTTGCAAGCCTGTCCACCCA f4 GGGCCCTGCTAAAGAAGGAATGGTCC CCAGCCTGTTTTGTCCCCTCTGTGGC TTCTTAGTTCTGGACACTGAGCCAGT CTGGGCAGCAGGCAATTCACACTGTG AATTTCTGTGGAAAGCATTTTGGGGG TTCTGAAAGCCCTGTACATTCTGTGT TAAGGACAGAGGGCCTCCTGCATG IM000473 CATGGGGGCTATGTCCTAGGGTAGAC 807 K Fgf3/Fg ACCCCCTTTATCCCTCAGCTCCTTCC f4 CTGTCTTAGCAGTGGTGTCCCCCACT GTGACTCTACTGCATCTGGGAGCTGT CTCCCGGGGGACTTCCTCCTGCTGGA GTGAGTAGGTGGCTAGGGCGAAGCCT GTGTTAGAGGCAGGAGGTGTTTTGCA CAACTCCAAAGGGTGCAGATCCTGCT GGCTCCAGCTTCCCAGGGCCAGACCC CGAAATACCCTTCACCCAGC IM000474 GTGTATGTTCTCTGGTGAAAGTGTTA 808 D — ACCAGCTCACTCCGTGAAGAGCACGC TGCTTTCAGATCAGTGTTCAGAGTCT TGAATAATTGGTTTTTAGAATCATAA AATTGCAGTCCTTTACAAAGGACTGG AAGTGACTCATG IM000475 CATGTGAATTCTCTATTTGCAATGTG 809 D — CTTGGTTCATACTTCCATACTCTACC CAGAGCCTGTTAGAAAAATCACTCTT CCCCACCCTATTCTTCACCAGTCAAT ATGTATCTAGTATTCTAAACTTCCTC CCTCCTAAGGCAGTGGGGAAG IM000476 CATGTGTACTCTCACCATCAGAATTA 810 C — TGAGCAACCCACAATTTCTTCACATT TATAACTGACCCAGTCTGAGGTATTG TGCCTTTAGCAACAGAAACTGAACTC AAAACAATCGGCACAC IM000477 CCATATCAGACCAACCTTCCCACACA 811 D — ACAGTAGGCCACCAGGTGGGGGCAAA GTCCTGGGTAAGGTTCTTGGCACTGT AATTTTGAATCCCAATAATAATGACT GTGTTATTTGCTCATG IM000478 TAAAACCTTTAGGGAGCTGATAAAAA 812 C — TCTATCAAAACAACACTCTGTCTCTC GTATCCAGCCATCCATG IM000479 TCTGCCCAGCCTTTGCTTCCTCCCTG 813 B AAT1177 GTAACAGGATGCTAATTAGAATTCATG 84 IM000480 CATGTAAAAAAAAACTTCATTAACAA 814 D — CTACAACAAAGCAGAGACCTTGGCC CTTGGATTGGGGCCCCTCTGAGAGC TATAGGCTGGGATACTGG IM000481 GTGCGTGATAACCAGGCTGGCAGTGC 815 D — CCTCTGCATCCCACATTGGGAACAGC AGCCTGATACTCCAAGGCTGCCATG IM000482 ATGTCAACATTGAGTCCAGTAAGGAC 816 K Wnt1 ATCGTATATGCTGGTCATTATTATAG CTCTTTAGGGTTCATACATGAGACAG ACCACCCCCTTACCCCCTCCCCCGTC TGGGCTAAAAGCAGACACACTGGGTT GGTGAGAGAGCAGCAG IM000483 CATGAGACAGACCACCCCCTTACCCC 817 K Wnt1 CTCCCCCGTCTGGGCTAAAAGCAGAC ACACTGGGTTGGTGAGAGAGCAGCAG IM000484 CATGAGAAAAATTTGTCTCTAATTCT 818 R — CTTTGTTGAATTTTTGTGTGGTTTTG ATATCAGGTGATTGTGGCCTCATACA ATGAATGTGG IM000485 CCAGTGAAGTAAACCCAGCAGGAGCC 819 D — TTTACAAAGCCAGGACATG IM000486 TCGGGGGAAAGTTATTTTTATACCTT 820 D — CCCGCTCTGGATTAAGGGAGGGTAGG AAAGGATTGGATGAAGCTAGAGACAG AGTGGCAGGAAGGTGGTAGACCTGAA ATTGTCAGACAACCACTTATCGTTGG GAAGGGTATAAGGTGACCACAGCACT AGCAGACTGTTCTGGACGTAGTAAGG AGTTCCTGCAGGGGAGGAGTGGGTCA GCCETTGAATCCCATATGGTGGTTCA CAAGTCAGCCTACATG IM000487 CATGTGTTTTTAGCAACTGTGCTCAT 821 D — TTTCTGCTGCTGCTAGGAATAAAATC AAATCTAGTANAATTGCTTTAATACA AAGTTATTGTCATCCATCTCTGAAGA TCTGAAGTATTGCTGGGGGGTCTCCA ACTCACCCACC IM000488 CAAGGGCCTCTCCTCCCACTGATGGT 822 R — CGACCAGGCCATCCTCTGCTACATAT GCAGCTAGAGACACAGCTCTGGGGGG GGGGTACTGGTTAGTTCATATTGTTG TCCCTCCTATAGGGTTGCAGACCACT AGGTCCCTGGGTACTTTCTCTAGCTC CTTCNTTAGGGGCCCTGTGTTCCATC CTATAGATGACTGTGAGCTTCTTATA AGCATAAACTTTCACTTACCACATG IM000489 CATGGTGTTAGCCTCCAGGCAGGAAG 823 D — CATACCAGAGGAGAACTCCACAGGGA AGCCTTTGTTTTCTGCTGTTAAAAAC AAAGTATGATGGGGCTTAGAAGAGGC TTTAAGAGGTCCTCTGGAGAAAAGAA TCTATTTTCCATT IM000490 CATGAGAGGTTTTTAAGTCCTGAAAG 824 D — ACCATCATACCTAGAGTCTATACAAC AAATAAACTTGGTATACAGTGAAGCT AGTAAAAATAACTTCCTGAGCTTATGG IM000491 CACAGTCAGGAAGCAGTTGATGAACG 825 K Fgf3/Fg TTGACTCTCAGCTCTCCTTCTCCCTT f4 TAGTTCTATGGAGGTCTCCAGCCCATG IM000492 CATGATAAAAGTCTTGGAAAGATCAA 826 R — GAATTCAAGGCCCATAAATAAACATA GTACAAGCAATATACAGCAAACACAG TAGCCAACATCAAACTAAATAGAGAG AAACTTGAAACAATCCCACTAAAATC AGGGACTAGACAAAGTTGCCCACTCT CTCTTTAACTGTTCAATAGAGTACTC AAAATCCTAGC IM000493 CATGGTAGCTTTCTAGTGAGGTCTCT 827 D — TCC IM000494 AGTACCCTTAGCCTATAAACCATCCC 828 K Fgf3/Fg TCTAGTCCCTGTTTGTTTTGTTTTTT f4 TTTTAAAGACAGGGTCTCACCATG IM000495 CATGAGCTAGGCCATCTGCAAGCTGG 829 D — TCTCGTCTTGACCAGGAGTACACAGA AGCCTGGCTCAGGACTTGGTAAC IM000496 GTTGTTTATGCAGATCTCTCAGCGTT 830 D — AGCATTCTATGGGATTCTTTGGAAAG ACCTTTTCAGTTATCTTCCATTTCTG AGGCTGTTTCTAGGCAACGGAGTGGT ACCTTCCTTTAATCTTCCCCTGACCT TTTCTGCCTATGAAGATGTTGACTAG TGAGCCCGTGGGGATGTGTATTATCT GTTACATTTATTTATGGCTTGGTAGC GACTCCTTGGTTGTTGTTCAGCTTTT CATG IM000497 CATGCCTCCCTCAGCCTCCTCCCAC 831 K Wnt1 CCCTTCCTGTCCTGCCTCCTCATCAC TGTGTAAATAATTTGCACCGAAATGT GGCCGCAGAGCCACGCGTTCGGTTA TGTAAATAAAACTATTTATTGTGCTG GGTTC IM000498 TCTAAGTCCAGTCTTTCACACACACT 832 D — GACTTTGGTCATCTGTAATCACAACA TG IM000499 CATGCACACAAACTGGCCCTGAACTT 833 K Fgf3/Fg TTGACTTCCAGGCCTCTGCCTCTCTG f4 CGCGCACACACACACTCGCACTCCTG TATATGAAGCGTATATGTGTTTCTCT GGGAACTGTTTTTATCAGGTGAAG IM000500 GGGCTGAAGGAAAATGTTGTGTCAT 834 D — CTTTTGTGGCATG IM000501 CATGTACCACTTTTGCTAATCCCCTA 835 D — ACCGCCCCTTGGTAAGCATCTAAAG TGATATATCTCTTGGTCTACTGAAGT TCTGCCCTGTCTCCATCGGGGATTC TCGGGAGGCTAAAATTATAGACTATT TGTGAAAG IM000502 CATGTCCTTATGATATGGAAAAA 836 D — IM000503 CATGTGCCAAGAGCCATTACAGGCT 837 D — CAGACTAACATCTGCCTGTAAACAAC GGTTGCTAAGTTTCCAGGGAAGCGT AAG IM000504 CCAGATGACCTTGAACTCAGAGATCT 838 R — CCTTGCCTTAGCCTCCTGGGATTCAT AGCCGCTATGCCTCAAGATCTCCATG IM000505 CATGTAGTTTGCAAACAAGACATCCC 839 D — TGGTATATCCAGAACCTGAGCTATGC IM000506 GGATATAGTGTCAAACAGTCTGATGT 840 D — ATTCATAGGTTTGTATCCATAGTTAT CAAATCTCTCATG IM000507 CATGTACCACACACAGACTTGGTAAT 841 D — AAGTTAGATGATAATTACAAAAGCAA CAAATAAAACCAACAAAACAAAACAA AGCTTGGTAATA IM000508 GTTAGGAGCACGAACTGCTGTTTCAG 842 R — AGGACCTGGGTTTAATTCCCAACACT CACATG IM000509 CATGGTCAATGATAAACATTCCAAAA 843 D — CACCAAAACCATCCTCTCTGTACAGG CTATGATGATTCAACTGCTGCCCTTC CTCATTTCTTGTTCCCAACTCCTACT GAATATTTCCTGCAT IM000510 CATGATAGAAGACCACGTCTGGGATG 844 D — GGGTAAGGGTTTCTCAGAGTACCTTG CCCTGGGGCCACATCCTAAATCTACA ACAAAGCTGACCCTA IM000511 CAAGTTTTTGTAAGGGAGCTAAGAAA 845 D — GGCATTGTTGGTTAGGTTGGAAAGAG GGGGCAGGACCTGGCTCTCGCTTCAG CCCACTCCCCTCTGCCCCCCAGCCTC AAACACTTTTACCCTAGCATAGCAGA AACATG IM000512 CATGAACTCAGTGGGCAGATGAAGAG 846 K Fgf3/Fg TTTTTGTGTGAACTGGGGCTTTGCCC f4 TTATCATCCTGTGTGTTCTCCTGGTG ACCCTCAAGCTTGGCTGCAATGATCC CCACTTACAGAT IM000513 GTTTATTACTCCAATGATTCGCACAG 847 R — CCGGGTTGCAAGTCTAAGGCAGGCTG TCTGCCTTCCTGGAGGTACTTACCCC ACCTCCCCCTCTGGGGGAGCTCCACT TGGCCATG IM000514 CATGATTTTCAGTTTTCTTGCCATAT 848 R — TCCACGTTCTACAGTAGACATTTCTA AATTTTCCAACTTTTTCAGTTTTCCT CGCCATATTTCACGTCCTAAAGTGTG AATTTCTCATTTTCCGTGATTTTCAG TTTTCTCGCCATATTCCAGGTC IM000515 GTAACCACTCATTTACCTGCCCCAAT 849 D — GATGTCTGGGCCAAGGCACTTTTAAA TTCATATCTACTGTGACTATAGGTGC CCATG IM000516 CATGACACTGCTCACTGTTGCTCTCT 850 D — AACCTTGGTCCAG IM000517 GNGCTTGGCAGAGTAGAGAAACTCTT 851 C — TGGGAAACTTGGTTCAGATCCAGACA TG IM000518 CACCTCTGCCTCAGTTTCCCTGATTA 852 D — TCAACAAGTGCTCATG IM000519 CATGTAACTCAAGAAAGTCTAGTAGG 853 R — CGTAGTGGTAAATGCCTGATCCCAGC ACTTGGGAGGTAGAGGCAGGTGGGAT CTCTACAAATTCAAGACTGGTCTGGT CTATATAGTGAGTTCCAGGCCAAGCT TCACATTGAAATTCATCTCAAAACAA TAAAAATAGAGGAAGATATAGTCAGG CAC IM000520 GAAGACATTCATTTTTTTCTTGGGAG 854 D — GGGATAGAATCCAAGGCTCCAAAGCA GAGTTCATG IM000521 GACCACGCTGGCCTCGAACTCAGAAA 855 R — TCTGCCTGCCTCTGCCTCCCAAGTGC TGGGATTAAAGGCTGTGCCACCACTG TGCTTACTGATCTCTTTGATGTCCCA GTTATAGCTCTTGGGTTCCCCACCCA TTTGTAGGGGGACCCAGGACACCTCA GAGCTCTCCCAAGTCTAAAAAGGGCA GGGTTCCTGGCTCCCTTAATGCCTTA TCAAGCACAACAGAACTCAGGGGCAG AAAATGTTCCCAGGAAGAACTTAGCT GTGGGGAGAGTCATG IM000522 CATTTTTCTTTATAGCTGAGTGTTAT 856 D — TCCACTGCAAAAATTTGAATATTCCA CTATTCTGTTGATGAATGTCTAGGCT GGTCACGTTCTCTTGCCTTTGTGAAT GGAGCAGCAATAAACATAAGTGGGCA TG IM000523 CTCCATTGGGCCGAGTGAAGCTGTGG 857 D — TTCAGAGAAACTCTATGGACAAGCTT GACTTCCAGAACATTGACCTGGTCTC TGAGATCAACAAGCGTAGGAAAGCCA TG IM000524 CATGGGAAAGTAATCCGTGGCTAACA 858 D — CAAAGGGGAAATAAAGTAATATT IM000525 CATGTAGGACCCTGAATGCCAGCAAT 859 D — GAACAATACCAGCTTGGTTTTCCGAC TCTTGCTTTCTCCTCCCTCCACTACT AACTAGCCTCACCGTTGCATCTTGTG ACTCAGAGGTCTTGTTTCCAGGGCTT CCTTCCTTCCAGTGTTCTTCTAATGC ATCTAAAGTGAAGGGGTGG IM000526 CATGCAAAGCCTCTGCAGGGCCGACA 860 D — GCAAGGAAGGCCCTTCTAGATCTCCA GCACTCTGTCAAAAGCCATCACTCGG CAGGCAGGCAACCACAATGTAGGGAA GACCTGTAAAGCCTTCAGAGAGGAAC AGCTGGCAGCCCCTGGGTCACTCAGA GTGGCCAACAGCTACTCTTGTGGAGA CAGCAGGAGGAGGCCTAGACTATAGA AGGATGGAGGAC IM000527 CATGCACACAAACTGGCCCTGAACTT 861 K Fgf3/Fg TTGACTTCCAGGCCTCTGCCTCTCTG f4 CGCTCACACACACACTCGCACTCCTG TATATGAAGCGTATATGTGTTTCTCT GGG IM000528 CATGAAACATTATTTNTTTTGGAAGT 862 R — CTGCAGGTAAACTTAAATAGGTTAA IM000529 AGCAAGAACAAAGGAAGTACTTCAGC 863 K Fgf3/Fg TGATAAAAACAGTTCCCAGAGAAACA f4 CATATACGCTTCATATACAGGAGTGC GAGTGTGTGTGTGAGCGCAGAGAGGC AGAGGCCTGGAAGTCAAAAGTTCAGG GCCAGTTTGTGTGCATG IM000530 GATTTTTATTTCCTTAGCATCCTGAT 864 K Fgf3/Fg TGGAGATGGCTGGGTGCACATG f4 IM000531 CATGTAGAGACTGCCATATCCAGGGA 865 R — TCCACCCCATAATCAGCATCCAAACA CTGACACGATTGCATACACTAGCAAG ATTTTATTGAAAGGACGCAGATGTAG IM000532 GACCTGTACCCTACCCTCTGATGGAG 866 D — GCCATCTATTTGCCTGTCCCCAGGAG TCCCCAAACTGCTCAAAGAACAGACT GTGGGCTCTGGAAAGCTAGCAGGTGA CCCCGGGGGATGTTCTGAGCAGTGCC TTACTGAAGTTTATCCAGGCCCTAGG GTCCCCTCAACTGCTCACACAGCCTA GGGTGGGTCTCTTGAGGAGTCACTTG TCACTTCTGTTGCTTCCCAAGAGACC CAGGGAAAAAAGGAAGGAAGGCCATG IM000533 ATCTCACTCGTAAAATGAACAAAGGG 867 K Fgf3/Fg ACTGCAGAGATGGCTCTGAGCTTTTA f4 AGACCATAGCCTGCTTTTCCAGAGAG CCCAGGCTTCATTTCCCAGCCCACAT ATGGCAGTTCACAACCATCTACAACT CTAGTTCCTGGGGATCTCACACTTTT GTCTTCTGTGGGCACTGCGCAAATGT GCACAGAAATACACGCAAGGAAAACA CCCATG IM000534 AAGAAACACTCTTAGCTGGGCCTGGA 868 D — AGTGCACATG IM000535 CTAAAGCAGATTATTATACTTATTCT 869 D — ACTGACCATAATGCAACCACTATTAT ATAAACAGAACATACTATAAAGTGAA TAACATTAGGATACAAAATGTATAAA AGGGGAGAGAGGATAACCATTGTGAA GTATGTTTAAATAAAATGTTTGGGAT TTGAGGAAATTAATAAATTAGTTACC CTTTTTGCTTTGGGGAAAGAAAGGCA GCATG IM000536 CAGCCCCAAACCCATCAGCCTGAGAC 870 D — TGATGCACAGGAGGCAGGCCAGTTAG TTATTCTCTGGGCCCCTCTATTTTGC CTTCTGTAGGTTAATCCCACCGCTCC CAGTGCTGGAAAGTGCAAGCATTGTG GGAAGTTAAAAACGTGCCACCATG IM000537 CATGGACAATGCACCCCTCAAGCAGT 871 K Fgf3/Fg GTCTTCCATACAGACAAGCATATTTA f4 TTTTCTATACAGACAGCAACTTTGCT GAGGTGTAAGG IM000538 GGATGAAGAAGCCCAAGGTATTAGGT 872 D — CAGTCTTGCTCTGACTTCTCACAGTA AAAATACAACTCCCAGGGACTAAAAT GACACAGAACAGCTTAGCCTCTGGAC ATTGCTTTTGGATTGCAAAGTGATAA GTGAAAAAGTAATAAGTCTATCTACA TTGGAAAACATTTGGTAACTTCATTT AAACACACTTCCCCATG IM000539 CATGTCCTACATTGGACATTTCTAAA 873 R — TTTTCCATCTTTTTCAGTTTTCCTCAC CATATTTCACGTCCTAAAGTGTGTAT TTCTCACGTGTATTCGTTGGTTGTTG GTTTAGTTCCTGGGAGCTCTGGAAAT CTGATTATT IM000540 TGGAAAATGAGAAACATCCACTTGAC 874 R — GACTTGAAAAATGACGAAATCACTAA AAAACGTGAAAAATGAGAAATGCACA CTGAGGGACCTGGAATATGGCGAGAA AACTGAAAATCACGGAAAATGAGAAA TACACACTTTAGGACGTGTAATATGT CGAGGAAAACTGAAAAGGGTGGAGAA TAGAAATGTCCACTGTAGGACGTGGA ATATGGCAAGAAAACTGAAAATCATG IM000541 TGACATACAGAAAGAACACAAATACC 875 C — TGTAGCTGCTGTGACAGGACCAACCA TTCTAAATATCAAAGCAGCTGTTGAC ACCTAAGGACTGGTCTGACTGCTAGA TCTAGGAGTTTCTTACTTGCAAAAGC TGGCTTGATGCTCATG IM000542 TTATATATATATATCGTTTTCTCTTA 876 D — CTCCTGAATCAGTGACATG IM000543 CATGTCAGCCCTCAGCTTTACACAGG 877 D — TGTCAAAAAAAAAAAAAAACACTGAC TGAGATCTTCCGTCTGCCATTAGCTG TTATTGTGTACATTAAGTAGAATCCA CTGCTTAACCCAGGCTACTGGGCTCA CCCCAGTATTCAAGGAGGTGCCACAG GAACTCAAAGGATACAGAAGTTACAT ATTAAAACCCAATCTCGTAGAGGATTC AGAGGAACTAAGTTTGGTAGGGGCAC AGATTGTAGTACCATTAAGCCCCTCT GTTCCTCGTGGAGAACCACTACTGTC CAGCTAGGCGGGAAGGACCCAAATCA AGCAAATGAGACTTGTTCTGG IM000544 CATGATANATCCCTTTTTGTGAGCAT 878 D — TCCATAGCCTCAGTAATAGTGTCTGA CCTTGGGACCACGCTGTATCCCACT NTGGGACCTTCTTTTCNTCAGGCTAC TCTCCATTTCCATTNCTGTAATTCTTT CAACAGAAACATTTATGGGTCANAG GTGTGACTGTGGGAGGACAACCCCA TCCCTCACTTGATGTCCTGTCTTCCT GCTGGAGGTGGGCTTTATAAGTTCC CTNCCCCTACTGNCCAGCATTTCATC AAAGATCCCTCCCTAGGAATCCTGG GAACCTCTC IM000545 GATAAGCTTATCTTGAACTTGAATGT 879 D — ATATGGAGAAGCAGAAACCTTGAAAC AGCCCACAGAAACTGAAGAAGGATGA AGGTGGAACTCTCAGCTGGAATATTC ATG IM000546 CATGTTCCCAGCTGGGCAAGGCCTCG 880 B Al4132 GGTTCCTCGGTGAAGAGTGTGGACCA 88 GCCGATGAGCCCTCCGACGTGTGGAT GAAACGGGTGGCTTTTGTTTAGTTTT GTTTTAACCTCCCCAACGAGACTTTG ATCAGCTCCACCTCGAAAATGTTCGC GAAAGATGCGGAGAGCCTGAGGGACT GCGGGGCAGCAACGGGCTCCGGCCTA GCCCGGCCCGCCGGCCCCCAGA IM000547 ACCAAGTGTTAATAATGTACTGATGG 881 C — CTTCTGCCTGTGGCAGTACACTTGTC CTCTACACATG IM000548 CCTTACTGCAGAGATGACTCGGCCAA 882 D — CGGCTTCGAGCCCCTGACCACTTCCT CAGGTTTGGTTTTGTTAGTTTTTTCT CACAGCAATGGGAAGCATTTATCAAT ACAACTTCCCAGAATGCGACCTGTGA CAAGGCCAATGAGCAGACTCAAGGCT GGGCACATAAAAGCACCAAAAAAAAA AACTCCCTTGCAGTTATTGTTCATG IM000549 GACTGAGCCTGCCTGGGGCCGTAG 883 K Wnt1 GGAAGGGGGGGTTGGACCCTCTGG TATTTGCAGTTACCACTGACAGGGTT TTTCCGAGATGCCAGTGTCAGGGTG TTCGGTGCTGACCCCCCAGGGACCG TGCAGCCCCGATGGCTGTCTCGGTC CTCTCANCTTTTCCGCCACCCCTGG GATATTTCAGGACTCANTCCCCGCAA CAGCTCTGACTGAGGTCAGCTCTGT GACCAGGGNCCCTGTCCCCGGTGT GNNGTGTATTTGCATG IM000550 CATGTAGAAGGCAGAGGACAACCTTC 884 C — AGGGATTATTTCTGCCCTTTCAC IM000551 GTTCCTCCATTCTGCTGCTTCTCCCT 885 K Wnt1 GATACATTGAGTTACAGCAGCCCACG CGTACACACTCTCGCACATG IM000552 CATGCCACCAACAAATAAGTAAGTAA 886 D — AAAAGAAGGAAGGAAGGAAGGAAGGA AAGAAAGAAAACATTTTAAATCTGTA AT IM000553 CGGAGCTTAGGTCTATCATTTAAAGA 887 R — TACAACCAAATAGGCAGAATCATTTC CTGAGGAGCCCATTTTCTTTATCTCA GGTCCTGCAGATTTCTCCCTGGTATT ATCAGGGAGGAGCAGCAGCTGAGCTA TCCTATCTCCTTTACTAATAGAAAAA ACGCCTTTAGGGCTTGAGCACAGGAC CTGTATTTCAGGGGAATGTTGACAAT CCATAACTCCAGGGTGGACTACTAAG CCCTGCAAGGTGAGTGAACCCCGGCC GAGAATAAGGGCCATG IM000554 CATGGCCTGAGAGTTGGAAAGAGTAT 888 D — TGTAAGCAGGGGTTGTTCCAGAAAGT TTAGAATATAGAGACACTATACTCTA TCCAGACTTCTTGGCAGAGGGAGTTC AAATGTAGACTCTGAGCCCCGTCCTG GGGCAGCTTCTTCCACCTGCTTTGGG TAGAAGCAGGCAGACTCTGGGTAGAC TCTGATTCCAAGGCTAAGTAACCCCT GAACCCAGAACAGTGTTTTC IM000555 CCAGATATCATACTGAGTTCGTAGGT 889 D — GGTTTTAATTAATCACGGGCCCCTGG GATG IM000556 TTGGTGATCCAAACCCAAAGAGACAA 890 D — ATGCTGAATGTTCACTCTCATTTTCT GTTCTTAGCTCCAAATCTTCAGATAT GAGTAAGCAACACATAAATTATGAAG GGACCATACTGGGATGTAGGGGGCTT GCATG IM000557 CATGAGCACTGCTCTAGGGACACCT 891 K Wnt-3 CCCATCCCTTCCTAGCACCCCAAAT GCCCCTTCCCATCTCTCCTTCCAGAA GTTGGA IM000558 ATATAGCTGTCTCCTGAGGGCCTATG 892 R — CCAGTGCCTGGCAAATACAGAAGTGG ATGCTCACAATCATCCATTGGACAGA GCACAGAGTCCCCAATGAAGGAGCTA GAGAAAGTACCCAAGGAGCTGAAGGG GTCTGAAGCCCCATAGGAGGAACATC AATATGAACTAACCAGTGCCCCCAGA GTTCCTTAGAACTAAACCACCAATCA AAGAAAACACATG IM000559 CATGATAAGGTTAGAGTTTTGTGAGC 893 D — CTCCTTAACCTTGCTCAGCAAGCGTT GGGCTCTTGGCAGCCGAGCTGCCATC TTTCTCATCCCCGATAGAGCCAGCCG CCCTTGTCGTGTCTTGAATAAGTTAG AGGAGGCATTATAGAGCGGACCTAAA CATTTGCCTTGGAGCCTGAGGGATGG GGATTGGCTGAATGTGAAT IM000560 CAGAACTGTGCTCTTTAGGAAGCCAG 894 D — ACGCTATGCCTTAGGCCCTGTTCCCT CCAGACCTTGCTCTGTGCTACAGTGT AAAAGCGAAGATCATG IM000561 GAGAATTAGTAAAGAGATAACAAAGG 895 D — CGAGAAAGAGAGGCGTGTGAGAGCATG IM000562 GTTTCCAGATTGTCCTAGTAGCTGGG 896 C — CTGCAGGAACAGCCAGCATG IM000563 GGGGGTGGGGGTGGTAAGAGAAGATT 897 D — AATTAGCCTAGCATATATAAGGTTTT GGATTCAATCTTCAACTCCACCCCTT AAAGAATAAATAAACAAGTAGATAGA TTATAGACAGACAGCTAGATGGATAG ACAGATAGCTACATAGATACATAGAT AGATGATAGATAATAGACAGACAGAC AGATAAATGATAGATAGATGATAGGA AGTCCCAGTTAACAAATGGAAATAAA AAGACAAAAGTCCCCTTTGTCCATG IM000564 GTATATGGAATATGGCAAGAAAACTG 898 R — AAAATCATG IM000565 CATGGTAAAGGTCAGGAGTACACCTG 899 B AA1113 TGCTTCTGTGTTCTTCTGTGTTGGCT 54 GACAGCTGGGCAGAAGTGAGTTCAGG AGGNCAACCCATACGATGAGACAAGC CGGGGCAAAGTGGGATATGTGGACCG CAGCACATCAGAAGGGTGTGCCCGAC ATAAAC IM000566 CATGAAGTATATTATTAGAGGGGAAC 900 R — TAGTCTTACTGCTGAGCAGCGTGTTG TCTTCTACAGAGGATGTTTGTGTTCT GGAATTTAAAATTACTTAAAGTAATA GTGTCAATGAAACGTTGTCCGGTGAC TTGCTTCTTTTAAATGATCACTGTTA GACAGGGA IM000567 AATAATCAGATTTCCAGAGCTCCCAG 901 R — GAACTAAACCAACAACCAACGAATAC ACATG IM000568 CATGATTTGATAGGGTTATGGTTCTC 902 R — TGGAATCTAACTTCTTGAGTTCTTTG TGTATATTGGATATTAGCCCTCT IM000569 GCAAATAGTCCTTTGTACCGAACTTC 903 R — CACACACTAATGTAGTGAATTATTTA AAATTTATTCCTTAATCTTTTTTTAA AGTCCAGACTCTATCCCCCTCCTTGT CCACCCTCTGATTGTTCCACATCCCA TACCTCCTTGCCTCATG IM000570 TTCCATCTCTTGTATTCTGTTGCTGA 904 C — TGCTCACATCTATGTTTCCAGATTTC TTTCCTAGTGTTTCTATCTCCACTGT TGCCTCACTGGGTTTTCTTTATTGTG TCCACTTTCCTTTTTAGGTCTTGGAT GGTTTTATTGAATTCCATCACCTGTT TGGTTGTGTTTTCCTGCAATTCTTTA AGGGATTTTTGTGTTTCCTCTTTAAT GTCTTCTACCTGTTTGGTTATGTTTT CCTGTAATTCTTTAAGGGATTTTTGT GTTTCCTCTTTAATGTCTTCTACTTG TTTAGCAGTGTTCTCCTGCATTTCTT TAAGTGAGTTATTTAAGTCCTTCTTG ATGTCCTCTACCATCATCATG IM000571 GATGAGTTTTCTACTTTTTTATAAAA 905 D — TTATATAAAGTCATTTAGTAGAACCT AGCTTTATTTAATTTTACCAATTAAT ATAAGGCCACTGATATTATTGACTTT TGTCACTACAAAATACAGCAATGAAA TAATCTTTCTTCTAGGCTCCTTCCTC ATCAAACTAGTTCTTCAGCTCACATT AATACTTTTTTCAAGTTGTAAGGGAC CTCAGGGACAGGGGGC IM000572 CATGAGCTTATAGTTTCAGTAAGAGA 906 D — GCATAGATAGAATATAGGTGCCTGTG CGCTGGCTCTTTTGGTTGTATTTAAA TCCTTTATCTCTGAGAAGTCGGAACT GTTGGCAACAGACAATATGGTAGCC IM000573 CTGACACAGGTATGCCCAGTCCATAG 907 D — TGTGCAGAGCACAGATGGCCAAGGAT AACTAGGAATGAGACCTACTTAACCC AAACTCCAAACATTATGAAACTTTAA AAAAATGACTTCAGTTGAACTTTGCA GGTAACCACATCATG IM000574 ATTGTGTCCTTTTAACATTCTTGCTT 908 R — TAGTAGAACATCCTCTGACCCGTATC TGATTCAGTGAAAAATTCCTTCACGA GTCTGCCTTAGCAAAACATCCTTTCA CCTGTGTCTGCTTCAGGAAAACACCC CTTCACATG IM000575 CATGTTGGTAACAGATACAACAAGCA 909 D — GACTTAAACTAATAAGAAAACAGCTA TGATTAATATGTTTATAACTTAGCTG AAGAGAATGTATGGAGCTTTGAAGTT AATCTTTTCATATACACAGGAATGCC TTCAAAAAGCATTGCAGCAGATTTCA AAGGATTAAACTCAT IM000576 CATGTGGCGAACCAGCATCACTTTTG 910 D — CTCTTTCCTTACTAACCCAGGACATC CATCATTATTTTTATAGCATCCACCC TAGTAGATATAAGGTGATACCTTATT GTGATTTCATTTGCCTTTCTCTGAAG ATCACTAACAATCAAAATCTGGTTCA TTTTATTTATGAATTCTCATTTGTCT TTTGCTAAATATATGTTCACAATTCT TTTCAATTTAAAAGCAAATTGTTTTG TTAATAATGAGCTAACTTTTCATACA TTGAAG IM000577 TTGCTGTGGGCCTAATTCAAGGCTG 911 B Al6639 ATAGATCACCACAGAAGGACACTGTT 69 TTCCTCCGGGCAGCAGGAAGTACAG GGTAGGGACTCTAGAATCACTGCCC TAGGGCATG IM000578 GTACTTGAAGTTTTAGCTAGAGCAAA 912 R — AAGACAATGGAAGGAGATCAAGGGAA TACAAAGTGGGAAAGAAGTCAGAGTA TCATTATGTCCAGGTGATATGATAGT ATACATAAATGACCCTATAGATTACA CCTAAGACCTCTACAGTGGATAAATA CTAAAATATTTACTACACAGAAATCA CCCCATG IM000579 CATGCAAGGTATGAACTCACTAATAA 913 D — GGGGATA IM000580 CATGGTTCACACTCCATAATATCTTG 914 D — TTCTCACTAATTCCTCTAATCCCATA ATATACACCAATAATTTAACAAGGGA ATTTCTACATTGATTTGTAATAAGGG AGATACTGTGTGAACTTACCCAACAA AAGTCTCCAATAGAAGTGTGGATACC ACAGGAAGTGTTGTGACAACCATTAA AATTTGGGTCTGATAAGAAGATAACC CTTTAAATATATAGATTTATGTAAAG IM000581 CATGGGCTGGGGAAAGGCAGAGAGAA 915 D — GAACATCTGGATTGTTCGTAACTTTG GCTTTAAAATGAGACTTCAATAATAC TTAGACGTACCAGCTTCTCACAGTCA GTTAAAATGTGACACACACACCTCTC AGCAGACTGAATGGGTGAG IM000582 AGAGATGGTTGGGATTTAAGTTACCA 916 D — GGGTAGGGTCACCACAATCAACCCT TGATGCCTTTATAGGAAGAAACATG IM000583 CATGGAAGTCTAAAAGACATTAGGTT 917 C — CTGGATGGAAGAAGAGAAAATTATCT TTAAGTTTTAGAAAAGGGATGATAAA ACAAGTCTTAAATCTTCTCAATTTTG CCATAATTCATTTGAATTAATATTGG TAAATGCTTTGTGTGGTCCCATAAAG TTCAATGTGTTATATCACTAAGTAGT TATGTAAAATTATAAATAGCCTCTAT IM000584 CTTGTGAATTGTTTAACTGTTTTGAA 918 D — AAAGTAGATGTTTTCTCTATTTATTT TTGGGACAATTATCAGAATTTGAAAC AAACTGTGTATCTCTTATTTACTTTC TGCTTAACCCCCATG IM000585 CATGGTTGCTATATTCATTAACACAA 919 D — ATCATTTAAAATCCTTAATGTAAAAT GGGCACATTTTCAAAATTAAAATATA TGAAAACCAATAAAGATAGAAAATTT AGGAAAAAAAATAATCCAAGCAAGAT GTTAACATCCAACCACAGCAGCATAT TAGCAGCAGGACAAAAATAAGGACAA CAACCAAGAAAGGGATTGTGGTTAAT GTATGCCTCATTGGAAGGGATAATAG GATGTAAAAGTGTGACAATAAAGAGA AAAAAATCTCTTTTTTAAATGTAAGT TAAAATAATAAAAATAATTTAAAAAT TGGTGTTCTCAGGGCTGGATAATATT ACTAACAAAACCAGGGAATTATTAAT AAAAAATCTCTTATCAGTTAT IM000586 AACAAGTTTTAAATGGGGCATAGTGG 920 D — ATCACATTTGTGATCCCAGCACTTGG AAGGTAGAAATAGGTAAATTAAGAGT TCAAGGTCATTTCTCAGTTATGTAGT TGTACATTTCTAGCGATGTAGTTGAG TTCAAGGCCATG IM000587 GTCCTCCAATGTGCATTTCTCATTTT 921 R — TCACGTTTTTCAGGGTTTCTCGCCAT ATTCCATG IM000588 AATTGCATTGAATCTGTGGATTTCTA 922 R — TTAACAAGATGGCCATTTTTTTCCTA TGTTAATCGTACTGATCCATCAGGAT GGCAGTCTTTCCATCTTCTGATATCG GCCTCAATTTCTTTCTTCAGGGGCTT GAAGTTATCGCCATG IM000589 GGCTAGGTACTCCTAAACCTTCCTCT 923 D — GCTATCCTAGGCCCAATAGAAAAAAA GTGGCCCATG IM000590 AATAATACTCACTGTACTTTAAAATA 924 D — TTATCTCCTATCTCACTCTAATACTT CTGTGAAAGAAGCAATATCGTCTCTT TGTAGATAAAAATGGCTGAGAAGGGC ACCTTCAAGACACTAAGTGACTAACT CAGACTCAGAAGTTCAGAGACCATG IM000591 CATGCTCTACTATGTTCACAGCAGTC 925 R — TTATTTATAACTTCCAGATACTGGAA GCAACTCAGATGTTCCTCAATGTAAG AATGGATACAGAAAAAATATGGTACA TTTACACAATGGGGTACAACTCAGCT ATTAAGAACAATGAC IM000592 AAAACCCAAGAACAATTAAGCTGTAG 926 C — TTCCCAAGTGTAATTATATTATGGTT GTTTCTGCTTGCTTTATATCCCTATAT ACAATTTATGATTCAAGTATTAGTGG GAATAGACTAATGGCATG IM000593 CATGCCAAGCCTTCTGGTATCACCCT 927 C — AAAGGC IM000594 CATGCTCTTCTCTGCTGTTCTTACTG 928 D — AATTTTTAATAAGAACTATTCCACAC AGCTCGAAAGCACTGCTCAATTAAGA GATATTCCTACCAGGCATCTTTGGAA TCCTGCAAGCACCTCTTCTCTGTTTC CTGATGACCCTCAATTTGGTTGTGTC CAGAGGTTGGTGGGGAGGAGGGGAGG GGAAACGAAGCTTATTTTTTTTTAAT TGCAAGTTCAATTTTACAATGTTCTC GAT IM000595 CATGCTAGGCAAATGCTCCACTGAAT 929 D — GAATTACATTTCCAATCCTTTAGATG CATTTTAAAGAGAAAAGATTGAGTAC TGAAGTTTTGAATAGAATACAGGAAT AAGGGACTAAACATATATATAGCCTT ATATAGAGAAATATTAAGTAAGTAGT AACTTTGCTTGTGTGTGTGTGTGTGT TGCACAC IM000596 CATGCCATTAGTCTATTCCCACTAAT 930 C — ACTTGAATCATAAATTGTATATAGGG ATATAAAGCTAAGCAGAAACAACCAT AATATAATTACACTTGGGAACTACAG CTTAATTGTTCTTGGGTTTT IM000597 CATGCACAGCTGGTGAGTGAGTTGTC 931 D — TTCTGGTACAAAAATCTCCTCACAGG CACATTTACAAGTGCCTATATCTTTG CTAGCTTCAAGAACACAAAGAAGGGA CACACAAAAGCTCTTCTGAGTCTCCT TCTCCTGCTGTTATTTTG IM000598 ATCGTCAAAGTTAGCAAAATTATAAA 932 D — TGTGAAAGTCATG IM000599 CATGAATTATGTTTGTTTTATTTCTTT 933 D — TGTACATCATTCAATGCAGTAATCTA AAGTTTGGGGTCTTGGTCTTATATCT TGGAACTTCAGTGACTTATTGGTTCT AACG IM000600 AGAGACAGTCACAAAAGGGGCCCATT 934 K Fgf3/Fg CTTGTTAAGAATGGGCCAGTGGAGAA f4 GTTCGGGTTAGTGGAGTAGCCTGCCT CAGTTTCCTCCTGTCTTCTGTAGTTA AATGTGTTAATGGTTAACATG IM000601 CATGTAGCATATCTTAGCCAGCAC 935 D — IM000602 CATGTACAGACTATGAACAGGAAATG 936 D — TTTTTGCAATTACTCTGTGCATTAGA ATTTTCTTCAGAAATATAACCATTTT GACAGTTGTAGGTTACACTTTTAAAA TTACAAAATCAATAAAATTGATCTAC AAACCGAGGCCTACAAAACCCTTGCT GGATATTGAAGACGGCATAATATTAAG IM000603 AATTCCCACCACCCACAGGGTGGCTC 937 K Fgf3/Fg CATAACCATCTGTTTACTCCAGTCTG f4 AGGGACTCCAAGGCCCTCTTTTGGCT TGCAAGGGCTTGCACACACACAGCGC ACACATG IM000604 CATGGTGAATGATTGTTTTGATGTGT 938 R — TCTTGGATTTGGTCGAGAATTTTATT GACTATTTTGGCATTAATACTCATAA GGGAAATTGGTCTGAAGTTCTTTCCT TGTTGAGTCTTTATGAGGGTATCAAT ATAATTGTGGATTCATAGAGCAAGTT AGATTGTGTTCCTTCTGTTTATATTT TGTGGAATATTTTGAAGAGTATTGGT ATTAGATGTTCCTTGAAGGTATGATA GAATTCTGAACTAAACCCATATGGTT CTGGATTTTTTTTGGTTGGAAGACCT ATGACTGCTTCTATTTCTTTAGGTGT TATGGGACTGTATAGATGGTTTATCT GAACCAGATTTAACTTTGGTATTTGT TATCTGTTTAGAAAATTGCCCATTTC ATCCATATTTCCCAGTTGTGTTGAGT ATAGGCTTTTGTAGTAGGATATAATG ATTTTTGAATTTCCTCAGTATGTTTT CTTATATCTCCCTTTCCATTTCTGAT TTTGTTAATGTGGATACTATCTCTGT GTCCTCTGTTTAGTCTGGCTAAGGGT TTTTCTATCTTGTTGATTTTCTG IM000605 CATGGGTTAACAGTGGGCCCTAAACT 939 K Wnt1 TGAACTAGAAAACTTAAAGATGCTCA TAGGGAAGAAGAAAAGAGCAGAAAGC TTAGCTTCTAGACAGGGGTAAGGCTT AGAGCTCAATAAAAAAGGAACCCC IM000606 CATGGCCTGTCTCAGTTTACTTCACA 940 K Wnt1 GCTGAACAAGAGGCAGAGAGTGACAG GTAG IM000607 CATGCTCGCCAGTCCCAGAACCTGG 941 D — AAGGCTGAGGCAGGAGGATTAAAAA GCCTTGGGGACACCAGGCTTGGTGG CACCGGTCGTAAATCCAGCACTGGG GAGTTAAGAAGCAAGTGAGTCACAT CTGTGAGTCTGAGGCTATCTTGGTCT ACGTAACCAGCTCTAGTATAGCCAG CCTGGGATACATAGTAACCAGTTCTA GTATAGCCAGCCTGGGATACACAGT AACCAGTTCTAGTATAGCCAGCCTG GGATACACC IM000608 CATATGCGTATTCACATTTGTGTGGG 942 R — AACGTCCTTGGAGAAAGCAGGAGCAG GAGTTACAGACAGTTATAAGCTGCCT GACCTGGGTGCTGGGAAACACCTCAG GTCCTCTGGAAGAGCAGTAAGTCCCC TTAACCAATGAACCATCTATCCGTCC AGCCTACATTTAATTTGTTTTCTTAT TTACTTTGTCTGCATG IM000609 CACACACACACACACACGGCTGGGGA 943 K Wnt1 TCCAACCCATCTCGTCCTTACACGTG CTCTACCATCACGCCACACATTTCCA GCACNTTTATCTGAAGTGTTTCCTTT TATTTGTGCATG IM000610 CATGCCTGGTGCCTGCAGAGGTCAGA 944 K Notch1 AAGTGTTGGATGCCCTGGAATTAGAG TAACACATAGTTATAAGATGCTGCGT GGGTGCTGGGATTTGAACCCTTGTCC TCTGCAAGAGCAGCCAGTGCTCTTTA CCACCGAGCCATCCCTCCAGCCCCTG ATTACTCACTCTTCACGGCCTCAATC TTGTAAGGAATATTGAGGCTGCCAAG TGACGCAAGAGCACCTAGGAAGGCAG CCACATCGGTGGCACTCTGGTAGCAC TGCGAGGATGACTGCACACATTGCCG GTTGTC IM000611 CATGCTGGCCATTTATTTTGATTTAA 945 D — GTTATACTCTAGACCTTTGTAAATAT TAGCCATTGCATATTACAGAAATTTC TTAGCAGAGATAGTCTCTCACTCTTA GTGATGAGCAAGCTGGAGCTCAGCAT TATTCTCCCAGCTAAGATACAGAATT ACAGACGTTTATGACGGACACATCTT GGATGTAGTTACTTAGTCCAC IM000612 CCCCCCCCGCCCCTGCCAGACCGCAG 946 D — CCCCAAGCACAGCATG IM000613 CATGCCTCCCTCAGCCTCCTCCACCC 947 K Fgf3/Fg CTTCCTGTCCTGCCTCCTCATCACTG f4 TGTAAATAATTTGCACCGAAATGTGG CCGCAGAGCCACGCGTTCGGTTATGT AAATAAAACTATTTATTGTGCTGGGT TCCAGCCTGGGTTGCAGAGACCACCCT IM000614 CATGAATTCAATGGTGTGCTTGCTAT 948 D — AAATGCAAATAAACCATATATATCAT ATTACACTCAATTTTAAATATTTTTC CTAATATTAATAAAGGTGATGGGGAA CTT IM000615 CATGTCTACTTTATTGCATATTAGGA 949 D — TGTCAGGTCCTGCTCGTTTCCTGGG ACCATTTGCCTGGAAGACATTTTTCC ATTCTT1TACTCTGAGATAGTTCCTG TCTTTGTTGTTGAGGTGTGTTTCnG TATTCAGCAAAATGCTGGATCTTGTT TGCGAATCCAGTCTGTTAGCTTATGT CTTTTTACAGGTGAATTGAGTCCATT AATATTGAGAGATATTAAAGAGAAAT GACTTTTGGTTCCTGATATATTTGTTT TTTCTAGTTAGTTTTGTGTGCTTGGGA CTCTCTCCCTTTGACTGTGTTGTGAG ATGCTTAATATCTTGTCCTATCTTTG GTGCAGGTGTCTTCCTTGTGTTAGA GTTTTCATTCCAGGTTTCTCTGTAGT GTTATGTTAGAAGACATATACTGCTT GAATTTAGTTTTGCCTGGAATATTTT GTTTTCTCCATCTATGTTGATTGAGA GTTTTTCTGGGTAAAATAGCCTANCC TGGCATTTGTGTTCTCTTAAAAGTCT GTATGACCTCTGACTANGCTTTTCTG GCC IM000616 CATGGTGAATGATTGTTTTGATGTGT 950 R — TCTTGGATTTTGGTTTCGAGAATTTTA TTGACTATTTTGGCATTAATACTCATA AGGGAAATTGGTCTGAAGTTCTTTCC TTGTTGAGTCTTTATGAGGGTATCAA TATAATTGTGGATTCATAGAGCAAGT TGGATTGTGTTCCTTCTGTTTATATTT TGTGGAATATTTTGAAGAGTATTGGT ATTAGATTTTCTTTGAAGGTATGATA GAATTCTGAACTAAACCCATATGGTT CTGGATTTTTTTTGGTTGGAAGACCA ATGACTGCTTCTATTTCTTTAGGTGT TATGGGACTGTATAGATGGTTTATCT GAACCAGATTTAACTTTGGTATTTGT TATCTGTTTAGAAAATTGCCCATTTC ATCCATATTTCCCAGTTGTGTTGAGT ATAGGCTTTTGTAGTAGGATATAATG ATTTTTTGAATTTCCTCAGTATGTTTT CTTATATCTCCCTTTCCATTTCTGATT TTGTTAATGTGGATACTATCTCCGTG TCCCC IM000617 CCATGTCAGGTGGTTAACCTGTGAGT 951 D — CTAACTTCCAGGAATGCAATGCCTCT GGCATCTACAGGCATAAACATACTTG TGGCTTACACTCAAACTGACACACCA ACACATATGTGCACGCGCACACACAC ACACACCAAATTAAAAATAAAATAAC CCTTTTTAAAAAAATATAGAATCTAT AGATAATTGCTTTACTGCACTCACAA ACATTTTAGGATC IM000618 ACACTAACACAAAGAAGGGGATC 952 D —

Lengthy table referenced here US07820447-20101026-T00001 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00002 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00003 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00004 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00005 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00006 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00007 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00008 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00009 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00010 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00011 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00012 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00013 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00014 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00015 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00016 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00017 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00018 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00019 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00020 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00021 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00022 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00023 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00024 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00025 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00026 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00027 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00028 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00029 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00030 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00031 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00032 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00033 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00034 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00035 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00036 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00037 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00038 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00039 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00040 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00041 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00042 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00043 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00044 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00045 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00046 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00047 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00048 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00049 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00050 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00051 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00052 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00053 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00054 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00055 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00056 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00057 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00058 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00059 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00060 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00061 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00062 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00063 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00064 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00065 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00066 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00067 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00068 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00069 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00070 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00071 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00072 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00073 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00074 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00075 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00076 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00077 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00078 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00079 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00080 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00081 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00082 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00083 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00084 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00085 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00086 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00087 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00088 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00089 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00090 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00091 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00092 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00093 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00094 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00095 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00096 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00097 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00098 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00099 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00100 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00101 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00102 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00103 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00104 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00105 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00106 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00107 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00108 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00109 Please refer to the end of the specification for access instructions.

Lengthy table referenced here US07820447-20101026-T00110 Please refer to the end of the specification for access instructions.

LENGTHY TABLES The patent contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US07820447B2). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 

1. A method for diagnosing colon cancer comprising comparing levels of PPP3CC protein in a patient colon sample to that of a non-cancerous colon control sample, wherein the PPP3CC protein is encoded by a nucleic acid having the nucleotide sequence set forth in SEQ ID NO: 1587, wherein an increase in the level of PPP3CC protein in the patient colon sample of at least 50% relative to said non-cancerous colon control is indicative of colon cancer.
 2. A method for diagnosing colon cancer comprising comparing levels of a polypeptide encoded for by a nucleic acid comprising a nucleotide sequence at least 98% identical to SEQ ID NO:1587 in a patient colon sample to a non-cancerous colon control sample, wherein an increase in the level of the polypeptide in the patient colon sample of at least 50% relative to said non-cancerous colon control is indicative of colon cancer, said polypeptide having protein phosphatase activity. 